0001802768 December 31 2024 Q3 FALSE xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:GBP xbrli:shares xbrli:pure rprx:noncontrolling_interest rprx:tranche rprx:quarter rprx:payment rprx:class rprx:vote rprx:quarterly_dividend 0001802768 2024-01-01 2024-09-30 0001802768 us-gaap:CommonClassAMember 2024-11-01 0001802768 us-gaap:CommonClassBMember 2024-11-01 0001802768 2024-09-30 0001802768 2023-12-31 0001802768 us-gaap:CommonClassAMember 2024-09-30 0001802768 us-gaap:CommonClassAMember 2023-12-31 0001802768 us-gaap:CommonClassBMember 2023-12-31 0001802768 us-gaap:CommonClassBMember 2024-09-30 0001802768 rprx:ClassRRedeemableStockMember 2024-09-30 0001802768 rprx:ClassRRedeemableStockMember 2023-12-31 0001802768 rprx:FinancialRoyaltyAssetsMember 2024-07-01 2024-09-30 0001802768 rprx:FinancialRoyaltyAssetsMember 2023-07-01 2023-09-30 0001802768 rprx:FinancialRoyaltyAssetsMember 2024-01-01 2024-09-30 0001802768 rprx:FinancialRoyaltyAssetsMember 2023-01-01 2023-09-30 0001802768 rprx:RoyaltyIncomeOtherMember 2024-07-01 2024-09-30 0001802768 rprx:RoyaltyIncomeOtherMember 2023-07-01 2023-09-30 0001802768 rprx:RoyaltyIncomeOtherMember 2024-01-01 2024-09-30 0001802768 rprx:RoyaltyIncomeOtherMember 2023-01-01 2023-09-30 0001802768 2024-07-01 2024-09-30 0001802768 2023-07-01 2023-09-30 0001802768 2023-01-01 2023-09-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2024-06-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2024-06-30 0001802768 us-gaap:CommonStockMember rprx:ClassRRedeemableStockMember 2024-06-30 0001802768 rprx:DeferredSharesMember 2024-06-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001802768 us-gaap:RetainedEarningsMember 2024-06-30 0001802768 us-gaap:NoncontrollingInterestMember 2024-06-30 0001802768 us-gaap:TreasuryStockCommonMember 2024-06-30 0001802768 2024-06-30 0001802768 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0001802768 us-gaap:CommonClassAMember 2024-07-01 2024-09-30 0001802768 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2024-07-01 2024-09-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2024-07-01 2024-09-30 0001802768 rprx:DeferredSharesMember 2024-07-01 2024-09-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001802768 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2024-09-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2024-09-30 0001802768 us-gaap:CommonStockMember rprx:ClassRRedeemableStockMember 2024-09-30 0001802768 rprx:DeferredSharesMember 2024-09-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001802768 us-gaap:RetainedEarningsMember 2024-09-30 0001802768 us-gaap:NoncontrollingInterestMember 2024-09-30 0001802768 us-gaap:TreasuryStockCommonMember 2024-09-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-06-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2023-06-30 0001802768 us-gaap:CommonStockMember rprx:ClassRRedeemableStockMember 2023-06-30 0001802768 rprx:DeferredSharesMember 2023-06-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001802768 us-gaap:RetainedEarningsMember 2023-06-30 0001802768 us-gaap:NoncontrollingInterestMember 2023-06-30 0001802768 us-gaap:TreasuryStockCommonMember 2023-06-30 0001802768 2023-06-30 0001802768 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001802768 us-gaap:CommonClassAMember 2023-07-01 2023-09-30 0001802768 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-07-01 2023-09-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2023-07-01 2023-09-30 0001802768 rprx:DeferredSharesMember 2023-07-01 2023-09-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001802768 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-09-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2023-09-30 0001802768 us-gaap:CommonStockMember rprx:ClassRRedeemableStockMember 2023-09-30 0001802768 rprx:DeferredSharesMember 2023-09-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001802768 us-gaap:RetainedEarningsMember 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember 2023-09-30 0001802768 us-gaap:TreasuryStockCommonMember 2023-09-30 0001802768 2023-09-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-12-31 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2023-12-31 0001802768 us-gaap:CommonStockMember rprx:ClassRRedeemableStockMember 2023-12-31 0001802768 rprx:DeferredSharesMember 2023-12-31 0001802768 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001802768 us-gaap:RetainedEarningsMember 2023-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2023-12-31 0001802768 us-gaap:TreasuryStockCommonMember 2023-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-09-30 0001802768 us-gaap:CommonClassAMember 2024-01-01 2024-09-30 0001802768 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2024-01-01 2024-09-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2024-01-01 2024-09-30 0001802768 rprx:DeferredSharesMember 2024-01-01 2024-09-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001802768 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-09-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-12-31 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-12-31 0001802768 us-gaap:CommonStockMember rprx:ClassRRedeemableStockMember 2022-12-31 0001802768 rprx:DeferredSharesMember 2022-12-31 0001802768 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001802768 us-gaap:RetainedEarningsMember 2022-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2022-12-31 0001802768 us-gaap:TreasuryStockCommonMember 2022-12-31 0001802768 2022-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-09-30 0001802768 us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0001802768 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0001802768 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2023-01-01 2023-09-30 0001802768 rprx:DeferredSharesMember 2023-01-01 2023-09-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001802768 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-09-30 0001802768 rprx:ExchangeOfferTransactionMember rprx:LegacyInvestorsPartnershipsMember 2020-02-11 2020-02-11 0001802768 rprx:RoyaltyPharmaInvestmentsOldRPIMember rprx:ExchangeOfferTransactionMember 2020-02-11 0001802768 rprx:RoyaltyPharmaCollectionTrustMember 2020-02-11 0001802768 rprx:RoyaltyPharmaCollectionTrustMember rprx:LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember 2020-02-11 0001802768 rprx:RoyaltyPharmaInvestmentsOldRPIMember 2022-12-31 0001802768 rprx:RoyaltyPharmaInvestmentsOldRPIMember 2023-12-31 0001802768 rprx:RoyaltyPharmaInvestmentsOldRPIMember rprx:LegacyInvestorsPartnershipsMember 2023-12-31 0001802768 rprx:VertexMember us-gaap:CustomerConcentrationRiskMember us-gaap:FinanceReceivablesMember 2024-01-01 2024-09-30 0001802768 rprx:VertexMember us-gaap:CustomerConcentrationRiskMember us-gaap:FinanceReceivablesMember 2023-01-01 2023-12-31 0001802768 rprx:CytokineticsMember rprx:ExpandedFundingMember 2024-05-01 2024-05-31 0001802768 rprx:CytokineticsMember rprx:DevelopmentFundingMember 2024-05-01 2024-05-31 0001802768 rprx:CytokineticsMember rprx:CommercialLaunchFundingMember 2024-05-01 2024-05-31 0001802768 rprx:Phase3TrialMember rprx:CytokineticsMember rprx:DevelopmentFundingMember 2024-05-01 2024-05-31 0001802768 rprx:TrancheOneMember rprx:CytokineticsMember rprx:CommercialLaunchFundingMember 2024-05-01 2024-05-31 0001802768 rprx:TrancheSixMember rprx:CytokineticsMember rprx:CommercialLaunchFundingMember 2024-05-01 2024-05-31 0001802768 rprx:TrancheTwoMember rprx:CytokineticsMember rprx:CommercialLaunchFundingMember 2024-05-01 2024-05-31 0001802768 rprx:TrancheThreeMember rprx:CytokineticsMember rprx:CommercialLaunchFundingMember 2024-05-01 2024-05-31 0001802768 rprx:TrancheFourMember rprx:CytokineticsMember rprx:CommercialLaunchFundingMember 2024-05-01 2024-05-31 0001802768 rprx:TrancheFiveMember rprx:CytokineticsMember rprx:CommercialLaunchFundingMember 2024-05-01 2024-05-31 0001802768 rprx:TrancheSevenMember rprx:CytokineticsMember rprx:CommercialLaunchFundingMember 2024-05-01 2024-05-31 0001802768 rprx:TrancheFourMember rprx:CytokineticsFundingCommitmentsMember rprx:CytokineticsMember rprx:CommercialLaunchFundingMember 2024-04-30 0001802768 rprx:TrancheFourMember rprx:CytokineticsMember rprx:CommercialLaunchFundingMember 2024-04-30 0001802768 rprx:TrancheFourMember rprx:CytokineticsMember rprx:CommercialLaunchFundingMember 2024-04-01 2024-04-30 0001802768 rprx:TranchesOneFourFiveSixAndSevenMember rprx:CytokineticsMember rprx:CommercialLaunchFundingMember 2024-05-01 2024-05-31 0001802768 rprx:CytokineticsMember rprx:CommercialLaunchFundingMember 2024-09-30 0001802768 rprx:CytokineticsMember rprx:DevelopmentFundingMember 2024-09-30 0001802768 rprx:CytokineticsMember rprx:RDFundingDerivativeMember 2024-09-30 0001802768 rprx:CytokineticsMember rprx:PartnershipCommonStockMember 2024-09-30 0001802768 rprx:CytokineticsMember 2024-09-30 0001802768 rprx:CytokineticsMember rprx:CommercialLaunchFundingMember 2024-01-01 2024-09-30 0001802768 rprx:CytokineticsMember rprx:ResearchAndDevelopmentFundingMember 2024-05-01 2024-05-31 0001802768 rprx:MorphoSysMember rprx:DevelopmentFundingMember 2022-09-01 2022-09-30 0001802768 us-gaap:DebtSecuritiesMember 2024-09-30 0001802768 rprx:FundingCommitmentsMember 2024-09-30 0001802768 us-gaap:DebtSecuritiesMember 2023-12-31 0001802768 rprx:FundingCommitmentsMember 2023-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2024-09-30 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2023-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001802768 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel1Member rprx:RoyaltyInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel2Member rprx:RoyaltyInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:RoyaltyInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001802768 us-gaap:FairValueMeasurementsRecurringMember rprx:RoyaltyInvestmentsMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel1Member rprx:RoyaltyInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel2Member rprx:RoyaltyInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel3Member rprx:RoyaltyInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember rprx:RoyaltyInvestmentsMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel1Member rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel2Member rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001802768 us-gaap:FairValueMeasurementsRecurringMember rprx:CytokineticsFundingCommitmentMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel1Member rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel2Member rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel3Member rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember rprx:CytokineticsFundingCommitmentMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2024-06-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:DebtSecuritiesMember 2024-06-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:FundingCommitmentsMember 2024-06-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:DerivativeAssetMember 2024-06-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:RoyaltyMember 2024-06-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2024-07-01 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:DerivativeAssetMember 2024-07-01 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:DebtSecuritiesMember 2024-07-01 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:FundingCommitmentsMember 2024-07-01 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:DebtSecuritiesMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:FundingCommitmentsMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:DerivativeAssetMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:RoyaltyMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2023-06-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:DebtSecuritiesMember 2023-06-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:FundingCommitmentsMember 2023-06-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:DerivativeAssetMember 2023-06-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:RoyaltyMember 2023-06-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2023-07-01 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:DerivativeAssetMember 2023-07-01 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:DebtSecuritiesMember 2023-07-01 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:FundingCommitmentsMember 2023-07-01 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:RoyaltyMember 2023-07-01 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:DebtSecuritiesMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:FundingCommitmentsMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:DerivativeAssetMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:RoyaltyMember 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:DebtSecuritiesMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel3Member rprx:FundingCommitmentsMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel3Member rprx:DerivativeAssetMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:RoyaltyMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2024-01-01 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:DebtSecuritiesMember 2024-01-01 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:DerivativeAssetMember 2024-01-01 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:FundingCommitmentsMember 2024-01-01 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:RoyaltyMember 2024-01-01 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:DebtSecuritiesMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel3Member rprx:FundingCommitmentsMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel3Member rprx:DerivativeAssetMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:RoyaltyMember 2022-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2023-01-01 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:DerivativeAssetMember 2023-01-01 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:DebtSecuritiesMember 2023-01-01 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:FundingCommitmentsMember 2023-01-01 2023-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:RoyaltyMember 2023-01-01 2023-09-30 0001802768 us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-03-01 2023-03-31 0001802768 us-gaap:CommonStockMember rprx:CytokineticsMember 2024-05-01 2024-05-31 0001802768 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember rprx:CytokineticsMember rprx:ResearchAndDevelopmentFundingMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputOptionVolatilityMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputOptionVolatilityMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember srt:MaximumMember 2023-12-31 0001802768 rprx:FinancialRoyaltyAssetsCurrentMember 2024-01-01 2024-09-30 0001802768 rprx:FinancialRoyaltyAssetsCurrentMember 2023-01-01 2023-12-31 0001802768 rprx:FinancialRoyaltyAssetsNonCurrentMember 2024-01-01 2024-09-30 0001802768 rprx:FinancialRoyaltyAssetsNonCurrentMember 2023-01-01 2023-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0001802768 rprx:CysticFibrosisFranchiseMember 2024-09-30 0001802768 rprx:EvrysdiMember 2024-09-30 0001802768 rprx:TrelegyMember 2024-09-30 0001802768 rprx:TysabriMember 2024-09-30 0001802768 rprx:VoranigoMember 2024-09-30 0001802768 rprx:TremfyaMember 2024-09-30 0001802768 rprx:OtherFinancialRoyaltyAssetMember 2024-09-30 0001802768 rprx:OlpasiranPelacarsenKarXTSeltorexantOlanzapineLAIAficamtenEcopipamAndFrexalimabMember 2024-09-30 0001802768 rprx:FinancialRoyaltyAssetFexalimabMember 2024-09-30 0001802768 rprx:CysticFibrosisFranchiseMember 2023-12-31 0001802768 rprx:EvrysdiMember 2023-12-31 0001802768 rprx:TrelegyMember 2023-12-31 0001802768 rprx:TysabriMember 2023-12-31 0001802768 rprx:TremfyaMember 2023-12-31 0001802768 rprx:XtandiMember 2023-12-31 0001802768 rprx:OtherFinancialRoyaltyAssetMember 2023-12-31 0001802768 rprx:LegacyInvestorsPartnershipsMember 2020-02-11 0001802768 rprx:LegacyInvestorsPartnershipsMember 2024-07-01 2024-09-30 0001802768 rprx:LegacyInvestorsPartnershipsMember 2024-01-01 2024-09-30 0001802768 rprx:LegacyInvestorsPartnershipsMember 2023-07-01 2023-09-30 0001802768 rprx:LegacyInvestorsPartnershipsMember 2023-01-01 2023-09-30 0001802768 rprx:AvillionEntitiesMember 2024-07-01 2024-09-30 0001802768 rprx:AvillionEntitiesMember 2024-01-01 2024-09-30 0001802768 rprx:AvillionEntitiesMember 2023-07-01 2023-09-30 0001802768 rprx:AvillionEntitiesMember 2023-01-01 2023-09-30 0001802768 rprx:AvillionIMember 2024-01-01 2024-09-30 0001802768 rprx:AvillionIMember 2023-01-01 2023-09-30 0001802768 rprx:MerckAssetPhaseIIAndPhaseIIIClinicalTrialMember rprx:AvillionIIMember 2018-05-31 0001802768 rprx:AvillionIIMember 2023-01-01 2023-03-31 0001802768 rprx:AvillionIIMember 2024-07-01 2024-09-30 0001802768 rprx:AvillionEntitiesMember 2024-09-30 0001802768 rprx:AvillionEntitiesMember 2023-12-31 0001802768 rprx:CytokineticsMember 2023-01-01 2023-09-30 0001802768 rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2024-09-30 0001802768 rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2024-01-01 2024-09-30 0001802768 rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2023-12-31 0001802768 rprx:OnePointSevenFivePercentSeniorNotesDue2027Member us-gaap:UnsecuredDebtMember 2024-09-30 0001802768 rprx:OnePointSevenFivePercentSeniorNotesDue2027Member us-gaap:UnsecuredDebtMember 2024-01-01 2024-09-30 0001802768 rprx:OnePointSevenFivePercentSeniorNotesDue2027Member us-gaap:UnsecuredDebtMember 2023-12-31 0001802768 rprx:FivePointOneFivePercentSeniorNotesDue2029Member us-gaap:UnsecuredDebtMember 2024-09-30 0001802768 rprx:FivePointOneFivePercentSeniorNotesDue2029Member us-gaap:UnsecuredDebtMember 2024-01-01 2024-09-30 0001802768 rprx:FivePointOneFivePercentSeniorNotesDue2029Member us-gaap:UnsecuredDebtMember 2023-12-31 0001802768 rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member us-gaap:UnsecuredDebtMember 2024-09-30 0001802768 rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member us-gaap:UnsecuredDebtMember 2024-01-01 2024-09-30 0001802768 rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member us-gaap:UnsecuredDebtMember 2023-12-31 0001802768 rprx:TwoPointOneFivePercentSeniorNotesDue2031Member us-gaap:UnsecuredDebtMember 2024-09-30 0001802768 rprx:TwoPointOneFivePercentSeniorNotesDue2031Member us-gaap:UnsecuredDebtMember 2024-01-01 2024-09-30 0001802768 rprx:TwoPointOneFivePercentSeniorNotesDue2031Member us-gaap:UnsecuredDebtMember 2023-12-31 0001802768 rprx:FivePointFourZeroPercentSeniorNotesDue2034Member us-gaap:UnsecuredDebtMember 2024-09-30 0001802768 rprx:FivePointFourZeroPercentSeniorNotesDue2034Member us-gaap:UnsecuredDebtMember 2024-01-01 2024-09-30 0001802768 rprx:FivePointFourZeroPercentSeniorNotesDue2034Member us-gaap:UnsecuredDebtMember 2023-12-31 0001802768 rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member us-gaap:UnsecuredDebtMember 2024-09-30 0001802768 rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member us-gaap:UnsecuredDebtMember 2024-01-01 2024-09-30 0001802768 rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member us-gaap:UnsecuredDebtMember 2023-12-31 0001802768 rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member us-gaap:UnsecuredDebtMember 2024-09-30 0001802768 rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member us-gaap:UnsecuredDebtMember 2024-01-01 2024-09-30 0001802768 rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member us-gaap:UnsecuredDebtMember 2023-12-31 0001802768 rprx:ThreePointThreeFivePercentDue2051Member us-gaap:UnsecuredDebtMember 2024-09-30 0001802768 rprx:ThreePointThreeFivePercentDue2051Member us-gaap:UnsecuredDebtMember 2024-01-01 2024-09-30 0001802768 rprx:ThreePointThreeFivePercentDue2051Member us-gaap:UnsecuredDebtMember 2023-12-31 0001802768 rprx:FivePointNineZeroPercentSeniorNotesDue2057Member us-gaap:UnsecuredDebtMember 2024-09-30 0001802768 rprx:FivePointNineZeroPercentSeniorNotesDue2057Member us-gaap:UnsecuredDebtMember 2024-01-01 2024-09-30 0001802768 rprx:FivePointNineZeroPercentSeniorNotesDue2057Member us-gaap:UnsecuredDebtMember 2023-12-31 0001802768 rprx:A2024NotesMember us-gaap:UnsecuredDebtMember 2024-06-30 0001802768 rprx:A2021NotesMember us-gaap:UnsecuredDebtMember 2021-07-26 0001802768 rprx:A2020NotesMember us-gaap:UnsecuredDebtMember 2020-09-02 0001802768 rprx:A2020NotesMember us-gaap:UnsecuredDebtMember 2023-09-01 2023-09-30 0001802768 rprx:A2020NotesMember us-gaap:UnsecuredDebtMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2020-09-02 2020-09-02 0001802768 rprx:A2021NotesMember us-gaap:UnsecuredDebtMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2021-07-26 2021-07-26 0001802768 rprx:A2024NotesMember us-gaap:UnsecuredDebtMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2024-06-01 2024-06-30 0001802768 rprx:A2024NotesMember us-gaap:UnsecuredDebtMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2024-06-01 2024-06-30 0001802768 rprx:A2021NotesMember us-gaap:UnsecuredDebtMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2021-07-26 2021-07-26 0001802768 rprx:A2020NotesMember us-gaap:UnsecuredDebtMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2020-09-02 2020-09-02 0001802768 us-gaap:FairValueInputsLevel2Member rprx:TheNotesMember us-gaap:UnsecuredDebtMember 2024-09-30 0001802768 us-gaap:FairValueInputsLevel2Member rprx:TheNotesMember us-gaap:UnsecuredDebtMember 2023-12-31 0001802768 rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:RevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2023-12-22 0001802768 rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:RevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember srt:ScenarioForecastMember 2028-12-22 2028-12-22 0001802768 rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:RevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember srt:ScenarioForecastMember 2027-10-31 2027-10-31 0001802768 rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:RevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2023-12-31 0001802768 rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:RevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2024-09-30 0001802768 rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:RevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember rprx:OvernightBankFundingRateMember 2024-01-24 2024-01-24 0001802768 rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:RevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember us-gaap:FederalFundsPurchasedMember 2024-01-24 2024-01-24 0001802768 rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:RevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-24 2024-01-24 0001802768 rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:RevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2024-01-24 0001802768 rprx:TheNotesMember us-gaap:UnsecuredDebtMember 2024-09-30 0001802768 rprx:ClassRRedeemableStockMember 2024-01-01 2024-09-30 0001802768 us-gaap:CommonClassAMember 2023-03-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2024-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2024-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2024-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2024-07-01 2024-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2024-07-01 2024-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2024-07-01 2024-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2024-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2024-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2024-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyaltyPharmaSelectFinanceTrustMember 2023-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2023-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2023-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2023-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyaltyPharmaSelectFinanceTrustMember 2023-07-01 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2023-07-01 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2023-07-01 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2023-07-01 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyaltyPharmaSelectFinanceTrustMember 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2023-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2023-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2023-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2024-01-01 2024-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2024-01-01 2024-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2024-01-01 2024-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyaltyPharmaSelectFinanceTrustMember 2022-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2022-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2022-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2022-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyaltyPharmaSelectFinanceTrustMember 2023-01-01 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2023-01-01 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2023-01-01 2023-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2023-01-01 2023-09-30 0001802768 rprx:RPHoldingsMember rprx:ContinuingInvestorsPartnershipMember 2024-09-30 0001802768 rprx:RoyaltyPharmaPlcMember 2024-09-30 0001802768 rprx:RPHoldingsMember rprx:ContinuingInvestorsPartnershipMember 2023-09-30 0001802768 rprx:RoyaltyPharmaPlcMember 2023-09-30 0001802768 2023-01-01 2023-12-31 0001802768 2024-01-01 2024-06-30 0001802768 2024-04-01 2024-06-30 0001802768 2024-01-01 2024-03-31 0001802768 rprx:A2020EquityIncentivePlanMember us-gaap:CommonClassAMember 2020-06-15 0001802768 rprx:ContinuingNonControllingInterestsMember 2024-07-01 2024-09-30 0001802768 rprx:ContinuingNonControllingInterestsMember 2023-07-01 2023-09-30 0001802768 rprx:ContinuingNonControllingInterestsMember 2024-01-01 2024-09-30 0001802768 rprx:ContinuingNonControllingInterestsMember 2023-01-01 2023-09-30 0001802768 rprx:LegacyNonControllingInterestsMember 2024-07-01 2024-09-30 0001802768 rprx:LegacyNonControllingInterestsMember 2023-07-01 2023-09-30 0001802768 rprx:LegacyNonControllingInterestsMember 2024-01-01 2024-09-30 0001802768 rprx:LegacyNonControllingInterestsMember 2023-01-01 2023-09-30 0001802768 rprx:CobenfyMember 2024-01-01 2024-09-30 0001802768 rprx:CobenfyMember 2023-01-01 2023-09-30 0001802768 rprx:ErleadaMember 2024-01-01 2024-09-30 0001802768 rprx:ErleadaMember 2023-01-01 2023-09-30 0001802768 rprx:CytokineticsFundingCommitmentsMember 2024-01-01 2024-09-30 0001802768 rprx:CytokineticsFundingCommitmentsMember rprx:CytokineticsMember rprx:CommercialLaunchFundingMember 2024-01-01 2024-09-30 0001802768 rprx:TevaDevelopmentFundingCommitmentsMember 2023-11-01 2023-11-30 0001802768 rprx:TevaDevelopmentFundingCommitmentsMember 2024-07-01 2024-09-30 0001802768 rprx:TevaDevelopmentFundingCommitmentsMember 2024-01-01 2024-09-30 0001802768 us-gaap:RelatedPartyMember rprx:OperatingAndPersonnelPaymentsMember 2024-09-30 0001802768 us-gaap:RelatedPartyMember rprx:OperatingAndPersonnelPaymentsMember 2024-01-01 2024-09-30 0001802768 us-gaap:RelatedPartyMember rprx:OperatingAndPersonnelPaymentsMember 2024-07-01 2024-09-30 0001802768 us-gaap:RelatedPartyMember rprx:FormerOperatingAndPersonnelPaymentsMember 2023-07-01 2023-09-30 0001802768 us-gaap:RelatedPartyMember rprx:FormerOperatingAndPersonnelPaymentsMember 2023-01-01 2023-09-30 0001802768 rprx:BristolMyersSquibbMember rprx:AssignmentAgreementBenefitOfPaymentStreamMember 2017-12-08 2017-12-08 0001802768 rprx:BristolMyersSquibbMember rprx:AssignmentAgreementFundingObligationsMember 2017-12-08 2017-12-08 0001802768 us-gaap:RelatedPartyMember rprx:BristolMyersSquibbMember 2024-09-30 0001802768 us-gaap:RelatedPartyMember rprx:BristolMyersSquibbMember 2023-12-31 0001802768 us-gaap:RelatedPartyMember rprx:ErrolDeSouzaMember 2024-01-01 2024-01-31 0001802768 rprx:AgreementWithMSCIMember 2021-04-16 2021-04-16 0001802768 rprx:AgreementWithMSCIMember 2024-01-01 2024-09-30 0001802768 rprx:AgreementWithMSCIMember 2023-01-01 2023-12-31 0001802768 us-gaap:RelatedPartyMember rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember 2024-01-01 2024-09-30 0001802768 us-gaap:TreasuryStockCommonMember us-gaap:RelatedPartyMember rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember 2023-12-31 0001802768 us-gaap:TreasuryStockCommonMember us-gaap:RelatedPartyMember rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember 2024-09-30 0001802768 us-gaap:NoncontrollingInterestMember us-gaap:RelatedPartyMember rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember 2024-09-30 0001802768 us-gaap:NoncontrollingInterestMember us-gaap:RelatedPartyMember rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember 2023-12-31 0001802768 us-gaap:SubsequentEventMember rprx:SyndaxPharmaceuticalsMember 2024-11-01 2024-11-06
UNITED STATES
蚌åžååŒå§å¡äŒ
ã¯ã·ã³ãã³DC20549
ãã©ãŒã 10-Q
ïŒè¡š1ïŒ
â 蚌åžååŒæ³ç¬¬13æ¡ãŸãã¯15(d)æ¡ã«åºã¥ãååæå ±åæž
å ±åæéãçµäºãã2023幎6æ30æ¥ããã£ãŠ2024幎9æ30æ¥
OR
â 1934幎ã®èšŒåžååŒæ³ç¬¬13æ¡ãŸãã¯ç¬¬15æ¡ (d) ã«åºã¥ã移è¡å ±åæž
_________ãã_________ãžã®ç§»è¡æéã«ã€ããŠ
å§å¡äŒãã¡ã€ã«çªå· 001-39329
ãã€ã€ã«ãã£ãã¡ãŒã
ïŒäŒç€Ÿèšç«æã®æå®åïŒ
ã€ã³ã°ã©ã³ãããã³ãŠã§ãŒã«ãº
98-1535773
ïŒèšç«ãŸãã¯çµç¹ã®å·ãŸãã¯ç®¡èœåºåïŒ
ïŒåœçšåºéçšè
èå¥çªå·ïŒ
110 East 59th Street, New York, NY 10022. é ã¹ããªãŒã
ãã¥ãŒãšãŒã¯ , ãã¥ãŒãšãŒã¯ 10022
ïŒäž»èŠçµå¶äºåæã®äœæãšéµäŸ¿çªå·ïŒ
(212 ) 883-0200
ïŒç»é²è
ã®é»è©±çªå·ãåžå€å±çªãå«ãïŒ â ååŒéå§åã®éä¿¡
æ³ç¬¬12(b)æ¡ã«åºã¥ãç»é²èšŒåžïŒ
åã¯ã©ã¹ã®å称 ååŒã·ã³ãã«
ç»é²ãããŠããåååŒæã®å称 ã¯ã©ã¹Aæ®éæ ªåŒã1æ ªã®é¡é¢äŸ¡å€ã¯$0.0001 RPRX The Nasdaq Stock Market LLC
ååŒææ³ç¬¬13æ¡ãŸãã¯15æ¡ïŒdïŒã§èŠå®ããããã¹ãŠã®å ±åæžãåã®12ãæéã«æåºããŠãããïŒãŸãã¯æåºãå¿
èŠãªçãæéã«ã€ããŠãç»é²è
ããã®ãããªå ±åæžãæåºããå¿
èŠããã£ãããå«ãïŒããã€éå»90æ¥éãã®æåºèŠä»¶ã®å¯Ÿè±¡ãšãªã£ããããã§ãã¯ããŒã¯ã§ç€ºããŠãã ããã     ã¯ã   â     No   â Â
èŠå405ã«åºã¥ããæ¬ç« ã®Â§232.405ã«èŠå®ãããŠãã察話åããŒã¿ãã¡ã€ã«ããéå»12ãæéïŒãŸãã¯ãã®ãããªãã¡ã€ã«ãæåºãã矩åããã£ãæéã®çãå ŽåïŒã«é»åæåºãããã©ããããã§ãã¯ããŒã¯ã§ç€ºããŠãã ããã     ã¯ã   â    ããã   â
åç· åœ¹äŒã®èŠæš¡ã«ãã£ãŠã倧åå éãã¡ã€ã©ãŒãå éãã¡ã€ã©ãŒãéå éãã¡ã€ã©ãŒãå°èŠæš¡å ±åäŒç€ŸããŸãã¯æ°èäŒæ¥ã§ãããã©ããããã§ãã¯ããŒã¯ã§ç€ºããŠãã ãããExchange Actã®èŠå1202ã«ãããã倧åå éãã¡ã€ã©ãŒãããå éãã¡ã€ã©ãŒãããå°èŠæš¡å ±åäŒç€Ÿãããæ°èäŒæ¥ãã®å®çŸ©ã«ã€ããŠã¯ãåç
§ããŠãã ããã
倧åå éãã¡ã€ã©ãŒ â
å éãã¡ã€ã©ãŒ
â
éå éãã¡ã€ã©ãŒ
â
ã¬ããŒã矩åã®ããäžå°äŒæ¥
â
æ°èæé·äŒæ¥
â
               Â
æ°èæé·äŒæ¥ã®å Žåã¯ã蚌åžååŒæ³ç¬¬13æ¡ïŒaïŒã«åºã¥ãæ°ãããŸãã¯æ¹èšããã財åäŒèšåºæºã®éµå®ã«å¯Ÿãã延é·ç§»è¡æéã䜿çšããªãããšãéžæãããã©ããã«ãã§ãã¯ããŒã¯ãã€ããŠãã ããã â
ç»é²ç³è«è
ãååŒææ³ã®èŠå120å2ã«å®çŸ©ãããŠããã·ã§ã«äŒæ¥ã§ãããã©ããããã§ãã¯ããŒã¯ã§ç€ºããŠãã ããã ã¯ã   â     No   â
2024幎11æ1æ¥æç¹ã§ããã€ã€ã«ãã£ãã¡ãŒãæ ªåŒäŒç€Ÿã¯ 444,301,661 æ®éæ ªåŒã¯ã©ã¹Aãçºè¡ããŠããŸããã 144,881,122 Bã¯ã©ã¹æ®éæ ªåŒãçºè¡æžã¿ã§ãã
ãã€ã€ã«ãã£ã»ãã¡ãŒãã»ããŒãšã«ã·ãŒ
index
第äžéšå 財åæ
å ± é
ç®1ã é£çµèŠçŽè²¡åè«žè¡š 2024幎9æ30æ¥ãš2023幎12æ31æ¥ã®éç£æ»ã®èŠçŽé£çµè²žå察ç
§è¡š 2024幎9æ30æ¥ãŸã§ã®3ãæããã³9ãæéã®æªç£æ»ã®ç·åæçèšç®æž 2024幎9æ30æ¥ããã³2023幎ã®3ãæããã³9ãæéã«çµäºããæ ªäž»è³æ¬ã®çž®å°é£çµèšç®æžïŒæªç¢ºèªïŒ 2024幎9æ30æ¥ãŸã§ã®9ãæéã«é¢ãããã£ãã·ã¥ãããŒèšç®æžïŒæªç¢ºèªïŒ ç°¡çŽåãããé£çµè²¡å諞衚泚èšïŒæªç£æ»ïŒ ã¢ã€ãã 2. çµå¶é£ã«ãã財åç¶æ³ãšæ¥çžŸã«é¢ããäŒè©±ãšåæ é
ç®3ã åžå Žãªã¹ã¯ã«é¢ããæ°éçããã³è³ªçãªé瀺 é
ç®4ã å
éšçµ±å¶ããã³æé ç¥ãããŠããããã³æªç¥ã®å€æ°ã®ãªã¹ã¯ããã³äžç¢ºå®èŠå ã®çµæãšããŠ, åœç€Ÿã®å®éã®çµæãããã©ãŒãã³ã¹ã¯ããããã®ååãã®å£°æã«ãã£ãŠçºè¡šãããçµæãšå€§ããç°ãªãå ŽåããããŸããå®éã®çµæãç°ãªãå¯èœæ§ã®ããèŠå ã«ã€ããŠã¯ãPart IIãItem 1Aã®ããªã¹ã¯ãã¡ã¯ã¿ãŒãããã³SECãžã®ãã®ä»ã®æåºã«èšèŒãããŠããŸãã
ãã®ä»ã®æ
å ± é
ç®1ã æ³çæªçœ® é
ç®1Aã ãªã¹ã¯ãã¡ã¯ã¿ãŒ ã¢ã€ãã 2. æªç»é²ã®æ ªåŒã®è²©å£²ããã³ææ°æã®å©çš é
ç®3ã åªå
æ䟡蚌åžã«å¯Ÿããåµåäžå±¥è¡ é
ç®4ã é±å±±å®å
šé瀺 é
ç®5ã ãã®ä»ã®æ
å ± é
ç®6ã å±ç€ºè³æ
å°æ¥äºæž¬ã«é¢ããç¹èšäºé
ã«ã€ããŠ
ãã®åœ¢åŒ10-Qã«æ²èŒãããŠããååæå ±åæžã«ã¯ã1995幎ã®æ°äºèšŽèšæ¹é©æ³ã«ããããååããªèŠéãã§ãã声æããæ§æããç§ãã¡ã®å°æ¥ã®ããã©ãŒãã³ã¹ã«é¢ããèŠè§£ãåæ ãããŠããŸããããã€ãã®å Žåããããã®å£°æããå¯èœæ§ãããããããããããªããããããã¹ãã§ãããããæåŸ
ããããããèšç»ããããããäºæž¬ããããããä¿¡ãããããããèŠç©ãããããããç®æšãããäºæž¬ãããã¬ã€ãã³ã¹ãããç®æšãããäºæž¬ããããããžã§ã¯ããããæœåšçãªããŸãã¯ãç¶ç¶çãªããšãã£ãååããªèšèã§ç¹å®ããããšãã§ããŸãããããã®ååããªèŠéãã®å£°æã¯æŽå²çäºå®ã§ã¯ãªããçŸåšã®ç§ãã¡ãç§ãã¡ã®çŸåšãšå°æ¥ã®è³ç£ãæ¥çš®ã信念ãããã³åæã«ã€ããŠã®æåŸ
ãèŠç©ãããäºæž¬ã«åºã¥ããŠããŸãããããã®å£°æã¯å°æ¥ã®ããã©ãŒãã³ã¹ãä¿èšŒãããã®ã§ã¯ãªããç§ãã¡ã®ã³ã³ãããŒã«ãè¶
ãããªã¹ã¯ãäžç¢ºå®æ§ãããã³äºæž¬å°é£ãªä»ã®èŠå ã«åœ±é¿ãåããååããªå£°æã§è¡šæããããäºæž¬ãããçµæãšå®éã®çµæãå®è³ªçã«ç°ãªãå¯èœæ§ããããŸããç§ãã¡ã®å®éã®çµæã掻åã¬ãã«ãããã©ãŒãã³ã¹ããŸãã¯éæãååããªå£°æã§ç€ºããããã®ãšã¯ç°ãªãçµæã掻åã¬ãã«ãããã©ãŒãã³ã¹ããŸãã¯éæã«ã€ããŠå·®ç°ãçããéèŠãªèŠå ããããŸãã ãã®åœ¢åŒ10-Qã®ååæå ±åæžã§è¡ããããã¹ãŠã®ååããªå£°æãã第IIé
ç®1Aã®ããªã¹ã¯ãã¡ã¯ã¿ãŒãã®é
ç®ã®äžã«æŠèª¬ãããæ°ã
ã®ãªã¹ã¯ã®æèã§è©äŸ¡ãã¹ãã§ãã
ãããã®ãªã¹ã¯ãäžç¢ºå®æ§ã«ã¯ããã®ä»ã®ãããã¯ã«é¢é£ããèŠå ãå«ãŸããŸã:
⢠ç§ãã¡ããã€ã€ã«ãã£ãåãåããã€ãªå»è¬åã®è²©å£²ãªã¹ã¯;
⢠RP管çæ ªåŒäŒç€ŸïŒä»¥äžã管ç人ããšããïŒãç§ãã¡ãååŸããããã®é©åãªè³ç£ãèŠã€ããèœå;
⢠éçºæ®µéã®ãã€ãªå»è¬ååè£ã®å©çã®ååŸã«é¢é£ããäžç¢ºå®æ§ãšã補åããŒããã©ãªãªã«éçºæ®µéã®è£œååè£ãè¿œå ããæŠç¥;
⢠ç§ãã¡ã®ããžãã¹ã¢ãã«ã®åææ¡ä»¶;
⢠ç§ãã¡ããã€ã€ãªãã£ãŒååŸæŠç¥ãæåè£ã«å®è¡ããèœå;
⢠競äºåã掻ããèœå;
⢠ãããŒãžã£ãŒããã³ãã®é¢é£äŒç€Ÿãšã®å®éã®ããã³æœåšçãªå©ççžå
⢠ãããŒãžã£ãŒãŸãã¯ãã®é¢é£äŒç€Ÿãé«åºŠãªæèœããå°é家ãåŒãã€ããä¿æããèœå;
⢠çšå¶ã®å€æŽã®åœ±é¿ãšçšåç¶æ³ã«é¢ãã
⢠米åœèšŒåžååŒå§å¡äŒïŒ"SEC"ïŒãžã®ãã®ååæå ±åæžããã®ä»ã®æåºç©ã§ç¹å®ãããªã¹ã¯ãäžç¢ºå®æ§ããã³ãã®ä»ã®èŠå
ååããªçºèšã«åæ ãããŠããæåŸ
ã¯çã«ããªã£ãŠãããšèããŠããŸããããããã®æåŸ
ã®ããããäžæ£ç¢ºã§ããããšãå€æããå¯èœæ§ãããããã®çµæããããã®æåŸ
ã«åºã¥ãååããªçºèšãäžæ£ç¢ºã§ããå¯èœæ§ããããŸãããããããã³ãã®ä»ã®äžç¢ºå®æ§ãèæ
®ãããšããã®ãã©ãŒã 10-Qã«ãããäºæž¬ãŸãã¯ååããªèšè¿°ã®æ²èŒã¯ãç§ãã¡ãèšç»ãããžãã¹ç®æšãéæãããšããè¡šæãšã¿ãªãã¹ãã§ã¯ãããŸãããããã«ããããååããªçºèšã®æ£ç¢ºæ§ãšå®å
šæ§ã«ã€ããŠã¯ç§ãã¡ããã®ä»ã®äººç©ã責任ãè² ããã®ã§ã¯ãããŸãããç§ãã¡ã¯ããã®ãã©ãŒã 10-Qã®æåºæ¥ä»¥éãå®çžŸãä¿®æ£ãããæåŸ
ã«å
ç«ã€å£°æãå®éã®çµæãä¿®æ£ãããæåŸ
ã«åèŽããããããããååããªçºèšã®ããããæŽæ°ãã矩åãè² ã£ãŠããŸããã
ããŒã1. 財åæ
å ±
é
ç®1ã èŠçŽé£çµè²¡åè«žè¡š
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽé£çµè²žå察ç
§è¡š
ïŒåãã«ã衚瀺éé¡ãé€ãïŒ
(æªç£æ»)
2022幎9æ30æ¥æç¹ã®è³ç£ 2022幎12æ31æ¥æç¹ã®è³ç£ 2024 2023 è³ç£ æµåè³ç£ çŸéåã³çŸéåçç© $ 950,052  $ 477,010  ãã¡ã€ãã³ã·ã£ã«ãã€ã€ã«ãã£è³ç£ 765,773  738,438  売åŽäºå®ã®åµåžã»åµåèšŒåž 48,500  18,300  ãã®ä»ã®ãã€ã€ã«ãã£åçåµæš© 24,901  22,405  ãã®ä»ã®æµåè³ç£ 4,969  18,040  æµåè³ç£åèš 1,794,195  1,274,193  éèçæè³ç£ãçŽè³ç£ 14,968,074  14,088,655 Â æ ªåŒèšŒåž 228,867  199,487  åµåžã»åµå蚌åžã«è²©å£²å¯èœ 657,300  437,100  ãšã¯ã€ãã£ã¡ãœããæè³ 351,017  375,894  ãã®ä»ã®è³ç£ 42,789  6,522  ç·è³ç£ $ 18,042,242  $ 16,381,851 Â è² åµãšæ ªäž»è³æ¬ æµåè² åµ æ§éæ¯é
æ ªäž»ã«æ¯æãåé
é $ 79,149  $ 83,155  æ¯æ調æŽéããã³æªæé 22,055  15,165  éçŸéè²»çšã®èª¿æŽ: 38,412  51,682  é·æåå
¥éã®çæéšå 996,942  â  ãã®ä»ã®æµåè² åµ 31,200  11,375  æµåè² åµåèš 1,167,758  161,377  æ°èŠè²·åµå 6,610,437  6,135,285  ãã®ä»ã®è² åµ 5,580  900 Â è² åµåèš 7,783,775  6,297,562  ã³ãããã¡ã³ãåã³äºæ
ã«é¢ããæ³šèš æ ªäž»è³æ¬ èªå¯æžã¿æ ªåŒæ°9,000,000,000æ ªã2024幎3æ31æ¥ããã³2023幎12æ31æ¥æç¹ã§ãéåéæ ªåŒã¯çºè¡ãããŠããããæªæãã®ãã®ããããŸããã0.0001 é¡é¢ïŒçºè¡æžã¿æ ªåŒæ°ïŒ2024幎â446,038 ããã³2023幎â446,692
45  45  ã¯ã©ã¹bæ®éæ ªåŒã$0.000001 åç®éé¡ïŒçºè¡æžã¿æ ªåŒæ°ïŒ2024幎â144,881 ããã³2023幎â150,743
â  â  ã¯ã©ã¹Rã®æž
ç®å¯èœæ ªåŒã£åç®éé¡ïŒçºè¡æžã¿æ ªåŒæ°ïŒ2024幎â1 ããã³2023幎â50 Deferredæ ªã$åç®éé¡ïŒçºè¡æžã¿æ ªåŒæ°ïŒ2024幎â50
63  63  ããã³2023幎â0.000001 Deferredæ ªã$åç®éé¡ïŒçºè¡æžã¿æ ªåŒæ°ïŒ2024幎â390,502 and 2023â384,640
â  â  远å ã®è³æ¬é 4,107,742  4,011,435  çä¿å©ç 2,764,685  2,517,583  éæ¯é
æ ªäž»æå 3,388,589  3,557,792  Treasury interests (2,657 ) (2,629 ) ç·æ ªäž»è³æ¬
10,258,467  10,084,289 Â è² åµããã³æ ªäž»è³æ¬ã®åèš $ 18,042,242  $ 16,381,851 Â
ãããæªç£æ»ã®èŠçŽé£çµè²¡åè«žè¡šã«æ·»ä»ããã泚èšãåç
§ããŠãã ããã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
ç°¡æåç®æçèšç®æž
(åãã«åäœã1æ ªåœããéé¡ä»¥å€)
(æªç£æ»)
2021幎9æ30æ¥çµäºã®3ãæéã®æ±ºç®ã«ã€ã㊠2021幎9æ30æ¥çµäºã®9ãæéã®æ±ºç®ã«ã€ã㊠2024 2023 2024 2023 åœæçŽå©çããã³ãã®ä»ã®åç ãã¡ã€ãã³ã·ã£ã«ãã€ã€ã«ãã£è³ç£ããã®åå
¥ $ 533,166  $ 508,657  $ 1,587,577  $ 1,674,689  ãã®ä»ã®ãã€ã€ãªãã£åå
¥ããã³åç 31,524  27,656  82,358  83,797  åå
¥ããã³ãã®ä»ã®åçã®åèš 564,690  536,313  1,669,935  1,758,486  éå¶ïŒåçïŒ/è²»çš äºæ³ãããçŸéãããŒã®å€åã«å¯Ÿããéèãã€ã€ãªãã£è³ç£ããã®åŒåœé (227,604 ) 277,137  568,425  637,169  ç 究éçºè³éã®çµè²» 500  50,500  1,500  51,500  äžè¬ç®¡çè²»çš 56,720  57,234  169,080  190,563  ç·éå¶ïŒåçïŒ/è²»çšãçŽé¡ (170,384 ) 384,871  739,005  879,232  å¶æ¥å©ç 735,074  151,442  930,930  879,254  ãã®ä»ã®ïŒåçïŒ/è²»çš é¢é£äŒç€Ÿæ³ã«ããåºè³å©çïŒæ倱ã®æå (10,407 ) 5,222  2,039  (28,614 ) å©åè²»çš 66,506  46,033  159,751  139,932  ããªããã£ãéèååã®æç (3,000 ) 8,680  (3,000 ) 2,290 Â æ ªåŒæ䟡蚌åžã®å©ç (50,849 ) (1,541 ) (81,455 ) (31,994 ) 売åŽå¯èœåµåžã®å©ç (57,680 ) (7,300 ) (103,900 ) (122,500 ) å©æ¯åå
¥ (17,508 ) (23,436 ) (38,306 ) (65,791 ) ãã®ä»ã®éå¶æ¥è²»åçãçŽ 1,654  1,707  (661 ) 3,429  ãã®ä»ã®ïŒåçïŒ/è²»çšåèšãçŽé¡ (71,284 ) 29,365  (65,532 ) (103,248 ) æ³äººçšåŒåã®é£çµçŽå©ç 806,358  122,077  996,462  982,502  æ³äººçšç課çšåœæçŽå©ç â  â  â  â  åœæçŽå©ç 806,358  122,077  996,462  982,502  éæ¯é
æ ªäž»ã«åž°å±ããåœæçŽå©ç
262,371  49,963  345,693  342,008  ãã€ã€ã«ãã£ãã¡ãŒãplcã«åž°å±ããåœæçŽå©ç $ 543,987  $ 72,114  $ 650,769  $ 640,494  1æ ªã®æ®éæ ªåŒåœããå©çïŒ åºæ¬ $ 1.22  $ 0.16  $ 1.45  $ 1.43  åžèååŸ $ 1.21  $ 0.16  $ 1.44  $ 1.43  æ®éæ ªåŒã®å éå¹³åçºè¡æ ªæ°ïŒ ãããåºæ¬ 447,628  448,439  449,085  448,162  ãããåžèååŸ 592,726  601,138  595,683  604,717 Â
ãããæªç£æ»ã®èŠçŽé£çµè²¡åè«žè¡šã«æ·»ä»ããã泚èšãåç
§ããŠãã ããã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
æ ªäž»è³æ¬ã®ã³ã³ãã³ã¹åãããé£çµè²¡åè«žè¡š
(åãã«åäœã1æ ªåœããéé¡ä»¥å€)
(æªç£æ»)
ã¯ã©ã¹A æ®éæ ªåŒ Bã¯ã©ã¹ æ®éæ ªåŒ ã¯ã©ã¹ R åéå¯èœæ ªåŒ å ±é
Œ
延ã°ãæ ª è³æ¬å°äœé ä¿çå©ç éæ¯é
æå åœåº«èšŒåžå©ç å
šã»ã¯ã¿ãŒã«ãããæ ªäž»è³æ¬åèšé¡ æ ªåŒ æ°é æ ªåŒ æ°é æ ªåŒ æ°é æ ªåŒ æ°é 2024幎6æ30æ¥ã®æ®é« 449,065 $ 45  145,328 $ â  50 $ 63  390,055 $ â  $ 4,100,554  $ 2,378,251  $ 3,275,566  $ (2,661 ) $ 9,751,818 Â è²¢ç® â â â â â â â â â â 2,245  â 2,245  åé
â â â â â â â â â â (113,182 ) â (113,182 ) é
åœ($0.21 1æ ªã®Açš®æ®éæ ªåŒããã)
â â â â â â â â â (94,061 ) â â (94,061 ) ãã®ä»ã®ååŒæ 447  â (447 ) â â â 447  â 38,407  â (38,411 ) 4  â Â æ ªåŒå ±é
¬ããã³é¢é£ããAçš®æ®éæ ªåŒã®çºè¡ 3  â â â â â â â 525  â â â 525  Açš®æ®éæ ªåŒã®èªå·±ååŸ (3,477 ) â â â â â â â (31,744 ) (63,492 ) â â (95,236 ) åœæçŽå©ç â â â â â â â â â 543,987  262,371  â 806,358  2024幎9æ30æ¥ã®æ®é« 446,038 $ 45  144,881 $ â  50 $ 63  390,502 $ â  $ 4,107,742  $ 2,764,685  $ 3,388,589  $ (2,657 ) $ 10,258,467 Â
ã¯ã©ã¹A æ®éæ ªåŒ Bã¯ã©ã¹ æ®éæ ªåŒ ã¯ã©ã¹Råéå¯èœæ ªåŒ å ±é
Œ
延ã°ãæ ª è³æ¬å°äœé ä¿çå©ç éæ¯é
æå åœåº«å©ç å
šã»ã¯ã¿ãŒã«ãããæ ªäž»è³æ¬åèšé¡ æ ªåŒ æ°é æ ªåŒ æ°é æ ªåŒ æ°é æ ªåŒ æ°é 2023幎6æ30æ¥ã®æ®é« 450,352 $ 46  152,896 $ â  50 $ 63  382,487 $ â  $ 4,031,242  $ 2,252,945  $ 3,532,019  $ (2,629 ) $ 9,813,686 Â è²¢ç® â â â â â â â â â â 2,850  â 2,850  åé
â â â â â â â â â â (120,198 ) â (120,198 ) é
åœ($0.20 1æ ªåœãã
â â â â â â â â â (89,751 ) â â (89,751 ) ãã®ä»ã®ååŒæ 350  â (350 ) â â â 350  â 18,454  â (18,459 ) 5  â  ã·ã§ã¢ããŒã¹ã®å ±é
¬ããã³é¢é£ããã¯ã©ã¹Aæ®éæ ªã®çºè¡ 3  â â â â â â â 581  â â â 581  ã¯ã©ã¹Aæ®éæ ªã®ååŸ (4,862 ) (1 ) â â â â â â (43,519 ) (100,628 ) â â (144,148 ) åœæçŽå©ç â â â â â â â â â 72,114  49,963  â 122,077  2023幎9æ30æ¥ã®æ®é« 445,843 $ 45  152,546 $ â  50 $ 63  382,837 $ â  $ 4,006,758  $ 2,134,680  $ 3,446,175  $ (2,624 ) $ 9,585,097 Â
ãããæªç£æ»ã®èŠçŽé£çµè²¡åè«žè¡šã«æ·»ä»ããã泚èšãåç
§ããŠãã ããã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
æ ªäž»è³æ¬ã®ã³ã³ãã³ã¹åãããé£çµè²¡åè«žè¡š
(åãã«åäœã1æ ªåœããéé¡ä»¥å€)
(æªç£æ»)
ã¯ã©ã¹A æ®éæ ªåŒ Bã¯ã©ã¹ æ®éæ ªåŒ ã¯ã©ã¹ R åéå¯èœæ ªåŒ å ±é
Œ
延ã°ãæ ª è³æ¬å°äœé ä¿çå©ç éæ¯é
æå åœåº«å©ç å
šã»ã¯ã¿ãŒã«ãããæ ªäž»è³æ¬åèšé¡ æ ªåŒ æ°é æ ªåŒ æ°é æ ªåŒ æ°é æ ªåŒ æ°é 2023幎12æ31æ¥ã®æ®é« 446,692  $ 45  150,743  $ â  50  $ 63  384,640  $ â  $ 4,011,435  $ 2,517,583  $ 3,557,792  $ (2,629 ) $ 10,084,289 Â è²¢ç® â â â â â â â â â â 6,797  â 6,797  åé
â â â â â â â â â â (367,320 ) â (367,320 ) é
åœ($0.63 1æ ªåœãã
â â â â â â â â â (282,809 ) â â (282,809 ) ãã®ä»ã®ååŒæ 5,862  1  (5,862 ) â â â 5,862  â 154,400  â (154,373 ) (28 ) â  ã·ã§ã¢ããŒã¹ã®å ±é
¬ããã³é¢é£ããã¯ã©ã¹Aæ®éæ ªã®çºè¡ 78  â â â â â â â 1,819  â â â 1,819  ã¯ã©ã¹Aæ®éæ ªã®ååŸ (6,594 ) (1 ) â â â â â â (59,912 ) (119,750 ) â â (179,663 ) åœæçŽå©ç â â â â â â â â â 650,769  345,693  â 996,462  RPCTã®æåæ³æè³ã®ååŸ â â â â â â â â â (1,108 ) â â (1,108 ) 2024幎9æ30æ¥ã®æ®é« 446,038 $ 45  144,881 $ â  50 $ 63  390,502 $ â  $ 4,107,742  $ 2,764,685  $ 3,388,589  $ (2,657 ) $ 10,258,467 Â
ã¯ã©ã¹ A æ®éæ ªåŒ ã¯ã©ã¹ B æ®éæ ªåŒ ã¯ã©ã¹ R åéå¯èœãªæ ªåŒ ç¹°å»¶æ ªåŒ è¿œå æ蟌è³æ¬ å©çå°äœé éæ¯é
æå 財åçã®å©ç æ ªäž»è³æ¬ã®åèš æ ªåŒ éé¡ æ ªåŒ éé¡ æ ªåŒ éé¡ æ ªåŒ éé¡ 2022幎12æ31æ¥çŸåšã®æ®é« 443,166  $ 44  164,058  $ â  50  $ 63  371,325  $ â  $ 3,666,160  $ 1,964,689  $ 3,897,223  $ (2,806 ) $ 9,525,373 Â è²¢ç® â â â â â â â â â â 9,690  â 9,690  ãã£ã¹ããªãã¥ãŒã·ã§ã³ â â â â â â â â â â (386,590 ) â (386,590 ) é
åœ ($)0.60 ã¯ã©ã¹AãããïŒæ®éæ ªåŒïŒ
â â â â â â â â â (268,989 ) â â (268,989 ) ãã®ä»ã®ååŒæ 11,512  2  (11,512 ) â â â 11,512  â 415,972  â (416,156 ) 182  â  ã¯ã©ã¹Aæ®éæ ªåŒã®æ ªåŒããŒã¹ã®å ±é
¬ããã³é¢é£ããçºè¡ 54  â â â â â â â 1,740  â â â 1,740  ã¯ã©ã¹Aã®æ®éæ ªåŒã®è²·æ»ã (8,889 ) (1 ) â â â â â â (77,114 ) (201,514 ) â â (278,629 ) çŽå©ç â â â â â â â â â 640,494  342,008  â 982,502  2023幎9æ30æ¥ã®æ®é« 445,843 $ 45  152,546 $ â  50 $ 63  382,837 $ â  $ 4,006,758  $ 2,134,680  $ 3,446,175  $ (2,624 ) $ 9,585,097 Â
ãããæªç£æ»ã®èŠçŽé£çµè²¡åè«žè¡šã«æ·»ä»ããã泚èšãåç
§ããŠãã ããã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
ãã£ãã·ã¥ãããŒã®æŠèŠ
å¶æ¥æŽ»åã«ãããã£ãã·ã¥ãããŒïŒ
(æªç£æ»)
2021幎9æ30æ¥çµäºã®9ãæéã®æ±ºç®ã«ã€ã㊠2024 2023 å¶æ¥æŽ»åã«ãããã£ãã·ã¥ãããŒ: éèãã€ã€ã«ãã£è³ç£ããã®çŸéåå
¥ $ 2,205,933  $ 2,454,054  ç¡åœ¢è³ç£ã®ãã€ã€ã«ãã£ã«ããçŸéåå
¥ 14,420  1,067  ãã®ä»ã®ãã€ã€ã«ãã£çŸéåå 79,334  84,275  ååé
åœéïŒå
±ååºè³æ³ã«ããæè³äŒç€ŸããïŒ 13,396  18,823  å©æ¯åå 37,447  63,135  éçºæ®µéã®è³éæ¯åº-ç¶ç¶äž (1,500 ) (1,500 ) éçºæ®µéã®è³éæ¯åº-åæãããã³ãã€ã«ã¹ãã³ â  (50,000 ) éå¶åã³å°éã³ã¹ãæ¯æã (163,804 ) (188,839 ) æ¯æå©æ¯ (158,765 ) (165,841 ) å¶æ¥æŽ»åã«ãããã£ãã·ã¥ãã㌠2,026,461  2,215,174  æè³æŽ»åã«ãããã£ãã·ã¥ãããŒïŒ ååé
åœéïŒå
±ååºè³æ³ã«ããæè³äŒç€ŸããïŒ 20,397  39,225  æ¯é
äžæè³ã®æåæ³é©çšè³ç£ (10,955 ) (10,550 ) æ ªåŒã®ååŸ (62,500 ) â Â æ ªåŒèšŒåžããã®åç 98,575  â  売åŽå¯èœæ䟡蚌åžã®è³Œå
¥ (150,000 ) â  売åŽå¯èœãªåµåžã«ããåç 7,200  â  売åŽããã³æºæã«å°éãã売買å¯èœèšŒåžããã®ååéé¡ â  24,391  財åãã€ã€ã«ãã£è³ç£ã®ååŸ (2,009,283 ) (1,113,283 ) ãã®ä»ã®éèè³ç£ã®ååŸ (18,000 ) â  ãã€ã«ã¹ããŒã³æ¯æã (50,000 ) (12,400 ) ä» 2,039  â  æè³æŽ»åã«ãããã£ãã·ã¥ãããŒã®çŽæµåº (2,172,527 ) (1,072,617 ) 財å掻åããã®ãã£ãã·ã¥ãããŒ: æ§èŠå¶éæ¯é
æ ªäž»ãžã®é
åœ-ããŒããã©ãªãªåé (281,078 ) (284,637 ) ç¶ç¶çãªéæ¯é
æ ªäž»ãžã®é
åœ (93,711 ) (95,045 ) æ ªäž»ãžã®é
åœ (282,809 ) (268,989 ) ã¯ã©ã¹Aæ®éæ ªã®ååŸ (177,044 ) (274,559 ) æ§èŠå¶éæ¯é
æ ªäž»ããã®å¯ä»-ç 究éçº 527  455  éæ¯é
æ ªäž»ããã®å¯ä»-ãã®ä» 3,329  5,915  é·æåå
¥éã®è¿æž â  (1,000,000 ) å²åŒåŸã®é·æåµåã®çºè¡ã«äŒŽãåç 1,471,235  â  åµåã®çºè¡è²»çšããã³ãã®ä» (12,316 ) â Â ä» (9,025 ) â  財åè«žè¡šã®å
容ã«åºã¥ãã(è³é調é掻åã«ãã)æ£å³çŸéæµå
¥/(æµåº) 619,108  (1,916,860 ) çŸéåã³çŸéåçç©ã®çŽå€å 473,042  (774,303 ) çŸéåã³çŸéåçç©æéŠæ®é« 477,010  1,710,751  ææ«çŸéåã³çŸéåçç© $ 950,052  $ 936,448 Â
ãããæªç£æ»ã®èŠçŽé£çµè²¡åè«žè¡šã«æ·»ä»ããã泚èšãåç
§ããŠãã ããã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªå®¡æ žïŒ
1. çµç¹ãšç®ç
ãã€ã€ã«ãã£ãã¡ãŒãæ ªåŒäŒç€Ÿã¯ãã€ã³ã°ã©ã³ãããã³ãŠã§ãŒã«ãºã®æ³åŸã«åºã¥ããŠèšç«ãããæ ªåŒäŒç€Ÿã§ããåœç€Ÿã®æ®éæ ªåŒã¯ã©ã¹Aã®åã®å
¬éæ ªåŒåéïŒIPOïŒãä¿é²ããããã«èšç«ãããŸããããRoyalty PharmaãããäŒç€Ÿãããç§ãã¡ãããæã
ãããåœç€Ÿããšããçšèªã¯ããã€ã€ã«ãã£ãã¡ãŒãæ ªåŒäŒç€Ÿããã³ãã®é¢é£äŒç€Ÿãçµ±åçã«æããŸãã
ç§ãã¡ã¯ãã€ã³ã°ã©ã³ãããã³ãŠã§ãŒã«ãºã®æ³åŸã«åºã¥ãèšç«ããããã©ã€ããŒãã»ãªããããã»ã«ã³ãããŒã§ãããã€ã®ãªã¹çšå±
äœè
ã§ãããã€ã€ã«ãã£ãã¡ãŒãããŒã«ãã£ã³ã°ã¹æ ªåŒäŒç€ŸïŒãRP HoldingsãïŒãã³ã³ãããŒã«ããŠããŸããããã¯ãRP Holdingsã®ã¯ã©ã¹Aæ®éæ ªåŒïŒãRP Holdingsã¯ã©ã¹Aæ ªåŒå©çãïŒããã³RP Holdingsã®ã¯ã©ã¹bæ®éæ ªåŒïŒãRP Holdingsã¯ã©ã¹bæ ªåŒå©çãïŒãææããããšã«ãããã®ã§ããç§ãã¡ã¯ãRP Holdingsããã³ãã®åäŒç€ŸãéããŠããžãã¹ãè¡ã£ãŠããŸãã
RP Holdingsã¯ãã¢ã€ã«ã©ã³ãã®å
±åè³ç£ç®¡çè»äž¡ã§ããRoyalty Pharma Investments 2019 ICAVïŒãRPI 2019 ICAVãïŒã®å¯äžã®ææè
ã§ããããªãŒã«ãRPIãšããã¢ã€ã«ã©ã³ãã®ãŠãããä¿¡èšïŒãå€ãRPIãïŒã®åŸç¶è
ã§ãã RP Holdingsã¯ãRoyalty Pharma plcã«ãã£ãŠææãããŠãããéæ¥çã«ã¯ããã©ãŠã§ã¢å·ã®éå®ããŒãããŒã·ããã§ããRPI US Partners 2019ãLPãããã³ã±ã€ãã³è«žå³¶ã®å
çšéå®ããŒãããŒã·ããã§ããRPI International Holdings 2019ãLPïŒä»¥äžãç¶ç¶çãªæè³å®¶ããŒãããŒã·ãããšããïŒã亀æåéïŒä»¥äžå®çŸ©åç
§ïŒã®åãå€ãRPIã¯ãããŸããŸãªããŒãããŒã·ããïŒãéºç£æè³å®¶ããŒãããŒã·ããããšç§°ãããïŒã«ãã£ãŠææãããŠããŸããã
RP ãããžã¡ã³ãLLCïŒä»¥äžããããŒãžã£ãŒããšããïŒã¯ãã¢ããã€ã¶ãªãŒããã³ãããžã¡ã³ãå¥çŽïŒä»¥äžç·ç§°ããŠã管çå¥çŽããšããïŒã«åºã¥ããæ¥ã
ã®æ¥åãå«ãåœç€Ÿã®ç®¡çãè¡ã£ãŠããŸãã
åœç€Ÿã¯ãã€ãªè£œè¬ã®ãã€ã€ãªãã£ãŒã®æ倧ã®è²·ãæã§ããããã€ãªè£œè¬æ¥çš®å
šäœã§ã®é©æ°ã®äž»èŠãªè³éæäŸè
ã§ããç§ãã¡ã¯ãæ°è£œåã®éçºãšèšåºè©Šéšã®åŸæå
±åè³éæäŸãè¡ãéã«ãå°æ¥ã®ãã€ã€ãªãã£ãŒãšåŒãæãã«äŒæ¥ãšææºããããšã§çŽæ¥çã«ãã€ãªè£œè¬æ¥çš®ã®é©æ°ãæ¯æŽãããŸããæ¢åã®ãã€ã€ãªãã£ãŒãå
ã®ã€ãããŒã¿ãŒããååŸããããšã§éæ¥çã«æ¯æŽããŠããŸãã
2. Â
èŠç©ã®äœæãšäœ¿çšã®åºæº
æ·»ä»ãããæªç£æ»ã®èŠçŽé£çµè²¡åè«žè¡šã¯ãç±³åœäžè¬äŒèšååïŒãGAAPãïŒã«åŸã£ãŠäœæãããŠããŸãã
çµå¶é£ã®æèŠã§ã¯ãååæããšã®çµæãé©åã«æ瀺ããããã«å¿
èŠãšãããå
šãŠã®èª¿æŽãå«ãŸããéåžžã®ç¹°ãè¿ã調æŽã§æ§æãããŠããŸããç¹å®ã®æ
å ±ãè泚ã®é瀺ã¯GAAPã«åºã¥ãç°¡ç¥åãŸãã¯çç¥ãããŠããŸãããããã£ãŠããã®ç¬¬10-Qãã©ãŒã ã®ååæå ±åæžã«å«ãŸããæ
å ±ã¯ãåŒç€Ÿã2023幎12æ31æ¥ãŸã§ã®ç£æ»æžã¿ã®é£çµè²¡åè«žè¡šããã³é¢é£ãã泚éãšäœµããŠèªãŸããã¹ãã§ããå¹Žæ¬¡å ±åæžã®ç¬¬10-Kãã©ãŒã ã«æ²èŒãããŠããŸãã
æªæ€æ»ã®ççž®é£çµè²¡åè«žè¡šã®æºæ ã¯ãGAAPã«æºæ ããŠç®¡çãè³ç£ããã³è² åµã®å ±åé¡ãåçš®è³ç£ããã³è² åµã®é瀺ããŸãã¯è²¡åè«žè¡šã®æ¥ä»æç¹ã«ãããåå
¥ãåçãçµè²»ã®å ±åé¡ã«åœ±é¿ãäžããèŠç©ãããä»®å®ãè¡ãããšãå¿
èŠãšããŸãã å®éã®çµæã¯ããããã®èŠç©ãããšç°ãªãå ŽåããããŸãã äžéæéã®çµæã¯ãéæã®çµæãå¿
ããã瀺ããã®ã§ã¯ãããŸããã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªå®¡æ žïŒ
å䜵ã®åºç€
æªçµæ»ã®èŠçŽé£çµè²¡åè«žè¡šã«ã¯ããã€ã€ã«ãã£ãã¡ãŒãããã³äž»èŠãªåäŒç€Ÿãšæ¯é
ããå
šã»ã¯ã¿ãŒã®åå®ãå«ãŸããŠãããå€æ°å©çé¢é£å£äœãå«ãŸããŸãããŸããäž»èŠãªå©çé¢é£å£äœã®æŽ»åãçŽæ¥æ瀺ããæš©éïŒæ祚暩ãŸãã¯é¡äŒŒã®æš©éïŒã«åºã¥ããŠè©äŸ¡ããããã«ããæãçµæžçãªåœ±é¿ãäžããä»ã®å£äœãã³ã³ãœãªããŒãããŸããæã
ãçµæžäžã®æææš©ã100ïŒ
æªæºã§ãããéæ¯é
æåã該åœããæ³äººã®çµæžçãŸãã¯æææš©çã«ä¿æãããŠããå²åãšçãããæäœèŠçŽé£çµè²¡åè«žè¡šã«èšé²ããŸãã éæ¯é
æ ªäž»ã«åž°å±ããåœæçŽå©ç
äž»èŠãªéæ¯é
æåè
ã«ãã£ãŠä¿æãããçµæžçãŸãã¯æææš©çã®å²åã«çãããåœè©²å£äœã«æ®ãããä¿ææš©çãããã¯çµæžçå©çã®å²åããåœç€Ÿã®èŠçŽé£çµæçèšç®æžã«èšé²ããŸãã
2020幎2æ11æ¥ã«ååŒæææ¡ãå®è¡ããIPOãä¿é²ããŸãããååŒæææ¡ãéããŠããã€ã€ã«ãã£ãã¡ãŒãã®æ ªåŒäŒç€Ÿã®æéäŒç€Ÿã®åæããŒãããŒã·ããã®ç·æ°ã®ãã¡ãäŒæ¥å®¶ã代衚ããæè³å®¶ã¯ 82 %ããã¬ã¬ã·ãŒæè³å®¶ããŒãããŒã·ããã®æéäŒç€Ÿã®æ ªåŒäŒç€Ÿã®æ ªåŒäŒç€Ÿããã³ã³ãã£ãã¥ã€ã³ã°æè³å®¶ããŒãããŒã·ããã®æéäŒç€Ÿã®æ ªåŒäŒç€Ÿã®æåãšäº€æããŸãããååŒæææ¡ã®åŸãç§ãã¡ã¯ãã©ãŠã§ã¢æ³äººä¿¡èšã§ããRPI 2019 Intermediate Finance TrustãéããŠãå€ãRPIã®çµæžå©çã®%ã®éæ¥ææè
ã«ãªããŸãããç§ãã¡ã¯ãå€ãRPIã®å®å
šåäŒç€Ÿã§ãããã©ãŠã§ã¢æ³äººä¿¡èšïŒãRPIFTãïŒã®çµæžã®%ãããã³ãã©ãŠã§ã¢æ³äººä¿¡èšïŒãRPCTãïŒã®ãã€ã€ã«ãã£ãã¡ãŒãã³ã¬ã¯ã·ã§ã³ãã©ã¹ãã®%ãåãåãæš©å©ããããŸãã2023幎12æ29æ¥ä»¥åãRPCTã®æ®ãã®%ã¯ãå€ãæè³å®¶ããŒãããŒã·ãããšãã©ãŠã§ã¢æ³äººä¿¡èšã§ãããã€ã€ã«ãã£ãã¡ãŒãã»ã¬ã¯ããã¡ã€ãã³ã¹ãã©ã¹ãïŒãRPSFTãïŒã«ãã£ãŠææãããŠãããRPSFTã¯ã¢ã€ã«ã©ã³ãåäœä¿¡èšã§ãããã€ã€ãªãã£ãã¡ãŒãã»ã¬ã¯ãã«å®å
šã«ææãããŠããŸããã 82 %ã®çµæžå©çãOld RPIã«éæ¥çã«ææããŠããŸãã 82 %ã¯ãOld RPIã®å®å
šåäŒç€Ÿã§ãããã©ãŠã§ã¢æ³äººä¿¡èšïŒãRPIFTãïŒã®çµæžå©çã®%ãšããã©ãŠã§ã¢æ³äººä¿¡èšïŒãRPCTãïŒã®ãã€ã€ã«ãã£ãã¡ãŒãã³ã¬ã¯ã·ã§ã³ãã©ã¹ãã®%ã«æš©å©ãæããŠããŸãã 66 %ããªã¬ã·ãŒæè³å®¶ããŒãããŒã·ãããšãã€ã€ãªãã£ãã¡ãŒãã»ã¬ã¯ããã¡ã€ãã³ã¹ãã©ã¹ãïŒãã©ãŠã§ã¢æ³äººä¿¡èšãRPSFTãïŒã«ãã£ãŠææãããRPCTã®æ®ãã®%ãææãããŠãããæ¢ã«æãæ»ãããåã«ã2023幎12æ29æ¥ãŸã§ã 34 %ã¯ããã€ã€ãªãã£ãã¡ãŒãã»ã¬ã¯ããã¡ã€ãã³ã¹ãã©ã¹ãïŒãã©ãŠã§ã¢æ³äººä¿¡èšãRPSFTãïŒãšãã€ã€ãªãã£ãã¡ãŒãIrelandãŠãããä¿¡èšã«å®å
šææãããŠãããã€ã€ãªãã£ãã¡ãŒãã»ã¬ã¯ããã¡ã€ãã³ã¹ãã©ã¹ããRPCTã®æ®ãã®%ãææããŠããŸããã
2022幎ã«ãç§ãã¡ã¯ãã€ã€ã«ãã£ãã¡ãŒãæè³ICAVïŒRPI ICAVïŒã®éæ¥çãªææè
ãšãªããŸããã以åã¯Old RPIãçŽæ¥ææããŠããŸããã 82 ïŒ
ã®çµæžå©çããã€ã€ã«ãã£ãã¡ãŒãæè³ICAVïŒRPI ICAVïŒã«æã€éæ¥çãªææè
ãšãªããŸããã以åã¯Old RPIãçŽæ¥ææããŠããŸããã
2023幎12æãRPI 2019 ICAVã¯RPSFtãææããRPCtãžã®æ®äœæåãååŸãããã®çµæãRPSFtã¯ãã¯ãRPCtã«éæ¯é
çæåãä¿æããŠããŸããã2023幎12æ以åãç§ãã¡ã¯IPO以åããååšããŠããOld RPIããã³RPI ICAVã®ã¬ã¬ã·ãŒéæ¯é
çæåãšãšãã«ãRPSFtãä¿æããRPCtã«ãããæäœéã®å©çã«é¢é£ããéæ¯é
çæåãå ±åããŠããŸããã
ç§ãã¡ã¯å ±åããŸã éå»1é±éã¯æ ªäž»ã«ãšã£ãŠå€§å€ãªæéã§ãã£ããããåºæ¬çãªãã¡ã³ãã¡ã³ã¿ã«åæãè¡ããäœãåŠã¶ããšãã§ãããã調ã¹ãŠã¿ãŸãããã éæ¯é
æ ªäž»æåïŒ(1)ã¬ã¬ã·ãŒã»ã€ã³ãã¹ã¿ãŒãºã»ããŒãããŒã·ããããç§ãã¡ã®IPOããåã«ååšããŠããOld RPIããã³RPI ICAVã«ããã%ã®æææš©ãæã£ãŠããããšãåã³ç§ãã¡ã®IPOãå®äºããåŸã(2)ã³ã³ãã£ãã¥ãŒã€ã³ã°ã»ã€ã³ãã¹ã¿ãŒãºã»ããŒãããŒã·ããããRP Holdingsã¯ã©ã¹bã€ã³ã¿ã¬ã¹ã(ãç¶ç¶çéæ¯é
æåããšããéæ¥çã«RP HoldingsãéããŠRP Holdingsãžã®éæ¥æææš©ãæã£ãŠããããš)ã«ããRP Holdingsãžã®éæ¥æææš©ã§ããRP HoldingsãéããRP Holdingsã®éæ¥æææš©ãåã³(3)RPI EPA Holdings, LPãïŒãEPA HoldingsããšããŠïŒãRP Holdingsã®Cã¯ã©ã¹æ®éæ ªåŒïŒãRP Holdingsã®Cã¯ã©ã¹ç¹å¥æåããšããŠïŒãä¿æããŠããããšãäžå®ã®æ¥çžŸæ¡ä»¶ãéæããããŸã§ãåçã¯EPA Holdingsã«å²ãåœãŠãããŸããã 18 åçã¯ãç¹å®ã®æ¥çžŸæ¡ä»¶ãæºãããããŸã§ãEPA Holdingsã«å²ãåœãŠãããŸããã
å
šã»ã¯ã¿ãŒå
ååŒããã³æ®é«ã¯ãçµ±åã«ãããŠåãé€ãããŠããŸãã
ååé¡
äžå®ã®åæéé¡ã¯ãçŸåšæã®è¡šç€ºã«åãããããååé¡ãããŸããã
ä¿¡çšãªã¹ã¯ã®éäž
åµåžã»åµå蚌åžãéèç¹èš±è³ç£ã掟çååããã³åµåžã«å©çšå¯èœãªçŸéåã³çŸéåçç©ãªã©ãç§ãã¡ã«èããä¿¡çšãªã¹ã¯ã垯ã³ãéèååã¯äž»ã«ãããã§ããçŸéã®ç®¡çã»æè³æ¹éã§ã¯ãè³æ¬ãä¿å
šããäºæ¥éå¶ã«å¿
èŠãªè³éãå¿
èŠã«ãªããŸã§æµåæ§ãç¶æããç®çã§ãæè³ååãæè³é©æ Œæ Œä»ãã®èšŒåžã«éå®ããŠããŸãã2024幎9æ30æ¥ããã³2023幎12æ31æ¥æç¹ã®çŸéåã³çŸéåçç©æ®é«ã¯ããã³ã¯ãªãã¢ã¡ãªã«ãã¹ããŒãã¹ããªãŒããTDéè¡ãã·ãã£ãã³ã¯ãU.S.éè¡ãDNbéè¡ãã¹ã³ã·ã¢ãã³ã¯ã«é èšãããŠããŸãããäž»èŠãªéçšå£åº§ã¯é£éŠé éä¿éºå
¬ç€Ÿã®é床é¡ã倧å¹
ã«äžåã£ãŠããŸãã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªå®¡æ žïŒ
åœç€Ÿã®éèçæè³ç£ããã³åµæš©ã®å€§éšåã¯ãå¥çŽäžã®çæå¥çŽããçºçããŠãããç±³åœããšãŒããããããã³äžçã®æ®ãã®å£²äžã«å¯Ÿããçæãåœç€Ÿã«æš©å©ä»ããŠããŸããã¯ã¬ãžãããªã¹ã¯ã®éäžã¯ãçææ¯æããæ
åœããå¹
åºãç¯å²ã®ããŒã±ã¿ãŒãšã補å売äžã«å¯Ÿããåœç€Ÿã®çæã掟çããå°ççå€æ§æ§ã«ãã£ãŠå¶éãããŠããŸããåœç€Ÿãçæãä¿æãã補åã¯ãäž»èŠãªæ¥çš®åå è
ã«ãã£ãŠããŒã±ãã£ã³ã°ãããŠããããã®äžã«ã¯ãããŒããã¯ã¹ãGSKããã·ã¥ããžã§ã³ãœã³ïŒãžã§ã³ãœã³ããã€ãªãžã§ã³ãã¢ããŽã£ãã¢ã¹ãã©ã¹ããã¡ã€ã¶ãŒãããã«ãã£ã¹ãããã³ã®ãªã¢ããªã©ãå«ãŸããŠããŸãã2024幎9æ30æ¥ããã³2023幎12æ31æ¥æç¹ã§ãããŒããã¯ã¹ã¯ãã·ã¹ãã£ãã¯ç·ç¶çãã©ã³ãã£ã€ãºã®ããŒã±ãã£ã³ã°æ
åœè
ãã€åœç€Ÿã®çæã®æ¯æãè
ãšããŠãåœç€Ÿã®éèçæè³ç£ã®çŸåšã®éšåã®ïŒ
ãå ãããããããæ倧ã®åå¥ã®ããŒã±ã¿ãŒããã³æ¯æãè
ã§ããã 33 % ããã³ 32 % ãå ããåœç€Ÿã®éèçæè³ç£ã®çŸåšã®éšåã¯ããããããæã
ã®çæã®æ倧ã®åå¥ã®ããŒã±ã¿ãŒãã€æ¯æãè
ãè¡šããŠããŸããã
ç§ãã¡ã¯ããã€ã€ã«ãã£å¥çŽã®çžææ¹ã®è²¡åããã©ãŒãã³ã¹ãšä¿¡çšåãç£èŠãã圌ãã®ä¿¡çšãããã¡ã€ã«ã®å€åã«é©åã«è©äŸ¡ã察å¿ã§ããããã«ããŠããŸãããããŸã§ã«ããã€ã€ã«ãã£è³ç£ã®åå
¥ãåçã®ååã«é¢ããŠé倧ãªä¿¡çšæ倱ã®çµéšã¯ãããŸããã
éèŠãªäŒèšæ¹é
éèŠãªäŒèšæ¹éã«é¢ããŠã2023幎12æ31æ¥ã«çµäºãã幎床ã®å¹Žæ¬¡å ±åæž10-K ããã¯ãå®è³ªçãªå€æŽã¯ãããŸããã
3. 売買å¯èœãªåµåžã»åµå蚌åž
ãµã€ãã«ã€ããã£ãã¯ã¹ãšã®è³é調éå¥çŽ
2024幎5æãç§ãã¡ã¯ãµã€ãã«ã€ããã£ãã¯ã¹æ ªåŒäŒç€ŸïŒä»¥äžããµã€ãã«ã€ããã£ãã¯ã¹ãïŒãšã®è³éææºãæ¡å€§ããæ倧ïŒãæäŸããããšã«ãªããŸããã575 çºå±çãªè³éææºã®äžç°ãšããŠãæã
ã¯ãµã€ãã«ã€ããã£ãã¯ã¹ã®ãªã¡ã«ã ãã£ãã»ã¡ã«ãã«ã®ç¬¬3çžèšåºè©Šéšã®ããã®ïŒãæäŸãã2022幎ã«ãµã€ãã«ã€ããã£ãã¯ã¹ãšç· çµããè³éåå®ãæ¹èšããŠãè¿œå ã®è³éåå²ãæäŸããŸããïŒæ¹èšåŸã®ããµã€ãã«ã€ããã£ãã¯ã¹åæ¥å±éè³éãïŒã100 2024幎5æã®æ¹å®åŸããµã€ãã«ã€ããã£ãã¯ã¹åæ¥å±éè³éã¯ãæ倧ïŒã®è³éã§æ§æãããåå²ã«åãããŠããŸãã two  4ã€ã®äžé£ã®è³éæäŸã§ãã å
šäžå€§éžïŒ 2024幎5æãæã
ã¯ãµã€ãã«ã€ããã£ãã¯ã¹æ ªåŒäŒç€Ÿãšã®è³éææºãæ¡å€§ããæ倧ïŒãæäŸããããšã«ãªããŸããã525 2024幎4æ15æ¥æç¹ã§ãç»é²è
ã¯3,119,226ãä¿æããŠããŸããã
ãµã€ããããã£ã¯ã¹éçºè³éã®ååçã¯ãomecamtiv mecarbilã®ç¬¬3çžèšåºè©Šéšã®çµæãšç±³åœé£åå»è¬åå±ïŒãFDAãïŒã®æ¿èªã«ãã£ãŠæ±ºãŸããŸããomecamtiv mecarbilã®ç¬¬3çžèšåºè©Šéšãæåããç¹å®ã®æéå
ã«FDAã®æ¿èªãåŸãããå Žåã$ã®è¿éãåãåããŸã100 çŸäžãã€ã³ã¯ãªã¡ã³ã¿ã«ã®ãã¡å€§ããæ¹ 2.0 omecamtiv mecarbilã®å¹ŽéçŽå£²äžé«ãŸãã¯ååæããšã®åºå®æ¯æãã«å¯Ÿãããã€ã€ãªãã£ã®å²å 18 ã¯ã©ãŒã¿ãŒãšã€ã³ã¯ãªã¡ã³ã¿ã« 2.0 以åŸ% ã®ãã€ã€ãªãã£ãç¹å®ã®æéå
ã«FDAã®æ¿èªãåŸãããªãå Žåã¯ã次ã®è¿åãåãåããŸã 2.4 åã®ãµã€ããããã£ã¯ã¹éçºè³éãéããŸãã 18 ååæã第3çžèšåºè©Šéšãäžå®æéå
ã«æåããªãã£ãå Žåã¯ã以äžã®è¿éãéããŸã 2.3 åã®ãµã€ããããã£ã¯ã¹éçºè³éãéããŸãã 22 ååæã
ãµã€ãã«ã€ããã£ãã¯ã¹åæ¥å±éè³éã®ãã¡ å
šäžå€§éžïŒ ã®ãã©ã³ã·ã§ 1人 ãã㊠ã«ããŽãªãŒ6ã®6ã€ã®èšé²ãç ŽããŠã©ãŒã¿ãŒã¹ã©ã€ããŒããæµ·ãã154ãã£ãŒãäžç©ºã«ããã¯ã©ãŠã³ãºãšããžäœéšãªã©ãæŒãå€ã楜ããã8ã€ã®ç®çå°ã«ã¯ããããã楜ãããã¢ãã¬ããªã³ããã¯ãã¯ãããããããããªåããŠã®ãã®ã次ã®ã¬ãã«ã®ãæ°ã«å
¥ãããããŸãããããŠã1é±éã®ãã¡ã®1æ¥çšã®7ã€ã®ããŒã«ããããæµ·äžåã®åãäžãåŒç¡éããŒã«ãªã©ããã€ããã®æ¹æ³ã¯æ¯é¡ãããŸããã 件ãè³éæäŸãããŸããããã©ã³ã·ã§ two ãã㊠éå»1é±éã¯æ ªäž»ã«ãšã£ãŠå€§å€ãªæéã§ãã£ããããåºæ¬çãªãã¡ã³ãã¡ã³ã¿ã«åæãè¡ããäœãåŠã¶ããšãã§ãããã調ã¹ãŠã¿ãŸãããã é¢é£ããèŠå¶ãã€ã«ã¹ããŒã³ãéæãããªãã£ãããããã以äžã¯å©çšã§ããŸããã "4人" , 5æ¥é ãã㊠å
šäžå€§éžïŒ ç¹å®ã®èŠå¶ããã³èšåºéçºã®ãã€ã«ã¹ããŒã³ã®çºçã«åºã¥ããŠåŒãåºãå¯èœãªãã©ã³ã·ã§ããããŸãïŒããµã€ãã«ã€ããã£ãã¯ã¹è³éã³ãããã¡ã³ããïŒã2024幎4æã«ã4çªç®ã®ãã©ã³ã·ã§ã®ã³ã³ãã£ã³ãžã§ã³ã·ãŒãæºãããããµã€ãã«ã€ããã£ãã¯ã¹ãå°ãªããšã$ãåŒãåºãå¿
èŠæ§ãçºçããŸããã50 çŸäžãã«ã§ãããã«$ãåŒãåºãèœåããããŸã25 ããžãã¹æ¥ã«å
ã«ãå
šã»ã¯ã¿ãŒã§1,000äžãã«ä»¥äžã®æ¯æããåæãããŸããã3ãæéã®æéã§ã2023幎6æ30æ¥ãŸã§ã«æ¯æããåãåããŸããã 1幎 ãã©ã³ã1ã4ã5ã6ã7ã«ã€ããŠãæ¯æãé¡ã®åã®åçãåŸãããšãæåŸ
ããŠããŸã 1.9 ããžãã¹æ¥æ°ãè¶
ããåæ°ã§åŒãåºããéé¡ã®å 34 åãã©ã³ãã®è³é調éæ¥ã®ç¿7ååæã®æçµããžãã¹æ¥ããå§ãŸãé£ç¶ããååææ¯æããåããèŠèŸŒã¿ã§ãã2023幎第4ååæã«ãæåã®ãã©ã³ãã«ã€ããŠååæããšã®è¿æžãåãå§ããŸãã
ç§ãã¡ã¯ããµã€ããããã£ã¯ã¹éçºè³éãšãµã€ããããã£ã¯ã¹ã®åæ¥çç«ã¡äžãè³éïŒç·ç§°ããŠããµã€ããããã£ã¯ã¹è³éåå®ãïŒãèæ
®ããŠå
¬æ£äŸ¡å€ãªãã·ã§ã³ãéžæããŸãããããã¯ãè³é調éã®åã決ãã®æ§è³ªãæãæ£ç¢ºã«åæ ããŠããããã§ããè³éæäŸãåãããµã€ããããã£ã¯ã¹ã»ãã¡ã³ãã£ã³ã°ã»ã¢ã¬ã³ãžã¡ã³ãã¯æ¬¡ã®å Žæã«èšé²ãããŠããŸã 売åŽå¯èœãªè² åµèšŒåž èŠçŽé£çµè²žå察ç
§è¡šã«ããªãã·ã§ã³ãšãã©ã¯ãŒããå«ããµã€ããããã£ã¯ã¹ã®è³é調éã³ãããã¡ã³ãã¯ã以äžã®åœã§å
¬æ£äŸ¡å€ã§èªããããŠããŸã ãã®ä»ã®è² åµ èŠçŽé£çµè²žå察ç
§è¡šã«ãè³éæäŸãåãããµã€ããããã£ã¯ã¹ã»ãã¡ã³ãã£ã³ã°ã»ã¢ã¬ã³ãžã¡ã³ããšãµã€ããããã£ã¯ã¹ã»ãã¡ã³ãã£ã³ã°ã»ã³ãããã¡ã³ãã®å
¬æ£äŸ¡å€ã®å€åã¯ã以äžã«èšé²ãããŠããŸã 売åŽå¯èœãªè² åµèšŒåžã®å©ç èŠçŽãããé£çµå¶æ¥å ±åæžã«ã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªå®¡æ žïŒ
ããã«ã2024幎5æã®æ¡å€§ãããè³éååã®äžç°ãšããŠãç§ãã¡ã¯Ck-586ã®èšåºè©Šéšã®ããã®è³éãæäŸãããã€ã€ãªãã£ãåãåãããµã€ãã«ã€ããã£ãã¯ã¹ã®æ®éæ ªåŒã賌å
¥ããŸããããããã®è©³çŽ°ã«ã€ããŠã¯ãããŒã4-å
¬æ£äŸ¡å€ã®æž¬å®ãšè²¡åæ¥åã«ããã«èª¬æããããŸããæåŸã«ããã®è³éååã«ã¯aficamtenã®ãã€ã€ãªãã£ã®åæ§ç¯ãå«ãŸããŠããŸããã
以äžã®è¡šã¯2024幎9æ30æ¥æç¹ã§ã®ãµã€ãã«ã€ããã£ãã¯ã¹ãšã®è³éååããã³é¢é£ããè³éç¶æ³ã®æŠèŠããŸãšãããã®ã§ãïŒåäœïŒåïŒ:
è³éæŽå©ãã å¿
èŠãªæªæ¥ã®åŒãåºã
æœåšçæªæ¥ã®åŒãåºã
ç·èš ãµã€ãã«ã€ããã£ãã¯ã¹ã®åæ¥å±éè³é (1)
$ 100,000  $ 50,000  $ 300,000  $ 450,000  ãµã€ãã«ã€ããã£ãã¯ã¹ã®éçºè³é
100,000  â  â  100,000  ãµã€ãã«ã€ããã£ãã¯ã¹ã®R&Dè³é掟çç© (2)
50,000  â  150,000  200,000  ãµã€ãã«ã€ããã£ãã¯ã¹æ®éæ ªåŒ
50,000 Â â Â â Â 50,000 Â ç·èš
$ 300,000 Â $ 50,000 Â $ 450,000 Â $ 800,000 Â
(1) åèšã«ã¯$ãå«ãŸããŠããŸãã75  çŸäžãã« two å©çšã§ããªããªã£ããã©ã³ã·ã§ã®åèšãé€ããŸãããåèšã«ã¯$ãåæ ãããŠããŸã225 2024幎5æã«æ¡å€§è³éææºã«ããè¿œå ãã©ã³ã·ã§ã®ããã®$çŸäžãå«ãŸããŠããŸã two
(2) Ck-586ã®èšåºè©Šéšã®è³éã«é¢é£ããŠããŸããè¿œå è³éãæ倧ã§ããã«$ãŸã§æäŸãããªãã·ã§ã³ããããŸãã150 è¿œå èšè°ã«ã¯ãèŠç©ããã®ããŒã4-å
¬æ£äŸ¡å€ã®æž¬å®ãšéèæ©åšããåç
§ãã ããã
ã¢ã«ãã©ã·ã¹éçºè³éåµåž
2022幎9æãç§ãã¡ã¯ã¢ã«ãã©ã·ã¹AGïŒä»¥äžããã¢ã«ãã©ã·ã¹ãïŒã«è³éãæäŸãã$300 çŸäžç±³ãã«ã®ãã¢ã«ãã©ã·ã¹éçºè³éä»ãåµåžããåãåãäºå®ã§ãã 2.2 ã¢ã«ãã©ã·ã¹éçºè³éä»ãåµåžã®çµæã2024幎第4ååæããååæããšã«æ¯æãããè¿æžãæåŸ
ããŠããŸãã 9幎 åãæåã®æ¯æãã¯2024幎第4ååæã«éå§ãããŸãã
ç§ãã¡ã¯ãã¢ã«ãã©ã·ã¹éçºè³éåµåžãäŒèšããããã«å
¬æ£äŸ¡å€ãªãã·ã§ã³ãéžæããŸãããããã¯ããã®ååŒã®æ§è³ªãæãæ£ç¢ºã«åæ ããŠããŸããã¢ã«ãã©ã·ã¹éçºè³éåµåžã¯å£åº§ã«èšé²ãããŠããŸãã åµåžã»åµå蚌åžãšããŠå£²åŽå¯èœãªåµåžã¯ãç°¡æé£çµè²žå察ç
§è¡šã«èšèŒãããŠããŸãã ã¢ã«ãã©ã·ã¹éçºè³éåµåžã®å
¬æ£äŸ¡å€ã®å€åã¯ãç°¡æé£çµæçèšç®æžã«èšé²ãããŠããŸãã 売åŽå¯èœåµåžã®å©ç ç°¡æé£çµæ¥çžŸèšç®æžã«ããããã¢ã«ãã©ã·ã¹éçºè³éåµåžã®å
¬æ£äŸ¡å€ã®å€åã¯èšé²ãããŸãã
以äžã®è¡šã¯ãå
¬æ£äŸ¡å€ã§èšé²ãããå©çšå¯èœãªå£²ãåºãåµåžãèŠçŽããŠããŸãïŒåååäœïŒïŒ
ã³ã¹ã æªå®çŸå©ç
å
¬æ£äŸ¡å€ æµåè³ç£ éæµåè³ç£ é·æè² åµ ç·èš 2024幎9æ30æ¥çŸåš åµåžã»åµåèšŒåž (1)
$ 512,554  $ 193,246  $ 705,800  $ 48,500  $ 657,300  $ â  $ 705,800  è³éã®ç¢ºçŽ (2)
(12,300 ) 7,700 Â (4,600 ) â Â â Â (4,600 ) (4,600 ) ç·èš
$ 500,254  $ 200,946  $ 701,200  $ 48,500  $ 657,300  $ (4,600 ) $ 701,200  2023幎12æ31æ¥çŸåš åµåžã»åµåèšŒåž (1)
$ 359,667  $ 95,733  $ 455,400  $ 18,300  $ 437,100  $ â  $ 455,400  è³éã®ç¢ºçŽ (2)
(7,300 ) 6,400 Â (900 ) â Â â Â (900 ) (900 ) ç·èš
$ 352,367 Â $ 102,133 Â $ 454,500 Â $ 18,300 Â $ 437,100 Â $ (900 ) $ 454,500 Â
(1) ãµã€ãã«ã€ããã£ãã¯ã¹ã®åæ¥ããŒã³ããã¡ã³ãã£ã³ã°ã®ãã©ã³ã1ãš6ã«é¢é£ããè²»çšãšããµã€ãã«ã€ããã£ãã¯ã¹ã®éçºãã¡ã³ãã£ã³ã°ã«é¢é£ããè²»çšã¯ãããããã®ãã¡ã³ãã£ã³ã°æ¥ã«ãããå
¬æ£ãªäŸ¡å€ãåæ ããŠããŸãããµã€ãã«ã€ããã£ãã¯ã¹ã®åæ¥ããŒã³ããã¡ã³ãã£ã³ã°ã®ãã©ã³ã1ã«é¢é£ããè²»çšã¯ãååæããšã®è¿æžãåãåãããããšã«ååŽãããŸããã¢ã«ãã©ã·ã¹éçºãã¡ã³ãã£ã³ã°ãã³ãã®è²»çšã¯ãè³éæäŸé¡ãè¡šããŠããŸãã
(2) ãµã€ãã«ã€ããã£ãã¯ã¹ã«é¢é£ããè³é調éã³ãããã¡ã³ãã¯ãå貞å察ç
§è¡šã®æ¥ä»æç¹ã§å©çšå¯èœãªãã©ã³ã·ã§ãå«ã¿ãŸãããµã€ãã«ã€ããã£ãã¯ã¹è³é調éã³ãããã¡ã³ãã«é¢é£ããè²»çšã¯ãããããã®ååŒæ¥ã®å
¬æ£ãªäŸ¡å€ãè¡šããŸãã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªæ€æ»ïŒ
4. å
¬æ£äŸ¡æ Œè©äŸ¡ããã³éèååŒ
â
以äžã®è¡šã¯ããã§ã¢ããªã¥ãŒéå±€å
ã®ã¬ãã«å¥ã«å®æçã«æž¬å®ãããè³ç£ããã³è² åµãèŠçŽãããã®ã§ãïŒååäœã§è¡šèšïŒ:
2024幎9æ30æ¥çŸåš 2023幎12æ31æ¥çŸåš 掟çè² åµ - å
ç©è²·ä»å¥çŽ ã¬ãã«2 ã¬ãã«3 ç·èš 掟çè² åµ - å
ç©è²·ä»å¥çŽ ã¬ãã«2 ã¬ãã«3 ç·èš è³ç£: ãã¹ãŠæä¿¡ (1)
$ 354,930  $ â  $ â  $ 354,930  $ 157,420  $ â  $ â  $ 157,420  åµåžã»åµå蚌åžã«è²©å£²å¯èœ (2)
â  â  48,500  48,500  â  â  18,300  18,300  æµåè³ç£åèš $ 354,930  $ â  $ 48,500  $ 403,430  $ 157,420  $ â  $ 18,300  $ 175,720 Â æ ªåŒèšŒåž (3)
175,968  â  52,899  228,867  199,190  â  297  199,487  åµåžã»åµå蚌åžã«è²©å£²å¯èœ (2)
â  â  657,300  657,300  â  â  437,100  437,100  ããªããã£ãååŒ (4)
â Â â Â 21,000 Â 21,000 Â â Â â Â â Â â Â å
¬æ£ãªäŸ¡å€ã§ã®ãã€ã€ã«ãã£ãŒ (3)
â  â  5,323  5,323  â  â  1,778  1,778  éæµåè³ç£åèš $ 175,968  $ â  $ 736,522  $ 912,490  $ 199,190  $ â  $ 439,175  $ 638,365 Â è² åµ: è³éã®ç¢ºçŽ (5)
â  â  (4,600 ) (4,600 ) â  â  (900 ) (900 ) éæµåè² åµã®åèš $ â  $ â  $ (4,600 ) $ (4,600 ) $ â  $ â  $ (900 ) $ (900 )
(1) é£çµè²žå察ç
§è¡šã«èšèŒ çŸéåã³çŸéåçç© çŸåšã®é£çµè²žå察ç
§è¡šã«èšèŒãããŠããŸãã
(2) ãµã€ãã«ã€ããã£ãã¯ã¹ã®åæ¥åããŒã³ãšã¢ã«ãã©ã·ã¹ã®éçºè³éä»äžåµåžã®ãã©ã³ã·ã§1ã«é¢é£ããŠããŸãã2024幎9æ30æ¥æç¹ã§ãéé¡ã«ã¯ããµã€ãã«ã€ããã£ãã¯ã¹ã®åæ¥åããŒã³ã®ãã©ã³ã·ã§6ãšãµã€ãã«ã€ããã£ãã¯ã¹ã®éçºè³éãå«ãŸããŠããŸãã
(3) ïœ
ïœïœ
ïœãïŒã«åæ ãããéé¡ã¯ãæ ªåŒããã³æ£å³å£²äžæš©ã«é¢é£ããŠãããéäžå ŽäŒæ¥ã§ããApiJect Holdings, Inc.ïŒä»¥äžããApiJectããšããïŒããååŸãããã®ã§ããæã
ã¯ãApiJectããååŸããéèååã«é¢é£ããå
¬æ£äŸ¡å€ããå°æ¥ã®ãã£ãã·ã¥ãããŒãå éå¹³åè³æ¬ã³ã¹ããå«ãã¬ãã«ïŒã®ã€ã³ãããã䜿çšããŠå²åŒãã£ãã·ã¥ãããŒæ³ãçšããŠæšå®ããŸããã売äžæš©ã¯ãããã«èšé²ãããŸããããããªãè°è«ã«é¢ããŠã¯ãã第ïŒé
ïŒéé£çµé¢é£äŒç€Ÿããã芧ãã ããã2024幎9æ30æ¥çŸåšãã¬ãã«ïŒã«åæ ãããéé¡ã«ã¯ã第ïŒé
ïŒå£²åŽå¯èœãªåµåžã»åµå蚌åžã«èšèŒãããæ¡å€§è³éææºã®äžç°ãšããŠè³Œå
¥ãããµã€ãã«ã€ããã£ãã¯ã¹ã®æ®éæ ªåŒãå«ãŸããŠããŸãã ãã®ä»ã®è³ç£ ãïœïœïœïœ
ïœïœïœ
ïœãïœïœïœïœïœïœïœïœïœïœ
ïœãïœïœïœïœïœïœ
ãïœïœ
ïœ
ïœïœã«èšèŒãããŠããŸããè¿œå ã®è°è«ã«ã€ããŠã¯ãã第ïŒé
ïŒéé£çµé¢é£äŒç€Ÿããã芧ãã ããã2024幎9æ30æ¥çŸåšãã¬ãã«ïŒã«åæ ãããéé¡ã«ã¯ã第ïŒé
ïŒå£²åŽå¯èœãªåµåžã»åµå蚌åžã«èšèŒãããæ¡å€§è³éææºã®äžç°ãšããŠè³Œå
¥ãããµã€ãã«ã€ããã£ãã¯ã¹ã®æ®éæ ªåŒãå«ãŸããŠããŸãã
(4) 以äžã§å®çŸ©ããããµã€ãã«ã€ããã£ãã¯ã¹ã®RïŒDãã¡ã³ãã£ã³ã°ããªããã£ãã«é¢é£ããŠèšé²ãããŠããŸã ãã®ä»ã®è³ç£ ç°¡çŽåç®è²žå察ç
§è¡šã«èšé²ãããŠããŸãã
(5) ãµã€ãã«ã€ããã£ãã¯ã¹æ¯æŽã³ãããã¡ã³ãã«é¢é£ããå
容ãèšé²ãããŠããŸã ãã®ä»ã®è² åµ ç°¡çŽé£çµè²žå察ç
§è¡šã«ãããŠ
2024幎第3ååæãšç¬¬1ååæã«ã€ããŠã2024幎9æ30æ¥çŸåšã«ä¿æããŠããæ ªåŒã«ã€ããŠããããå©çãèªèããŸããã50.8 çŸäžãã«ããã³çŸäžãã«ãããããèªèããŸããã $33.3 2023幎第3ååæãšç¬¬1ååæã«ã€ããŠã2024幎9æ30æ¥çŸåšã«ä¿æããŠããæ ªåŒã«ã€ããŠããããå©çãèªèããŸããã4.7 $çŸäžã®å£²äžé«ãèªèããŸãã14.4 çŸäžãã«ãããããèªèããŸããã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªæ€æ»ïŒ
以äžã«ç€ºãè¡šã¯ãã¬ãã«3ã®éèæ©é¢ïŒæµåããã³éæµåïŒã®ç·å
¬æ£äŸ¡å€ã®å€åãèŠçŽããŠããŸãïŒååäœã§ïŒïŒ
2024幎9æ30æ¥ãŸã§ã®3ãæéã«ããã æ ªåŒèšŒåž åµåžã»åµåèšŒåž è³éã®ã³ãããã¡ã³ã ããªããã£ãéèåå (2)
å
¬æ£äŸ¡å€ã§ã®ãã€ã€ã«ã㣠æéŠæ®é« $ 52,322  $ 668,400  $ (22,000 ) $ 18,000  $ 5,323 Â æ ªåŒæ䟡蚌åžã®å©ç
577  â â â â ããªããã£ãéèååã®å©ç â â â 3,000  â 売åŽå¯èœåµåžã®å©ç
â 40,280  17,400  â â åé (1)
â (2,880 ) â â â ææ«æ®é« $ 52,899  $ 705,800  $ (4,600 ) $ 21,000  $ 5,323 Â
(1) éé¡ã¯ããµã€ãã«ã€ããã£ãã¯ã¹åæ¥å±éè³éã®ç¬¬1匟ã®ååæè¿æžã«é¢é£ããŠããŸãã
(2) 以äžã«å®çŸ©ããããµã€ãã«ã€ããã£ãã¯ã¹ã®R&Dãã¡ã³ãã£ã³ã°ããªããã£ãã«é¢é£
2023幎9æ30æ¥ãŸã§ã®3ã¶æéã®å£²äžé«ã«ã€ããŠ æ ªåŒèšŒåž åµåžã»åµåèšŒåž åºè³ã³ãããã¡ã³ã ããªããã£ãååŒ
å
¬æ£ãªäŸ¡å€ã®ãã€ã€ã«ã㣠æéŠæ®é« $ 5,718  $ 348,800  $ (8,500 ) $ 8,680  $ 16,583 Â æ ªåŒèšŒåžã®æ倱 (1,546 ) â â â â ããªããã£ãéèååã«é¢ããæ倱 â â â (8,680 ) â 売åŽå¯èœåµåžã»åµå蚌åžã«é¢ããå©çïŒæ倱ïŒ
â 10,100  (2,800 ) â â ãã®ä»ã®å¶æ¥å€è²»çš â â â â (252 ) ææ«æ®é« $ 4,172  $ 358,900  $ (11,300 ) $ â  $ 16,331 Â
2024幎9æ30æ¥ãŸã§ã®9ã¶æéã«ã€ããŠ æ ªåŒèšŒåž åµåžã»åµåèšŒåž åºè³ã³ãããã¡ã³ã ããªããã£ãéèåå (3)
å
¬æ£ãªäŸ¡å€ã®ãã€ã€ã«ã㣠æéŠæ®é« $ 297  $ 455,400  $ (900 ) $ â  $ 1,778  賌å
¥ 46,500  150,000  â 18,000  â åæèªèæã®å©ç/(æ倱) (1)
â 5,000  (5,000 ) â âÂ æ ªåŒæ䟡蚌åžã®å©ç 6,102  â â â â ããªããã£ãéèååã®å©ç â â â 3,000  â 売åŽå¯èœåµåžã®å©ç
â 102,600  1,300  â â ãã®ä»ã®å¶æ¥å€åå
¥
â â â â 3,545  åé (2)
â (7,200 ) â â â ææ«æ®é« $ 52,899  $ 705,800  $ (4,600 ) $ 21,000  $ 5,323 Â
(1) ååèªèæã«é©åãªå
¬æ£äŸ¡å€ã«å°éããããã®è³Œè²·äŸ¡æ Œé
åãè¡šããŸãã
(2) éé¡ã¯ããµã€ãã«ã€ããã£ãã¯ã¹åæ¥å±éè³éã®ç¬¬1匟ã®ååæè¿æžã«é¢é£ããŠããŸãã
(3) 以äžã«å®çŸ©ããããµã€ãã«ã€ããã£ãã¯ã¹ã®R&Dãã¡ã³ãã£ã³ã°ããªããã£ãã«é¢é£
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªæ€æ»ïŒ
2023幎9æ30æ¥ãŸã§ã®9ãæé æ ªåŒèšŒåž åµåžã»åµåèšŒåž åºè³ã³ãããã¡ã³ã ããªããã£ãååŒ
(1)
å
¬æ£ãªäŸ¡å€ã®ãã€ã€ã«ã㣠æéŠæ®é« $ 8,472  $ 227,600  $ (2,500 ) $ 96,610  $ 14,500 Â æ ªåŒèšŒåžã®æ倱 (4,300 ) â â â â ããªããã£ãéèååã«é¢ããæ倱
â â â (2,290 ) â 売買å¯èœåµåžã«é¢ããå©ç/(æ倱)
â 131,300  (8,800 ) â â ãã®ä»ã®å¶æ¥å€åå
¥
â â â â 1,831  決æž
â â â (94,320 ) â ææ«æ®é« $ 4,172  $ 358,900  $ (11,300 ) $ â  $ 16,331 Â
(1) åœç€Ÿã®ãªãã·ã§ã³ã«é¢é£ããåã蟌ã¿åããªããã£ãååŒãè¡šããŸãã2023幎3æãFDAã¯Zavzpretãæ¿èªããŸãããåœç€Ÿã¯Zavzpretã®éŒ»å
補å€ã§ããzavegepantã«é¢ãããã€ã«ã¹ããŒã³æ¯æããäžæ¬ã§å éãããªãã·ã§ã³ãåé ããŸããã475 çºçããæ°çŸäžãã«ã®ãã€ã«ã¹ããŒã³æ¯æãã«ãããåã蟌ã¿åããªããã£ãååŒã®äžéšãéšåçã«æ±ºæžãããŸããã
ç¹°ãè¿ãã®å
¬æ£äŸ¡å€æž¬å®ã®ããã®è©äŸ¡å
¥å
2024幎9æ30æ¥ããã³2023幎12æ31æ¥æç¹ã®ãã¡ãŒããªã¥ãŒããšã©ã«ããŒã«ãããã¬ãã«3èšæž¬ãšããŠåé¡ãããéèæ©åšã®è©äŸ¡å
¥åã«é¢ããè°è«ã以äžã«ç€ºãããŠããŸãã2024幎9æ30æ¥ããã³2023幎12æ31æ¥æç¹ã§ã¯ãã¬ãã«2ã®å
¥åã䜿çšããŠå
¬æ£å€ã§èšé²ãããéèæ©åšã¯ãããŸããã§ããã
ãµã€ãã«ã€ããã£ãã¯ã¹æ®éæ ªåŒ
2024幎5æãç§ãã¡ã¯çŽââæ ªã®ãµã€ãã«ã€ããã£ãã¯ã¹ã®æ®éæ ªåŒã賌å
¥ããŸããã 980 ååŒã®äžç°ãšããŠãååŒå®äºåŸã®ââæéã¯ãµã€ãã«ã€ããã£ãã¯ã¹ã®æ®éæ ªåŒã売åŽããããšãå¶éãããŠããŸãã å幎é 2024幎9æ30æ¥æç¹ã®ãµã€ãã«ã€ããã£ãã¯ã¹ã®æ®éæ ªåŒã®å
¬æ£äŸ¡å€ã¯ãæçµæ ªäŸ¡ã«åºã¥ããŠèª¿æŽãããããããªãã·ã§ã³ã®å€ãèšç®ããŠç§»è»¢å¶éã«åãããããã«æ±ºå®ãããŸããããã®æ¹æ³è«ã«ã¯ããµã€ãã«ã€ããã£ãã¯ã¹ã®æ®éæ ªåŒã®æšå®å€åçãªã©ã®ã¬ãã«3ã®èŠå ãçµã¿èŸŒãŸããŠãããèããå€æåãå¿
èŠã§ããç§ãã¡ã®æšå®å€åçã¯å®éã®ãµã€ãã«ã€ããã£ãã¯ã¹ã®æ®éæ ªåŒã®å€åçãšã¯ç°ãªãå¯èœæ§ãããããã®çµæããµã€ãã«ã€ããã£ãã¯ã¹ã®æ®éæ ªåŒã®æšå®å
¬æ£äŸ¡å€ã¯ãç¹å®ã®æ¥ä»ã«ãããŠç®¡çéšéã«ãã決å®ãããå
¬æ£äŸ¡å€ããã倧å¹
ã«é«ããŸãã¯äœãå ŽåããããŸãã
ãµã€ãã«ã€ããã£ãã¯ã¹ç 究éçºïŒãR&DãïŒè³é掟çç©
2024幎5æãç§ãã¡ã¯è³éãæäŸããŸãã fund50 è¿œå ã§æ倧$ãè³éæäŸãããªãã·ã§ã³ããããããã«ããCk-586ã®ãã€ã«ã¹ããŒã³ãã€ã¡ã³ããæ倧$åãåãæš©å©ãåŸãããŸãã150 èŠå¶æ¿èªåŸãCk-586ã®å¢å ãã€ã€ã«ãã£ã«å ããŠæ倧$ã®ãã€ã«ã¹ããŒã³ãã€ã¡ã³ããåãåãè³æ ŒããããŸãã150 çµå¶æš©å€æŽãçºçããå ŽåãCytokineticsã«å¯ŸããŠæåã®è³éæäŸé¡ãšè¿œå è³éé¡ã®åèšã«å¯ŸããŠããã€ã€ã«ãã£ããã€ã«ã¹ããŒã³ãã€ã¡ã³ãã®æš©å©ãçµäºããããã«ã圌ãã«æ¯æããæ±ãããªãã·ã§ã³ããããŸãã 1.5 Ck-586ã«é¢ããåœç€Ÿã®è³éæäŸå¥çŽã¯æŽŸçã€ã³ã¹ãã¥ã«ã¡ã³ããšããŠåŠçãããå
¬æ£äŸ¡å€ã§èšé²ãããŠããŸãïŒãCytokinetics RïŒamp; Dãã¡ã³ãã£ã³ã°ããªããã£ããïŒã
2024幎9æ30æ¥æç¹ã§ããµã€ãã«ã€ããã£ãã¯ã¹ã®RïŒDãã¡ã³ãã£ã³ã°ããªããã£ãã®å
¬æ£äŸ¡å€ã確ç調æŽå²åŒãã£ãã·ã¥ãããŒèšç®ã䜿çšããŠæšå®ããŸããããã®èšç®ã«ã¯ãè¿œå è³éãªãã·ã§ã³ã®è¡äœ¿ç¢ºçãèŠå¶æ¿èªãããã³å¥çŽæéäžã®çµ±å¶æš©ã®çºçã®ç¢ºçãªã©ã®Level 3ã®ã€ã³ããããå«ãŸããŠããŸãããŸãããªã¹ã¯èª¿æŽå²åŒçãä»®å®ããŸããã 11.2 2024幎9æ30æ¥æç¹ã§ã®å©çšçãå©çšãã確ç調æŽå²åŒãã£ãã·ã¥ãããŒèšç®ã䜿çšããŠããµã€ãã«ã€ããã£ãã¯ã¹ã®RïŒDãã¡ã³ãã£ã³ã°ããªããã£ãã®å
¬æ£äŸ¡å€ãæšå®ããŸããããã®èšç®ã«ã¯ãè¿œå è³éãªãã·ã§ã³ã®è¡äœ¿ã®æåŸ
ãèŠå¶æ¿èªãããã³çµ±å¶æš©ã®äºè±¡ã®çºçã®æåŸ
å€ãããã³ãªã¹ã¯èª¿æŽããå²åŒçãšå©åã¬ãŒãã®å€åãèæ
®ããŸããã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªæ€æ»ïŒ
ãµã€ãã«ã€ããã£ãã¯ã¹ã®è³é調éããã³ãµã€ãã«ã€ããã£ãã¯ã¹ã®è³éæäŸ
2024幎9æ30æ¥ãš2023幎12æ31æ¥æç¹ã§ããµã€ãã«ã€ããã£ãã¯ã¹è³éæäŸååŒã®å
¬æ£äŸ¡å€ã確ç調æŽå²åŒçŸéæµèšç®ã䜿çšããŠæšå®ããŸãããããã«ã¯ããªã¹ã¯èª¿æŽå²åŒçãšçµ±å¶å€æŽã€ãã³ããçºçãã確çãªã©ãã¬ãã«3ã®èŠçŽ ãå«ãŸããŠããŸãããµã€ãã«ã€ããã£ãã¯ã¹è³éæäŸååŒã®æéäžã«ãªã¹ã¯èª¿æŽå²åŒçãéçºããçµ±å¶å€æŽã€ãã³ããçºçãã確çãè©äŸ¡ããã«ã¯ãéèŠãªå€æãå¿
èŠã§ãããªã¹ã¯èª¿æŽå²åŒçã®æšå®å€ã¯åžå Žåå è
ãéžæããå²åŒçãšç°ãªãå¯èœæ§ããããããã«ããæšå®ãããå
¬æ£äŸ¡å€ã¯å€§å¹
ã«é«ããªããäœããªããããããŸãããçµ±å¶å€æŽã€ãã³ããçºçãã確çãšãã®ã¿ã€ãã³ã°ã«å¯Ÿããç§ãã¡ã®äºæ³ã¯ãå®éã®çµ±å¶å€æŽã€ãã³ãã®ã¿ã€ãã³ã°ãšç°ãªãå¯èœæ§ãããããã®å Žåãæšå®ãããå
¬æ£äŸ¡å€ã¯ãç¹å®ã®æ¥ä»ã«ããã管çåŽã«ãã£ãŠæ±ºå®ãããå
¬æ£äŸ¡å€ããã倧å¹
ã«é«ããªããäœããªãå¯èœæ§ããããŸãã
2024幎9æ30æ¥ããã³2023幎12æ31æ¥çŸåšã®ãµã€ããããã£ã¯ã¹ã»ãã¡ã³ãã£ã³ã°ã»ã³ãããã¡ã³ãã®å
¬æ£äŸ¡å€ãã幟äœåŠçãã©ãŠã³éåã«åºã¥ãäŸ¡æ Œèšå®ã¢ãã«ã䜿çšããŠéå©å€åã®ã·ãã¥ã¬ãŒã·ã§ã³ãå«ãã¢ã³ãã«ã«ãã·ãã¥ã¬ãŒã·ã§ã³ææ³ã䜿çšããŠæšå®ããŸããããã®æ¹æ³è«ã¯ãå°æ¥ã®å²åŒçãååŒçžæã®æ³å®è² åµã³ã¹ããè¶
ããå¯èœæ§ãã·ãã¥ã¬ãŒãããŸããããã¯ãCytokineticsãããããã®ãã©ã³ã·ã§ãåŒãåºããªãã·ã§ã³ãè¡äœ¿ãããšãã決å®ã«åœ±é¿ãäžããŸãã2024幎9æ30æ¥ããã³2023幎12æ31æ¥çŸåšããã®æ¹æ³è«ã«ã¯ãæè³æéäžã«æ¯é
æš©å€æŽäºè±¡ãçºçãã確çãæ³å®ãããéå©å€åæ§ãªã©ãã¬ãã«3ã®ã€ã³ããããçµã¿èŸŒãŸããŠããŸãã 40.0 % ãš 37.5 ãããã%ãããã³æ³å®ããããªã¹ã¯èª¿æŽåŸã®å²åŒç 11.2 % ãš 10.9 ãããã%ããŸããèŠå¶ãèšåºã®åãã€ã«ã¹ããŒã³ã®çºç確çãæ³å®ããŠããŸãããããã¯ãå°æ¥ã®åè³éã®å©çšå¯èœæ§ã«åœ±é¿ããŸããæ¯é
æš©å€æŽäºè±¡ãçºçãã確çãšã¿ã€ãã³ã°ããªã¹ã¯èª¿æŽåŸã®å²åŒçãéå©ã®ãã©ãã£ãªãã£ãããã³åºç€ãšãªãåãã€ã«ã¹ããŒã³ã®ç¢ºçã«ã€ããŠã®ç§ãã¡ã®äºæ³ã¯ãåžå Žåå è
ãéžæããä»®å®ãšã¯ããªãç°ãªãå¯èœæ§ããããŸããã€ãŸããæšå®å
¬æ£äŸ¡å€ã倧å¹
ã«é«ããªã£ããäœããªã£ããããå¯èœæ§ããããŸãã
ã¢ã«ãã©ã·ã¹éçºè³éåµ
ç§ãã¡ã¯ã2024幎9æ30æ¥ããã³2023幎12æ31æ¥æç¹ã§ã¢ã«ãã©ã·ã¹éçºè³éåµã®å
¬æ£äŸ¡å€ããæšå®ããããªã¹ã¯èª¿æŽå²åŒçãçšããå²åŒãã£ãã·ã¥ãããŒèšç®ã«åºã¥ããŠè©äŸ¡ããŸããããããã®æšå®ãªã¹ã¯èª¿æŽå²åŒçã¯Lv.3ã®ã€ã³ãããã§ããç§ãã¡ã®ãªã¹ã¯èª¿æŽå²åŒçã®æšå®å€ã¯ãåžå Žåå è
ãéžæããå²åŒçãšç°ãªãå¯èœæ§ããããããã«ããæšå®ãããå
¬æ£äŸ¡å€ãããªãé«ããªããäœããªãå¯èœæ§ããããŸãã
å
¬æ£äŸ¡å€ã§æž¬å®ãããŠããªã財åè³ç£
財åãã€ã€ãªãã£è³ç£ã¯ãå¹ççãªå©åæ³ãçšããŠååŽå䟡æ³ã«åºã¥ããç°¡çŽãããé£çµè²žå察ç
§è¡šã«èšèŒããã³é転ãããŸãã財åãã€ã€ãªãã£è³ç£ã«ã¯ãå
šæè³ããŒããã©ãªãªå
šäœãå«ãŸããŠããããç¹ã«ä»¥äžãé€å€ããŠããŸã:
1. éçºæ®µéã®è£œååè£ã«ã€ããŠãè³éã¯(i)ç²åŸæã«åæãã®R&Dè²»çšãšããŠååŽãããïŒäŸïŒTrodelvyãNurtec ODTïŒã(ii)ç¶ç¶çãªR&Dè²»çšãšããŠååŽãããïŒäŸïŒæŽå²çã«ããµããã£ãšã®å
±ååºè³å¥çŽã«ããSoliquaïŒãŸãã¯(iii)掟çéèååãšããŠåãæ±ãããïŒäŸïŒCk-586ïŒïŒãããŠ
2. å©çšå¯èœãªå£²è²·åµåžïŒäŸïŒã¢ã«ãã©ã·ã¹éçºè³éåµããã³ãµã€ãã«ã€ããã£ãã¯ã¹è³é調éååŒïŒã«ç»é²ãããå¥çŽè³éæäŸååŒã
éèãã€ã€ãªãã£è³ç£ã®å
¬æ£äŸ¡å€ã¯ãéèŠãã€èŠ³æž¬äžå¯èœãªå
¥åã«åºã¥ããŠæ±ºå®ãããŠãããããå
¬æ£äŸ¡å€éå±€å
ã§ã¬ãã«3ã«åé¡ãããŠããŸããçµå¶é£ã¯ã売ããµã€ãã®æ ªåŒãªãµãŒãã¢ããªã¹ãã®ã³ã³ã»ã³ãµã¹ã»ãŒã«ã¹äºæž¬ã䜿çšããŠæšå®ãããå
šãã€ã€ã«ãã£è£œåã®è²©å£²ã«åºã¥ããŠãã€ã€ãªãã£è³ç£ã®å
¬æ£äŸ¡å€ãèšç®ããŠããŸãããããã®äºæž¬ãããå°æ¥ã®ãã€ã€ãªãã£åå
¥ãšãæè³å®¶ã®å©çã«ãªãããæ¯åºãšãªããããããªããã€ã«ã¹ããŒã³æ¯æãã¯ãé©åãªåå¥ã®å²åŒçã䜿çšããŠçŸåšäŸ¡å€ã«å²ãåŒãããŸãã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªæ€æ»ïŒ
çŸåšã®è²¡åãã€ã€ãªãã£è³ç£ã®è©äŸ¡é¡ã®ãã¡ãçŽ 9.8 % ããã³ 10.1 % ã¯ããããã2024幎9æ30æ¥ããã³2023幎12æ31æ¥æç¹ã§éºç£éæ¯é
æ ªäž»ã«åž°å±ããŠããŸãããéæµåéšéã®è²¡åãã€ã€ãªãã£è³ç£ã®å
¬æ£äŸ¡å€ã«ã¯ããããã2024幎9æ30æ¥ããã³2023幎12æ31æ¥æç¹ã§ãçŽ 8.1 % ããã³ 9.4 % ãéºç£éæ¯é
æ ªäž»ã«åž°å±ããŠããŸããã
çŸåšã®è²¡åçæš©è³ç£ã®èŠç©ããããå
¬æ£äŸ¡å€ãšé¢é£ãã垳簿䟡é¡ïŒåäžååäœã§ïŒã¯ã以äžã«ç€ºãããŠããŸãã
2024幎9æ30æ¥çŸåš 2023幎12æ31æ¥çŸåš 財åç宀è³ç£
å
¬æ£äŸ¡å€ æã¡åºã䟡å€ãçŽé¡
å
¬æ£äŸ¡å€ æã¡åºã䟡å€ãçŽé¡
çŸåšã®ä»»æ
$ 765,773  $ 765,773  $ 738,438  $ 738,438  éæµåè² åµ
20,909,498 Â 14,968,074 Â 19,077,706 Â 14,088,655 Â ç·èš
$ 21,675,271 Â $ 15,733,847 Â $ 19,816,144 Â $ 14,827,093 Â
5. 財åç宀è³ç£
財åç宀è³ç£ã¯ãç¹èš±ã§ä¿è·ããããã€ãªè£œåã®äºæ³ããã売äžã«é¢é£ãããã€ã€ã«ãã£ãŒãã掟çããçŸéãããŒã«å¯Ÿããå¥çŽäžã®æš©å©ããæ§æãããåœç€Ÿããã³é¢é£äŒç€Ÿã«ç¬¬äžè
ã«ãããããã®è£œåã®å£²äžããã®äžéšãåãåãæš©å©ãèªããŠããŸãã
çŸåšããã³éæµåã®éèç¹èš±æš©è³ç£ã®ç·ç°¿äŸ¡ãäºæ³ããããã£ãã·ã¥ãããŒã®å€æŽã«å¯Ÿãã环ç©è²žååŒåœéãå«ãææ°æçšã®åŒåœéãé€ããçŽé¡ç°¿äŸ¡ã¯æ¬¡ã®ãšããã§ãïŒåäœ: åïŒ:
2024幎9æ30æ¥çŸåš äºæž¬ããããã€ã€ãªãã£ã®æé (1)
ç·åž³ç°¿äŸ¡é¡ äºæ³ããããã£ãã·ã¥ãããŒã®å€åã«å¯Ÿãã环ç©ç©ã¿å¢ãé¡ïŒæ³š6ïŒ çŽåž³ç°¿äŸ¡é¡ (4)
ã·ã¹ãã£ãã¯ãã£ãããŒã·ã¹ã®ãã©ã³ãã£ã€ãº 2039-2041 (2)
$ 5,182,429  $ (190,534 ) $ 4,991,895  ãšããªã¹ã㣠2035-2036
2,083,375  (208,212 ) 1,875,163  ãã¬ã¬ãžãŒ 2029-2030 1,109,464  (21,937 ) 1,087,527  ã¿ã€ãµã㪠(3)
1,361,608  (349,093 ) 1,012,515  ãã©ã㎠2038
921,142 Â â Â 921,142 Â Tremfya 2031-2032
936,289 Â (100,798 ) 835,491 Â ä»
2025-2042
7,764,785  (2,553,010 ) 5,211,775  ç·èš $ 19,359,092  $ (3,423,584 ) $ 15,935,508  ãã®ä»: ä¿¡çšæ倱ã®çŽ¯ç©ç©ç«é¡ïŒæ³š6ïŒ (201,661 ) çŽåšåº«ã®éèãã€ã€ã«ãã£è³ç£ã®ç·èšïŒæµååã³éæµåïŒ $ 15,733,847 Â
(1) 衚瀺ãããæéã¯ãçŸåšã®å ±åæ¥æç¹ã§ã®èŠç©ãããè¡šããç¹èš±ãå®è³ªçã«çµäºããèŠèŸŒã¿ã®å°çã«ãã£ãŠç°ãªãå Žåããããèšåºè©ŠéšçµæãèŠå¶æ¿èªãå¥çŽæ¡ä»¶ãåæ¥çãªé²å±ãèŠå¶ç¬å æéã®èŠç©ãããç¹èš±ã®æºäºæ¥ïŒæšå®ç¹èš±æéã®å»¶é·ãå«ãå ŽåããããŸãïŒãã®ä»ã®èŠå ã«äŸåããå ŽåããããŸããç¹èš±ã¯æåŸ
éãã«æºäºãããšã¯éããŸããã
(2) ãã€ã€ã«ãã£ãŒã¯æ°žç¶çã§ããç¯å²ã«ã¯ããŽã¡ã³ã¶ã«ãã¿ãŒ/ãã¶ã«ãã¿ãŒ/ããŠãã£ãã«ãã¿ãŒïŒããŽã¡ã³ã¶ã«ãã¿ãŒããªãã«ãïŒãæ¿èªãããå Žåãæ³å®ããŠãããç¹èš±ã®æå¹æéåããšãæœåšçãªãžã§ããªãã¯åå
¥ã®ææã«åºã¥ããäºæ³ããã売ãäžãã®æžå°ã瀺ããŠããŸãã
(3) RPIFtã¯Tysabriã®çŽå£²äžã«ã€ããŠæ°žç¶ãã€ã€ãªãã£ãååŸããŸããããã€ã€ã«ãã£æéäžã®åçã®å ç®ãç®çãšããŠ2031幎ã®çµäºæ¥ãé©çšããå®æçã«èŠçŽãããŠããŸãã
(4) è³ç£ããšã®çŽæåå€ã¯ä¿¡çšæ倱åŒåœéã®åã«ç€ºãããŠããŸãã詳现ã«ã€ããŠã¯ãããŒã6-环èšåŒåœéãšéèãã€ã€ã«ãã£è³ç£ã®äºæ³ãã£ãã·ã¥ãããŒå€åã®åèãåç
§ããŠãã ããã
2024幎9æ30æ¥çŸåšã$ã®æ®é«15.7 ç·æµåããã³éæµåéèçäœè³ç£ã§äžåã£ã$1.2 ã³ã¹ãã«ä¿æãããæªæ¿èªã®ãã¬ããµãªããé¢é£ã®éèçäœè³ç£ã§$521.5 äž»ã«ãªã«ãã·ã©ã³ããã©ã«ãŒã»ã³ããªã©ã³ã¶ãã³ LAI ïŒTEV-'749ïŒãå«ããã®ä»ã®è³ç£ãã$
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªæ€æ»ïŒ
2023幎12æ31æ¥çŸåš èŠç©ãããããã€ã€ãªãã£ã®æé (1)
ç·åž³ç°¿äŸ¡é¡ äºæ³ãã£ãã·ã¥ã»ãããŒå€åã®çŽ¯ç©æåœïŒæ³š6ïŒ çŽåž³ç°¿äŸ¡é¡ (4)
ã·ã¹ãã£ãã¯ãã£ãããŒã·ã¹ã®ãã©ã³ãã£ã€ãº 2037 (2)
$ 5,288,833  $ (2,539 ) $ 5,286,294  ãšããªã¹ã㣠2035-2036
1,793,088  â  1,793,088  ãã¬ã¬ãžãŒ 2029-2030 1,208,807  â  1,208,807  ã¿ã€ãµã㪠(3)
1,511,957 Â (434,568 ) 1,077,389 Â Tremfya 2031-2032
927,488  (120,733 ) 806,755  Xtandi 2027-2028 911,045  (268,701 ) 642,344 Â ä» 2024-2041 6,251,020  (2,100,897 ) 4,150,123  ç·èš $ 17,892,238  $ (2,927,438 ) $ 14,964,800  åµåç£èŠèšç¥ã®çŽ¯ç©æžå°é¡ïŒæ³šèšäºé
6ïŒ (137,707 ) åèšã®æµåè³ç£ããã³éæµåè³ç£ã®ãã€ã€ãªãã£è³ç£ïŒçŽé¡ïŒ $ 14,827,093 Â
(1) 2023幎12æ31æ¥çŸåšã®èŠç©ããã«åºã¥ããŠç€ºãããŠããæéã¯ãç¹èš±ãå®è³ªçã«çµäºãããšäºæ³ãããææãè¡šããŠãããå°çã«ãã£ãŠç°ãªãå Žåããããèšåºè©Šéšã®çµæãèŠå¶æ¿èªãå¥çŽæ¡ä»¶ãåæ¥çãªååãèŠå¶ç¬å æš©ã®èŠç©ãããç¹èš±ã®æš©å©ã®æºäºæ¥ïŒæšå®ç¹èš±æé延é·ãå«ãå ŽåããããŸãïŒãŸãã¯ãã®ä»ã®èŠå ã«äŸåããããšããããŸããäºæ³ãããããã«ç¹èš±ãæºäºããããšã«ã€ããŠãä¿èšŒãããã®ã§ã¯ãããŸããã
(2) çæš©ã¯æ°žç¶çã§ããã幎ã¯ããªã«ãã¿ã®ç¹èš±ã®æå¹æéæºäºããã³æœåšçãªãžã§ããªãã¯åå
¥ã®ææã«åºã¥ã販売æžå°ã瀺ããŠããŸãã
(3) RPIFtã¯Tysabriã®çŽå£²äžã«å¯Ÿããæ°žä¹
ãã€ã€ã«ãã£ãååŸããŸããããã€ã€ã«ãã£æéäžã®åçã环ç©ããç®çã§2031幎ãçµäºæ¥ãšããŠé©çšããå®æçã«èŠçŽããŠããŸãã
(4) è³ç£ããšã®çŽæåå€ã¯ä¿¡çšæ倱åŒåœéã®åã«ç€ºãããŠããŸãã詳现ã«ã€ããŠã¯ãããŒã6-环èšåŒåœéãšéèãã€ã€ã«ãã£è³ç£ã®äºæ³ãã£ãã·ã¥ãããŒå€åã®åèãåç
§ããŠãã ããã
6. 財åãã€ã€ã«ãã£è³ç£ããã®äºæ³ãã£ãã·ã¥ãããŒã®å€æŽã«é¢ãã环ç©æåœãšæºåé
財åãã€ã€ãªãã£è³ç£ã®äºæ³ãã£ãã·ã¥ãããŒå€åãžã®çŽ¯èšæåœã¯ã財åãã€ã€ãªãã£è³ç£ã®éæµåéšåå
ã«çŽé¡ã§æ瀺ãããŠããŸãã ç°¡çŽé£çµè²žå察ç
§è¡šã«ã¯ã以äžãå«ãŸããŠããŸã:
⢠売ããµã€ãã®æ ªåŒèª¿æ»ã¢ããªã¹ãã®ã³ã³ã»ã³ãµã¹è²©å£²äºæž¬ã«åºã¥ãåãåãèŠèŸŒã¿ã®å°çšæ¯æãã®å€æŽã«é¢é£ãã环ç©ç©ç«é¡ã«ãããåãã¯ãäž»ã«è»žå補åã®äºæž¬è²©å£²ããçããã
⢠ãã€ã€ã«ãã£è³ç£ã®å¯¿åœã®çµããã«çŽ¯ç©åŒåœéãååŽããããšã¯ãç°¡æé£çµè²žå察ç
§è¡šã«ã®ã¿åœ±é¿ãäžããŸãã
⢠æ°èŠã®è²¡åçæš©è³ç£ã®éãããä¿è·æš©ã«äž»ã«é¢é£ããçŸè¡ã®äºæ³ä¿¡çšæ倱ã®èç©èš±å®¹å·®åãšãéãããä¿è·æš©ãæã€è²¡åçæš©è³ç£ã®åºç€ãšãªããã£ãã·ã¥ã»ãããŒäºæž¬ã®å€åã«é¢é£ããŠããŸãã
次ã®è¡šã¯ã財åçãªãã€ã€ã«ãã£è³ç£ã®äºæ³ãã£ãã·ã¥ãããŒã®å€åã«äŒŽã环ç©èš±å®¹é¡ãã¯ã¬ãžããæ倱ã®çŽ¯ç©èš±å®¹é¡ã瀺ããŠããŸãïŒåãã«åäœïŒ:
æéã®æŽ»å 2023幎12æ31æ¥ã®æ®é« (1)
$ (3,065,145 ) äºæ³çŸéæµå
¥å€åã®ããã®è²¡åçãã€ã€ã«ãã£è³ç£ã®çŽ¯ç©æåœã®å¢å (1,083,352 ) äºæ³ãããçŸéæµå
¥ã®å€åã«å¯Ÿãã財åãã€ã€ã«ãã£è³ç£ã®çŽ¯ç©æåœã®æžå° 578,881  环ç©æåœã®ååŽ 8,325  信çšæ倱ã«å¯Ÿããåœæã®åµååŒåœéãçŽé¡ (2)
(63,954 ) 2024幎9æ30æ¥ã®æ®é« $ (3,625,245 )
(1) 6æ30æ¥ããã³2023幎12æ31æ¥æç¹ã§è³é調éãªãŒã¹ã®å¯Ÿè±¡ãšãªãåºå®è³ç£ã«é¢é£ããè²»çšåã³çŽ¯ç©ååŽè²»çšã®ãã¡ã$ãå«ã¿ãŸãã$137.7 貞åãåµæš©ç©ç®ç¹äŸã«é¢é£ãã100äžãã«
(2) ä¿¡çšæ倱ã®åãè²»çšã¯ãäž»ã«YorvipathãVoranigoãecopipamã®ããŒããã©ãªãªãžã®è¿œå ã«é¢é£ããŠããŸãã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªæ€æ»ïŒ
7. éé£çµé¢é£äŒç€Ÿ
ç¹å®ã®å®äœã«å¯Ÿããæ ªåŒæè³ãè¡ã£ãŠãããéèŠãªåœ±é¿åãæã£ãŠããŸãããã®ãããªæè³ã¯ãæåæ³ã«åºã¥ãæè³ãŸãã¯å
¬æ£äŸ¡å€ãªãã·ã§ã³ãéžæããŠããæ ªåŒèšŒåžãšããŠåãæ±ã£ãŠããŸãã
ApiJect
2022幎4æãApiJectããæ®éæ ªåŒãšå£²äžé«ã«å¯Ÿããæš©å©ãååŸããŸãããåœç€Ÿã¯ããã®ãããªæè³ã«é¢ããçŸåšã®äŸ¡å€ãããåæ ããããã«ãApiJectãžã®æè³ãäŒèšããããã«å
¬æ£äŸ¡å€ãªãã·ã§ã³ãéžæããŸããããŸããç¹å®ã®ãã€ã«ã¹ããŒã³ãéæãããå ŽåãApiJectããè¿œå ã®æ®éæ ªåŒã賌å
¥ãã矩åããããŸããåœç€Ÿã®ApiJectã«ãããæ ªåŒæè³ã®å
¬æ£äŸ¡å€ã¯ããå¶æ¥è²»çšãå
ã«èšäžãããŠããŸãã æ ªåŒèšŒåž ããã³å
¬æ£äŸ¡å€ã®å€åã¯ããè³ç£ãå
ã«èšé²ãããŠããŸãã æ ªåŒæ䟡蚌åžã®å©ç 売äžé«ã«å¯Ÿããæš©å©ã®å
¬æ£äŸ¡å€ã¯ãããã®ä»ãå
ã«èšé²ãããŠããããã®å
¬æ£äŸ¡å€ã®å€åã¯ã ãã®ä»ã®è³ç£ å
ã«èšé²ãããŠããŸãã ãã®ä»ã®éå¶æ¥è²»åçãçŽ 2024幎9æ30æ¥ããã³2023幎12æ31æ¥æç¹ã§ã売äžé«ãžã®é¢é£ã«ããApiJectããã®æ¯æéé¡ã¯ãããŸããã§ããã
ã¬ã¬ã·ãŒSLPã€ã³ã¿ã¬ã¹ã
ãšã¯ã¹ãã§ã³ãžã»ãªãã¡ãŒã«é¢é£ããŠãç¶ç¶æè³å®¶ããŒãããŒã·ããããã¬ã¬ã·ãŒã»ã€ã³ãã¹ã¿ãŒãºã»ããŒãããŒã·ããã®ç¹å¥ãªããããã»ããŒãããŒã·ããæåïŒãã¬ã¬ã·ãŒã»SLPæåãïŒã$ã§ååŸããŸãã303.7 åäŒç€Ÿã®æ ªåŒçºè¡ãšåŒãæãã«100äžåã§ãããã®çµæãç§ãã¡ã¯ã¬ã¬ã·ãŒã»ã€ã³ãã¹ã¿ãŒãºã»ããŒãããŒã·ããã®ç¹å¥ãªããããã»ããŒãããŒã«ãªããŸãããã¬ã¬ã·ãŒSLPå©æ¯ã«ãããã¬ã¬ã·ãŒã»ã€ã³ãã¹ã¿ãŒãºã»ããŒãããŒã·ããã®ãŒãã©ã«ããŒãããŒã«æ¯æãããã¯ãã®æ¥çžŸåé
éãšåçã®å ±é
¬ãšãåæ§ã®åºæºã§ã®åçé
åãåããããšãã§ããŸããåœç€Ÿã®åçé
åã¯ãã¬ã¬ã·ãŒã»ã€ã³ãã¹ã¿ãŒãºã»ããŒãããŒã·ããã®åçã«å¯ŸãããŒãã©ã«ããŒãããŒã®ä»¥åã®å¥çŽäžã®æš©å©ãããåºæ¬å·®é¡ã®ååŽãå·®ãåŒãããã®ãšçãããªããŸããåœç€Ÿã®ãããŒãžã£ãŒã¯ã¬ã¬ã·ãŒã»ã€ã³ãã¹ã¿ãŒãºã»ããŒãããŒã·ããã®ãããŒãžã£ãŒã§ãããã倧ããªåœ±é¿åãè¡äœ¿ã§ãããããã¬ã¬ã·ãŒSLPã®æåã¯æåæ³ã§äŒèšåŠçãããŸããã¬ã¬ã·ãŒã»ã€ã³ãã¹ã¿ãŒãºã»ããŒãããŒã·ããã¯ã2020幎6æ30æ¥ããæè³æ©äŒã«åå ããªããªããããã¬ã¬ã·ãŒã»SLPæåã®äŸ¡å€ã¯æéã®çµéãšãšãã«äœäžãããšäºæ³ãããŸãããŸããã¬ã¬ã·ãŒã»ã€ã³ãã¹ã¿ãŒãºã»ããŒãããŒã·ããã¯ããªãŒã«ãRPIãšRPI ICAVã®éæ¯é
æåãéæ¥çã«ææããŠããŸãã
ã¬ã¬ã·ãŒã»ã€ã³ãã¹ã¿ãŒãºã»ããŒãããŒã·ããã¯ãå ±åãé
ããæ°éããŒãããŒã·ããã§ãããããã¬ã¬ã·ãŒã»SLPã€ã³ã¿ã¬ã¹ãããã®åçé
åã¯æšå®ã«åºã¥ããŠããŸããåœæã®ã¬ã¬ã·ãŒSLPå©æ¯ããã®æ ªäž»è³æ¬å©çã«é¢ããçµå¶é£ã®èŠç©ããã¯ã次ã®æéã®éå»ã®çµæã«åãããŠæŽæ°ãããŸããã¬ã¬ã·ãŒSLPå©æ¯ããã®å©çã®æåã¯ãã«èšé²ãããŸã æåæ³æè³å
ã®æ ªåŒïŒåçïŒ/æ倱ã $ã®åå
¥é
åãèšé²ããŸãã10.2 çŸäžãš $5.5 2024幎ã®ç¬¬3ååæãšæåã®9ãæã§ãããã100äžã§ãã$ã®æ倱é
åãèšé²ããŸãã2.3 çŸäžã§ãåå
¥é
åã¯0.6 2023幎ã®ç¬¬3ååæãšæåã®9ãæã§ãããã100äžã§ãã$ã®ã¬ã¬ã·ãŒSLPå©æ¯ããçŸéé åæžãéããŸãã11.0 çŸäžãš $19.9 2024幎ã®ç¬¬3ååæãšæåã®9ãæã§ãããã100äžã§ãã$ã®ã¬ã¬ã·ãŒSLPå©æ¯ããçŸéé åæžãéããŸãã4.8 çŸäžãš $9.7 2023幎ã®ç¬¬3ååæãšæåã®9ãæã§ãããã100äžã§ãã
ã¢ãŽã£ãªãªã³ã»ãšã³ãã£ãã£ãŒãº
Avillion Financing IãLPããã³é¢é£äŒç€ŸïŒä»¥äžãAvillion IããšããïŒãšBAv Financing IIãLPããã³é¢é£äŒç€ŸïŒä»¥äžãAvillion IIããšçµ±ããŠãAvillion EntitiesããšããïŒã«ãããããŒãããŒã·ããåºè³ãæåæ³ã§èšèŒããŠããŸããããã¯ãRPIFtãAvillion Entitiesã«å¯ŸããŠèãã圱é¿åãè¡äœ¿ã§ããããã§ããAvillion Entitiesããã®çŽå©çã¯ã æåæ³é©çšäŒç€Ÿã®çŽå©ç/(æ倱)ã«ã€ããŠã®æå 2024幎第3ååæããã³2024幎床ã®æåã®9ãæéã«ã$0.2 çŸäž ãåçé
åãšããŠèšé²ããŸããã7.6 2024幎第3ååæããã³2023幎床ã®æåã®9ãæéã«ããããã$3.0 ãæ倱å²åœãŠã$28.0 ãåçé
åãšããŠèšé²ããŸããã
2017幎12æ19æ¥ãFDAã¯ãã¡ã€ã¶ãŒã®Bosulifã®è£è¶³æ°è¬æ¿èªãæ¿èªããŸãããAvillion Iã¯ããã¡ã€ã¶ãŒãšã®å
±åéçºå¥çŽã®äžããã®æ¿èªã«åºã¥ããŠãã¡ã€ã¶ãŒããåºå®æ¯æããåããè³æ ŒããããŸããAvillion Iã®å¯äžã®æ¥åã¯ããã¡ã€ã¶ãŒããã®åºå®å¹Žæ¬¡æ¯æãã®çŸéã®ååããã³å²åŒã®è§£é€ã§ãããã¡ã€ã¢ã·ãªãŒãºããã®åºå®å¹Žæ¬¡æ¯æããAvillion Iãã2024幎ãš2023幎ã®æåã®9ãæéã«åèš1000äžãã«ã®é
åœãåãåããŸããã13.4 $çŸäžã®å£²äžé«ãèªèããŸãã13.6 2024幎ããã³2023幎ã®æåã®9ãæéã«ã1000äžãã«ãå«ãAvillion Iããã®åé
ãåãåããŸããã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªæ€æ»ïŒ
2018幎5æãRPIFtã¯åŸã«ä¿®æ£ãããAvillion IIãšã®å¥çŽãç· çµããè€æ°å¹Žã«ããã£ãŠåèš$ãåºè³ããããšã«ãªããŸããã155 çºè²ä¿é²ååç©ãšããŠä»¥åã¯PT027ãšããŠç¥ãããŠããAirsupraã®ç¬¬2ããã³ç¬¬3çžèšåºè©Šéšã®äžéšã®è²»çšã«å¯Ÿããè³éæäŸãé²ããããã«FDAã2023幎1æã«æ¿èªããããšãåããAvillion IIã¯ã¢ã¹ãã©ãŒãã«ãšå
±åéçºåå®ãç· çµããåæ¯ã®æ²»çã®ããã«Airsupraãéçºããããããã€ã€ã«ãã£ãæåã«åºã¥ãäžé£ã®ãã€ã«ã¹ããŒã³ããã®ä»ã®æœåšçãªæ¯æãã«äº€æããããšã«ãªããŸããã2023幎第1ååæã«ãã¢ã¹ãã©ãŒãã«ã¯ã¢ããªãªã³IIã«å¯ŸããŠãã¢ã¡ãªã«ã§Airsupraãåæ¥åãããªãã·ã§ã³ãè¡äœ¿ããããã«$ã®ææ°æãæ¯æãããšãéžæããããšãã¢ããªãªã³IIã«éç¥ããç§ãã¡ã¯ã¢ããªãªã³IIããè¡äœ¿æã®$ã®çžåœåãåãåããŸããã2024幎第3ååæã«ãç§ãã¡ã¯Airsupraã®ãã€ã€ãªãã£ã«é¢é£ããæåã®é
åœãšããŠ$ã®é
åœãã¢ããªãªã³IIããåãåããŸããã80 2018幎5æãRPIFtã¯åŸã«ä¿®æ£ãããAvillion IIãšã®å¥çŽãç· çµããè€æ°å¹Žã«ããã£ãŠåèš$ãåºè³ããããšã«ãªããŸããã34.8 2018幎5æãRPIFtã¯åŸã«ä¿®æ£ãããAvillion IIãšã®å¥çŽãç· çµããè€æ°å¹Žã«ããã£ãŠåèš$ãåºè³ããããšã«ãªããŸããã0.5 2024幎第3ååæã«ãç§ãã¡ã¯Airsupraã®ãã€ã€ãªãã£ã«é¢é£ããæåã®é
åœãšããŠ$ã®é
åœãã¢ããªãªã³IIããåãåããŸããã
ç¹å®ã®å ±åæ¥ã«ãããæ倱ãžã®æ倧é²åºã¯ãæåæ³é©çšæè³ã®ç°¿äŸ¡ãšæªæ±ºå®è³éã³ãããã¡ã³ãã«å¶éãããŠããŸãã2024幎9æ30æ¥ããã³2023幎12æ31æ¥çŸåšãç§ãã¡ã¯ã¢ããªãªã³ã»ãšã³ãã£ãã£ã«é¢é£ããæªæ±ºå®è³éã³ãããã¡ã³ããæã£ãŠããŸãã $10.3 $çŸäžã®å£²äžé«ãèªèããŸãã16.3 çŸäžãã«
8. ç 究éçºè³éæ¯åº
éçºè²»ã¯ã補ååè£ã®ãã€ã€ã«ãã£ããã€ã«ã¹ããŒã³ãååŸããããã«åœäºè
ã«æ¯æã£ãæ¯åºãå«ã¿ãŸãã éçºè²»ã«ã¯ãäºåã«åæããŸãã¯æ¿èªåã®ãã€ã«ã¹ããŒã³ã«åºã¥ããŠåœäºè
ã«æ¯æãããéçºæ®µéã®è³éæ¯æããããã³é¢é£ãã補ååè£ãåœäºè
ãšãšãã«èšåºè©Šéšãçµãã«ã€ããŠåœäºè
ã«æ¯æãããéçºæ®µéã®è³éæ¯æããå«ãŸããŸãã 2024幎ãš2023幎ã®æåã®9ãæéãç§ãã¡ã¯æ°ããç¶ç¶çãªç 究éçºè³éæäŸå¥çŽã«åå ããŸããã§ããã
2024幎第3ååæããã³2024幎ã®æåã®9ãæéã«ãæç¶çãªéçºæ®µéã®è³éæ¯åºã«é¢é£ããç 究éçºæ¯åºãšããŠ1,000äžãã«ãèªèããŸããã0.5 $çŸäžã®å£²äžé«ãèªèããŸãã1.5 2023幎第3ååæããã³2023幎ã®æåã®9ãæéã«ãäž»ã«ã¢ãã£ã«ã ãã³ã®ããã«ãµã€ãã«ã€ããã£ãã¯ã¹ã«å¯Ÿãã1,000äžãã«ã®èšåºæ®µéã®ãã€ã«ã¹ããŒã³æ¯æãã«é¢é£ããç 究éçºæ¯åºãšããŠ1,000äžãã«ãèªèããŸããã50.5 çŸäž $ã«å¯Ÿãããå²åŒåŸã®å°æ¥æäœé床ã®è³è²žææ¯æãåèšé¡ã¯ä»¥äžã®éãã§ãã51.5 2024幎第3ååæããã³2024幎ã®æåã®9ãæéã«ãæç¶çãªéçºæ®µéã®è³éæ¯åºã«é¢é£ããç 究éçºæ¯åºãšããŠ1,000äžãã«ãèªèããŸããã50.0 2023幎第3ååæããã³2023幎ã®æåã®9ãæéã«ãäž»ã«ã¢ãã£ã«ã ãã³ã®ããã«ãµã€ãã«ã€ããã£ãã¯ã¹ã«å¯Ÿãã1,000äžãã«ã®èšåºæ®µéã®ãã€ã«ã¹ããŒã³æ¯æãã«é¢é£ããç 究éçºæ¯åºãšããŠ1,000äžãã«ãèªèããŸããã
9. åå
¥é
åœç€Ÿã®åå
¥éã¯ä»¥äžã®éãã§ããïŒååäœã§ïŒïŒ
åå
¥ã®çš®é¡ çºè¡æ¥ æºæ 2024幎9æ30æ¥çŸåš 2023幎12æ31æ¥çŸåš åªå
ç¡æ
ä¿åµ: $1,000,000 , 1.20 %ïŒçºè¡é¡ã®æ°èŠè²·%ïŒ 98.875 %ïŒé¡é¢ã®æ°èŠè²·%ïŒ
9/2020 9/2025 1,000,000  1,000,000  $1,000,000 , 1.75 %ïŒçºè¡æ¥ïŒ 98.284 %ïŒçºè¡æã®1ïŒ
9/2020 9/2027 1,000,000  1,000,000  $500,000 , 5.15 %ïŒçºè¡æ¥ïŒ 98.758 %ïŒçºè¡æã®2ïŒ
6/2024 9/2029 500,000  â  $1,000,000 , 2.20 %ïŒçºè¡æ¥ïŒ 97.760 %ïŒçºè¡æã®3ïŒ
9/2020 9/2030 1,000,000  1,000,000  $600,000 , 2.15 %ïŒçºè¡æ¥ïŒ 98.263 %ïŒçºè¡æã®4ïŒ
7/2021 9/2031 600,000  600,000  $500,000 , 5.40 % (çºè¡é¡ã®%
97.872 ããŒã®%
6/2024 9/2034 500,000  â  $1,000,000 , 3.30 % (çºè¡é¡ã®%
95.556 ããŒã®%
9/2020 9/2040 1,000,000  1,000,000  $1,000,000 , 3.55 % (çºè¡é¡ã®%
95.306 ããŒã®%
9/2020 9/2050 1,000,000  1,000,000  $700,000 , 3.35 % (çºè¡é¡ã®%
97.565 ããŒã®%
7/2021 9/2051 700,000  700,000  $500,000 , 5.90 %ïŒçºè¡æ¥ 97.617 % ã®é¢é¡ïŒ
6/2024 9/2054 500,000  â  çºè¡å²åŒåµåæ®é«ããã³çºè¡è²»çš (192,621 ) (164,715 ) ç·åµå垯åäŸ¡å€ 7,607,379  6,135,285  æ°èŠè²·: é·æåå
¥éã®çæåéåã®æžé¡ (996,942 ) â åèšé·æåµå
$ 6,610,437 Â $ 6,135,285 Â
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªæ€æ»ïŒ
åªå
ç¡æ
ä¿ããŒã
2024幎6æã«ãç§ãã¡ã¯$ãçºè¡ããŸããã1.5 åã®ç¡æ
ä¿åªå
ããŒãïŒä»¥äžãã2024ããŒããïŒã2024ããŒãã¯ç·å²åŒé¡$ã§çºè¡ãããŸããã28.8 åãã«ãè³æ¬åããäž»ã«ã¢ã³ããŒã©ã€ãã£ã³ã°ææ°æã§æ§æãããçºè¡è²»çšçŽ$ãç©ç«ããŸããã12.6 2024ããŒãã¯å éå¹³åã¯ãŒãã³ã¬ãŒãåã³å éå¹³åå®è³ªå©åããæã£ãŠçºè¡ãããŸããã 5.48 % ããã³ 5.92 äºå®éãããããã®å¹Žå©ã¯ããããã3.84ïŒ
ã3.36ïŒ
ã§ãã
$ãçºè¡ããŸãã1.3 10åãã«ãš6.0 2021幎ïŒã2021幎åµåžãïŒãš2020幎ïŒã2020幎åµåžãïŒã«ãããã10å件ã®ã·ãã¢ç¡æ
ä¿åµåžã2021幎çŽå¹£ãš2020幎çŽå¹£ã¯åèš$å²åŒã§çºè¡ãããŸãã176.4 çŸäžãç§ãã¡ã®è³æ¬éã¯çŽ$ã§ã52.7 äž»ã«åŒåææ°æã§æ§æãããŠãã100äžãã«ã®åµåçºè¡è²»çšã2021幎ã®åµåžã¯ãå éå¹³åã¯ãŒãã³ã¬ãŒããšå éå¹³åå®å¹éå©ã§çºè¡ãããŸãã 2.80 % ãš 3.06 ãããã%ã2020幎ã®åµåžã¯ãå éå¹³åã¯ãŒãã³ã¬ãŒããšå éå¹³åå®å¹éå©ã§çºè¡ãããŸãã 2.13 % ãš 2.50 ãããã%ã2023幎9æã«ãç§ãã¡ã¯ãã«ãè¿æžããŸãã1.0 æºæã«ãªããš2020幎ã®åµåžã10åæã«ãªããŸãã
2024幎ã®åã·ãªãŒãºã2021幎ã®ããŒãããã³2020幎ã®ããŒãïŒä»¥äžããããŒãããšããïŒã®å©æ¯ã¯ã幎çããšã«éèšãããæ¯å¹Ž3æ2æ¥ããã³9æ2æ¥ã«æ¯æãããé
ããŠæ¯æãããŸãã 2024幎ã®ããŒãã®æåã®å©æ¯æ¯ææ¥ã¯2025幎3æ2æ¥ã«ãªããŸãã
ããŒãã¯ãåéäŸ¡æ ŒãšããŠã(i) ããŒãã®åéããªã³ã·ãã«é¡ã®ãã¡å€§ããæ¹ãš(i) ããŒãã®åéããªã³ã·ãã«ããã³å©æ¯ã®æ®ãã®ã¹ã±ãžã¥ãŒã«ãããæ¯æé¡ã®çŸåšäŸ¡å€ã®åèšïŒåéæ¥ã®åææ¯ã®è²¡åçã¬ãŒãã§å²åŒãããã®ãåµåå¥çŽæžã§å®çŸ©ãããŠããã¡ã€ã¯ã»ããŒã«ã»ãã¬ãã¢ã ãè¿œå ïŒãçãããªãããåŒç€Ÿã®å€æã§åéå¯èœã§ããã©ã¡ãã®å Žåããåéæ¥ãŸã§ã®å©åãå«ãåéãããŠããªãå©æ¯ãåéããå¿
èŠããããŸãã 100 ããŒãã¯ãåéäŸ¡æ ŒãšããŠã(i) ããŒãã®åéããªã³ã·ãã«é¡ã®ãã¡å€§ããæ¹ãš(i) ããŒãã®åéããªã³ã·ãã«ããã³å©æ¯ã®æ®ãã®ã¹ã±ãžã¥ãŒã«ãããæ¯æé¡ã®çŸåšäŸ¡å€ã®åèšïŒåéæ¥ã®åææ¯ã®è²¡åçã¬ãŒãã§å²åŒãããã®ãåµåå¥çŽæžã§å®çŸ©ãããŠããã¡ã€ã¯ã»ããŒã«ã»ãã¬ãã¢ã ãè¿œå ïŒãçãããªãããåŒç€Ÿã®å€æã§åéå¯èœã§ããã©ã¡ãã®å Žåããåéæ¥ãŸã§ã®å©åãå«ãåéãããŠããªãå©æ¯ãåéããå¿
èŠããããŸãã
æ¯é
æš©ããªã¬ãŒã€ãã³ãã®çºçãšç§ãã¡ã®ããŒãã®æ Œä»ãã3ã€ã®ã¯ã¬ãžããæ©é¢ã®ãã¡2ã€ã«ãã£ãŠããŠã³ã°ã¬ãŒããããå Žåãæ¿èªè
ã¯ç§ãã¡ã«å¯ŸããŠãã¹ãŠãŸãã¯äžéšã®ããŒãã®è²·ãæ»ããèŠæ±ããããšãã§ããŸããè²·ãæ»ãäŸ¡æ Œã¯ã 101 ããŒãã®ç·å
æ¬éé¡ã®ïŒ
ã®æ¯æãã«çããäŸ¡æ Œã«ãè²·ãæ»ãæ¥ãŸã§ã®å©åã®æ¯æããå«ã¿ãŸãã
ç§ãã¡ã®èŠå®æžã«åºã¥ã矩åã¯ãéå®å
šææåäŒç€Ÿã§ããRP Holdingsã«ãã£ãŠå®å
šãã€ç¡æ¡ä»¶ã§ä¿èšŒãããŠããŸããç§ãã¡ã¯èŠå®æžã®äžéšãéµå®ãã矩åãããã2024幎9æ30æ¥æç¹ã§ã¯ãå
šã»ã¯ã¿ãŒã®é©çšå¯èœãªèŠå®ãéµå®ããŠããŸããã
2024幎9æ30æ¥ãš2023幎12æ31æ¥æç¹ã«ããããåœç€Ÿã®æªæ±ºæžããŒãã®å
¬æ£äŸ¡å€ã¯ãã¬ãã«2ã®ããŒã¿ã䜿çšããŠãããã$ãšãªããŸããã6.8 ç§ãã¡ã®å
¥åã«ãããšããã®ææžã«ã¯æ°åããããŸããã5.1 åå , ããããã
ã·ãã¢ç¡æ
ä¿ãªãã«ãã³ã°ã¯ã¬ãžããæœèš
åœç€Ÿã®åäŒç€Ÿã§ããRPããŒã«ãã£ã³ã°ã¹ã¯ãåãæãšããŠã2021幎9æ15æ¥ã«ãç¡æ
ä¿ãªãã«ãã³ã°ã»ã¯ã¬ãžããã»ãã¡ã·ãªãã£ïŒããªãã«ãã³ã°ã»ã¯ã¬ãžããã»ãã¡ã·ãªãã£ãïŒãæäŸããä¿®æ£ã»æ¹èšãªãã«ãã³ã°ã»ã¯ã¬ãžããå¥çŽïŒãã¯ã¬ãžããå¥çŽãïŒãæåã«ç· çµããŸããã2023幎12æ22æ¥ã«ç· çµãããã¯ã¬ãžããå¥çŽã®ä¿®æ£ç¬¬3å·ã«ãããåå
¥èœåã¯ãã«ã«å¢ããŸãã1.8 äžè¬äŒæ¥çšéã§10åãã«1.69 2028幎12æ22æ¥ã«æºæãè¿ãããªãã«ãã³ã°ã»ã³ãããã¡ã³ãã®10åãã«ãšæ®ãã®ãã«110.0 2027幎10æ31æ¥ã«æºæãè¿ããäœçŸäžãã®ãªãã«ãã³ã°ã»ã³ãããã¡ã³ãã2024幎1æ24æ¥ãç§ãã¡ã¯ç¹å®ã®æè¡çå€æŽãå ããããã«ã¯ã¬ãžããå¥çŽã®ä¿®æ£ç¬¬4å·ãç· çµããŸããã2024幎9æ30æ¥ããã³2023幎12æ31æ¥ã®æç¹ã§ã ããã ãªãã«ãã³ã°ã»ã¯ã¬ãžããã»ãã¡ã·ãªãã£ã®äžã§ã®æªæãã®åå
¥éã
ãªãã«ãã³ã°ã»ã¯ã¬ãžããã»ãã¡ã·ãªãã£ã«ã¯ãåœç€Ÿã®éžæã«ããã(a) (1) 管ç代ç人ã®ãã©ã€ã ã¬ãŒãã(2) é£éŠè³ééå©ã足ããæé«é¡ãåºæºã«ããŠæ±ºå®ãããåºæ¬éå©ã®ã©ã¡ããã®éå©ãé©çšãããŸãã 0.5 % ãš (3) ã¿ãŒã SOFRãã©ã¹ 1 ïŒ
ãŸãã¯ïŒbïŒæ¥æ¬¡SOFRãã¿ãŒã SOFRã代æ¿é貚ã¿ãŒã ã¬ãŒãããŸãã¯ä»£æ¿é貚ãã€ãªãŒã¬ãŒãïŒããããã¯ã¬ãžããå¥çŽã§å®çŸ©ãããŠããŸãïŒãããã³ããããã®å Žåã«é©çšãããããŒãžã³ãå ç®ããŸãããªãã«ãã³ã°ã»ã¯ã¬ãžããã»ãã¡ã·ãªãã£ã«é©çšãããããŒãžã³ã¯ãåœç€Ÿã®å
¬çåµåæ Œä»ãã«ãã£ãŠç°ãªããŸãããããã£ãŠããªãã«ãã³ã°ã»ã¯ã¬ãžããã»ãã¡ã·ãªãã£ã®éå©ã¯ãé©çšãããéå©ã®å€åãšå
¬çåµåæ Œä»ãã®å°æ¥ã®å€åã«åºã¥ããŠããã¡ã·ãªãã£æéäžå€åããŸãã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªæ€æ»ïŒ
ãªãã«ãã³ã°ã»ã¯ã¬ãžããã»ãã¡ã·ãªãã£ãèŠå®ããã¯ã¬ãžããå¥çŽã«ã¯ããšãããã(i) é£çµã¬ãã¬ããžæ¯çã以äžã§ç¶æããããšãèŠæ±ããç¹å®ã®æ
£ç¿çãªèŠçŽãå«ãŸããŠããŸã 4.00 ãã 1.00 (ãŸãã¯ãã以äž) 4.50 調æŽåŸEBITDAã«å¯Ÿããé£çµç©ç«è² åµïŒé©æ Œè³æååŸåŸïŒ1.00ãŸã§ããããããã¯ã¬ãžããå¥çŽã§å®çŸ©ããã³èšç®ããã調æŽåŸEBITDAã«ãïŒiiïŒïŒiiïŒãã以äžã®é£çµè£åç 2.50 é£çµæ¯æå©æ¯ã«å¯Ÿãã調æŽåŸEBITDAã® 1.00ïŒãããããã¯ã¬ãžããå¥çŽã§å®çŸ©ããã³èšç®ãããŠããïŒãããã³ïŒiiiïŒé£çµããŒããã©ãªãªã®ãã£ãã·ã¥ãããŒçãŸãã¯ããä»¥äž 5.00 ãã 1.00 (ãŸãã¯ãã以äž) 5.50 ããŒããã©ãªãªã»ãã£ãã·ã¥ãããŒãžã®é£çµç©ç«è² åµã®ïŒå¯Ÿè±¡ãšãªãéèŠãªè²·ååŸïŒ1.00ãŸã§ãããããã¯ã¬ãžããå¥çŽã§å®çŸ©ããã³èšç®ãããŠããŸãããªãã«ãã³ã°ã»ã¯ã¬ãžããã»ãã¡ã·ãªãã£ã«åºã¥ããã¹ãŠã®çŸ©åã¯ãåœç€Ÿã«ãã£ãŠç¡æ¡ä»¶ã«ä¿èšŒãããŸããä¿¡çšå¥çŽã«åºã¥ãã¬ãã¬ããžæ¯çãããŒããã©ãªãªã®ãã£ãã·ã¥ãããŒæ¯çãã€ã³ã¿ã¬ã¹ãã»ã«ãã¬ããžã»ã¬ã·ãªã®èŠçŽã«åŸããªããšã貞ãæã¯åããéé¡ããã¹ãŠçŽã¡ã«è¿æžããããèŠæ±ããå¯èœæ§ããããŸããã¯ã¬ãžããå¥çŽã«ã¯ãè¿œå ã®è² åµã®çºçãé
åœã®æ¯æããç¹å®ã®æ¯æããè³ç£ã®ååŸãšåŠåãªã©ãç¹å®ã®æŽ»åã«åŸäºããåœç€Ÿã®èœåãå¶éãããã®çš®ã®ã¯ã¬ãžãããã¡ã·ãªãã£ã«é¢ããæ
£ç¿çãªå¥çŽãå«ãŸããŠããŸãã2024幎9æ30æ¥çŸåšãRPããŒã«ãã£ã³ã°ã¹ã¯ãããã®èŠçŽãéµå®ããŠããŸããã
ããŒãã®å
éæ¯æã
2024幎9æ30æ¥æç¹ã®åœç€Ÿã®åå
¥éã«å¯Ÿããå°æ¥ã®å
æ¬è¿æžé¡ã¯ããã®åŸ5幎éããã³ãã以éã以äžã®éãã§ãïŒåäœïŒåãã«ïŒ:
幎 å
éã®æ¯æã 2024幎ã®æ®ãã®æé
$ â  2025 1,000,000  2026 â  2027 1,000,000  2028 â  ãã以é 5,800,000  ç·èš (1)
$ 7,800,000 Â
(1) 9æ30æ¥æç¹ã®å²åŒåã³çºè¡è²»çšãååŽããããã®åèšé¡ã¯$ã§ãã192.6 ãããã¯åºç€ãšãªãåµåã®æ®åæéäžã«å©æ¯è²»çšãšããŠååŽãããŸãã
10. æ ªäž»è³æ¬
è³æ¬æ§é
ç§ãã¡ã¯æã£ãŠããŸã äº è°æ±ºæš©æ ªåŒã®ã¯ã©ã¹ïŒã¯ã©ã¹Aæ®éæ ªåŒãšã¯ã©ã¹Bæ®éæ ªåŒãããããã« äž æ®éæ ª1æ ªãããã®æ祚æ°ãã¯ã©ã¹Aã®æ®éæ ªåŒãšã¯ã©ã¹Bã®æ®éæ ªåŒã¯ãé©çšæ³ã§å¥æ®µã®å®ããããå Žåãé€ããæ ªäž»ã®æ祚ã«æåºããããã¹ãŠã®äºé
ã«ã€ããŠã1ã€ã®ã¯ã©ã¹ãšããŠãŸãšããŠè°æ±ºããŸããåœç€Ÿã®ã¯ã©ã¹Bæ®éæ ªåŒã¯äžå ŽãããŠããããã¯ã©ã¹Bæ®éæ ªåŒã®ä¿æè
ã¯ãæž
ç®ã解æ£ãæž
ç®ã®éã«åç®äŸ¡å€ãšåçã®åé
ãåããæš©å©ãéãããŠããŸãã2024幎9æ30æ¥çŸåšãç§ãã¡ã¯ 446,038 åæ ªã®ã¯ã©ã¹Aæ®éæ ªåŒãš 144,881 1000æ ªã®çºè¡æžã¿ã¯ã©ã¹Bæ®éæ ªåŒã
ç§ãã¡ãRP Holdingsãç¶ç¶æè³å®¶ããŒãããŒã·ãããRPI International Partners 2019ãLPãRPI US Feeder 2019ãLPãRPI International Feeder 2019ãLPãããã³EPA Holdingsã«ãã£ãŠç· çµãããååŒåå®ïŒä»¥äžãååŒåå®ããšãããŸããïŒã¯ãç¶ç¶æè³å®¶ããŒãããŒã·ãããéæ¥çã«ä¿æããRP Holdingsã¯ã©ã¹bã€ã³ã¿ã¬ã¹ããšåœç€Ÿã®Aé¡æ®éæ ªåŒãšã®äº€æãèŠå¶ããŠããŸããååŒåå®ã«åºã¥ããRP Holdingsã¯ã©ã¹bã€ã³ã¿ã¬ã¹ãã¯ç¶ç¶æè³å®¶ããŒãããŒã·ãããæã€åœç€Ÿã®Aé¡æ®éæ ªãšïŒå¯ŸïŒã® æ¯çã§ååæããšã«äº€æå¯èœã§ãã 1人 å亀æã¯ãåãæ°ã®åœç€Ÿã®Bé¡æ®éæ ªãç¹°å»¶æ ªãšããŠåæå®ããããšããããããŸãããã®ãããªç¹°å»¶æ ªã¯éè°æ±ºæš©ã§ãããäŒç€Ÿã®å©çã«åå ããæš©å©ãé
åœãåãåãæš©å©ã¯ãããŸããã2024幎9æ30æ¥çŸåšãç§ãã¡ã¯ ã thousand ç¹°å»¶æ ªãæªæãã®ãŸãŸãšããŠä¿æããŠããŸãã 390,502 åã®ç¹°å»¶æ ªãæªæãã®ãŸãŸã§ãããšã®ããšã
ããã«ãåé¡ããããŸã 50 ææè
ã«è°æ±ºæš©ãé
åœæš©ãäžãããã®ã§ã¯ãªããåæ ªã®ã¯ã©ã¹Rã®åéå¯èœãªæ ªåŒã2006幎ã®è±åœäŒç€Ÿæ³ã§çŸ©åä»ããããŠããããã«ããã€ã€ã«ãã£ãã¡ãŒããªããããã2020幎ã«å
¬éäŒç€Ÿã§ãããã€ã€ã«ãã£ãã¡ãŒãplcãšããŠåç»é²ããããšãã«ãååãªè±ãã³ã建ãŠã®æ ªåŒè³æ¬ã確ä¿ããããã«ãã¯ã©ã¹Rã®åéå¯èœãªæ ªåŒãçºè¡ãããŸãããã¯ã©ã¹Rã®åéå¯èœãªæ ªåŒã¯ãå°æ¥ãåœç€Ÿã®ãªãã·ã§ã³ã§åéãããå¯èœæ§ããããŸãããã®ãããªåéã¯ãé¡é¢éé¡ã®Â£ã«ãªããŸã1 ããããã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªæ€æ»ïŒ
ã¯ã©ã¹Aæ®éæ ªã®èªå·±æ ªåŒè²·ãæ»ã
2023幎3æãåœç€Ÿã®åç· åœ¹äŒã¯ãæ倧$ãŸã§è²·ãæ»ããèªç€Ÿæ ªè²·ãããã°ã©ã ãæ¿èªããŸãã1.0 10åæ ªã®ã¯ã©ã¹Aæ®éæ ªåŒãèªç€Ÿæ ªè²·ãããã°ã©ã ã®æ¿èªã¯2027幎6æ23æ¥ã«å€±å¹ããè²·ãæ»ãã¯å
¬éåžå ŽãŸãã¯ç§çã«äº€æžããååŒã§è¡ãããšãã§ããŸãã2024幎ã®æåã®9ãæã§ãç§ãã¡ã¯è²·ãæ»ããŸãã 6.6 çŸäž çŽ$ã®è²»çšã§æ ªã179.7 çŸäžã2023幎ã®æåã®9ãæã§ãç§ãã¡ã¯è²·ãæ»ããŸãã 8.9 çŽ$ã®è²»çšã§100äžæ ª278.6 çŸäžã2024幎9æ30æ¥ã®æç¹ã§ãããããã®ãã«515.6 100äžæ ªãèªç€Ÿæ ªè²·ãã®ããã°ã©ã ã§åŒãç¶ãå©çšå¯èœã§ããã
éæ¯é
æå
éæ¯é
æ ªäž»æåæ®é«ã®å€åã¯ä»¥äžã®éãã§ãïŒåååäœïŒïŒ
ã¬ã¬ã·ãŒã»ã€ã³ãã¹ã¿ãŒã»ããŒãããŒã·ãã ç¶ç¶çãªæè³å®¶ããŒãããŒã·ãã EPAããŒã«ãã£ã³ã°ã¹ ç·èš 2024幎6æ30æ¥ $ 1,199,719  $ 2,075,847  $ â  $ 3,275,566 Â è²¢ç® 1,291  954  â  2,245  åé
(82,163 ) (31,019 ) â  (113,182 ) ãã®ä»ã®ååŒæ â  (38,411 ) â  (38,411 ) åœæçŽå©ç 86,972  175,399  â  262,371  2024幎9æ30æ¥ $ 1,205,819  $ 2,182,770  $ â  $ 3,388,589 Â
RPSFT Legacy Investors Partnerships Continuing Investors Partnerships EPA Holdings ç·èš 2023幎6æ30æ¥ $ (103 ) $ 1,420,864  $ 2,111,258  $ â  $ 3,532,019 Â è²¢ç® â  1,413  1,437  â  2,850  åé
(848 ) (88,112 ) (31,238 ) â  (120,198 ) ãã®ä»ã®ååŒæ â  â  (18,459 ) â  (18,459 ) åœæçŽå©ç 285  25,623  24,055  â  49,963  2023幎9æ30æ¥ $ (666 ) $ 1,359,788  $ 2,087,053  $ â  $ 3,446,175 Â
Legacy Investors Partnerships Continuing Investors Partnerships EPA Holdings ç·èš 2023幎12æ31æ¥ $ 1,339,716  $ 2,218,076  $ â  $ 3,557,792 Â è²¢ç® 3,863  2,934  â  6,797  åé
(273,609 ) (93,711 ) â  (367,320 ) ãã®ä»ã®ååŒæ â  (154,373 ) â  (154,373 ) åœæçŽå©ç 135,849  209,844  â  345,693  2024幎9æ30æ¥ $ 1,205,819  $ 2,182,770  $ â  $ 3,388,589 Â
RPSFT Legacy Investors Partnerships Continuing Investors Partnerships EPA Holdings ç·èš 2022幎12æ31æ¥ $ (597 ) $ 1,527,887  $ 2,369,933  $ â  $ 3,897,223 Â è²¢ç® â  6,614  3,076  â  9,690  åé
(4,755 ) (286,674 ) (95,161 ) â  (386,590 ) ãã®ä»ã®ååŒæ â  â  (416,156 ) â  (416,156 ) åœæçŽå©ç 4,686  111,961  225,361  â  342,008  2023幎9æ30æ¥ $ (666 ) $ 1,359,788  $ 2,087,053  $ â  $ 3,446,175 Â
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªæ€æ»ïŒ
æè³å®¶ãšã®é£æºãç¶ç¶ãã
ç¶ç¶æè³å®¶ããŒãããŒã·ããã¯ãéæ¥çã«ä¿æããRP Holdings Class bå©çã®æ°ãšåãã§ããç§ãã¡ã®Bçš®æ®éæ ªåŒãä¿æããŠããŸããç¶ç¶æè³å®¶ããŒãããŒã·ããããRP Holdings Class bå©çãClass Aæ®éæ ªåŒã«äº€æãããšãç¶ç¶æè³å®¶ããŒãããŒã·ããã®RP Holdingsãžã®éæ¥çæææš©ã¯æžå°ããŸããç§ãã¡ã¯ãRP Holdingsã®äºæ¥ãææããRP Holdings Class Aå©çãšRP Holdings Class bå©çãéããŠéå¶ã管çããŠããŸãã2023幎第2ååæã«å§ãŸã£ãåœç€Ÿã®Class Aæ®éæ ªåŒã®è²·ãæ»ãã«é¢é£ããŠãRP Holdingsã¯åœç€Ÿãä¿æããRP Holdings Class Aå©çãåŒãåããããã«ããRP Holdingsã§ã®ç§ãã¡ã®æææš©ãæžå°ããŸããRP Holdingsã®æææš©ã®å€åã¯ç¶ç¶æè³å®¶ããŒãããŒã·ãããšã®éããã³ç§ãã¡ãšã®éã§ã(1)RP Holdings Class bå©çãClass Aæ®éæ ªåŒãšã®äº€æãããã³(2)RP Holdings Class Aå©çã®èåŸç掻ã«ããçµæãåæ ãããŸãã ãã®ä»ã®ååŒæ äžèšã®è¡šããã³åœç€Ÿã®ç°¡çŽé£çµæ ªäž»è³æ¬èšç®æžã«ãåæ ãããŠããŸãã
2024幎9æ30æ¥æç¹ã§ãç¶ç¶çãªæè³å®¶ããŒãããŒã·ããã¯RPããŒã«ãã£ã³ã°ã¹ã®çŽïŒ
ãéæ¥çã«ææããŠããŸããã 24 RPããŒã«ãã£ã³ã°ã¹ã®æ®ãïŒ
ã¯ããã€ã€ã«ãã£ãã¡ãŒãplcãææããŠããŸããã 76 2023幎9æ30æ¥æç¹ã§ãç¶ç¶çãªæè³å®¶ããŒãããŒã·ããã¯RPããŒã«ãã£ã³ã°ã¹ã®çŽïŒ
ãéæ¥çã«ææããŠããŸããã 25 RPããŒã«ãã£ã³ã°ã¹ã®æ®ãïŒ
ã¯ããã€ã€ã«ãã£ãã¡ãŒãplcãææããŠããŸããã 75
RPSFT
ç§ãã¡ã¯ãããŸã§ãRPSftãä¿æããrPCTã®ããããã¹æåã«é¢é£ããéæ¯é
æåãå ±åããŠããŸããã2023幎12æãç§ãã¡ã¯RPsFTãšãã®èŠªäŒç€Ÿã®çŽè³ç£ïŒäž»ã«çŸéãšãRPCTãåãåã£ããã€ã€ã«ãã£ã®äžéšãåãåãRPSFTã®æš©å©ã§æ§æãããŠããïŒãå®è³ªçã«è³Œå
¥ããããšã«ãããRPSftãä¿æããRPCTã®æ®ãã®æåãååŸããŸãããçŽ$ã®è³Œå
¥äŸ¡æ Œ11.4 ã«100äžãèšé²ãããŸãã ãã®ä»ã®æµåè² åµ 2023幎12æ31æ¥çŸåšã®èŠçŽé£çµè²žå察ç
§è¡šã«èšèŒãããŠããŸããæçµçãªè³Œå
¥äŸ¡æ Œã¯çŽ$ã§ã12.5 200äžãã«ã¯ãäž»ã«çŽè³ç£äŸ¡å€ãšæž
ç®è²»çšã®æçµæ±ºå®ã«é¢é£ããã¯ããŒãžã³ã°åŸã®èª¿æŽã®å¯Ÿè±¡ã§ãããã2024幎6æ30æ¥ã®æç¹ã§å
šé¡æ¯æãããŸããã2023幎12æã®ãã®ååŒãåããŠãRpSFTã¯rPCTã®éæ¯é
æåã§ã¯ãªããªããŸããã
EPA Holdingsãä¿æããRP Holdings Class Cã®ç¹å¥å©ç
EPAããŒã«ãã£ã³ã°ã¹ã¯ãããã©ãŒãã³ã¹ã«åºã¥ããŠEquity Performance AwardsïŒä»¥äžå®çŸ©ïŒãRP Holdingsã¯ã©ã¹Cç¹å®æåãéããŠåãåãæš©å©ããããŸããå2幎éã«è¡ãããæè³ã¯ãããŒããã©ãªãªããšã«å¥ã
ã®ããŒããã©ãªãªïŒåã
ããããŒããã©ãªãªãïŒãšããŠã°ã«ãŒãåãããŸããç¹å®ã®æ¡ä»¶ã«åŸããå決ç®ååæã®çµããã«ãEPA Holdingsã¯ã該åœããèšæž¬æéã®ããããã®ããŒããã©ãªãªã«é¢ããRP Holdingsããã®é
åœãã該åœããŒããã©ãªãªã«ã€ããŠã®Net Economic ProfitïŒãã¹ãŠã®æ°ããããŒããã©ãªãªæè³ã®çŽçŸéååé¡ããç·è²»çšïŒå©æ¯è²»çšãéå¶è²»çšã該åœããŒããã©ãªãªã«é¢é£ããååŸå䟡ã®ååïŒãå·®ãåŒãããã®ïŒã®äžå®å²åã«çããåãåãæš©å©ããããŸã 20 å
šæè³ã«å¯Ÿããç·çŸéååé¡ããïŒå©æ¯è²»çšãéå¶è²»çšãåœè©²ããŒããã©ãªãªã«é¢é£ããååŸå䟡ã®ååãããããïŒã®åèšè²»çšïŒTotal ExpensesïŒãå·®ãåŒãããã®ãšå®çŸ©ãããNet Economic Profitã®ïŒ
ã«çžåœãããEquity Performance Awardsãããé©çšãããèšæž¬æéã®ããããã®ããŒããã©ãªãªã«ã€ããŠRP Holdingsããé
åãããŸããEquity Performance Awardsã¯ãRP Holdingsã¯ã©ã¹Cç¹å®æåä¿æè
ã§ããEPA Holdingsã«å²ãåœãŠãããé£çµæçèšç®æžã«ãéæ¯é
æåã«åž°å±ããåœæçŽå©çããšããŠèšäžãããŸã éæ¯é
æ ªäž»ã«åž°å±ããåœæçŽå©ç ãå«ããé£çµæçèšç®æžã§èšé²ãããŸã
æ ªåŒã®ããã©ãŒãã³ã¹è³ã¯ãçºè¡æã«ã¯ã©ã¹Aã®æ®éæ ªåŒãšäº€æãããRP Holdingsã¯ã©ã¹bã€ã³ã¿ã¬ã¹ãã§æ¯æãããŸããå¿
èŠã«å¿ããŠãEPA Holdingsã¯RP Holdingsã¯ã©ã¹Cç¹å¥å©çã«é¢é£ããŠå®æçãªçŸéå貞ããåãåãå ŽåããããŸããããã¯ãEPA HoldingsãŸãã¯ãã®æ©æµãåããè
ãããã®RP Holdingsã¯ã©ã¹Cç¹å¥å©çã®ä¿æã«ãã賊課ãããæåŸçšãæ¯æãéã«å¿
èŠãšãããéé¡ã®æ¯æããè¡ããŸããæ ªåŒã®ããã©ãŒãã³ã¹è³ã¯ãæ ªäž»éååŒãšããŠççž®å䜵貞åå¯Ÿè±¡æ ªäž»è³æ¬èšç®æžã«åæ ãããé¢é£ããå®æçãªçŸéåé
ã¯ççž®éçŽè²žå察象ãã£ãã·ã¥ã»ãããŒèšç®æžã«ãããŠè³é調é掻åãšããŠæ瀺ãããŸãã ç¹å®ã®ããã©ãŒãã³ã¹æ¡ä»¶ãæºãããããŸã§ãæ ªåŒã®ããã©ãŒãã³ã¹è³ã®éèŠãªæ¯æãã¯äºæ³ãããŠããŸãããåæ§ã«ããããã®ããã©ãŒãã³ã¹æ¡ä»¶ãæºãããããŸã§ãEPA Holdingsã«å²ãåœãŠãããéèŠãªæåŸãäºæ³ãããŠããŸããã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªæ€æ»ïŒ
é
åœ
ã¯ã©ã¹Aæ®éæ ªæ ªäž»ã¯ãåœç€Ÿåç· åœ¹äŒã®æ¿èªãåããŠé
åœãåãåãæš©å©ããããŸããã¯ã©ã¹bæ®éæ ªæ ªäž»ã«ã¯é
åœãåãåãæš©å©ã¯ãããŸããããRP Holdingsã¯ã©ã¹bæ ªåŒã®å©çæš©ã¯RP Holdingsããé
åœéãšåé
éãåãåãæš©å©ããããŸãã2024幎ã®æåã®9ãæéã«ãåœç€Ÿã¯ã¯ã©ã¹Aæ®éæ ªæ ªäž»ã«åããŠåèš$çŸäžã®çŸéé
åœéã宣èšããæ¯æããŸããã éå»1é±éã¯æ ªäž»ã«ãšã£ãŠå€§å€ãªæéã§ãã£ããããåºæ¬çãªãã¡ã³ãã¡ã³ã¿ã«åæãè¡ããäœãåŠã¶ããšãã§ãããã調ã¹ãŠã¿ãŸãããã ã¯ã©ã¹Aæ®éæ ªã®ååæçŸéé
åœã¯$ã«ãªããŸã0.21 ã¯ã©ã¹Aæ®éæ ªæ ªäž»ã«å¯ŸããŠãç·é¡$çŸäžã®çŸéé
åœéãæ¯æããŸããã282.8
2020幎ç¬ç«åç· åœ¹ã®æ ªåŒå ±é
¬ã€ã³ã»ã³ãã£ããã©ã³ããã³æ ªåŒå ±é
¬
2020幎6æ15æ¥ã«ã2020幎ã®ç¬ç«åç· åœ¹å ±é
¬ã€ã³ã»ã³ãã£ãèšç»ãæ¿èªãããå¹åãçºæ®ããŸããããã®çµæã 800 åæ ªã®Açš®æ®éæ ªåŒãç¬ç«åç· åœ¹ã«RSUã®åœ¢ã§çºè¡ãèªããããŸãããèšç»ã®äžã§ä»äžãããRSUã¯ãäžè¬çã« 1幎 ã§ãé¢é£ããã·ã§ã¢ããŒã¹ã®å ±é
¬è²»çšãåçèšäžãããŸãã2024幎ããã³2023幎ã®ç¬¬3ååæãšåæ9ãæéã§ã¯ãåœç€Ÿã¯éèŠãªã·ã§ã¢ããŒã¹ã®å ±é
¬è²»çšãèªèããŠããŸããã§ããã äžè¬ç®¡çè²»çš ã§åçèšäžãããŸãã第3ååæããã³2024幎ããã³2023幎ã®æåã®9ãæéã«ãããŠãåœç€Ÿã¯éèŠãªã·ã§ã¢ããŒã¹ã®å ±é
¬è²»çšãèªèããŠããŸããã§ããã
11. 1æ ªåœããã®åç
2024幎ãš2023幎ã®ç¬¬3ååæããã³ç¬¬1ãã第9ã«æã«ãEPA Holdingsã«çºè¡å¯èœãªã¯ã©ã¹Bæ®éæ ªåŒãæ¡ä»¶ä»ã§è©äŸ¡ãããåžèåã®åœ±é¿ããªããšå€æãããŸããã
次ã®è¡šã¯ãåºæ¬æ ªåŒãšåžèååŸæ ªåŒã«å¯Ÿãã1æ ªåœããã®åçãèšç®ããã®ã«äœ¿çšãããååãšåæ¯ã®èª¿æŽã瀺ããŠããŸãïŒåäœïŒååã1æ ªåœããéé¡ãé€ãïŒã
2021幎9æ30æ¥çµäºã®3ãæéã®æ±ºç®ã«ã€ã㊠2021幎9æ30æ¥çµäºã®9ãæéã®æ±ºç®ã«ã€ã㊠2024 2023 2024 2023 åå åœæçŽå©ç $ 806,358  $ 122,077  $ 996,462  $ 982,502  åœæçŽå©çäžã®æåå ±åãªãã«åž°å±ããçŽå©ç 175,399  24,055  209,844  225,361  åœæçŽå©çäžã®éå»ã®æåå ±åãªãã«åž°å±ããçŽå©ç 86,972  25,908  135,849  116,647  ãã€ã€ã«ãã£ãã¡ãŒãã«åž°å±ããåœæçŽå©ç - ããŒã·ã㯠543,987  72,114  650,769  640,494  åžèååŸã®ã¯ã©ã¹bæ®éæ ªåŒã®åæå€æããã®æåå ±åãªãã«åž°å±ããçŽå©çã®åé
åãè¿œå 175,399  24,055  209,844  225,361  åžèååŸã®ãã€ã€ã«ãã£ãã¡ãŒãã«åž°å±ããåœæçŽå©ç $ 719,386  $ 96,169  $ 860,613  $ 865,855  åæ¯ åºæ¬çã«çºè¡æžã¿ã¯ã©ã¹Aæ®éæ ªåŒã®å éå¹³åæ° 447,628  448,439  449,085  448,162  å¥éã«ç€ºãåžèåå¹æãå ç® ã¯ã©ã¹Aæ®éæ ªåŒã«äº€æå¯èœãªã¯ã©ã¹Bæ®éæ ªåŒ 145,085  152,691  146,576  156,541  æªå®æœã®å¶éæ ªåŒ 13  8  22  14  åžèååŸã®åºæ¬çã«çºè¡æžã¿ã¯ã©ã¹Aæ®éæ ªåŒã®å éå¹³åæ° 592,726  601,138  595,683  604,717  åºæ¬ã®1æ ªåœããå©çé¡ - ããŒã·ã㯠$ 1.22  $ 0.16  $ 1.45  $ 1.43  åžèååŸã®1æ ªåœããå©ç $ 1.21  $ 0.16  $ 1.44  $ 1.43 Â
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªæ€æ»ïŒ
12. éæ¥ãã£ãã·ã¥ã»ãããŒ
é£çµåœæçŽå©çãå¶æ¥æŽ»åã«ãã£ãŠçããçŽçŸéãã調æŽããããã®èŠçŽã¯ä»¥äžã®éãã§ãïŒåååäœïŒ:
2021幎9æ30æ¥çµäºã®9ãæéã®æ±ºç®ã«ã€ã㊠2024 2023 å¶æ¥æŽ»åã«ãããã£ãã·ã¥ã»ãããŒïŒ åœæçŽå©ç $ 996,462  $ 982,502  é£çµåœæçŽå©çããå¶æ¥æŽ»åã«ãããã£ãã·ã¥ã»ãããŒãç®åºããããã®èª¿æŽ: ãã¡ã€ãã³ã·ã£ã«ãã€ã€ã«ãã£è³ç£ããã®åå
¥ (1,587,577 ) (1,674,689 ) äºæ³ãããçŸéãããŒã®å€åã«å¯Ÿããéèãã€ã€ãªãã£è³ç£ããã®åŒåœé 568,425  637,169  ãã®ä»ã®èª¿æŽé
ç® 14,256  15,658  ããªããã£ãéèååã®æç (3,000 ) 2,290 Â æ ªåŒæ䟡蚌åžã®å©ç (81,455 ) (31,994 ) æåæ³é©çšé¢é£äŒç€Ÿã®æ倱ïŒå©çïŒã«å¯Ÿããæå 2,039  (28,614 ) ååé
åœéïŒå
±ååºè³æ³ã«ããæè³äŒç€ŸããïŒ 13,396  18,823 Â æ ªåŒå ±é
¬è²»çš 1,819  1,740  売åŽå¯èœåµåžã®å©ç (103,900 ) (122,500 ) ä» (1,801 ) 3,263  å¶æ¥è³ç£ããã³è² åµã®å€å: 財åãã€ã€ãªãã£è³ç£ã®çŸéåå
¥ 2,205,933  2,454,054  ãã®ä»ã®ãã€ã€ã«ãã£åçåµæš© (2,496 ) (669 ) ãã®ä»ã®æµåè³ç£ 13,068  (1,942 ) æ¯æ調æŽéããã³æªæé 3,582  1,650  éçŸéè²»çšã®èª¿æŽ: (13,270 ) (41,567 ) ãã®ä»ã®è² åµ 980  â  å¶æ¥æŽ»åã«ãããã£ãã·ã¥ãã㌠$ 2,026,461  $ 2,215,174 Â
éçŸéã®æè³ããã³è²¡å掻åã¯æ¬¡ã®éãã«èŠçŽãããŠããŸãïŒåååäœïŒ:
2021幎9æ30æ¥çµäºã®9ãæéã®æ±ºç®ã«ã€ã㊠2024 2023 ãã€ã«ã¹ããŒã³æ¯æã - Cobenfy (1)
$ 25,000  $ â  ãã€ã«ã¹ããŒã³æ¯æã - Erleada (1)
6,200 Â â Â
(1) 2024幎9æ30æ¥æç¹ã§æ¯æãããŠããªãã£ãCobenfyïŒæ§KarXTïŒãšErleadaã®ãã€ã«ã¹ããŒã³æ¯æãã®éæã«é¢é£ããŸãã
13. ã³ãããã¡ã³ããšã³ã³ãã£ã³ãžã§ã³ã·ãŒ
ãµã€ãã«ã€ããã£ãã¯ã¹ã®è³éæ åº
2024幎9æ30æ¥çŸåšã$æ®ã£ãŠãããŸãã350 ãµã€ãã«ã€ããã£ãã¯ã¹ãã¡ã³ãã£ã³ã°ã³ãããã¡ã³ãã®äžã§ããŸã 1,000äžãã«ãå©çšå¯èœã§ãããæäœã§ãïŒãåŒãåºãå¿
èŠããããŸã50 ïŒcïŒçŽ$ã®éæ¯é
çå©çã«åž°å±ããåœæçŽå©çãå«ã¿ãŸããéæ¯é
çå©çã«åž°å±ããæåŸçšè²»çšã¯ãçŽ$ãäžåããŸãã
ããéçºè³éã®ã³ãããã¡ã³ã
2023幎11æãç§ãã¡ã¯ãããã¡ãŒãã¹ãŒãã£ã«ã«ã€ã³ãã¹ããªãŒãºã®åäŒç€Ÿã§ããTeva Pharmaceuticals International GmbHãšã®è³éæäŸå¥çŽãç· çµããŸããããã®å¥çŽã«åºã¥ããTEV-'749ã«å¯Ÿãããã€ã€ãªãã£æš©çã®ååŸã«æ倧ã§è³éãæäŸããããšãçŽæããŠããŸãã100 2024幎第3ååæãšç¬¬1ååæã«ã¯ããããã1000äžãã«ãTEV-'749ã®éçºã«è³éæäŸããŸããã19.6 çŸäž $ã«å¯Ÿãããå²åŒåŸã®å°æ¥æäœé床ã®è³è²žææ¯æãåèšé¡ã¯ä»¥äžã®éãã§ãã82.0 ç§ãã¡ã®ãã€ã€ãªãã£æš©çã®ååŸã«å¯Ÿããè³éã¯ã財åãã€ã€ãªãã£è³ç£ãšããŠåé¡ãããŠããŸãã2024幎9æ30æ¥çŸåšããã®å¥çŽã®æªæãã³ãããã¡ã³ãã¯1000äžãã«ã§ãã18.0 ãã®å¥çŽã«åºã¥ãã2024幎9æ30æ¥çŸåšã1000äžãã«ã®æªæ¯æãã³ãããã¡ã³ãããããŸãã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªæ€æ»ïŒ
ãã®ä»ã®ã³ãããã¡ã³ã
åœç€Ÿã¯ãAvillion Entitiesãžã®æè³ãéããŠååŒå
ã«ãã¹ãŠã®æè³ãåé²ããã矩åããããŸãããããã®åã決ãã®è©³çŽ°ã«ã€ããŠã¯ãããŒã7-éé£çµé¢é£äŒç€Ÿãåç
§ããŠãã ããããŸãããããžã¡ã³ãå¥çŽã®å¯¿åœã«ããã£ãŠãªãã¬ãŒãã£ã³ã°ããã³äººå¡æ¯æãïŒä»¥äžã§å®çŸ©ïŒãè¡ã矩åããããããã«ã€ããŠã¯ããŒã14-é¢é£åœäºè
ååŒã«èšèŒãããŠããŸãã
è£å
éåžžãåœç€Ÿã®ããžãã¹ã«ãããŠã¯ãæ©å¯ä¿æå¥çŽãæ³äººã®åç¶ããã³å¥çŽç· çµæš©éã«é¢ããè¡šæãªã©ãå«ãå¥çŽãåæãç· çµããããšããããŸãããã®ãããªå¥çŽã«åºã¥ãæ倧ã®æå®³è³ å責任ã¯ãã¯ã¬ãŒã ãããå ŽåãŸã§äžç¢ºå®ã§ãããã ããçŸæç¹ãŸã§ã«åœç€Ÿã«å¯Ÿãããã®ãããªã¯ã¬ãŒã ã¯ãããŸããããå°æ¥ãã®ãããªæç¶ããèµ·ããå¯èœæ§ã¯äœããšèããŠããŸãã
æ³çæªçœ®
ç§ãã¡ã¯ããžãã¹ã®éåžžæ¥åã«ãããŠæ§ã
ãªåé¡ã«é¢ãã蚎èšã®åœäºè
ã§ãããããã®èšŽèšã®ããã€ãã¯ãé倧ãªäžç¢ºå®æ§ãç®å®äžèœãªæ害ã䌎ãè€éãªè«æ±ã«åºã¥ããŠããå¯èœæ§ããããŸããä»ã«èšèŒããªãéããæ倱ã®ç¢ºçãå€æãããæ害é¡ãèŠç©ããããšã¯äžå¯èœã§ããããããã£ãŠã2024幎9æ30æ¥ããã³2023幎12æ31æ¥æç¹ã®ç°¡æé£çµè²žå察ç
§è¡šã«ã¯ãããã®èšŽèšã«å¯ŸããåŒåœéãèšå®ããŠããŸãããæ倱ã確å®ã§åççã«èŠç©ããããšå€æããå Žåãè² åµãèšäžããè² åµãé倧ã§ããã°ãæºåããè² åµé¡ãé瀺ããŸããç§ãã¡ã¯ãåœäºè
ã§ããæ¢åã®ãããªã蚎èšã®çµæããåå¥ã«ãç·åçã«ããåœç€Ÿã®ããžãã¹ã財åç¶æ³ãæ¥çžŸã«é圱é¿ãåãŒããšã¯èããŠããŸããã
14. é¢ä¿è
éååŒ
ãããŒãžã£ãŒ
ãããŒãžã£ãŒã¯ãã€ã€ã«ãã£ãã¡ãŒã瀟ãšãã®åäŒç€Ÿã®æè³ãããŒãžã£ãŒã§ãããããŒãžã£ãŒã®ãããŒãžã³ã°ã¡ã³ããŒã§ãããããã»ã¬ãŽã¬ãã¿ã¯åœç€Ÿã«é¢å¿ãæã¡ãåœç€Ÿã®æé«çµå¶è²¬ä»»è
ããã³åç· åœ¹äŒã®è°é·ãåããŠããŸãã
ååŒæãªãã¡ãŒã«é¢é£ããŠããããŒãžã£ãŒã¯ç§ãã¡ãšç§ãã¡ã®åäŒç€Ÿãç¶ç¶çãªæè³å®¶ããŒãããŒã·ãããããã³æ¢åã®æè³å®¶ããŒãããŒã·ãããšã®ãããŒãžã¡ã³ãå¥çŽãç· çµããŸããããããŒãžã¡ã³ãå¥çŽã®èŠå®ã«åŸããç§ãã¡ã¯ãããŒãžã£ãŒãŸãã¯ãã®é¢é£äŒç€Ÿã«ååæããšã®éå¶ããã³äººå¡æ¯æãïŒãéå¶ããã³äººå¡æ¯æããïŒãæ¯æããŸãã 6.5 ãã®ååæã®ãã€ã€ã«ãã£æè³ïŒãããŒãžã¡ã³ãå¥çŽã§å®çŸ©ãããŠããïŒããã®çŸéåå
¥ã®ïŒ
ããã³ 0.25 GAAPã«åºã¥ãã»ãã¥ãªãã£æè³ã®äŸ¡å€ã®ïŒ
ïŒè©²åœååæã®æ«ã«ïŒã®ïŒ
ãéå¶ããã³äººå¡æ¯æãã¯ãæ§RPIã®ããã®ãã®ã§ããããã¯æ¢åã®æè³å®¶ããŒãããŒã·ããã®çŸ©åã§ãããçµè²»ãåœç€Ÿã®é£çµåœæçŽå©çã«åæ ãããŠããŸãããã®æ¯æãã¯ãååæåœãã$1 çŸäžãš 0.3125 åã®åäºã«ã¬ã³ããŒæã«é¡åãããã€ã€ã«ãã£ããã®ïŒ
ããŸããç§ãã¡ã¯ãããŒãžã£ãŒã®äžå®ã®ã³ã¹ããçµè²»ãæ¯æããŸãã
å€ãRPIã«åž°å±ããéé¡ãå«ããçºçããç·éå¶ããã³äººå¡æ¯æãã¯ãæçèšç®æžå
šäœã§èªèãããŠããŸãã äžè¬åã³ç®¡çè²»çš 2024幎ã®ç¬¬3ååæãšç¬¬1ååæã«çºçããç·éå¶ããã³äººå¡æ¯æããå€ãRPIã«åž°å±ããéé¡ãå«ãã®ã¯ããããã$ããªãªã³ã§ããã49.5 çŸäž $ã«å¯Ÿãããå²åŒåŸã®å°æ¥æäœé床ã®è³è²žææ¯æãåèšé¡ã¯ä»¥äžã®éãã§ãã138.9 2023幎ã®ç¬¬3ååæãšç¬¬1ååæã«çºçããç·éå¶ããã³äººå¡æ¯æããå€ãRPIã«åž°å±ããéé¡ãå«ãã®ã¯ããããã$ããªãªã³ã§ããã43.0 $çŸäžã®å£²äžé«ãèªèããŸãã154.9 çŸäžãã«
ãã€ã€ã«ãã£ãã¡ãŒã PLC
èŠçŽãããé£çµè²¡åè«žè¡šã®æ³šèš
ïŒæªæ€æ»ïŒ
ã¬ã¬ã·ãŒéæ¯é
æ ªäž»ã«æ¯æãããé
åœé
Legacy Investors Partnershipsã®Old RPIããã³RPI ICAVã«ãããéæ¯é
çæåã«åºã¥ãåé
ãå¿
èŠãªå¥çŽçŸéæµéã以äžã«ç€ºãããŠããŸãã éºç£éæ¯é
çæåã«æ¯æãããé
åœ çŸåšã®é£çµè²žå察ç
§è¡šã«èšèŒãããŠããŸãã
ããªã¹ãã«ãã€ã€ãŒãºã¹ã¯ã€ãããã®ååŸ
2017幎11æãRPI AcquisitionsïŒã¢ã€ã«ã©ã³ãïŒæ ªåŒäŒç€ŸïŒä»¥äžãRPI AcquisitionsãïŒã¯ãäž»èŠãªåäŒç€ŸãšããŠãããªã¹ãã«ã»ãã€ã€ãŒãºã»ã¹ã¯ã€ãïŒä»¥äžãBMSãïŒãšè³Œå
¥å¥çŽãç· çµããBMSããã¢ã¹ãã©ãŒãã«ã販売ããOnglyzaãFarxigaããã³é¢é£ç³å°¿ç
補åã®äžççãªå£²äžã«å¯Ÿããå°æ¥ã®ãã€ã€ãªãã£ã®äžéšãååŸããŸããïŒä»¥äžããè²·åå¥çŽããšãããŸãïŒã2017幎12æ8æ¥ãRPI Acquisitionsã¯ãåœç€Ÿã«é¢é£ãããšã³ãã£ãã£ã§ããBioPharma Credit PLCïŒãBPCRãïŒã®å®å
šåäŒç€Ÿãšã®éã§ã売買ããã³è²æž¡å¥çŽïŒä»¥äžãè²æž¡å¥çŽããšãããŸãïŒãç· çµããŸãããè²æž¡å¥çŽã®æ¡ä»¶ã«åºã¥ããRPI Acquisitionsã¯ãBMSããååŸããæ¯æãã¹ããªãŒã ã®ïŒ
ããBPCRãã賌å
¥å¥çŽãã«åºã¥ãBMSã«å¯Ÿãã財æºçŸ©åã®ïŒ
ãæãã代ããã«è²æž¡ããŸããã 50 BMSã«ãã£ãŠè²·åãããæ¯æãã¹ããªãŒã ã®ïŒ
ã®ãã¡ãBPCRãBMSã«å¯Ÿãã賌å
¥å¥çŽã«ããåµåã®ïŒ
ãæããããšãæ¡ä»¶ã«ãRPI AcquisitionsãBPCRã«å©çãè²æž¡ããŸããã 50 BMSããè²·åå¥çŽãã«åºã¥ãBMSã«å¯Ÿããè³éæäŸçŸ©åã®ïŒ
ã®ãã¡ãBPCRãBMSã«å¯ŸããŠæããã¹ãåµåã®ïŒ
ãåããããã«ãRPI Acquisitionsã¯BPCRã«å²ãåœãŠãŸããã
2024幎9æ30æ¥ãš2023幎12æ31æ¥çŸåšãåœç€Ÿã®è²¡åãã€ã€ã«ãã£è³ç£ã¯ããããã$çŸäžãç°¡çŽé£çµè²žå察ç
§è¡šã«ä»£è¡šãããã®ã¯ãç§ãã¡ãBMSããååŸããå°æ¥ã®æ¯æãã¹ããªãŒã ã«å¯Ÿããæš©å©ã ãã§ãã52.8 $çŸäžã®å£²äžé«ãèªèããŸãã75.6 çŸäžãç°¡çŽé£çµè²žå察ç
§è¡šã«ä»£è¡šãããã®ã¯ãç§ãã¡ãbmsããååŸããå°æ¥ã®æ¯æãã¹ããªãŒã ã«å¯Ÿããæš©å©ã ãã§ãã
ãã®ä»ã®ååŒ
2024幎1æãåœç€Ÿã¯ãã€ãŠPsyadon Pharmaceuticals, Inc.ïŒãPsyadonãïŒææã ã£ãecopipamã®ãã€ã€ãªãã£æš©ãååŸããŸãããåŒç€Ÿã®åç· åœ¹äŒã®ç¬ç«åç· åœ¹ã§ããErrol De Souzaå士ã¯ãPsyadonã®æ ªäž»ã§ããããã®ååŒã«é¢é£ããŠãDe Souzaå士ã¯ã¹ã¿ãŒãæã«$ïŒæªæºïŒã®åæéãåãåããŸããã2.5 çŸäžãã«ããããŠå°æ¥çã«ã¯æ倧ã§çŸäžãã«ã®ãã€ã«ã¹ãã³ã»ãã€ã¡ã³ããåãåãå¯èœæ§ããããŸãã2.22 çŸäžãã«ã®ãã€ã«ã¹ãã³ã»ãã€ã¡ã³ããåãåãå¯èœæ§ããããŸãã
åœç€Ÿã®åç· åœ¹äŒã®äž»åžç¬ç«åç· åœ¹ã§ãããã³ãªãŒã»ãã§ã«ãã³ãã¹ã¯ãmsciã®äŒé·å
Œæé«çµå¶è²¬ä»»è
ãåããŠããŸãã2021幎4æ16æ¥ãåœç€Ÿã¯ãäž»é¡å¥ã©ã€ããµã€ãšã³ã¹ææ°ã®éçºãç®çãšããŠãmsciãšã®å¥çŽãç· çµããŸãããæåã®æéã¯ããã« äžå¹Ž ããã®msciã«ããåçã®äžéšãåãåããŸãã No ã®éé¡ã2024幎9æ30æ¥ããã³2023幎12æ31æ¥ã®äž¡æ¥ãŸã§ã«ãmsciããæ¯æãããäºå®ã§ããããã®ååŒã«é¢é£ãã財åäžã®åœ±é¿ã¯ãä»æ¥ãŸã§ã«ã¯éèŠã§ã¯ãããŸããã§ããã
ååŒæãªãã¡ãŒã«é¢é£ããŠãç¶ç¶ããæè³å®¶ããŒãããŒã·ããããLegacy SLPã€ã³ã¿ã¬ã¹ããååŸããåœç€Ÿã®åäŒç€Ÿã®æ ªåŒãšåŒãæãã«ååŸããŸããããã®çµæãLegacy Investors Partnershipsã®ç¹å¥éå®ããŒãããŒãšãªããŸãããLegacy Investors Partnershipsã¯Old RPIããã³RPI ICAVã«éæ¯é
çã€ã³ã¿ã¬ã¹ããææããŠããŸããLegacy SLPã€ã³ã¿ã¬ã¹ãããã³ãã®ä»ã®éé£çµãšã³ãã£ãã£ãžã®åœç€Ÿã®æè³ã®è©³çŽ°ã«ã€ããŠã¯ã泚é7ã®éé£çµé¢é£äŒç€Ÿãåç
§ããŠãã ããã
PRiftã¯ææããŠããŸã 27,210 ç¶ç¶æè³å®¶ããŒãããŒã·ããã«ããããªããããã»ããŒãããŒã·ããã®æåãå®è³ªçãªäºæ¥ã¯åäŒç€Ÿãžã®æè³ã ãã§ãã$ã®ç·æè³é¡4.3 100äžãåœåº«æåãšããŠèšé²ããããã®ãã¡$ã¯1.6 2024幎9æ30æ¥ããã³2023幎12æ31æ¥çŸåšã100äžæ ªãéæ¯é
æåã«ãã£ãŠä¿æãããŠããŸãã
åç¶ç¶æè³å®¶ããŒãããŒã·ããã¯ãRP Holdingsã®ææå²åã«åºã¥ããŠãåœç€Ÿããã³åœç€Ÿã®åäŒç€Ÿã®æ§æ³ãèšç«ããªã¹ãäžå Žãããã³éå¶ã«é¢é£ãããã¹ãŠã®ã³ã¹ãããã³çµè²»ã®åçãªéšåãæ¯æããŸãã ããã«ã¯ãåœç€Ÿãåœç€Ÿã®åäŒç€Ÿã管çããããã®ç¬¬äžè
è²»çšïŒäŒèšãç£æ»ãæ³çãå ±åãã³ã³ãã©ã€ã¢ã³ã¹ã管çïŒåœ¹å¡å ±é
¬ãå«ãïŒã財åã¢ããã€ã¶ãªãŒãã³ã³ãµã«ãã£ã³ã°ãæè³å®¶é¢ä¿ãä¿éºè²»çšïŒãå«ãŸããŸãã
15. ãã®åŸã®åºæ¥äº
2024幎11æãç§ãã¡ã¯ã·ã³ããã¯ã¹è£œè¬æ ªåŒäŒç€Ÿãããã¯ãã£ã ãã®ãã€ã€ã«ãã£æš©ãç²åŸããåæãéé¡ã¯$350 ïŒcïŒçŽ$ã®éæ¯é
çå©çã«åž°å±ããåœæçŽå©çãå«ã¿ãŸããéæ¯é
çå©çã«åž°å±ããæåŸçšè²»çšã¯ãçŽ$ãäžåããŸãã
çš®é¡2.         管ç â 財åç¶æ³ãšæ¥çžŸã®åæãšèå¯
以äžã®è²¡åç¶æ³åã³æ¥çžŸã«é¢ããçµå¶é£ã«ããåæã»è«ç¹ïŒãMD&AãïŒã¯ãèªè
ãåœç€Ÿã®æ¥çžŸããã£ãã·ã¥ãããŒã財åç¶æ
ã®ãã®ä»ã®å€åãããã³ããžãã¹ããã©ãŒãã³ã¹ãç解ããã®ã«åœ¹ç«ã¡ãŸããMD&Aã¯ãåœç€Ÿã®2023幎床10-Kãã©ãŒã ã«èšèŒãããç°¡ç¥åãããé£çµè²¡åè«žè¡šããã³ä»éãã泚èšãšäœµããŠãè£å®ãšããŠæäŸãããåç
§ãããã¹ãã§ãããã®è°è«ã«ã¯ããªã¹ã¯ãäžç¢ºå®æ§ã䌎ãçŸåšã®æåŸ
ã«åºã¥ããååããªå£°æãå«ãŸããå¯èœæ§ããããŸãããããã®ååããªå£°æã«ã¯ããã®10-Qã®ååæå ±åæžãPart IIãItem 1Aã«èšèŒãããä»ã®å Žæã«å«ãŸããååããªå£°æã«é¢ããç¹èšäºé
ã«èšèŒãããèŠå ãªã©ãæ§ã
ãªèŠå ã«ãããäºæ³ãšç°ãªãå®éã®çµæãçããå¯èœæ§ããããŸãããªã¹ã¯èŠå ã«é¢ããŠã¯ããã®ååæå ±åæžã®ä»ã®å ŽæãPart IIãItem 1Aã«èšèŒãããŠããŸãã
ãã€ã€ã«ãã£ãã¡ãŒãæ ªåŒäŒç€Ÿã¯ã2020幎ã«åã®å
¬éæ ªåŒçºè¡ïŒãIPOãïŒãä¿é²ããããã«ãã€ã³ã°ã©ã³ãããã³ãŠã§ãŒã«ãºã®æ³åŸã«åºã¥ããŠèšç«ãããæ ªåŒå
¬éæéäŒç€Ÿã§ããããã€ã€ã«ãã£ãã¡ãŒããããäŒç€Ÿãããç§ãã¡ãããæã
ãããåœç€Ÿããšã¯ããã€ã€ã«ãã£ãã¡ãŒãæ ªåŒäŒç€Ÿããã³ãã®é£çµåäŒç€ŸãæããŸãã
ããžãã¹æŠèŠ
ç§ãã¡ã¯çç©å»è¬åã®ãã€ã€ã«ãã£ãŒã®æ倧ã®è²·ãæã§ãããçç©å»è¬åæ¥çš®å
šäœã§ã®é©æ°ã®äž»èŠãªè³éæäŸè
ã§ãã1996幎ã®èšç«ä»¥æ¥ããã€ã€ã«ãã£ãŒåžå Žã§å
é§è
ãšããŠæŽ»åããåŠè¡æ©é¢ãç 究ç
é¢ãéå¶å©å£äœããäžå°åã®ãã€ãªãã¯ãããžãŒäŒæ¥ãã°ããŒãã«å»è¬åäŒæ¥ãŸã§ã®é©æ°è
ãšé£æºããŠããŸããç§ãã¡ã¯ãæ¥çã®äž»èŠãªæ²»çè¬ã®å£²äžé«ã«åºã¥ããŠæ¯æããåããæš©å©ãäžãããããã€ã€ã«ãã£ãŒã®ããŒããã©ãªãªãçµã¿ç«ãŠãŠãããããã«ã¯ããŒããã¯ã¹ã®TrikaftaãGSKã®Trelegyããã·ã¥ã®Evrysdiããžã§ã³ãœã³ïŒãžã§ã³ãœã³ã®Tremfyaããã€ãªãžã§ã³ã®TysabriãšSpinrazaãã¢ããŽã£ãšãžã§ã³ãœã³ïŒãžã§ã³ãœã³ã®Imbruvicaãã¢ã¹ãã©ã¹ãšãã¡ã€ã¶ãŒã®Xtandiãããã«ãã£ã¹ã®Promactaããã¡ã€ã¶ãŒã®Nurtec ODtãã®ãªã¢ããã®Trodelvyãªã©35以äžã®åæ¥è£œåã®ãã€ã€ã«ãã£ãŒãå«ã¿ãéçºæ®µéã®15補ååè£ãå«ã¿ãŸããç§ãã¡ã¯ãçç©å»è¬åæ¥çš®ã§ã®é©æ°ãçŽæ¥çããã³éæ¥çã«è³éæäŸããŠãããçŽæ¥çã«ã¯ãå°æ¥ã®ãã€ã€ã«ãã£ãŒäº€æã®ããã«äŒæ¥ãšææºããŠåŸæèšåºè©Šéšãšæ°è£œåã®ããŒã³ããå
±åè³éæäŸãããšããéæ¥çã«ã¯ãå
ã®é©æ°è
ããæ¢åã®ãã€ã€ã«ãã£ãŒãååŸããæã«è¡ã£ãŠããŸãã
ãã¬ãŒã³ããŒã·ã§ã³ã®èæ¯ãšãã©ãŒããã
ç§ãã¡ã¯2020幎2æ11æ¥ã«ååŒæææ¡ïŒãååŒæææ¡ãïŒãå®æœããåœç€Ÿã®IPOãåæ»åããŸãããååŒæææ¡ãéããŠããã€ã€ã«ãã£ãã¡ãŒãæè³ãä¿æããããŸããŸãªããŒãããŒã·ããïŒãã¬ã¬ã·ãŒæè³å®¶ããŒãããŒã·ããããšåŒã°ããïŒã«ãããç·æåå©çã®82ïŒ
ã代衚ããæè³å®¶ã¯ãã¬ã¬ã·ãŒæè³å®¶ããŒãããŒã·ããã«ãããéå®ããŒãããŒã·ããæåãããã©ãŠã§ã¢éå®ããŒãããŒã·ããã§ããRPI US Partners 2019, LPãããã¯ã±ã€ãã³è«žå³¶ç¹å®å
é€éå®ããŒãããŒã·ããã§ããRPI International Holdings 2019, LPïŒä»¥äžããç¶ç¶æè³å®¶ããŒãããŒã·ããããšãããŸãïŒã«äº€æããŸããã
åœç€Ÿã¯ãã€ã€ã«ãã£ãã¡ãŒãããŒã«ãã£ã³ã°ã¹æ ªåŒäŒç€ŸïŒãRPããŒã«ãã£ã³ã°ã¹ãïŒã®äºæ¥ãéå¶ããã³ç®¡çããŠããŸããåœç€Ÿã¯RPããŒã«ãã£ã³ã°ã¹ããã³ãã®åäŒç€Ÿãç°¡æé£çµè²¡åè«žè¡šã«å«ããŠããŸããRPããŒã«ãã£ã³ã°ã¹ã¯ã¢ã€ã«ã©ã³ãã®éåè³ç£ç®¡çè»äž¡ã§ããRoyalty Pharma Investments 2019 ICAVïŒãRPI 2019 ICAVãïŒã®å¯äžã®ææè
ã§ãããæ§RPIã®åŸç¶è
ã§ãã
ååŒæãªãã¡ãŒã®åŸããã©ãŠã§ã¢æ°äºä¿¡èšã§ããRPI 2019 Intermediate Finance TrustãéããŠãæ§RPIã®çµæžå©çã®82%ã®éæ¥ææè
ãšãªããŸãããç§ãã¡ã¯æ§RPIã®å®å
šåäŒç€Ÿã§ãããã©ãŠã§ã¢æ°äºä¿¡èšã§ããRPI Finance Trustã®çµæžã®82%ãããã³ãã©ãŠã§ã¢æ°äºä¿¡èšã§ããRoyalty Pharma Collection TrustïŒ"RPCT"ïŒã®66%ã«æš©å©ãæããŠããŸãã2023幎12æ29æ¥ä»¥åã«ãRPCtã®æ®ãã®34%ã¯ã¬ã¬ã·ãŒã€ã³ãã¹ãã¡ã³ãããŒãããŒã·ãããšãã©ãŠã§ã¢æ°äºä¿¡èšã§ããRoyalty Pharma Select Finance TrustïŒ"RPSFT"ïŒã«ãã£ãŠææãããŠãããããã¯ã¢ã€ã«ã©ã³ãæ³äººä¿¡èšã§ããRoyalty Pharma Selectãå®å
šææããŠããŸããã
2022幎ã«ãããããã¯æ§RPIãçŽæ¥ææããŠãããã€ã€ã«ãã£ãã¡ãŒã ã€ã³ãã¹ãã¡ã³ã ICAVïŒRPI ICAVïŒã®çµæžçå©çã®82%ãéæ¥çã«ææããããã«ãªããŸããã
2023幎12æãRPI 2019 ICAVã¯ååŸæ®ãã®å©ç RPSFtãææããRPCtããã®ããã«ããŠRPSFtã¯ãã¯ãRPCtã«éæ¯é
çãªå©çãä¿æããŠããŸããã 2023幎12æ以åãåœç€Ÿã¯éæ¯é
çãªå©å®³å ±åã«é¢é£ããde minimisé¢äžãå ±åããŸãããRPSFtã«ãã£ãŠä¿æãããRPCtãããã¯ãŸããIPOããåã«ååšããŠããŸããã
財åå ±åã®ç解
ç§ãã¡ã®æè³ããŒããã©ãªãªã«ã¯ãããŸããŸãªåœ¢æ
ãã€ã³ã¹ãã¥ã«ã¡ã³ããéããŠä¿æããããã€ã€ãªãã£ããã³ãã€ã€ã«ãã£ã«é¡ããæ¡ä»¶ãå«ãŸããŠããŸãã ç§ãã¡ãååŸãããã€ã€ãªãã£ã®ã»ãšãã©ã¯ããã£ãã·ã¥ãããŒã®æµããžã®æè³ãšããŠåãæ±ãããç±³åœã®äžè¬çãªäŒèšååïŒãGAAPãïŒã«åŸã£ãŠå¹æçãªå©æ¯æ³ã«åºã¥ããŠæž¬å®ãããéèè³ç£ãšããŠåé¡ãããŸãã ãã®äŒèšæ¹æ³è«ã®äžã§ã¯ãåéèãã€ã€ãªãã£è³ç£ã®å¹æçãªå©æ¯çããéèãã€ã€ãªãã£è³ç£ã®å¯¿åœãéããŠåãåãèŠèŸŒã¿ã®ãããã£ãã·ã¥ãããŒã®äºæž¬ã«å¯ŸããååååŸäŸ¡æ Œã«å¯ŸããŠèšç®ããŸãã åå ±åææ«ã§èšç®ãããå©åãã¯ããã®åŸååãã«é©çšãããéèãã€ã€ãªãã£è³ç£ã®äºæ³å¯¿åœãéããå¹æçãªåççã§åçã«èªèãããŸãã
財åãã€ã€ã«ãã£è³ç£ããã®åçã®æž¬å®ã«ã¯ãåºç€ãšãªããã€ã€ãªãã£ã®äºæ³ãããå°æ¥ã®ãã£ãã·ã¥ãããŒãšè²¡åãã€ã€ã«ãã£è³ç£ã®äºæ³ãããæéãäºæž¬ããããã«ãéèŠãªå€æãšè©äŸ¡ãå¿
èŠãšãããŸããåŒç€Ÿã®ãã£ãã·ã¥ãããŒäºæž¬ã¯ã売ãæåŽã®æ ªåŒèª¿æ»ã¢ããªã¹ãã®å補åã«é¢ããåæèŠç©ãã販売äºæž¬ãäž»ã«äœ¿çšããŠãåå ±åæã«æŽæ°ãããŸãããã®åŸããããã®åæèŠç©ãã販売äºæž¬ã«åŒç€Ÿã®ãã€ã€ã«ãã£æ¡ä»¶ãé©çšããŠãäºæ³ããããã€ã€ã«ãã£ååé¡ãèšç®ããŸããäºæž¬ããããã£ãã·ã¥ãããŒãå®æçã«æŽæ°ããæ®ãã®å°æ¥ãã£ãã·ã¥ãããŒã®çŸåšäŸ¡å€ãåèšç®ããéã財åãã€ã€ã«ãã£è³ç£ã®ç°¿äŸ¡ãšæ¯èŒããŠäžè¶³ãããã°ããã®å·®é¡ã¯éçŸéã®ååŽè²»çšãšããŠçŽæ¥æçèšç®æžã«èšäžãããŸããåŸã®æéã«ãããŠãäºæ³ããããã£ãã·ã¥ãããŒãå¢å ããå Žåãå®éã®ãã£ãã·ã¥ãããŒã以åã«äºæ³ããããã®ããã倧ããå Žåã以åã«èšé²ãããååŽè²»çšã®äžéšãŸãã¯å
šé¡ããéçŸéã®ååŽè²»çšãšããŠèšé²ããããšã§ãååŽè²»çšãå·®ãåŒããŠããŸãã
æ䟡蚌åžåçè³ç£ã«æå¹å©åæ³ãé©çšããããšã«é¢é£ããéçŸéè²»çšã®çµæãåœç€Ÿã®ç°¡ç¥é£çµæçèšç®æžã®æŽ»åã¯å€åãæ¿ããäºæž¬äžå¯èœãšãªãããšããããŸããé·æéã«ããã売ãåŽãšã¯ã€ãã£ã»ãªãµãŒãã»ã¢ããªã¹ãã®ã³ã³ã»ã³ãµã¹è²©å£²äºæž¬ã®ããããªæžå°ã¯ãå°æ¥æ°å¹Žéã«çŸéæµå
¥ãå®çŸãããªãã«ãããããããå³æã®éçŸéæçèšç®æžã®è²»çšèªèã«ã€ãªããå¯èœæ§ããããŸããããšãã°ã2014幎åŸåã«ã·ã¹ãã£ãã¯ç·ç¶çãã©ã³ãã£ã€ãºãååŸããŸããããããã«å£²ãåŽãšã¯ã€ãã£ã»ãªãµãŒãã»ã¢ããªã¹ãã«ããè¿æªæ¥ã®è²©å£²äºæž¬ã®æžå°ã«ãããåœç€Ÿã®ç°¡ç¥é£çµæçèšç®æžã«éçŸéåŒåœè²»çšã®èªèãçããŸããã10ååæã«ãããã販売äºæž¬ã®å€åã«ããéçŸéåŒåœè²»çšãåŒãç¶ãèªèãã2017幎9æ30æ¥ãŸã§ã«13åãã«ã®ããŒã¯çŽ¯ç©åŒåœé¡ã«éããŸããã2019幎10æã«ãŽã¡ãŒããã¯ã¹ç€Ÿã®ããªãã«ã³ã³ãããŒã·ã§ã³çæ³ãããªã«ãã¿ã®æ¿èªãåãã売ãåŽãšã¯ã€ãã£ã»ãªãµãŒãã»ã¢ããªã¹ãã®ã³ã³ã»ã³ãµã¹è²©å£²äºæž¬ãæ¡å€§å¯èœãªåžå Žãåæ ããããªã«ãã¿ã®ãã€ã€ãªãã£ã®èŠèŸŒã¿æéã延é·ãããããšã§ãæ®ãã®11åãã«ã®çŽ¯ç©åŒåœé¡ãåãæ¶ãããŸããã2019幎ã«é¢é£ããéçŸéåŒåœåç110åãã«ã®èªèã¯ããã€ã€ãªãã£ã®åé ã«ã¯é¢ä¿ããŠãããã販売äºæž¬ã®å¢å ã«é¢é£ããŠããŸãããã®äŸã¯ãåœç€Ÿã®äŒèšã¢ãã«ãç°¡ç¥é£çµæçèšç®æžã«ããããå€åæ§ã瀺ããŠããŸãã
財åãã€ã€ã«ãã£è³ç£ããã®åå
¥ãšãã€ã€ãªãã£ååã«ã¯ã財åãã€ã€ã«ãã£è³ç£ã«é©çšãããäŒèšæ¹æ³è«ã®æ§è³ªã«ãããçŽæ¥çãªçžé¢é¢ä¿ã¯ãªããšèããŠããŸããããã«ã財åãã€ã€ã«ãã£è³ç£ããã®åå
¥ãšãããã®è²¡åãã€ã€ã«ãã£è³ç£ã«é¢é£ããäºæ³ãã£ãã·ã¥ãããŒã®å€æŽã«å¯Ÿããåœåº§é éã¯äžå®å®ã§äºæž¬ã§ããªãããšããããŸãã
ç§ãã¡ã®çš®é¡ã¯æŽå²çã«ããã€ã€ã«ãã£ã«ãã£ãŠçã¿åºããããã£ãã·ã¥ãããŒã§äž»ã«è³é調éãããŠããŸããããã£ãã·ã¥ãããŒã®éèŠæ§ãšäºæž¬å¯èœæ§ã¯ãããžãã¹ã®çµå¶ãè¡ãéã®ãããžã¡ã³ãã«ãšã£ãŠéåžžã«éèŠã§ããããããããžã¡ã³ãã¯ããŒããã©ãªãªåå
¥ïŒä»¥äžå®çŸ©ããïŒãåœç€Ÿã®çš®é¡ããã©ãŒãã³ã¹ã®äž»èŠææšãšããŠäœ¿çšããŠããŸãã詳现ã«ã€ããŠã¯ã â ããŒããã©ãªãªæŠèŠããåç
§ããŠãã ããã
äºæ¥æ瞟ã®çµæãç解ãã
åœç€ŸãææããŠããªãæåã«é¢é£ããéæ¯é
å©çãå ±åããŸããããã¯ãåœç€ŸãææããŠããªãé£çµåäŒç€Ÿã®äžéšã«èµ·å ãã次ã®ãã®ã«åž°å±ããŸãïŒ
1. ã¬ã¬ã·ãŒã€ã³ãã¹ã¿ãŒããŒãããŒã·ããã¯ãå€ãRPIãšRPI ICAVã®çŽ18%ãææããŠããŸãããã®éæ¯é
çå©çã®äŸ¡å€ã¯ãå€ãRPIãšRPI ICAVã®è³ç£ãçµéããã«ã€ããŠæéãšå
±ã«æžå°ããŸãã
2023幎12æãRPSFtãä¿æããŠããRPCtã®æ®ãã®å©çãååŸãããã®ããRPSFtã¯ãã¯ãRPCtã«å¯ŸããŠéæ¯é
çå©çãä¿æããŠããŸããã
ã¬ã¬ã·ãŒã»ã€ã³ãã¹ã¿ãŒãºã»ããŒãããŒã·ãããšRPSFtã¯ããã¬ã¬ã·ãŒéæ¯é
çå©çããšããŠèšåãããŠããŸããã¬ã¬ã·ãŒéæ¯é
çå©çã¯ãç§ãã¡ã®IPOã®åã«ååšããŠããå¯äžã®æŽå²çãªéæ¯é
çå©çã§ãã
ããã«ãIPOã®å®äºåŸãç§ãã¡ã¯æ¬¡ã®ãããªéæ¯é
çå©çã«é¢ããå ±åãè¡ããŸã:
3. ç¶ç¶çãªæè³å®¶ããŒãããŒã·ãããRP Holdingsã«ãããæææš©æ¯çã¯2024幎9æ30æ¥æç¹ã§çŽ24ïŒ
ã§ããã RP Holdings Class b Interestsã¯Class Aæ®éæ ªåŒã«æéã§ããŸããç¶ç¶çãªæè³å®¶ããŒãããŒã·ããã亀æãå®æœãããšãRP Holdingsã«ãããç¶ç¶çãªæè³å®¶ããŒãããŒã·ããã®æææš©æ¯çãæžå°ãããã®éæ¯é
çåºè³ã®äŸ¡å€ãæžå°ããŸããããã«ãRP Holdingsã¯ãç§ãã¡ãClass Aæ®éæ ªåŒãè²·ãæ»ãååŒã«äŒŽã RP Holdings Class A Interestsãåéãå§ããŸããã RP HoldingsãRP Holdings Class A InterestsãåéãããšãRP Holdingsã«ãããç§ãã¡ã®æææš©æ¯çãæžå°ãããã®éæ¯é
çåºè³ã®äŸ¡å€ãå¢å ããŸãã
ç¶ç¶ããæè³å®¶ããŒãããŒã·ããã¯ããç¶ç¶çãªéæ¯é
çæåããšåŒã°ããŸãã
RPI EPA Holdings, LPïŒä»¥äžãEPA HoldingsããšããïŒãRP Holdingsã®Cã¯ã©ã¹æ®éæ ªïŒä»¥äžãRP Holdings Class Cç¹å¥å©çãïŒãææããŠããŸãã
EPAããŒã«ãã£ã³ã°ã¹ã¯ãRPããŒã«ãã£ã³ã°ã¹ã¯ã©ã¹Cç¹å¥å©çïŒãEquity Performance AwardsãïŒãéããŠæ ªåŒé
åœãåãåãæš©å©ããããŸãã EPAããŒã«ãã£ã³ã°ã¹ã«æ¯æãããEquity Performance Awardsã¯ã矩åãçºçãåçãRPããŒã«ãã£ã³ã°ã¹ã¯ã©ã¹Cç¹å¥å©çã«å²ãåœãŠãããéã«æ ªåŒååŒãšããŠèªèãããŸãã Equity Performance Awardsã¯ãClass Aæ®éæ ªåŒã«åŒãæããŠçºè¡ãããRPããŒã«ãã£ã³ã°ã¹ã¯ã©ã¹bå©çã§æ¯æãããŸãã EPAããŒã«ãã£ã³ã°ã¹ã¯ãRPããŒã«ãã£ã³ã°ã¹ã¯ã©ã¹Cç¹å¥å©çã«é¢ããŠãå¿
èŠã«å¿ããŠãEPAããŒã«ãã£ã³ã°ã¹ãŸãã¯ãã®åçè
ããããRPããŒã«ãã£ã³ã°ã¹ã¯ã©ã¹Cç¹å¥å©çãä¿æããããšã«ãã£ãŠèª²ããããæåŸçšãæ¯æãããã«æ¯æãããå®æçãªãã£ãã·ã¥ã¢ããã³ã¹ãåãåãå ŽåããããŸããçŸåšãç¹å®ã®æ¥çžŸæ¡ä»¶ãéæããããšèŠèŸŒãŸãã2025幎ã«Equity Performance Awardsã®æ¯æããè¡ãããããšãæåŸ
ããŠããŸãã
ç·åå
¥ãšãã®ä»ã®åç
ç·åå
¥ããã³ãã®ä»ã®åçã¯ãäž»ã«éèç宀è³ç£ããã®å©æ¯åå
¥ãç 究éçºïŒ"RïŒD"ïŒè³éæäŸå¥çŽã«åºã¥ã補åã®åæ¥åã«ãã£ãŠäžè¬çã«çºçãããã€ã€ã«ãã£åå
¥ããæ§æãããŠããŸããã»ãšãã©ã®ãã€ã€ã«ãã£ã¯ãæææš©ãäžè¬çã«ä¿è·çãã€ååçã§ãããããéèè³ç£ãšããŠåé¡ãããŸããäžéšã®ã±ãŒã¹ã§ã¯ãç¥ç財ç£æš©ãå«ãããå®è³ªçãªæš©å©ãæææš©ãå«ããã€ã€ãªãã£ãååŸããããšãããããã®ãããªãã€ã€ã«ãã£ãç¡åœ¢è³ç£ãšããŠåé¡ãããããã®ç¡åœ¢ã®ãã€ã€ã«ãã£è³ç£ããåçãèªèããŸãã
ãã®ä»åçã®10ïŒ
以äžãå ãããã€ã€ãªãã£æ¯æè
ã¯ã以äžã®è¡šã«ç€ºãããŠããŸã:
2021幎9æ30æ¥çµäºã®3ãæéã®æ±ºç®ã«ã€ã㊠2021幎9æ30æ¥çµäºã®9ãæéã®æ±ºç®ã«ã€ã㊠ãã€ã€ã«ãã£æ¯æãè
ãã€ã€ã«ã㣠2024 2023 2024 2023 ããŒããã¯ã¹ ã·ã¹ãã£ãã¯ãã£ãããŒã·ã¹ã®ãã©ã³ãã£ã€ãº 36 % 41 % 37 % 36 % ãã·ã¥ ãšãŽãªã¹ãã£ããã«ã»ã© 10 % * 10 % *
*10%æªæºãè¡šããŸãã
財åç宀è³ç£ããã®åå
¥
åœç€Ÿã®è²¡åçäœè³ç£ã¯ãä¿®æ£è²»çšæ³ã«åºã¥ããŠæž¬å®ãããããŒã³ã«æã䌌ãå©åãéšåãæã€ãã£ãã·ã¥ã»ãããŒã»ã¹ããªãŒã ãžã®æè³ãè¡šããŸãããã€ã€ã«ãã£è³ç£ã®ååååŸäŸ¡æ Œã«å¯Ÿãã寿åœå
šäœã§åãåãäºæ³ããããã£ãã·ã¥ã»ãããŒã䜿çšããŠãæå¹å©åçãèšç®ããŸãã éå©åå
¥ã¯ãè³ç£ã®äºæ³å¯¿åœå
šäœã§ã®æå¹åççã§èªèãããå ±åæã®çµããã«èšç®ãããå°æ¥çã«é©çšãããŸãã ã»ã«ãµã€ãã®æ ªåŒèª¿æ»ã¢ããªã¹ãã®ã³ã³ã»ã³ãµã¹å£²äžäºæ³ã®å€åãããæå¹åççãååæããšã«æŽæ°ãããŸããäŸãã°ãã»ã«ãµã€ãã®æ ªåŒèª¿æ»ã¢ããªã¹ãã®ã³ã³ã»ã³ãµã¹å£²äžäºæ³ãå¢å ãããšãéèçäœè³ç£ã§ã®åå
¥ãå°ãåºãå©åããäžæãããã®çµæãåŸç¶æéã®åå
¥ãå¢å ããŸãã
å°æ¥çãªæå¹å©æ¯æ¹æ³ã«åºã¥ãéèãã€ã€ãªãã£è³ç£ããã®å©ååå
¥ã®èªèã«åœ±é¿ãäžããå€æ°ã®äžã€ã«ã¯ã次ã®ãããããå«ãŸããŸãïŒ(1) è¿œå ã®ååŸã(2) äžéšã®å»è¬å補åã®äºæ³ãã£ãã·ã¥ãããŒã®å€æŽãäž»ã«å£²ãæåŽã®ãšã¯ã€ãã£ãªãµãŒãã¢ããªã¹ãã®ã³ã³ã»ã³ãµã¹è²©å£²äºæž¬ã«ç±æ¥ã(3) æ°ãããã£ãã·ã¥ãããŒåçãããããè¿œå ã®é©å¿ã®èŠå¶æ¿èªã(4) ãã€ã€ã«ãã£ã®èŠç©ããæéã®å€æŽïŒããšãã°ãç¹èš±æºäºæ¥ïŒã(5) äºæ³ããããã€ã€ã«ãã£ã®ååããã³ãã€ã«ã¹ããŒã³æ¯æã®éé¡ããã³ã¿ã€ãã³ã°ã®å€æŽãããã³(6) ãã€ã€ã«ãã£å¯Ÿè±¡ã§ãã売äžã®éšåã®å€æŽãããã¯ãã€ã€ã«ãã£å¯Ÿè±¡è²©å£²ãšããŠèšåãããŠããŸãã åœç€Ÿã®éèãã€ã€ã«ãã£è³ç£ã¯ãéåžžç¹å®ã®æç¹ã§ããŒã¯ãè¿ããäžéšå»è¬å補åã®å£²äžã«çŽæ¥é¢é£ããŠãããçµæãšããŠè³ç£æ®é«ãšãã€ã€ã«ãã£ã®å¯¿åœãéããå®æçãªå©ååå
¥ã«èªç¶ãªæžå°ãçããŸãã ãã€ã€ã«ãã£ããã®å©ååå
¥ã®èªèã«ã¯ãäžèšã®å€æ°ã«åœ±é¿ãäžããèŠçŽ ãåãå²ãå€ãã®èŠçŽ ã«ã€ããŠã®çµå¶äžã®èŠç©ãããšä»®å®ãå¿
èŠã§ãã
ãã®ä»ã®çæåå
¥ããã³åç
ãã®ä»ã®ãã€ã€ã«ãã£åå
¥ããã³åçã«ã¯ãå®å
šã«ååŽãããéèãã€ã€ã«ãã£è³ç£ããã®åå
¥ããRïŒDè³éæäŸå¥çŽããçããã·ã³ã»ãã£ãã¯ãã€ã€ã«ãã£ããã€ã«ã¹ããŒã³ããã®åå
¥ãäž»ã«å«ãŸããŠããŸããææãååã®æžå¿µã«ãããã€ã€ã«ãã£è³ç£ãå éååŽãããå Žåãããã解決ããã°å°æ¥ã®çŸéååãçºçãããããããŸãããããã®éãéèãã€ã€ã«ãã£è³ç£ãæ®ã£ãŠããªãå ŽåããããŸããåæ§ã«ãéèãã€ã€ã«ãã£è³ç£ãå®å
šã«ååŽãããå Žåã§ããæšå®æéãè¶
ããŠåŒãç¶ããã€ã€ã«ãã£ãåé ããããšããããŸããéèãã€ã€ã«ãã£è³ç£ãå®å
šã«ååŽãããã·ããªãªã§ã¯ããã®ãããªãã€ã€ã«ãã£ããã®åå
¥ãèªèãããŸãã ãã®ä»ã®ãã€ã€ãªãã£åå
¥ããã³åç .
ãã®ä»ã®ãã€ã€ãªãã£åå
¥ãåçã«ã¯ãç¡åœ¢ãã€ã€ãªãã£è³ç£ããã®åçããåœç€Ÿã®ççž®é£çµè²žå察ç
§è¡šã«å
¬æ£äŸ¡å€ã§èšé²ããããã€ã€ã«ãã£ããã®åçãå«ãŸããŠããŸãã
財åç宀è³ç£ã®äºæ³çŸéãããŒå€æŽã®ããã®åã
äºæ³ãããçŸéãããŒã®å€åã«å¯Ÿããéèãã€ã€ãªãã£è³ç£ããã®åŒåœé 次ã®ãã®ãå«ã
⢠äºæ³ããããã£ãã·ã¥ãããŒã®å€æŽã«é¢é£ãã环ç©åµååŒåœéã®èª¿æŽã«ãããçŸåšæéã®æŽ»åã«é¢é£ããéçŸéã®åå
¥ãŸãã¯è²»çš;
⢠åœåº§ã®ä¿¡çšæ倱ã«é¢é£ããéçŸéã®è²»çšãŸãã¯åçã¯ãäž»ã«æ°ãã財åãã€ã€ã«ãã£è³ç£ãéãããä¿è·æš©ãæã€è²¡åãã€ã€ã«ãã£è³ç£ã®ãã£ãã·ã¥ãããŒèŠç©ããã®å€æŽã«èµ·å ããæéã®æŽ»åãåæ ããŠããŸãã
åçã¯ãæå¹å©åæ³ã䜿çšããŠã財åç¹èš±è³ç£ã«ç©ã¿äžããããŸããäºæž¬ããããã£ãã·ã¥ãããŒãå®æçã«æŽæ°ããæ®ãã®å°æ¥ãã£ãã·ã¥ãããŒã®çŸåšäŸ¡å€ãåèšç®ããéã財åç¹èš±è³ç£ã®åž³ç°¿äŸ¡æ Œãšæ¯èŒããŠäžè¶³ãããå Žåã¯ãè²»çšé
åãéããŠçŽæ¥åççµ±åæçèšç®æžã«èšé²ãããŸãã äºæ³ãããçŸéãããŒã®å€åã«å¯Ÿããéèãã€ã€ãªãã£è³ç£ããã®åŒåœé 次ã®æéã«ãããŠãäºæ³ããããã£ãã·ã¥ãããŒãå¢å ããå Žåããäºåã«äºæ³ããããã£ãã·ã¥ãããŒãããå®éã®ãã£ãã·ã¥ãããŒãå¢å ããå Žåãåè¿°ã®åŒåœéè²»çšãäžéšãŸãã¯å
šé¡åãæ¶ããåŒåœéã«ä¿¡çšãèšé²ããŸãã
äžèšã®è²¡åãã€ã€ã«ãã£è³ç£ã«é¢ããå©ååå
¥ã®èªèã«åœ±é¿ãäžããåãå€æ°ãšçµå¶ã®èŠç©ããã¯ãåããçŽæ¥çã«åœ±é¿ããŸãã
ç 究éçºã®è³éæ¯åº
調æ»éçºè²»çšã¯ã補ååè£ã«é¢ãããã€ã€ãªãã£ããã€ã«ã¹ããŒã³ãååŸããããã«åœäºè
ã«æ¯æã£ãæ¯æããå«ã¿ãŸããäºåæããŸãã¯æ¿èªåã®ãã€ã«ã¹ããŒã³ã«åºã¥ãåœäºè
ãžã®éçºæ®µéã®è³éæäŸæ¯æããããã³é¢é£ãã補ååè£ãåœäºè
ãšãšãã«èšåºè©Šéšãåããã«ã€ããŠåœäºè
ã«æ¯æãããéçºæ®µéã®è³éæäŸæ¯æããå«ã¿ãŸãã
äžè¬åã³ç®¡çè²»çš
äžè¬ããã³ç®¡çïŒä»¥äžã§å®çŸ©ãããïŒãªãã¬ãŒã·ã§ã³ããã³äººå¡ã®æ¯æããæ³çè²»çšããã®ä»ã®ãããã§ãã·ã§ãã«ãµãŒãã¹ãªãã³ã«ã·ã§ã¢ããŒã¹ã®å ±é
¬ãå«ãäžè¬ç®¡çè²»ã¯ãäžè¬ç®¡çè²»ã®æãéèŠãªæ§æèŠçŽ ããªããªãã¬ãŒã·ã§ã³ããã³äººå¡ã®æ¯æãã«é¢é£ããè²»çšã§ãã
管çåå®ã«åºã¥ããç§ãã¡ã¯ãã€ã€ã«ãã£æè³ïŒç®¡çåå®ã§å®çŸ©ããããã®ïŒããã®çŸéåå
¥ã®6.5ïŒ
ããŸãã¯åœè©²ååæã®ããŒããã©ãªãªåå
¥ã«å¯ŸããŠããããŒãžã£ãŒãŸãã¯ãã®é¢é£äŒç€ŸïŒãéå¶ããã³äººå¡æ¯æããïŒã«ååæããšã«æ¯æããããã³ãã®ååææ«çŸåšã®ã»ãã¥ãªãã£æè³ã®GAAPã«åºã¥ã䟡å€ã®0.25ïŒ
ãæ¯æããŸãã
Legacy Investors Partnershipsã®éæ¯é
çå©çãšããŠã®Old RPIã®äºæ¥ããã³äººå¡æ¯æããããã³ãã®è²»çšãGïŒAè²»çšã§åæ ããã矩åã¯ãåã®12ãæéã®ã«ã¬ã³ããŒã«å®çŸ©ãããRoyalty InvestmentsïŒLegacy Investors Partnershipsã®æé責任äºæ¥çµåå¥çŽã§å®çŸ©ãããŠããïŒããåŸããããã€ã€ã«ãã£ãŒã®0.3125ïŒ
ãŸãã¯ã¯ã©ãŒã¿ãŒããã$100äžã®å€§ããæ¹ã§èšç®ãããŸãã
æåæ³é¢é£äŒç€Ÿã«ããã(å©ç)/æ倱ã®æå
æåæ³é©çšé¢é£äŒç€Ÿã®ïŒçŽå©çïŒ/æ倱ã«ãããæ ªäž»ã«åž°å±ããå©çãŸãã¯æ倱ã¯ã次ã®éé£çµé¢é£äŒç€Ÿããã®åçãŸãã¯æ倱ã®ã·ã§ã¢ãäž»ã«å«ãã§ããŸãïŒ
1. ã¬ã¬ã·ãŒSLPå©æ¯ã ãšã¯ã¹ãã§ã³ãžã»ãªãã¡ãŒã«é¢é£ããŠãåäŒç€Ÿã®æ ªåŒã®çºè¡ãšåŒãæãã«ãã¬ã¬ã·ãŒã»ã€ã³ãã¹ã¿ãŒãºã»ããŒãããŒã·ããã®ç¹å¥ãªããããã»ããŒãããŒã·ããæåïŒãã¬ã¬ã·ãŒã»SLPæåãïŒãšãã圢ã§ãã³ã³ãã£ãã¥ã€ã³ã°ã»ã€ã³ãã¹ã¿ãŒãºã»ããŒãããŒã·ããããæåæ³æè³ãååŸããŸãããã¬ã¬ã·ãŒSLPå©æ¯ã«ãããã¬ã¬ã·ãŒã»ã€ã³ãã¹ã¿ãŒãºã»ããŒãããŒã·ããã®ãŒãã©ã«ããŒãããŒã«æ¯æãããã¯ãã®æ¥çžŸåé
éãšåçã®æ¯æããšãåæ§ã®åºæºã§ã®æ¥çžŸå©çé
åãåããããšãã§ããŸããã¬ã¬ã·ãŒã»ã€ã³ãã¹ã¿ãŒãºã»ããŒãããŒã·ããã¯ãã¯ãæè³æ©äŒã«åå ããŠããªããããã¬ã¬ã·ãŒã»SLPæåã®äŸ¡å€ã¯æéã®çµéãšãšãã«äœäžãããšäºæ³ãããŸãã
2. ã¢ããªãªã³ã»ãšã³ãã£ãã£ã ã¢ããªãªã³ã»ãšã³ãã£ãã£ïŒä»¥äžã§å®çŸ©ãããïŒã¯ãååŒæã§ã°ããŒãã«ãªãã€ãªå»è¬åäŒç€Ÿãšææºãã補åãåååãããã°æåããŒã¹ã®ãã€ã«ã¹ããŒã³ãŸãã¯ãã€ã€ã«ãã£ãšåŒãæãã«ç 究éçºãè¡ããã¢ããªãªã³ãã¡ã€ãã³ã¹I, LPïŒâã¢ããªãªã³IâïŒããã³BAvãã¡ã€ãã³ã¹II, LPïŒâã¢ããªãªã³IIâããã³ã¢ããªãªã³IãšåãããŠãâã¢ããªãªã³ã»ãšã³ãã£ãã£âïŒãžã®æè³ã¯ãæåæ³ã«ãã£ãŠåŠçãããã
ãã®ä»ã®æåœãŠãçŽåç
ãã®ä»ã®åå
¥ã¯ãäž»ã«èªå·±è³æ¬èšŒåžãããªããã£ãååŒããã³å£²åŽçšåµåžã®å
¬æ£åžå ŽäŸ¡å€ã®å€åãé¢é£ããé²è¡ååŒããã³è³éã®ç¢ºå®ãããã³å©æ¯åå
¥ãå«ã¿ãŸãã
éæ¯é
æ ªäž»ã«åž°å±ããåœæçŽå©ç
é¢é£åœæçŽå©çã«ã¯ãæ§èŠªäºæ¥è
ã«åž°å±ããå©çãšç¶ç¶èŠªäºæ¥è
ã«åž°å±ããå©çãå«ãŸããŸãã2023幎12æã«RPSFtãä¿æããRPCtã®æ®ãã®èŠªæš©å©çãååŸããåŸãããã³ã¬ã¬ã·ãŒæè³å®¶ããŒãããŒã·ãããæè³æ©äŒã«åå ããªããªã£ãããšãããæ§èŠªäºæ¥è
ã«åž°å±ããé¢é£åœæçŽå©çã¯ãOld RPIããã³RPI ICAVãææããè³ç£ãæçããã«ã€ããŠæéã®çµéãšãšãã«ããã«æžå°ããèŠèŸŒã¿ã§ãã
åœæçŽå©çã«åž°å±ããç¶ç¶ããéæ¯é
æåã«ã¯ãç¶ç¶æè³ããŒãããŒã·ãããä¿æããRP Holdingsã¯ã©ã¹bã€ã³ã¿ã¬ã¹ããå«ãŸããããã¯2025幎ã«ç¹å®ã®æ¥çžŸæ¡ä»¶ãéæãããéã«EPA Holdingsãä¿æããRP Holdingsã¯ã©ã¹Cç¹å¥ã€ã³ã¿ã¬ã¹ãã«åž°å±ããåœæçŽå©çãå«ãŸããèŠèŸŒã¿ã§ããç¶ç¶æè³ããŒãããŒã·ãããéæ¥çã«ä¿æããRP Holdingsã¯ã©ã¹bã€ã³ã¿ã¬ã¹ãã«é¢é£ããéæ¯é
æåã«åž°å±ããå°æ¥ã®åœæçŽå©çã¯ãæè³å®¶ãåœç€Ÿã®Aã¯ã©ã¹æ®éæ ªåŒãšäº€æãè¡ã£ãå Žåãæéãšãšãã«æžå°ããŸãã
åœæçŽå©çã¯ãäžèšã®éæ¯é
æåã«åž°å±ãããã®ã¯ãäž»ã«åœç€Ÿã®è²¡åãã€ã€ã«ãã£è³ç£ã«æå¹å©çäŒèšæ¹æ³ãé©çšããããšã«äŒŽãéçŸéè²»çšã«ããåçèšç®æŽ»åã®å€åã«é§åãããæããæãžèããå€åããããšããããŸãããã®å€åã¯ãåœç€Ÿã®è²¡åè€åãã®ã»ã¯ã·ã§ã³ã§èª¬æãããŠããè³ç£ã®æåŸæå¹å©çè¡šã®æŽ»åã®å€åã«é§åãããŸãã
æ¥çžŸ
éå»ã®æ¥çžŸã®æ¯èŒã¯ä»¥äžã®éãã§ãïŒååäœïŒïŒ
9æ30æ¥ã«çµäºãã3ãæéã å€æŽããŸã 9æ30æ¥ã«çµäºãã9ãæéã¯ã å€æŽããŸã 2024 2023 $ % 2024 2023 $ % åå
¥ãšãã®ä»ã®åå
¥ éèãã€ã€ã«ãã£è³ç£ããã®åå
¥ $ 533,166 $ 508,657 24,509 4.8 $ 1,587,577 $ 1,674,689 (87,112) (5.2) ãã®ä»ã®ãã€ã€ãªãã£åå
¥ãšåå
¥ 31,524Â 27,656Â 3,868Â 14.0Â 82,358Â 83,797Â (1,439) (1.7) ç·åå
¥ãšãã®ä»ã®åå
¥ 564,690  536,313  28,377  5.3 1,669,935  1,758,486  (88,551) (5.0) å¶æ¥ïŒåçïŒ/è²»çš éèãã€ã€ã«ãã£è³ç£ããã®äºæ³ãã£ãã·ã¥ãããŒã®å€ååŒåœé (227,604) 277,137 (504,741) * 568,425 637,169 (68,744) (10.8) ç 究éçºè³éçµè²» 500 50,500 (50,000) (99.0) 1,500 51,500 (50,000) (97.1) äžè¬ç®¡çè²» 56,720 57,234 (514) (0.9) 169,080 190,563 (21,483) (11.3) å¶æ¥å©çïŒåçïŒ/è²»çšã®åèšãçŽé¡ (170,384) 384,871  (555,255) * 739,005  879,232  (140,227) (15.9) å¶æ¥å©ç 735,074  151,442  583,632  385.4 930,930  879,254  51,676  5.9 ãã®ä»ïŒåå
¥ïŒ/è²»çš æåæ³æè³å
ã®æ ªåŒïŒåçïŒ/æ倱 (10,407) 5,222 (15,629) * 2,039 (28,614) 30,653 * æ¯æå©æ¯ 66,506 46,033 20,473 44.5 159,751 139,932 19,819 14.2 ãã®ä»ã®åçãçŽé¡ (127,383) (21,890) (105,493) 481.9 (227,322) (214,566) (12,756) 5.9 ãã®ä»ïŒåå
¥ïŒ/çµè²»ã®åèšãçŽé¡ (71,284) 29,365  (100,649) * (65,532) (103,248) 37,716  (36.5) é£çµçŽå©ç 806,358  122,077  684,281  560.5 996,462  982,502  13,960  1.4 éæ¯é
æ ªäž»ã«åž°å±ããåœæçŽå©ç 262,371 49,963 212,408 425.1 345,693 342,008 3,685 1.1 ãã€ã€ã«ãã£ã»ãã¡ãŒã瀟ã«åž°å±ããçŽå©ç $ 543,987  $ 72,114  471,873  654.3 $ 650,769  $ 640,494  10,275  1.6Â
*å€åçã¯æå³ããããŸããã
ç·åå
¥ãšãã®ä»ã®åç
財ç£ããã®ãã€ã€ã«ãã£åå
¥
2024幎ã®æåã®9ãµæã®åå
¥ã«ãããããã補åå¥ã®è²¡åãã€ã€ã«ãã£è³ç£ããã®åå
¥ã¯æ¬¡ã®éãã§ãïŒåäœïŒåãã«ïŒïŒ
2021幎9æ30æ¥çµäºã®3ãæéã®æ±ºç®ã«ã€ã㊠å€æŽ 2021幎9æ30æ¥çµäºã®9ãæéã®æ±ºç®ã«ã€ã㊠å€æŽ 2024 2023 $ % 2024 2023 $ % ã·ã¹ãã£ãã¯ãã£ãããŒã·ã¹ã®ãã©ã³ãã£ã€ãº $ 205,701 $ 218,938 (13,237) (6.0) $ 619,113 $ 631,813 (12,700) (2.0) ãšããªã¹ã㣠56,747 20,519 36,228 176.6 166,277 58,005 108,272 186.7 ãã¬ã¬ãžãŒ 37,593 32,234 5,359 16.6 110,272 96,571 13,701 14.2 Tremfya 37,293 36,937 356 1.0 109,137 114,422 (5,285) (4.6) ã€ã ãã«ãã« 32,139 38,463 (6,324) (16.4) 100,280 136,785 (36,505) (26.7) ã¿ã€ãµã㪠30,355 42,682 (12,327) (28.9) 93,722 130,658 (36,936) (28.3) ãã®ä»è£œå 133,338 118,884 14,454 12.2 388,776 506,435 (117,659) (23.2) éèãã€ã€ã«ãã£è³ç£ããã®ç·åå
¥ $ 533,166 Â $ 508,657 Â 24,509 Â 4.8Â $ 1,587,577 Â $ 1,674,689 Â (87,112) (5.2)
2024幎9æ30æ¥ãŸã§ã®3ãæãš2023幎
2024幎第3ååæã«ã財åãã€ã€ã«ãã£ãŒè³ç£ããã®åå
¥ã¯ã2023幎第3ååæãšæ¯èŒããŠ2450äžãã«ããŸãã¯4.8%å¢å ããŸãããããã¯äž»ã«ã2023幎第4ååæããã³2024幎第2ååæã«ååŸããEvrysdiããã®åå
¥ã®å¢å ã«ãããã®ã§ãã ãã®å¢å ã¯ã売ãæåŽã®æ ªåŒãªãµãŒãã¢ããªã¹ãã«ããå¢èæ§ç·ç¶çãã©ã³ãã£ã€ãºã®ã³ã³ã»ã³ãµã¹å£²äžäºæž¬ã®æžå°ã«ãã£ãŠäžéšçžæ®ºãããŸããã
2024幎9æ30æ¥ããã³2023幎ã®9ãæ
2024幎ã®æåã®9ãæéã«ããã¡ã€ã¶ãŒã®ã¶ããã¬ããã®FDAæ¿èªã«ããã2023幎ã®æåã®9ãæéãšæ¯èŒããŠãéèãã€ã€ã«ãã£è³ç£ããã®åå
¥ã¯8,710äžãã«ããŸãã¯5.2ïŒ
æžå°ããŸããããã®FDAæ¿èªã«ããã2023幎第1ååæã«åœç€Ÿã¯$47,500äžã®ãã€ã«ã¹ããŒã³æ¯æããš$15,360äžã®å©ååå
¥ãåãåããŸããããããã¯äžèšã®è¡šã®ãã®ä»è£œåã«åæ ãããéåçºçåå
¥ã§ããããã®æžå°ã¯ã2023幎第4ååæãš2024幎第2ååæã«ååŸããå¢åãã€ã€ã«ãã£ã«èµ·å ããEvrysdiããã®åå
¥ã®å¢å ã«ãã£ãŠéšåçã«çžæ®ºãããŸããã
ãã®ä»ã®çæããã®åå
¥ãšåç
2024幎9æ30æ¥ãŸã§ã®3ãæéãš2023幎
ãã®ä»ã®ãã€ã€ã«ãã£åå
¥ãšåçã¯ã2024幎第3ååæã«2023幎第3ååæãšæ¯èŒããŠ390äžãã«ããŸãã¯14.0%å¢å ããŸãããããã¯äž»ã«Nurtec ODtãšTrodelvyã®å£²äžæé·ã«é¢é£ããŠãããå®å
šã«ååŽãããéèãã€ã€ã«ãã£è³ç£ããã®åå
¥ã®æžå°ã«éšåçã«çžæ®ºãããŸããã
2024幎9æ30æ¥ããã³2023幎ã®9ãæ
ãã®ä»ã®ãã€ã€ã«ãã£åå
¥ãšåçã¯ã2024幎ã®æåã®9ã¶æãš2023幎ã®æåã®9ã¶æãšæ¯èŒããŠã»ãŒæšªã°ãã§ããã
財åç宀è³ç£ã®äºæ³çŸéãããŒå€æŽã®ããã®åã
åã掻åã¯åå
¥ãšè²»çšé
ç®ã®çµã¿åããã§ããæéããšã®åã掻åã®æ倧ã®è²¢ç®è
ã«åºã¥ããŠãã€ã€ã«ãã£è³ç£å¥ã®åãåæïŒçŸè¡ã®äºå®ä¿¡çšæ倱åããé€ãïŒïŒåååäœïŒã¯æ¬¡ã®ããã«ãªããŸãã
2024幎9æ30æ¥ãŸã§ã®3ãæéã«ããã 2023幎9æ30æ¥ãŸã§ã®3ã¶æéã®å£²äžé«ã«ã€ã㊠ãã€ã€ã«ã㣠ãã€ã€ã«ã㣠ã¿ã€ãµã㪠$ (76,489) ã¿ã€ãµã㪠$ 145,004 Xtandi (52,410) Xtandi 52,705 ã·ã¹ãã£ãã¯ãã£ãããŒã·ã¹ã®ãã©ã³ãã£ã€ãº (44,501) Tremfya 45,873 ãšããªã¹ã㣠(36,513) Tazverik 6,606 ãã¬ã¬ãžãŒ (24,885) Crysvita (11,467) ä» (26,529) ä» 8,504 信çšæ倱åŒåœéãé€ããç·åŒåœé (261,327) ä¿¡çšæ倱åŒåœéãé€ããç·åŒåœé 247,225  çŸåšã®äºæ³ä¿¡çšæ倱åŒåœé 33,723 çŸåšã®äºæ³ä¿¡çšæ倱åŒåœé 29,912 ç·åŒåœé $ (227,604) ç·åŒåœé $ 277,137 Â
2024幎9æ30æ¥ãŸã§ã®9ã¶æéã«ã€ã㊠2023幎9æ30æ¥ãŸã§ã®9ãæé ãã€ã€ã«ã㣠ãã€ã€ã«ã㣠ãšããªã¹ã㣠$ 208,212 ã€ã ãã«ãã« $ 231,453 ã·ã¹ãã£ãã¯ãã£ãããŒã·ã¹ã®ãã©ã³ãã£ã€ãº 187,996 Tremfya 151,563 ã¯ãªã·ãã¿ 142,089 ã¿ã€ãµã㪠143,998 Promacta 59,410 Xtandi 60,536 ã¿ã€ãµã㪠(85,475) ãšããªã¹ã㣠(46,077) ä» (7,761) ä» 64,291 åæž¡éç·é¡ãä¿¡çšæ倱ã«é¢ããåæž¡éãé€ã 504,471  åæž¡éç·é¡ãä¿¡çšæ倱ã«é¢ããåæž¡éãé€ã 605,764  çŸåšã®äºæ³ä¿¡çšæ倱ã®ããã®åæž¡é 63,954 çŸåšã®äºæ³ä¿¡çšæ倱ã®ããã®åæž¡é 31,405 ç·åæž¡é $ 568,425  ç·åæž¡é $ 637,169 Â
2024幎9æ30æ¥ãš2023幎ã®äžãæé
2024幎第3ååæã«ã¯ãäºæ³ããããã£ãã·ã¥ãããŒã®å€åã«å¯Ÿãã2å6130äžãã«ã®åŒåœåå
¥ãšãçŸåšã®äºæ³ä¿¡çšæ倱ã«å¯Ÿãã3,370äžãã«ã®åŒåœè²»çšãããªãã2å2760äžãã«ã®åŒåœåå
¥ãèšé²ããŸããã売ããµã€ãæ ªåŒã¢ããªã¹ãã®ã³ã³ã»ã³ãµã¹è²©å£²äºæž¬ãå¢å ãããããTysabriãXtandiãå¢èæ§ç·ç¶çãã©ã³ãã£ã€ãºãããã³Evrysdiã«é¢é£ããäºæ³ããããã£ãã·ã¥ãããŒã®å€åã«å¯ŸããåŒåœåå
¥ãèšé²ããŸãããä¿¡çšæ倱ã®åŒåœè²»çšã¯ãYorvipathãããŒããã©ãªãªã«è¿œå ããããšã«ãããäž»ã«å¢å ããŸããã
2023幎第3ååæã«ã¯ãäºçŽè²»çšã®åçã2å7710äžãã«èšé²ããããã®å
èš³ã¯äºæ³ããããã£ãã·ã¥ãããŒã®å€æŽã«äŒŽã2å4720äžãã«ã®äºçŽè²»çšãšçŸåšã®äºæ³ä¿¡çšæ倱ã«é¢ãã2990äžãã«ã®äºçŽè²»çšããæ§æãããŠããŸããäºæž¬ããããã£ãã·ã¥ãããŒã®å€æŽã«é¢é£ããäºçŽè²»çšã¯ãäž»ã«TysabriãXtandiãTremfyaã«èµ·å ããŠããã売ãæã®æ ªåŒãªãµãŒãã¢ããªã¹ãã®ã³ã³ã»ã³ãµã¹è²©å£²äºæž¬ã®äœäžã«èµ·å ããŠããŸããä¿¡çšæ倱ã«å¯ŸããäºçŽè²»çšã¯ãäž»ã«SkytrofaãšAdstiladrinã®åœç€ŸããŒããã©ãªãªãžã®è¿œå ã«ãã£ãŠåŒãèµ·ããããŸããã
2024幎9æ30æ¥ããã³2023幎ã®9ãæ
2024幎ã®æåã®9ãæéã«ãäºåéé¡ã5å6840äžãã«ã«èšé²ãããŸããããã®å
èš³ã¯ãäºæ³ããããã£ãã·ã¥ãããŒã®å€åã«å¯Ÿãã50å4500äžãã«ã®äºåéé¡ãšãçŸåšã®äºæ³ä¿¡çšæ倱ã«å¯Ÿãã6,400äžãã«ã®äºåéé¡ãå«ãŸããŠããŸããäºæ³ããããã£ãã·ã¥ãããŒã®å€åã«å¯Ÿããäºåéé¡ã¯ãäž»ã«Evrysdié¢é£ã§å£²ã売ãåŽæ ªåŒã¢ããªã¹ãã®åæèŠéã販売äºæž¬ã®æžå°ã«èµ·å ããŠããŸããã·ã¹ãã£ãã¯ç·ç¶çã®ãã©ã³ãã£ã€ãºã«é¢ããäºæ³ããããã£ãã·ã¥ãããŒã®å€åã«å¯Ÿããäºåéé¡ã¯ãäž»ã«ç¬¬3çžèšåºããŒã¿ã®é瀺ããã³ãã€ã€ãªãã£ããŽã¡ã³ã¶ã«ãã¿ãŒã»ããªãã«ã®ãã¶ã«ãã¿ãŒæåã®ã¿ã§åéãããååéæ°ŽçŽ ã€ãã«ããã«æåã§ã¯ãªããšããä¿å®çãªåæã«åºã¥ããŠããŸãããŽã¡ã³ã¶ã«ãã¿ãŒã»ããªãã«ã®ååéæ°ŽçŽ ã€ãã«ããã«æåã¯ã€ãã«ããã«ãšåãã§ãããšèããŠãããã®ã®ãVertexã¯ãååéæ°ŽçŽ ã€ãã«ããã«æåããã€ã€ã«ãã£ãçããªããšä¿¡ããŠãããšå
¬è¡šããŠããŸããååéæ°ŽçŽ ã€ãã«ããã«ããã€ã€ã«ãã£ãçãããšå€æããå Žåã¯ãåœè©²æç¹ã§æ¥çžŸã«é¢ããäºååå
¥ãèªèããå¯èœæ§ããããŸããããã«ãã¯ãªã¹ãã€ã¿ã«é¢ããŠã¯ã販売äºæž¬ã®äœäžã«ããäºåéé¡ãèšé²ããŸãããä¿¡çšæ倱ã«å¯Ÿããäºåéé¡ã¯ãäž»ã«YorvipathãVoranigoãecopipamã®ååããŒããã©ãªãªãžã®è¿œå ã«ãã£ãŠåŒãèµ·ããããŸããã
2023幎ã®æåã®9ãæéã«ã¯ãæåŸ
ããããã£ãã·ã¥ãããŒã®å€åã«äŒŽãããããžã§ã³è²»çš605.8çŸäžãã«ãšãçŸåšã®äºæ³ä¿¡çšæ倱ã«å¯Ÿããããããžã§ã³è²»çš31.4çŸäžãã«ã®åèš637.2çŸäžãã«ãèšé²ãããŸãããImbruvicaãTremfyaãTysabriã®äºæ³ããããã£ãã·ã¥ãããŒã®å€åã«äŒŽãããããžã§ã³è²»çšã¯ã売åŽã®æ ªåŒèª¿æ»ã¢ããªã¹ãã®ã³ã³ã»ã³ãµã¹è²©å£²äºæž¬ã®æžå°ãäž»ãªèŠå ã§ãããä¿¡çšæ倱ã«å¯Ÿããããããžã§ã³è²»çšã¯ãSkytrofaãšAdstiladrinãããŒããã©ãªãªã«è¿œå ããããšãäž»ãªèŠå ã§ããã
ç 究éçºã®è³éæ¯åº
2024幎9æ30æ¥ãš2023幎ã®äžãæé
2024幎第äžååæã®ç 究éçºè²»ã¯ã2023幎第äžååæãšæ¯èŒããŠ5000äžãã«ããŸãã¯99.0ïŒ
æžå°ããŸããã2023幎第äžååæã«ã¯ãã¢ãã£ã«ã ãã³ã®èšåºãã€ã«ã¹ããŒã³æ¯æãã«é¢é£ãã5000äžãã«ã®ç 究éçºè²»ãèªèããŸããã
2024幎9æ30æ¥ããã³2023幎ã®9ãæ
2024幎ã®æåã®9ãæã«ç 究éçºè³éæ¯åºã¯5,000äžãã«ããŸãã¯å幎åææ¯97.1ïŒ
æžå°ããŸããã2023幎ã®æåã®9ãæã«ã¯ãã¢ãã£ã«ã ãã³ã®èšåºãã€ã«ã¹ããŒã³æ¯æãã«é¢é£ãã5,000äžãã«ã®ç 究éçºè³éè²»çšãèªèãããŸããã
äžè¬ç®¡çè²»
2024幎ãš2023幎9æ30æ¥ã«çµäºãã3ãæé
2023幎第3ååæãšæ¯èŒããŠã2024幎第3ååæã®GïŒAçµè²»ã¯æ¯èŒç暪ã°ãã§ããã
2024幎9æ30æ¥ãŸã§ã®9ãæéãš2023幎
2024幎ã®æåã®9ãæéã«ãéå»å¹ŽåºŠã®æåã®9ãæéãšæ¯èŒããŠãG&Açµè²»ã¯2150äžãã«ããŸãã¯11.3%æžå°ããŸãããäž»ã«ãçŸåšã®æéã«ãããéçšãšäººä»¶è²»ã®æ¯æããæžå°ããããšãèŠå ã§ãã2023幎ã®è²»çšã®å¢å ã¯ãããŒããã©ãªãªåå
¥ãå¢å ããããã§ãããããã«ã¯2023幎第1ååæã«47500äžãã«ã®Zavzpretãã€ã«ã¹ããŒã³æ¯æããå«ãŸããŠããŸããã
é¢é£äŒç€Ÿæ³ã«ããåºè³å©çïŒæ倱ã®æå
2024幎9æ30æ¥ãš2023幎ã®äžãæé
2024幎第3ååæã®æè³æ³ã«åºã¥ãé¢é£äŒç€Ÿã®å©çã«å ããæææš©ã¯1040äžãã«ã§ããã2023幎第3ååæã®é¢é£äŒç€Ÿã®æ倱ã«å ããæææš©ã®520äžãã«ãšæ¯èŒããŠãäž»ã«Legacy SLP Interestããã®åå
¥å²ãåœãŠã«ãããã®ã§ããã2024幎第3ååæã®å©çå²ãåœãŠã¯1020äžãã«ã§ããã2023幎第3ååæã®æ倱å²ãåœãŠã®230äžãã«ãšæ¯èŒããŠããŸãã
2024幎ããã³2023幎9æ30æ¥ã«çµäºãã9ãæé
2024幎ã®æåã®9ãæã«ãããæåæ³é©çšé¢é£äŒç€Ÿã®æ倱é
åœé¡ã¯2,000äžãã«ã§ããã2023幎ã®æåã®9ãæã«ãããæåæ³é©çšé¢é£äŒç€Ÿã®çŽå©çé
åœé¡28,600äžãã«ãšæ¯èŒããŠãäž»ã«2024幎ã®æåã®9ãæã«ãããAvillion Entitiesããã®æ倱é
åé¡7,600äžãã«ãšæ¯èŒããŠãã€ãã¹ã«ãªããŸããã2023幎ã®æåã®9ãæã«ãããAvillion Entitiesããã®åçé
åé¡28,000äžãã«ãšæ¯èŒããŠäž»ã«Avillion Entitiesãã2024幎ã®æåã®9ãæã«ããã8,000äžãã«ã®æ¯æããå«ãAstraZenecaãã¢ã¡ãªã«ã§Airsupraã®åååãè¡äœ¿ãããªãã·ã§ã³ãéžæããé¢é£ã§Avillion Entitiesãåãåã£ãåçé
åé¡ããããŸããã
äŒç€Ÿã®å©åè²»çšã¯äž¡æãšãã«çŽ200,000ãã«ã§ããã
2024幎9æ30æ¥ãš2023幎ã®äžãæé
å©æãè²»çšã¯2,050äžãã«å¢å ããŸãã , 2024幎第3ååæã«ã¯2023幎第3ååæãšæ¯èŒããŠ44.5%å¢å ããäž»ã«2024幎6æã«çºè¡ããã15åãã«ã®ç¡æ
ä¿äžäœããŒãã«ãã£ãŠåŒãèµ·ããããŸãããå¢å åã®äžéšã¯ã2023幎9æã«æºæãè¿ãã10åãã«ã®ç¡æ
ä¿äžäœããŒãã®è¿æžã«ãã£ãŠäžéšçžæ®ºãããŸããã
2024幎9æ30æ¥ããã³2023幎ã®9ãæ
2024幎ã®æåã®9ãæã«ã¯ãå©åè²»çšã¯1å9800äžãã«ããŸãã¯14.2%å¢å ããäž»ã«2024幎6æã«çºè¡ãã15åãã«ã®ç¡æ
ä¿ã·ãã¢ããŒãã«ãã£ãŠæšé²ãããŸããã 2024幎9æ30æ¥æç¹ã§åœç€Ÿã®æªæãã®ç¡æ
ä¿ã·ãã¢ããŒãã®å éå¹³åã¯ãŒãã³ã¬ãŒãã¯ããããã3.06%ãš2.24%ã§ããã
åœç€Ÿã®åµåéèååŒã«é¢ãã詳现ãªè°è«ã«ã€ããŠã¯ããæµåæ§ãšè³æ¬ãã®ã»ã¯ã·ã§ã³ãåç
§ããŠãã ããã
ãã®ä»ã®æåœãŠãçŽåç
2024幎9æ30æ¥ãš2023幎ã®äžãæé
2024幎第3ååæã®ãã®ä»ã®åå
¥ã¯ãäž»ã«å£²åŽå¯èœãªåµåžã»åµå蚌åžã«ãã57.7çŸäžãã«ãæ ªåŒèšŒåžã«ãã50.8çŸäžãã«ã®å©çãããã³å©æ¯åå
¥ã«ãã17.5çŸäžãã«ã§æ§æãããŠããŸããã売åŽå¯èœãªåµåžã»åµå蚌åžã®å©çã¯ãäž»ã«ãµã€ãã«ã€ããã£ãã¯ã¹è³éæäŸå¥çŽã®å
¬æ£äŸ¡å€ã®å€åã«ãã£ãŠçããŸããã
2023幎第3ååæã«ããããã®ä»ã®åå
¥çŽé¡ã¯ãäž»ã«ãã¡ã€ãã³ã·ã£ã«ã€ã³ã¹ãã£ãã¥ãŒã·ã§ã³ãºã§ä¿æããŠããçŸéåã³çŸéåçç©ã«ç²åŸãã2,340äžãã«ã®å©ååå
¥ã«èµ·å ããŠããŸããã
2024幎9æ30æ¥ããã³2023幎ã®9ãæ
2024幎ã®æåã®9ãæéã«ããããã®ä»ã®åå
¥ã¯ãäž»ã«å£²åŽå¯èœåµåžã«é¢ãã103.9çŸäžãã«ã®å©çãæ ªåŒã«é¢ãã81.5çŸäžãã«ã®å©çãããã³å©æ¯åå
¥ã®38.3çŸäžãã«ãå«ãã§ããã売åŽå¯èœåµåžã«é¢ããå©çã¯ãã¢ã«ãã©ã·ã¹éçºè³éåµã®å
¬æ£äŸ¡å€ã®å€åã«ãã£ãŠäž»ã«åŒãèµ·ããããŸããã
2023幎ã®æåã®9ãæã§ã®ãã®ä»ã®åçïŒ214.6çŸäžãã«ã®æ§é€åŸïŒã¯ãäž»ã«ãã¡ã€ãã³ã·ã£ã«ã€ã³ã¹ãã£ãã¥ãŒã·ã§ã³ãºã«ä¿æãããŠããçŸéåã³çŸéåçç©ããåŸãããå©æ¯åç65.8çŸäžãã«ã売åŽå¯èœãªåµåžã»åµå蚌åžããã®122.5çŸäžãã«ã®å©çåã³32.0çŸäžãã«ãå«ãã§ããŸããã 売åŽå¯èœãªåµåžã»åµå蚌åžããã®å©çã¯ãäž»ã«ã¢ã«ãã©ã·ã¹éçºè³éåµã®å
¬æ£äŸ¡å€ã®å€åã«ãã£ãŠæšé²ãããŸããã
éæ¯é
æåã«åž°å±ããåœæçŽå©ç
2024幎ãš2023幎9æ30æ¥ã«çµäºãã3ãæé
2024幎第3ååæã«ãããã¬ã¬ã·ãŒæè³å®¶ããŒãããŒã·ããã«åž°å±ããåœæçŽå©çã¯ã2023幎第3ååæãšæ¯èŒããŠ6130äžãã«å¢å ããäž»ã«çŸåšã®äŒèšå¹ŽåºŠã«ãããåŒåœè²»çšã®æžå°ã«ããå€ãRPIã«åž°å±ããåœæçŽå©çã®å¢å ã«ãããã®ã§ããã
2024幎第3ååæã®Continuing Investors Partnershipsã«åž°å±ããåœæçŽå©çã¯ã2023幎第3ååæãšæ¯èŒããŠ1å5130äžãã«å¢å ããŸãããããã¯ã2024幎第3ååæã«RP Holdingsã«åž°å±ããåœæçŽå©çãå¢å ããããšã«äž»ã«ãããã®ã§ãäžæ¹ã§ãContinuing Investors PartnershipsãææããRP Holdingsã®æææš©ãæžå°ãããããContinuing Investors Partnershipsã§RP Holdingsã¯ã©ã¹bã€ã³ã¿ã¬ã¹ããéæ¥çã«ææããæè³å®¶ã«ããåœç€Ÿã®Açš®æ®éæ ªåŒãšã®äº€æã«ããéšåçãªçžæ®ºããããŸãã
2023幎第3ååæã®åœæçŽå©çã¯ãRPSFtã«åž°å±ãããã®ã§ã30äžãã«ã§ããã2023幎12æãRPI 2019 ICAVã¯ãRPSFtãä¿æããŠããRPCtã®æ®ãã®æåãååŸãããã®ãããRPSFtã¯ãã¯ãRPCtã«å¯Ÿããéæ¯é
çå©çãæã£ãŠããŸããã
2024幎9æ30æ¥ããã³2023幎ã®9ãæ
2024幎ã®æåã®9ãæã«ãéå»ã®æè³ããŒãããŒã·ããã«åž°å±ããåœæçŽå©çã¯ã2023幎ã®æåã®9ãæãšæ¯èŒããŠ2390äžãã«å¢å ããŸãããããã¯ãçŸåšã®å¹ŽåºŠã«ãããåŒåœéè²»çšã®äœäžã«ããå€ãRPIã«åž°å±ããåå
¥ã®å¢å ãäž»ãªèŠå ã§ããã
2024幎ã®æåã®9ãæã«ãããŠãç¶ç¶æè³å®¶ããŒãããŒã·ããã«åž°å±ããåœæçŽå©çã¯ã2023幎ã®æåã®9ãæãšæ¯èŒããŠ1,550äžãã«æžå°ããŸãããããã¯ã2024幎ã«èªèãããå©æ¯åå
¥ã®æžå°ã«äž»ã«èµ·å ããŠãããRP Holdingsã«åž°å±ããåœæçŽå©çã®äœäžã®çµæã§ãã2023幎ã®å©æ¯åå
¥ã®å¢å ã¯ããã¡ã€ã¶ãŒã®ã¶ããã¬ããã®FDAæ¿èªã«ç¶ããŠèªèããã1å5360äžãã«ã®å©æ¯åå
¥ã«äž»ã«ãããã®ã§ãããéåçºçã§ãããããã«ãç¶ç¶æè³å®¶ããŒãããŒã·ããã«ããåœæçŽå©çã®æææš©ã®äœäžã¯ãéæ¥çã«RP Holdings Class b Interestsãææããæè³å®¶ã«ããåœç€Ÿã®æ®éæ ªåŒãšã®ååŒã«èµ·å ããŠããŸãã
2023幎ã®æåã®9ãæã«RPSFtã«åž°å±ããåœæçŽå©çã¯470äžãã«ã§ããã2023幎12æãRPI 2019 ICAVã¯RPSFtãææããRPCtã®æ®ãã®æåãååŸãããã®çµæãRPSFtã¯RPCtã«å¯Ÿããéæ¯é
çãªæè³ãä¿æããŠããŸããã
ããŒããã©ãªãªæŠèŠ
ç§ãã¡ã® ããžãã¹ ã¢ã㫠㯠åŸæ¥ã® æ¥çš® ã® éå¶ äŒç€Ÿ ãš ç°ãªããŸããç§ãã¡ã® éå¶ ããã©ãŒãã³ã¹ ã¯ãæŽå²çã« ã ãã€ã€ã«ã㣠ã«ãã£ãŠ çã¿åºããã ãã£ãã·ã¥ã»ãã㌠㧠䞻㫠èè³ ãããŠãããæ¥æ¬ ã® æµåæ§ ã«ãããã®ã§ããç§ãã¡ã¯ã æ¢å ã® ãã€ã€ã«ã㣠ã«ãã£ãŠ çã¿åºããã ãã£ãã·ã¥ ã ã æ°ãã ãã€ã€ã«ã㣠ã«æè³ ãããã ã« å©çš ããŠããŸããç§ãã¡ã¯ãããžãã¹ ã® æ瞟 ã è©äŸ¡ ããé ã«æ§ã
㪠ã¡ããªãã¯ã¹ ã èæ
® ããŠããŸãã ããŒããã©ãªãª åå
¥ ã¯ãåœç€Ÿã® ããŒããã©ãªãª æè³ ãã ãã£ãã·ã¥ ã çã¿åºã èœå ã è¡šã äž»èŠãª ããã©ãŒãã³ã¹ ã¡ããªãã¯ã¹ ã§ãããæ°ãã ããŒããã©ãªãª æè³ ã è¡ã ãã ã«äœ¿çš ã§ãã è³æ¬ ã® äž»èŠãª æºæ³ ã§ããããŒããã©ãªãª åå
¥ ã¯ãçµå¶è
ã åœç€Ÿã® æµåæ§ ãš é·æ æé· ã® èŠéã ã ãããã åæ ããããã«ã ãã€ã€ã«ã㣠æè³ ã® åºç€ ãšãªã ãã£ãã·ã¥ çæ ã® ãã詳现㪠補åå¥ è¡šç€º ã æäŸ ããããšã§ ã ããŸãã
ããŒããã©ãªãªåå
¥ãšã¯ããã€ã€ãªãã£åå
¥ãšãã€ã«ã¹ããŒã³ãããã³ãã®ä»ã®å¥çŽäžã®åå
¥ã®åèšãå®çŸ©ããŠããŸãããã€ã€ãªãã£åå
¥ã«ã¯ãååã®å£²äžã«åºã¥ãå€åæ¯æãããåœç€Ÿã«åž°å±ããã¬ã¬ã·ãŒéæ¯é
æåãžã®å¥çŽäžã®æ¯æããå·®ãåŒãããã®ãå«ãŸããŸãïŒããã€ã€ãªãã£åå
¥ãïŒããã€ã«ã¹ããŒã³ãä»ã®å¥çŽäžã®åå
¥ã«ã¯ã売äžã«åºã¥ããŸãã¯èŠå¶äžã®ãã€ã«ã¹ããŒã³æ¯æãããã³ä»ã®åºå®å¥çŽäžã®åå
¥ãå«ãŸãããããã¯åœç€Ÿã«åž°å±ãããã®ã§ããããŒããã©ãªãªåå
¥ã«ã¯ãæ ªåŒèšŒåžã®åçã売買å¯èœèšŒåžã®å£²è²·ã«ããåçã¯å«ãŸããŠããããããããåœç€Ÿã®åºæ¬çãªããžãã¹æŠç¥ã«ã¯äžå¿çã§ã¯ãããŸããã
ããŒããã©ãªãªåå
¥ã¯ãåœç€Ÿã®GAAPãã£ãã·ã¥ãããŒèšç®æžããã®ä»¥äžã®è¡é
ç®ã®åèšãšããŠèšç®ãããŸã: éèãã€ã€ã«ãã£è³ç£ããã®çŸéåå
¥ , ç¡åœ¢è³ç£ã®ãã€ã€ã«ãã£ã«ããçŸéåå
¥ , ãã®ä»ã®ãã€ã€ã«ãã£çŸéåå , 売åŽå¯èœãªåµåžã«ããåç ãã㊠å
±ååºè³æ³ã«ããé¢é£äŒç€Ÿããã®é
åœ æ§é€ãã æ§èŠå¶éæ¯é
æ ªäž»ãžã®é
åœ-ããŒããã©ãªãªåé ãã€ã€ã«ãã£åå
¥ããã€ã«ã¹ããŒã³ãããã³ãã®ä»ã®å¥çŽäžã®åå
¥ãRPSFtããã³ã¬ã¬ã·ãŒæè³å®¶ããŒãããŒã·ããã«åé
ãããã®ã§ãã
åœç€Ÿã®ããŒããã©ãªãªã«ã¯ã35以äžã®ããŒã±ãã£ã³ã°ãããŠããæ²»çæ³ãš15ã®éçºæ®µéã®è£œååè£ã®ãã€ã€ãªãã£ãå«ãŸããŠããŸããåœç€Ÿã®ããŒããã©ãªãªã®æ²»çæ³ã¯åžå°çŸç
ããããç¥çµç§åŠãææçãè¡æ¶²åŠãç³å°¿ç
ãªã©ã®æ²»çé åã«å¯Ÿå¿ããäžæ¬¡å»çããã³å°éå»çèšå®ã®äž¡æ¹ã®æ£è
ã«æäŸãããŠããŸãã以äžã®è¡šã¯ã2024幎ã®æåã®9ã¶æéã«ãããåèšãã€ã€ãªãã£åå
¥ã«å¯Ÿããåã
ã®è£œåãšãã€ã«ã¹ããŒã³ããã®ä»ã®å¥çŽäžã®åå
¥ã«ãããã€ã€ãªãã£åå
¥ã®è²¢ç®é ã«ããŒããã©ãªãªåé ã瀺ããŠããŸãïŒååäœïŒã
補å
ããŒã±ã¿ãŒ æ²»çé å 2021幎9æ30æ¥çµäºã®3ãæéã®æ±ºç®ã«ã€ã㊠å€æŽ 2021幎9æ30æ¥çµäºã®9ãæéã®æ±ºç®ã«ã€ã㊠å€æŽ 2024 2023 $ % 2024 2023 $ % ã·ã¹ãã£ãã¯ãã£ãããŒã·ã¹ã®ãã©ã³ãã£ã€ãº (1)
ããŒããã¯ã¹ åžå°çŸç
$ 206,988 $ 195,954 11,034 5.6 $ 620,218 $ 563,251 56,967 10.1 ãã¬ã¬ãžãŒ gsk plc åŒåžåš 90,541 58,240 32,301 55.5 209,615 143,111 66,504 46.5 ã¿ã€ãµã㪠ãã€ãªãžã§ã³ ç¥çµç§åŠ 68,262 71,464 (3,202) (4.5) 201,171 211,771 (10,600) (5.0) ã€ã ãã«ãã« ã¢ããŽã£ããžã§ã³ãœã³ïŒãžã§ã³ãœã³ ãã 46,198 51,245 (5,047) (9.8) 145,389 159,814 (14,425) (9.0) Xtandi ãã¡ã€ã¶ãŒãã¢ã¹ãã©ã¹ ãã 43,311 38,837 4,474 11.5 122,939 108,275 14,664 13.5 ãšããªã¹ã㣠ãã·ã¥ åžå°çŸç
47,953 15,749 32,204 204.5 117,832 46,318 71,514 154.4 Promacta Novartis è¡æ¶²åŠ 41,810 44,609 (2,799) (6.3) 114,856 117,376 (2,520) (2.1) Tremfya ãžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ å
ç«åŠ 34,264 27,194 7,070 26.0 100,336 81,117 19,219 23.7 Cabometyx/Cometriq ãšã¯ã»ãªã¯ã¹ãã€ãã»ã³ãæŠç° ãã 18,527 17,294 1,233 7.1 53,092 48,234 4,858 10.1 Trodelvy ã®ãªã¢ã ãã 11,473 9,114 2,359 25.9 32,129 23,191 8,938 38.5 Spinraza ãã€ãªãžã§ã³ åžå°çŸç
14,186 15,253 (1,067) (7.0) 30,422 27,815 2,607 9.4 ã¢ã¬ãã ãžã§ã³ãœã³ã»ãžã§ã³ãœã³ ãã 10,025 7,723 2,302 29.8 28,230 18,793 9,437 50.2 Orladeyo ãã€ãªã¯ãªã¹ã åžå°çŸç
10,358 7,776 2,582 33.2 27,592 21,130 6,462 30.6 Nurtec ODTïŒZavzpret ãã¡ã€ã¶ãŒ ç¥çµç§åŠ 7,843 5,300 2,543 48.0 18,025 13,347 4,678 35.0 ãã®ä»è£œå (2)
80,005 71,408 8,597 12.0 219,515 214,376 5,139 2.4 ãã€ã€ãªãã£åå
¥
$ 731,744 $ 637,160 94,584 14.8 $ 2,041,361 $ 1,797,919 243,442 13.5 ãã€ã«ã¹ããŒã³ãšãã®ä»å¥çŽåå
¥
2,880 â 2,880 ãªã 18,241 514,888 (496,647) (96.5) ããŒããã©ãªãªã®å
¥é
$ 734,624 Â $ 637,160 Â 97,464 Â 15.3 Â $ 2,059,602 Â $ 2,312,807 Â (253,205) (10.9)
(1) ã·ã¹ãã£ãã¯ç·ç¶çãã©ã³ãã£ã€ãºã«ã¯ã以äžã®æ¿èªããã補åãå«ãŸããŠããŸãïŒKalydecoãOrkambiãSymdeko/SymkeviãTrikafta/Kaftrioã
(2) ãã®ä»ã®è£œåã«ã¯ãCimziaãCrysvitaãEmgalityãEntyvioãFarxiga/OnglyzaãIDHIFAãLetairisãLexiscanãMirceraãNesinaãPrevymisãSoliqua ããã³ Legacy SLP Interest ããã®åé
ãå«ãŸããŸãããããã¯çŸéãããŒèšç®æžã«ãŠç€ºãããŠããŸãã æåæ³æè³å
ããã®åé
çŸéãããŒèšç®æžã«è¡šèšãããŠããŸãã
ããŒããã©ãªãªåé ã®åæ
ããŒããã©ãªãªåé ã®äž»èŠãªèŠå ã«ã€ããŠä»¥äžã§è°è«ãããŠããŸã:
⢠ã·ã¹ãã£ãã¯ãã£ãããŒã·ã¹ã®ãã©ã³ãã£ã€ãº ã·ã¹ãã£ãã¯ãã£ãããŒã·ã¹ã®ãã©ã³ãã£ã€ãºããã®ãã€ã€ãªãã£åå
¥ãKalydecoãOrkambiãSymdeko/SymkeviãTrikafta/Kaftrioãå«ãããããã¯ç¹å®ã®å€ç°ãã·ã¹ãã£ãã¯ãã£ãããŒã·ã¹ãåŒãèµ·ããæ£è
ã®ããã«Vertexã販売ããŠãã補åã«ã€ããŠã2024幎ã®æåã®9ãæéã¯2023幎ã®æåã®9ãæéã«æ¯ã¹ãŠ5,700äžãã«å¢å ããŸããããã®å¢å ã¯ãTrikaftaã®ç±³åœå
ã§ã®ç¶ç¶çãªããã©ãŒãã³ã¹ãšãç±³åœå€ã§ã®Kaftrioã®åŒ·åãªæ®åãç¹ã«è¥ã幎霢局ã§ã®æ®åã«ãã£ãŠäž»ã«æšé²ãããŸããã
⢠ãã¬ã¬ãžãŒ 2024幎ã®æåã®9ãæã«ãæ
¢æ§éå¡æ§èºçŸæ£ãåæ¯ã®ç¶ææ²»çã®ããã«GSKã販売ããŠããTrelegyããã®ãã€ã€ãªãã£åå
¥ã¯ã2023幎ã®æåã®9ãæã«æ¯ã¹ãŠ6650äžãã«å¢å ããäž»ã«åŒ·ãæ£è
éèŠãåäžåžå
¥åšã®3å€çæ³ã¯ã©ã¹ã®æé·ããããŠåžå Žã·ã§ã¢ã®æ¡å€§ã«ãã£ãŠæšé²ãããŸããã
⢠ã¿ã€ãµã㪠ãã€ãªãžã§ã³ãå€çºæ§ç¡¬åçã®æ²»çè¬ãšããŠè²©å£²ããŠããã¿ã€ãµããªããã®çç«åå
¥ã¯ã2024幎ã®æåã®9ãæã«ãããŠ2023幎ã®æåã®9ãæãšæ¯èŒããŠ1,060äžãã«æžå°ããŸãããããã¯äž»ã«äŸ¡æ Œç«¶äºãšç«¶äºããã®å§åã«ãããã®ã§ãã
⢠ã€ã ãã«ãã« ã¢ããŽã£ããã³ãžã§ã³ãœã³ïŒãžã§ã³ãœã³ãè¡æ¶²ããããã³æ
¢æ§ç§»æ€ç察宿䞻ç
ã®æ²»çè¬ãšããŠè²©å£²ããŠããã€ã ãã«ãã«ããã®ãã€ã€ã«ãã£åå
¥ã¯ã2024幎ã®æåã®9ãæéã«ã€ããŠã¯ã2023幎ã®æåã®9ãæéãšæ¯èŒããŠ1,440äžãã«æžå°ããäž»ã«ç«¶äºå§ã®åœ±é¿ã«ãããã®ã§ãã
⢠Xtandi â ããã¹ã¿ãŒãããã¡ã€ã¶ãŒãšã¢ã¹ãã©ã¹ã«ãã£ãŠè²©å£²ãããŠããXtandiããã®ãã€ã€ã«ãã£åå
¥ã¯ã2024幎ã®æåã®9ãæã«ã2023幎ã®æåã®9ãæãšæ¯èŒããŠ1470äžãã«å¢å ãããã¹ãŠã®ã»ã¯ã¿ãŒã®æé·ã«äž»ã«ãã£ãŠæšé²ãããŸããã
⢠ãšããªã¹ã㣠ãã·ã¥ã«ãã£ãŠè²©å£²ãããèé«æ§çèçž®çã®æ²»çè¬Evrysdiããã®ãã€ã€ãªãã£åå
¥ã¯ã2024幎ã®æåã®9ãæéã«ãããŠ2023幎ã®æåã®9ãæéãšæ¯èŒããŠ7150äžãã«å¢å ããäž»ã«2023幎第4ååæãš2024幎第2ååæã«ååŸããè¿œå ã®ãã€ã€ãªãã£ã«èµ·å ããŠããŸããå¢å ã¯å
šã»ã¯ã¿ãŒã§ã®æ£è
ã·ã§ã¢ã®å¢å ã«ãã£ãŠããã«æšé²ãããŠããŸãã
⢠Promacta â ããã«ãã£ã¹ãæ
¢æ§å
ç«æ§è¡å°æ¿æžå°æ§çŽ«æç
ïŒITPïŒããã³åçäžè¯æ§è²§è¡ã®æ²»çè¬ãšããŠããŒã±ãã£ã³ã°ãããããã¯ã¿ã«ãããã€ã€ãªãã£åå
¥ã¯ã2024幎ã®æåã®9ã¶æã«ãããŠ2023幎ã®æåã®9ã¶æã«æ¯ã¹ãŠ2.5çŸäžãã«æžå°ããŸãããããã¯äž»ã«ãé«ãåçæ§é€ãåå ã§ãããç±³åœã«ãããæ
¢æ§ITPããã³éçåçäžè¯æ§è²§è¡ã§ã®ãããã¯ã¿ã®äœ¿çšéã®å¢å ã«éšåçã«çžæ®ºãããŸããã
⢠Tremfya â ãžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ã販売ãããã©ãŒã¯ä¹Ÿç¬ãšæŽ»åæ§ä¹Ÿç¬æ§é¢ç¯çã®æ²»çè¬ã§ããTremfyaã®ãã€ã€ã«ãã£åå
¥ã¯ã2024幎ã®æåã®9ãæéã«ãåžå Žã®æé·ãåžå Žã·ã§ã¢ã®å¢å ãããã³æå©ãªæ£è
ããã¯ã¹ã«ããã2023幎ã®æåã®9ãæéã«æ¯ã¹ãŠ1å9200äžãã«å¢å ããŸããã
⢠Cabometyx/Cometriq ãšã¯ã»ãªã¯ã¹ãã€ãã»ã³ãæŠç°ãšå
±åã§å±éãããŠããCabometyx/Cometriqããã®ç宀åçã¯ã2024幎ã®æåã®9ã¶æã«ã€ããŠ2023幎ã®æåã®9ã¶æãšæ¯èŒããŠ490äžãã«å¢å ããŸãããããã¯ãç±³åœã«ãããåŒãç¶ãã®éèŠå¢å ãšOpdivoãšã®äœµçšã«ããåºç¯ãªç¬¬1æ²»çã©ã€ã³ã§ã®è
现èçã®èšåºãªã¹ã¯ã°ã«ãŒããšå®è·µç°å¢ã«ãããéèŠã®å¢å ãäž»ãªèŠå ã§ããã
⢠Trodelvy Trodelvyã®ç宀åå
¥ã¯ãGileadãåºåããŠããæ人ã®è»¢ç§»æ§äžéé°æ§ä¹³ããããã³äºåæ²»çããããã«ã¢ã³å容äœïŒHRïŒéœæ§ãããäžç®æé·å åå容äœ2ïŒHER2ïŒé°æ§è»¢ç§»æ§ä¹³ããã察象ãšããŠããŸãã2024幎ã®æåã®9ã¶æéã«æ¯ã¹ãŠ2023幎ã®æåã®9ã¶æéã«890äžãã«å¢å ããŸãããå¢å ã¯ã第2ã©ã€ã³ã®è»¢ç§»æ§äžéé°æ§ä¹³ãããšäºåæ²»çãããHRéœæ§/HER2é°æ§ã®è»¢ç§»æ§ä¹³ããã«å¯Ÿããæç¶çãªéèŠã«ãããã®ã§ãã
⢠Spinraza ã¹ããã«ãµåå€ãSpinrazaãã®äœ¿çšæåå
¥ã¯ã2024幎ã®æåã®9ãæéã«ãããŠã2023幎ã®æåã®9ãæéãšæ¯èŒããŠ260äžãã«å¢å ããŸãããããã¯ãæ¯èŒçäžè²«ããç±³åœå
ã®è²©å£²ã«ãããã®ã§ãããäžæ¹ãç±³åœå€ã§ã®æ¥çžŸã¯åºè·ã®ã¿ã€ãã³ã°ã競äºããã³äŸ¡æ Œç«¶äºã®åœ±é¿ãåããŸãããåœç€Ÿã¯2023幎第1ååæã«Spinrazaã®äœ¿çšæåå
¥æš©ãååŸãã2023幎第2ååæãã䜿çšæãåãåãå§ããŸããã
⢠ãšã«ã¬ã¢ããã â ãžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ãåç«è
ºããæ£è
ã®æ²»çè¬ãšããŠè²©å£²ããŠãããšã«ã¬ã¢ãããã®ãã€ã€ãªãã£é åæžã¯ãäž»ã«è»¢ç§»æ§å»å¢æåæ§åç«è
ºããã®ç¶ç¶çãªã·ã§ã¢å¢å ãšåžå Žæé·ã«ããã2023幎ã®æåã®9ãæãšæ¯èŒããŠã2024幎ã®æåã®9ãæã§940äžãã«å¢å ããŸããã2023幎ã®ç¬¬2ååæã«Erleadaã§è¿œå ãã€ã€ãªãã£ãååŸãã2023幎ã®ç¬¬3ååæã«è¿œå ã®ãã€ã€ãªãã£ãåãåãå§ããŸããã
⢠Orladeyo Orladeyoã®ãã€ã€ã«ãã£åå
¥ã¯ãéºäŒæ§ã¢ã³ã®ãªãšããã®æ²»çã®ããã«BioCrystã«ãã£ãŠè²©å£²ãããŠããã2024幎ã®æåã®9ãæã«å幎ã®åãææãšæ¯èŒããŠ650äžãã«å¢å ããäž»ã«æç¶çãªåŒ·ãæ£è
ã®åãå
¥ãã«ãããã®ã§ãã
⢠ãã«ããã¯ODT /ã¶ãã¶ã¬ãã âãã¡ã€ã¶ãŒãããŒã±ãã£ã³ã°ãè¡ã£ãŠããçé çæ¥æ§æ²»çè¬ãã«ããã¯ODTããã®ãã€ã€ãªãã£åå
¥ã¯ã2024幎ã®æåã®9ãæãš2023幎ã®æåã®9ãæãæ¯èŒããŠ470äžãã«å¢å ããŸããããã®å¢å ã¯ãç±³åœã§ã®åŒ·åãªéèŠãåœéåžå Žã§ã®æè¿ã®ç«ã¡äžãã«ãããã®ã§ãäžæ¹ã§ãç±³åœã§ã®ãããäŸ¡æ Œãäžå©ãªãã£ãã«ããã¯ã¹ã®å€åã«ããéšåçã«çžæ®ºãããŸããã
⢠ãã®ä»è£œå â 2024幎ã®æåã®9ã¶æã«ããããã®ä»è£œåããã®ãã€ã€ãªãã£åå
¥ã¯ãäž»ã«Tadjentaã®æªæããã€ã€ãªãã£ã®åé ãLegacy SLP Interestããã®ããå€ãã®é
åœããã³Entyvioã«ããããã€ã€ãªãã£åå
¥ã®ã¿ã€ãã³ã°ã«ãã£ãŠã2023幎ã®æåã®9ã¶æã«æ¯ã¹ãŠ510äžãã«å¢å ããŸãããäžæ¹ã§ããžã§ããªãã¯ç«¶äºã«ããLexiscanã®ãã€ã€ãªãã£åå
¥ã®æžå°ã«ãã£ãŠéšåçã«çžæ®ºãããŸããã
⢠ãã€ã«ã¹ããŒã³ããã®ä»ã®å¥çŽäžã®é åæž 2023幎ã®æåã®9ãæãšæ¯èŒããŠã2024幎ã®æåã®9ãæã§4å9,660äžãã«æžå°ããŸãããããã¯äž»ã«ã2023幎3æã«FDAãZavzpretãæ¿èªããåŸã«åãåã£ã4å7,500äžãã«ã®ãã€ã«ã¹ããŒã³æ¯æããšãã¢ã¹ãã©ãŒãã«ãæ¯æã£ã8,000äžãã«ã®ææ°æã®æ¯äŸé
åã«ã€ããŠãååŒæè³å
ã®Avillion IIãã2,870äžãã«ã®æ¯æãããã£ãããã§ããšã¢ã¹ãŒãã©ãç±³åœã§åååãããªãã·ã§ã³ãè¡äœ¿ããŸããã©ã¡ãã2023幎ã®ç¬¬1ååæã«äºå®ãããŠããŸããã
ç§ãã¡ã®ããŒããã©ãªãªã«é¢é£ããäž»ãªéçº
åœç€Ÿã®ããŒããã©ãªãªè£œåã«é¢é£ããæè¿ã®äž»èŠãªé²å±ã«ã€ããŠã¯ã以äžã§è°è«ãããŠããŸã:
åæ¥è£œå
⢠ã¹ã«ã€ãããã¡ã In September 2024, ã¢ã»ã³ãã£ã¹ã»ãã¡ãŒãã¯ãæé·ãã«ã¢ã³äžè¶³ãæ±ããæ人ã®æ²»ççšãšããŠè²©å£²ããããã©ã³ã¹ã³ã³hghïŒã¹ã«ã€ãããã¡ãšããŠè²©å£²ïŒã®è¿œå çç©è£œå€ã©ã€ã»ã³ã¹ç³è«ïŒsBLAïŒãFDAã«æåºãããšçºè¡šããŸããã
⢠Cobenfyã 2024幎9æãããªã¹ãã«ã»ãã€ã€ãŒãºã»ã¹ã¯ã€ããCobenfyïŒæ§KarXTïŒã®çµ±å倱調çæ²»çè¬ãšããŠã®FDAæ¿èªãçºè¡šããŸãããCobenfyã®FDAæ¿èªãåããŠã2024幎第4ååæã«ãã¥ã¢ããã¯ãã«ã¹ã«2,500äžãã«ã®ãã€ã«ã¹ããŒã³æ¯æããè¡ããŸãã
⢠Cabometyx 2024幎9æããšã¯ã»ãªã¯ã¹ã¯ãæ°ç®¡é¡æè¡ã®ç¬¬3çžäž»èŠãªCABINEtç 究ããã®æçµçµæãçºè¡šããã«ãã¶ã³ãããã«ããé²è¡æ§ç¡çŽ°èç€æ£è
ã®ç¡å¢æªçåæéã«ãããéèŠãªæ¹åã瀺ãããŸããããšã¯ã»ãªã¯ã¹ã¯è£è¶³çæ°è¬æ¿èªç³è«ãæåºããããã¯2025幎4æã«ãã¬ã¹ã¯ãªãã·ã§ã³ã»ãã©ãã°ã»ãŠãŒã¶ãŒã»ãã£ãŒã»ã¢ã¯ãïŒPDUFAïŒã®æéãšããŠå²ãåœãŠãããã€ãã»ã³ã¯æ¬§å·å»è¬ååºã«é©å¿æ¡å€§ã®ããŒã±ãã£ã³ã°æ¿èªãç³è«ããŸããã
2024幎9æããšã¯ã»ãªã¯ã¹ã¯ããã§ãŒãº3ã®éèŠãªCONTACt-02ç 究ã®æçµçµæãçºè¡šããŸããããã®ç 究ã¯ã2ã€ã®äž»èŠè©äŸ¡é
ç®ã®ãã¡ã®1ã€ãéæãã転移æ§å»å¢æµææ§åç«è
ºçæ£è
ã«ãããŠãã¢ããŸãªãºãããšäœµçšããã«ãã¶ã³ãããã®ç¡å¢æªçåæéã«ãããŠçµ±èšçã«ææãªå©çã瀺ããå
šçåæéã®æ°å€çæ¹åã¯ãã£ããã®ã®çµ±èšçã«ææã§ã¯ãããŸããã§ããããšã¯ã»ãªã¯ã¹ã¯ãä»å¹ŽåŸåã«FDAã«å¯ŸããŠè£è¶³æ°è¬ç³è«ãæåºããäºå®ã§ãã
⢠ãã¬ã³ãã 2024幎9æããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ã¯äžç床ããé床ã®æŽ»åæ§æœ°çæ§å€§è
žçãæ£ãæ人ã®æ²»çã®ããã®ãã¬ã³ããã®FDAæ¿èªãçºè¡šããŸããã
⢠ã¹ãã³ã©ã¶ã 2024幎9æããã€ãªãžã§ã³ã¯ãèé«æ§çèçž®çãæ£ãä¹³å
ã«ãããã¹ãã³ã©ã¶ã®ããé«çšéçæ³ã®å®å
šæ§ãšæå¹æ§ãè©äŸ¡ãã第2/3çžDEVOTEè©Šéšã®éèŠãªã³ããŒãïŒPart BïŒããäºãå®ããããäžèŽããåœè¬å¯Ÿç
§çŸ€ã«æ¯ã¹ãŠãçµ±èšçã«ææãªéåæ©èœã®æ¹åãéæããäž»èŠãšã³ããã€ã³ããéæãããšçºè¡šããŸããã
⢠ãã©ããŽã 2024幎8æãã»ã«ããšã¯ã¢ã€ãœã¯ãšã³é
žè±æ°ŽçŽ é
µçŽ 1ããã³2ïŒIDH1/2ïŒå€ç°æ£çºæ§ã°ãªãªãŒãã®æ£è
åãã®ç»æçãªã¿ãŒã²ããçæ³ã§ãããã©ããŽã®FDAæ¿èªãçºè¡šããŸããã
éçºæ®µéã®è£œååè£
⢠ã¢ãã£ã«ã¡ã³ã 2024幎10æã ãµã€ãã«ã€ããã£ãã¯ã¹ã¯ã2024幎第3ååæã«ã¢ãã£ã«ã¡ã³ã®æ°è¬ç³è«ãFDAã«æåºãããšçºè¡šããŸããããŸãããµã€ãã«ã€ããã£ãã¯ã¹ã¯ã2024幎第4ååæã«ã¢ãã£ã«ã¡ã³ã®ããŒã±ãã£ã³ã°æ¿èªç³è«ã欧å·å»è¬ååºã«æåºããèšç»ã§ãã
⢠BCX10013ã 2024幎8æã«ãBioCrystã¯ããã®çµå£Factor Dé»å®³å€ã§ããBCX10013ã®éçºãäžæ¢ããèšç»ãçºè¡šããŸããã芳å¯ãããèšåºæŽ»åã®ã¬ãã«ã¯ãåžå Žã®ä»ã®æ²»çæ³ãããäœãã£ãããã§ãã
⢠Mk-8189. 2024幎10æãã¡ã«ã¯ã¯å
¬éæ
å ±ãæŽæ°ããMk-8189ããã€ãã©ã€ã³ãã£ãŒãããåé€ããŸããããã®ããã°ã©ã ãžã®ãããªãæè³ã¯æåŸ
ã§ããŸããã
⢠ãã©ãã¬ã·ãã 2024幎10æãããã«ãã£ã¹ã¯ã第3çžMANIFESt-2è©Šéšã®48é±ããŒã¿ã®æ€èšã«åºã¥ãã骚é«ç·ç¶çã«ããããã©ãã¬ã·ãã®èŠå¶çµè·¯ãå€æããããã«ããé·ããã©ããŒã¢ããæéãå¿
èŠã§ãããšçºè¡šããŸãããããã«ãã£ã¹ã¯MANIFESt-2ã®æ£è
ãåŒãç¶ããã©ããŒã¢ããããç»é²ããµããŒãããããã®è¿œå ç 究ã®å¯èœæ§ãè©äŸ¡ããŸãã
⢠ããã³ãã£ãããã 2024幎10æããã·ã¥ã¯ã¢ã«ããã€ããŒç
ã®èšåºè©Šéšã§ããã³ãã£ãããã®ææ°ã®ç¬¬1b/2aäžéçµæãçºè¡šããŸãããããã«ãããæ²»çã®12ãã28é±åŸã«è¿
éãã€åŒ·åãªã¢ããã€ããã©ãŒã¯ã®é€å»ã瀺ãããéåžžã«éãããARI-Eã®èŠ³å¯ãããç·åçã«å¥œãŸããå®å
šæ§ãããã¡ã€ã«ã瀺ãããŸããã
æè³æŠèŠ
æ°èŠã®ãã€ã€ãªãã£ãžã®æè³ã¯ãåœç€Ÿã®ããžãã¹ã®é·æçå±æã«ãšã£ãŠåºæ¬çã§ããæ°èŠæè³ã¯ãæ¢åã®ããŒããã©ãªãªå
ã§ã®æé·ãè£å®ããåžå Žç¬å æš©ã倱ã£ã補åã®ãã€ã€ã«ãã£ã«å¯Ÿããæžå°ãçžæ®ºããããã®åçæºãæäŸããŸããåœç€Ÿã¯ç¶ç¶çã«ãã€ã€ã«ãã£ã®ç²åŸæ©äŒã®å¹
åºãéžæè¢ãè©äŸ¡ããããžãã¹ã®éåžžæ¥åã®äžç°ãšããŠä»åŸãååŸãç¶ããããšãæåŸ
ããŠããŸããåœç€Ÿã¯ãæ²»çé åãšæ²»çææ³å
šäœã«ãããäž»èŠè£œåã«é¢é£ãããã€ã€ã«ãã£ãžã®æè³ãç¹å®ããè©äŸ¡ããæè³ãã匷åºãªå®çžŸã確ç«ããŠããŸããæã
ã¯ãæŠå¿µã®å
åºãªèšŒæ ããŒã¿ãçã¿åºããŠããèªå¯è£œåããã³éçºæ®µéã®åè£è£œåã«æè³ããŸããæã
ã¯ããã€ããªããæè³ãæ¢åã®éèŠãªãã€ã€ã«ãã£è³ç£ãæã€äŒæ¥ã®ååŸããŸãã¯ãã®ãããªè³ç£ã®åµåºã®å¯èœæ§ãæã€äŒæ¥ã®ååŸã«ãã£ãŠããããã®æ²»çæ³ã«æè³ããŠããŸãã
2024幎ã®æåã®9ã¶æéã«ãå°çšããã€ã«ã¹ããŒã³ãããã³ãã®ä»ã®å¥çŽåå
¥ã«22åãã«ãæè³ããŸãããæ°èŠååŸè³éã®æè³ã«ã¯å€åæ§ããããæ°èŠæè³æ©äŒã®äºæž¬äžå¯èœãªã¿ã€ãã³ã°ã«ãã幎次ããŒã¹ã§ã®è³é調éã«ãããŠå€åããããŸãããé·æçãªèŠ³ç¹ã§èšæž¬ãããæã«ã¯ãå€é¡ã®çŸéãäžè²«ããŠæè³ããŠããŸãããåœç€Ÿã®ã¢ãããŒãã¯ãæäœå¹Žéæè³åºæºã«ãã£ãŠæ±ºå®ããããã®ã§ã¯ãªãéåžžã«å³æ Œãªè©äŸ¡ããã»ã¹ã«æ ¹ãããŠããŸãã
è²·å掻åæŠèŠ
⢠2024幎11æãç§ãã¡ã¯ã·ã³ããã¯ã¹è£œè¬ãããã¯ãã£ã ãã®åæãã€ã€ãªãã£ã35000äžãã«ã®åæãã§ååŸããŸããããã¯ãã£ã¢ã¯æ
¢æ§ç§»æ€ç察宿䞻ç
ã®æ²»çè¬ãšããŠæ¿èªãããŠãããã€ã³ãµã€ãã«ãã£ãŠå
±å販売ãããŸããè²·ååŸãç§ãã¡ã¯ãã¯ãã£ã ãã®ç±³åœçŽå£²äžé«ã«å¯Ÿãããã€ã€ã«ãã£ãåãåãæš©å©ããããŸãã
⢠2024幎9æãç§ãã¡ã¯BRAIN Biotech AGããdeucrictibantã®ãã€ã€ãªãã£æš©ãçŽ2100äžãã«ã®åæãéããã³äžå®ã®èŠå¶ããã³åæ¥çãã€ã«ã¹ããŒã³ã®éæã«å¿ããæ倧11050äžeurã®ãã€ã«ã¹ããŒã³æ¯æãã§ååŸããŸãããDeucrictibantã¯ãéºäŒæ§ã®è¡ç®¡æµ®è
«çºäœã®æ²»çã®ããã«Pharvaris N.V.ã«ãã£ãŠç¬¬3段éã®éçºäžã§ãã
⢠2024幎9æãç§ãã¡ã¯ã¢ã»ã³ãã£ã¹ãã¡ãŒãããYorvipathã®åæãã€ã€ã«ãã£æš©ã15,000äžãã«ã®äžæ¬æãã§ååŸããŸãããYorvipathã¯æ人ã®ç²ç¶è
ºæ©èœäœäžçã®æ²»çè¬ãšããŠæ¿èªãããŠããŸãã
⢠2024幎6æãPTCã»ã©ãã¥ãŒãã£ã¯ã¹ç€ŸïŒä»¥äžãPTCãïŒã¯ãæ¿èªæžã¿è£œåã§ããRocheã®Evrysdiã®æ®å
ãã€ã€ã«ãã£ã®ååãçŽ24200äžãã«ã§å£²åŽããéžææš©ãè¡äœ¿ããŸããããã®ãªãã·ã§ã³ã¯ã2023幎10æã«çºè¡šãããEvrysdiã®ãã€ã€ãªãã£ååŒã«èµ·å ããç§ãã¡ãEvrysdiã®è¿œå ã®ãã€ã€ãªãã£ã10åãã«ã§ååŸãããã®ã§ããPTCã«ã¯ã2025幎12æ31æ¥ãŸã§ã«åãåã£ããã€ã€ãªãã£ãé€ãã25000äžãã«ã§Evrysdiãã€ã€ãªãã£ã®æ®ãã®9.5%ã売åŽãããªãã·ã§ã³ããããŸãã
⢠2024幎5æãã¢ãžãªã¹ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºããVoranigoã®ãã€ã€ã«ãã£æš©ãååŸããååŒãçºè¡šããFDAã®æ¿èªãæ¡ä»¶ãšããç·é¡9å5,000äžãã«ã®åæããè¡ããŸããã2024幎8æãVoranigoã®FDAæ¿èªãåããŠåæããè¡ããŸããã
⢠2024幎5æãç§ãã¡ã¯ãµã€ãã«ã€ããã£ãã¯ã¹ãšã®æŠç¥çè³éææºãæ¡å€§ãããã€ã€ãªãã£ãšåºå®æ¯æãã®ããã«æ倧57500äžãã«ããã®ãã¡åæãã§25000äžãã«ãå«ãååŒæãæäŸãããŸããããã®ææºã«ã¯ä»¥äžã®äž»èŠãªéšåãå«ãŸããŸãïŒé·å»¶åå¿ççã®ããã®ã¢ãã£ã«ã ãã³ã®ãã€ã€ãªãã£æ¹ç·šïŒã¢ãã£ã«ã ãã³ã®è¿œå 2ãã©ã³ã·ã§ã®åæ¥åããŒã³ãè³éã®ä¿®æ£ïŒæ¿èªåŸã®oHCMã§ã¢ãã£ã«ã ãã³ã®è¿œå 17500äžãã«ãåŒãåºããªãã·ã§ã³ä»ãã§åæã5000äžãã«ïŒïŒå¿äžå
šã«å¯Ÿãããªã¡ã«ã ãã£ãã¡ã«ãã«ã®ç¬¬3çžç¢ºèªè©Šéšã®åæã10000äžãã«ããã³ä¿åçå°åºçäœäžæ§å¿äžå
šã®CK-586ã®ç¬¬2çžèšåºè©Šéšã®åæã500çŸäžãã«ãããã«ã¯CK-586ã®ç¬¬3çžéçºãè³éæäŸããããã®è¿œå 15000äžãã«ã®ãªãã·ã§ã³ãå«ãŸããŸãïŒããã³ãµã€ãã«ã€ããã£ãã¯ã¹ã®æ®éæ ªåŒã®500çŸäžãã«ã®è³Œå
¥ã
⢠2024幎5æã500å2500äžãã«ïŒèŠç©ããã®ååŒã³ã¹ããå«ãïŒã§ImmuNext, Inc.ãææãããã¬ããµãªããã®ãã€ã€ãªãã£ãšãã€ã«ã¹ãã³ãååŸããŸãããç§ãã¡ã¯ãã¬ããµãªããã®å¹ŽéäžççŽå£²äžé«ã«å¯Ÿãããã€ã€ãªãã£ãšãç¹å®ã®åæ¥çããã³èŠå¶é¢é£ã€ãã³ãã®éæã«é¢é£ãããã€ã«ã¹ãã³ãåãåãæš©å©ããããŸãããµããã£ã«ãã£ãŠéçºããããã¬ããµãªããã¯ã第2äžä»£ã®æCD40ãªã¬ã³ãã¢ãã¯ããŒãã«æäœã§ãããã¬ããµãªããã¯ãå€çºæ§ç¡¬åçã®æ²»çã®ããã®ç¬¬3çžèšåºè©Šéšã§è©äŸ¡ãããŠãããå
šèº«æ§ãšãªããããŒãã¹ãš1åç³å°¿ç
ã®ç¬¬2çžèšåºè©Šéšäžã§ãã
⢠2024幎1æã«ãç¹å®ã®èŠå¶ã®ãã€ã«ã¹ããŒã³ã®éæã«äŸåããæ倧4400äžãã«ã®ãã€ã«ã¹ããŒã³æ¯æããšåŒãæãã«ããšã³ããã ã®ãã€ã€ã«ãã£æš©ã4900äžãã«ã®åæãã§ååŸããŸããããšã³ããã ã¯ããã¥ã¬ããçå矀ã®æ²»çã®ããã«ãšãã¬ãã¯ã¹ãã€ãªãµã€ãšã³ã¹ã«ãã£ãŠç¬¬3çžéçºäžã§ãã
⢠2023幎11æã«ãçµ±å倱調çæ²»çã®ããã®ç¬¬3çžéçºæ®µéã®è£œåTEV-â749ã®éçºãã¬ãžã¹ã¿ã³ã¹ããããã«ãTevaããé·æäœçšå泚å°çšãªã©ã³ã¶ãã³ïŒTEV-â749ïŒã®ãã€ã€ãªãã£æš©ãæ倧12500äžãã«ã§ååŸããŸããã
⢠2023幎9æã«ãã¢ã»ã³ãã£ã¹ãã¡ãŒãããã¹ã«ã€ãããã¡ã«å¯Ÿãããã€ã€ãªãã£ã®æš©å©ã15000äžãã«ã®åæãã§ååŸããŸãããã¹ã«ã€ãããã¡ã¯ãå
å æ§æé·ãã«ã¢ã³ã®åæ³ãäžååãªããã«æé·äžå
šã®ããå°å
æ£è
ã®æ²»çã«æ¿èªãããŠããŸãã
⢠2023幎8æãFerring PharmaceuticalsããAdstiladrinã®ãã€ã€ãªãã£æš©ãååŸããŸãããå
æããšããŠ30000äžãã«ãç¹å®ã®è£œé æ¥ã®ç®æšã«äŸåãã20000äžãã«ã®è¿œå ãã€ã«ã¹ããŒã³æ¯æããå«ãŸããŠããŸããAdstiladrinã¯ãäžç®å
çã䌎ããŸãã¯äŒŽããªãä¹³é ç¶è
«çãæã€ããã€ãªã¹ã¯ã®ãã·ã©ã¹ã»ã«ã«ã¡ããã»ã²ã©ã³ã«åå¿ããªãéç䟵襲æ§èè±çã®æ人æ£è
ã®æ²»çã«æ¿èªãããŠããŸãã
⢠2023幎6æã«ãã«ãªãã©ã«ãã¢å€§åŠçäºäŒããErleadaã®è¿œå ãã€ã€ã«ãã£æš©ãååŸãã5900äžãã«ã®åæããè¡ããŸãããErleadaã¯åç«è
ºçã®æ²»çã«æ¿èªãããŠããããžã§ã³ãœã³ãšã³ããžã§ã³ãœã³ã«ãã£ãŠè²©å£²ãããŠããŸãã
⢠2023幎3æããã¥ã¢ããã¯ãã«ã¹ plc ãã KarXt ã®ãã€ã€ãªãã£æš©ãã10000äžãã«ã®åæãéãšãç¹å®ã®èŠå¶ããã³åæ¥çãã€ã«ã¹ããŒã³ã®éæã«äŸåããæ倧40000äžãã«ã®ãã€ã«ã¹ããŒã³æ¯æããæ¡ä»¶ãšããŠååŸããŸãããKarXt ã¯ã粟ç¥çŸæ£ããã³ç¥çµçŸæ£ã®æ²»çã®ããã«ã«ã«ãã»ã©ãã¥ãŒãã£ã¯ã¹ã«ãã£ãŠãã§ãŒãº3ã®éçºäžã§ãããçµ±å倱調çã®åå€çæ³ããã³è£å©çæ³ãã¢ã«ããã€ããŒç
ã«ããã粟ç¥ç
ã®æ²»çãå«ãã§ããŸããã«ã«ãã»ã©ãã¥ãŒãã£ã¯ã¹ã¯ã2024幎3æã«ããªã¹ãã«ã»ãã€ã€ãŒãºã¹ã¯ã€ãã«ãã£ãŠååŸãããŸããã
⢠2023幎1æã«ãã¢ã€ãªãã¹ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€ŸããSpinrazaããã³pelacarsenã®ãã€ã€ãªãã£æš©ãååŸããåæãã§50000äžãã«ã®æ¯æããè¡ããç¹å®ã®pelacarsenã®ãã€ã«ã¹ããŒã³éæã«å¿ããè¿œå æ¯æããšããŠ62500äžãã«ãŸã§ã®éé¡ãçŽæããŸãããSpinrazaã¯èé«æ§çèçž®çã®æ²»çã«æ¿èªãããŠãããpelacarsenã¯å¿è¡ç®¡çŸæ£ã®æ²»çã®ããã«ããã«ãã£ã¹ã«ãã£ãŠç¬¬3çžéçºäžã§ãã
æµåæ§ãšè³æ¬è³æº
æŠèŠ
ç§ãã¡ã®äž»ãªæµåæ§ã®æºã¯ãäºæ¥ããåŸãããçŸéã§ãã2024幎ãš2023幎ã®æåã®9ãæéã§ãç§ãã¡ã¯ãããã20åãã«ãš22åãã«ãçã¿åºããŸããã å¶æ¥æŽ»åã«ãã£ãŠæäŸãããçŽçŸé æ¢åã®è³æ¬ãªãœãŒã¹ãå¶æ¥æŽ»åããæäŸãããçŸéãåã³ä»¥äžã§å®çŸ©ãããåœç€Ÿã®å転信çšæ ãžã®ã¢ã¯ã»ã¹ã¯ãä»åŸãç§ãã¡ãå¶æ¥ããã³é転è³æ¬ã®èŠä»¶ãæºãããèšç»ãããæŠç¥çè²·åãç 究éçºã®è³é調éãè¡ããåµåãµãŒãã¹çŸ©åãæºããããšãå¯èœã«ãããšä¿¡ããŠããŸããç§ãã¡ã¯æŽå²çã«äœãåºå®å¶æ¥è²»çšã§éå¶ããŠããŸãããç 究éçºã®è³é調éã®çŸ©åãé€ãç§ãã¡ã®äž»ãªçŸéå¶æ¥è²»çšã«ã¯ãå©æ¯è²»çšãå¶æ¥ããã³äººä»¶è²»ãåã³æ³çããã³å°éçãªææ°æãå«ãŸããŸãã
è³æ¬åžå Žã«ãã㊠substantial ãªè³éæºã«ã¢ã¯ã»ã¹ã§ããæã
è¿œå ã®è³æ¬ãè¿œå ã®è² åµãæ ªåŒã®è³é調éã®çµã¿åããã«ãã£ãŠæ±ããããšããããŸãã2024幎9æ30æ¥ããã³2023幎12æ31æ¥çŸåšããã¹ãŠã®çºè¡ãããã·ãã¢ç¡æ
ä¿ç€Ÿåµã®é¡é¢äŸ¡å€ã¯ãããã78åãã«ããã³63åãã«ã§ãããããã«ããªãã«ãã³ã°ã¯ã¬ãžãããã¡ã·ãªãã£ã®äžã§æ倧18åãã«ã®å©çšå¯èœãªãªãã«ãã³ã°ã³ãããã¡ã³ãããããŸããåå
¥æŽ»åãæ®é«ãããã³ããŸããŸãªè³é調éã¢ã¬ã³ãžã¡ã³ãã®äžã§ã®ç¹å®ã®åµåå¥çŽã®éµå®ã«é¢ããæŠèŠã¯ããã®ååæå ±åæžã®ãã©ãŒã 10-Qã®ç¬¬1éšã第1é
ã«å«ãŸãã財åè«žè¡šã®æ³šèš9âåå
¥éã«ç€ºãããŠããŸãã
ç§ãã¡ã¯æŽå²çã«ãéå¶ããã®çŸéãããŒãè³æ¬ã®æ åºããããŠåå
¥ã«ãã£ãŠæè³ãè³éæäŸããŠããŸãããäœãéå¶ã³ã¹ãã«å ããè³æ¬çæ¯åºããªããäœãçšéãç§ãã¡ã®åŒ·åãªè²¡åãããã¡ã€ã«ã«å¯äžããé«ãéå¶ã¬ãã¬ããžãšé«ãçŸéãããŒå€æçãå®çŸããŠããŸããçŸåšããã³èšç»äžã®éå¶ã³ã¹ãïŒè²·åãé€ãïŒããäž»ã«éå¶ããã®çŸéãããŒããã³æè³ããã®çŸéãããŒããªãã³ã«æ ªåŒãšåµåã®çºè¡ãéããŠè³é調éãç¶ããããšãæåŸ
ããŠããŸããé
åçãªåµåè³æ¬ã§æå
ã®çŸéåã³çŸéåçç©ãè£å®ããç¹å®ã®æŠç¥çãªè²·åãè³éæäŸããŠããŸãã
é転è³æ¬ã®ããŒãºãåµåãµãŒãã¹ããã³ãã®ä»ã®çŸ©åãæºããèœåããªãã³ã«è³é調éå¥çŽã®äžã§ã®è²¡åå¥çŽã«åŸãèœåã¯ãå°æ¥ã®éå¶æ瞟ãšãã£ãã·ã¥ãããŒã«äŸåããŠããããããã¯çŸåšã®çµæžç¶æ³ããã®ä»ã®èŠå ã«ãã£ãŠå·Šå³ãããŸããããã®å€ãã¯æã
ã®å¶åŸ¡ãè¶
ããŠããŸãã
ãã£ãã·ã¥ãããŒ
以äžã®è¡šãšãã£ãã·ã¥ãããŒã®å€åã«é¢ããåæã¯ãç§ãã¡ã®ãã£ãã·ã¥ãããŒæŽ»åã®èŠçŽã瀺ããŠããŸãïŒååäœïŒïŒ
2023幎9æ30æ¥ãŸã§ã®9ã¶æé 2024 2023 å€å çŸéã®æäŸ/(䜿çš):
     å¶æ¥æŽ»å $ 2,026,461 $ 2,215,174 $ (188,713)      æè³æŽ»å (2,172,527) (1,072,617) (1,099,910)      財å掻å 619,108 (1,916,860) 2,535,968Â
ãã£ãã·ã¥ãããŒã®å€åã®åæ
å¶æ¥æŽ»å
2024幎ã®æåã®9ã¶æéã®å¶æ¥æŽ»åã«ãããã£ãã·ã¥ã¯ã2023幎ã®æåã®9ã¶æéãšæ¯èŒããŠ18870äžãã«æžå°ããäž»ã«éèãã€ã€ã«ãã£è³ç£ããã®ãã£ãã·ã¥åéã248.1çŸäžãã«æžå°ããããšã«ãããã®ã§ãã2023幎ã®ç¬¬äžååæã«ã¯ãéèãã€ã€ã«ãã£è³ç£ããã®ãã£ãã·ã¥åéã«47500äžãã«ã®ãã€ã«ã¹ããŒã³æ¯æããå«ãŸããŠããŸããããã®æžå°ã¯ã2024幎ã®æåã®9ã¶æéã«ãããéçºæ®µéã®è³éæäŸæ¯æãã®æžå°ãšãå¶æ¥çããã³å°éçè²»çšã®æ¯æãã®æžå°ã«ãã£ãŠéšåçã«çžæ®ºãããŸããã
æè³æŽ»å
2024幎ã®æåã®9ã¶æã§äœ¿çšãããæè³æŽ»åã®ããã®çŸéã¯ã2023幎ã®æåã®9ã¶æãšæ¯èŒããŠ11åãã«å¢å ããŸãããããã¯äž»ã«éèãã€ã€ãªãã£è³ç£ã®è³Œå
¥ã販売å¯èœãªåµåžã»åµå蚌åžããã³æ ªåŒèšŒåžã«å¯ŸããçŸéã®äœ¿çšãå¢ããããšã«ãããŸããçŸéã®äœ¿çšã®å¢å ã¯ãæ ªåŒèšŒåžããã®åçã«ãã£ãŠéšåçã«çžæ®ºãããŸããã
è³é調é掻å
2024幎ã®æåã®9ã¶æéã«ããã財å掻åã«ãã£ãŠæäŸãããçŸéã¯61910äžãã«ã§ããã2023幎ã®æåã®9ã¶æéã«ããã財å掻åã§äœ¿çšãããçŸéã®19åãã«ãšæ¯èŒãããŠããŸãã2024幎ã®æåã®9ã¶æéã«ãããŠã財å掻åã«ãã£ãŠæäŸãããçŸéã¯ãäž»ã«2024幎ããŒãã®çºè¡ããã®15åãã«ã®çŽåçã«ãã£ãŠæšé²ãããŸããïŒä»¥äžã«è©³è¿°ããŸãïŒã2023幎ã®æåã®9ã¶æéã«ãããŠã財å掻åã§äœ¿çšãããçŸéã¯ãäž»ã«10åãã«ã®åµåè¿æžã«ãã£ãŠæšé²ãããŸããã
è³æ¬ã®æº
2024幎9æ30æ¥ããã³2023幎12æ31æ¥çŸåšãç§ãã¡ã®çŸéåã³çŸéåçç©ã¯ãããã$95010äžãš$47700äžã«éããŸãããç§ãã¡ã¯ãçŸéåã³çŸéåçç©ãå°æ¥ã®å¶æ¥ããã®ãã£ãã·ã¥ãããŒããŸãã¯è¿œå ã®åµåçºè¡ãéããŠãçæããã³é·æã®éè矩åãæºããã€ããã§ããå¶æ¥ããã®ãã£ãã·ã¥ãããŒãçæããèœåãåµåçºè¡ããŸãã¯åãå
¥ãå¯èœãªæ¡ä»¶ã§ã®è³é調éå¥çŽã®ç· çµã¯ããã€ã€ãªãã£ãä¿æããŠããåºç€ãšãªãå»è¬åã®è²©å£²ã倧å¹
ã«æžå°ããå ŽåãéèŠãªè²¡åæ¯çãŸãã¯ä¿¡çšæ Œä»ãã®æªåããã®ä»ã®éèŠãªäžå©ãªããžãã¹ç¶æ³ã®å€åããã£ãå Žåã«æªåœ±é¿ãåããå¯èœæ§ããããŸããçŸåšãç§ãã¡ã¯ãåµåãçºè¡ãããã®ä»ã®è³é調éå¥çŽãç· çµããæé·ç®æšãæ¯æŽããããã«åãå
¥ãå¯èœãªæ¡ä»¶ã§é·æè³æ¬ãåŒãä»ããããã®ååãªè²¡åçæè»æ§ãæã£ãŠãããšèããŠããŸãã
åå
¥é
ç§ãã¡ã®åå
¥ã¯ä»¥äžã®éãã§ãïŒååäœïŒ:
åå
¥ã®çš®é¡
çºè¡æ¥ æºæ 2024幎9æ30æ¥çŸåš 2023幎12æ31æ¥æç¹ ã·ãã¢ç¡æ
ä¿ããŒã: $1,000,000ã1.20%ïŒé¡é¢ã®98.875%ã§çºè¡ïŒ 9/2020 9/2025 1,000,000 1,000,000 $1,000,000ã1.75%ïŒé¡é¢ã®98.284%ã§çºè¡ïŒ 9/2020 9/2027 1,000,000 1,000,000 500,000ãã«ã5.15%ïŒé¡é¢ã®98.758%ã§çºè¡ïŒ 6/2024 9/2029 500,000 â 1,000,000ãã«ã2.20%ïŒé¡é¢ã®97.760%ã§çºè¡ïŒ 9/2020 9/2030 1,000,000 1,000,000 600,000ãã«ã2.15%ïŒé¡é¢ã®98.263%ã§çºè¡ïŒ 7/2021 9/2031 600,000 600,000 500,000ãã«ã5.40%ïŒé¡é¢ã®97.872%ã§çºè¡ïŒ 6/2024 9/2034 500,000 â 1,000,000ãã«ã3.30%ïŒé¡é¢ã®95.556%ã§çºè¡ïŒ 9/2020 9/2040 1,000,000 1,000,000 1,000,000ãã«ã3.55%ïŒé¡é¢ã®95.306%ã§çºè¡ïŒ 9/2020 9/2050 1,000,000 1,000,000 700,000ãã«ã3.35%ïŒé¡é¢ã®97.565%ã§çºè¡ïŒ 7/2021 9/2051 700,000 700,000 500,000ãã«ã5.90%ïŒé¡é¢ã®97.617%ã§çºè¡ïŒ 6/2024 9/2054 500,000 â åèšã·ãã¢ç¡æ
ä¿åµå 7,800,000  6,300,000  æªååŽåµåå²åŒåã³çºè¡è²»çš (192,621) (164,715) ç·åµååž³ç°¿äŸ¡é¡ 7,607,379  6,135,285  æ°èŠè²·: é·æåå
¥éã®çæåéåã®æžé¡ (996,942) â åèšé·æåµå
$ 6,610,437 Â $ 6,135,285 Â
ã·ãã¢ç¡æ
ä¿åµ
2024幎6æãç§ãã¡ã¯å éå¹³åã¯ãŒãã³ã¬ãŒã5.48ïŒ
ã®15åãã«ã®ã·ãã¢ç¡æ
ä¿åµåžïŒã2024幎åµåžãïŒãçºè¡ããŸããã2021幎7æã«ãå éå¹³åã¯ãŒãã³ã¬ãŒã2.80ïŒ
ã®13åãã«ã®ã·ãã¢ç¡æ
ä¿åµåžïŒã2021幎åµåžãïŒãçºè¡ããŸããã2020幎9æã«ã60åãã«ã®ã·ãã¢ç¡æ
ä¿åµåžïŒã2020幎åµåžãïŒãçºè¡ããŸãããå éå¹³åã¯ãŒãã³ã¬ãŒãã¯2.13ïŒ
ã§ããç§ãã¡ã¯ã2020幎ã®çŽå¹£ã2021幎ã®çŽå¹£ã2024幎ã®çŽå¹£ãç·ç§°ããŠãã¡ã¢ããšåŒãã§ããŸããã¡ã¢ã«ã¯å幎ããšã«å©æ¯ãæ¯æãå¿
èŠããããŸãã2024幎åµã®æåã®å©æ¯æ¯æãæ¥ã¯2025幎3æ2æ¥ã§ããããŒãã管çããã€ã³ãã³ãã£ãŒã«ã¯ã次ã®ãããªç¹å®ã®å¥çŽãå«ãŸããŠããŸã e w 2024幎9æ30æ¥ã®æç¹ã§ã³ã³ãã©ã€ã¢ã³ã¹ãããŠããŸãã
ã·ãã¢ç¡æ
ä¿å転信çšæ
åœç€Ÿã®åäŒç€ŸRPããŒã«ãã£ã³ã°ã¹ã¯ãåãæãšããŠ2021幎9æ15æ¥ã«æ¹èšçäžä¿¡å¥çŽïŒãäžä¿¡å¥çŽãïŒãç· çµããç¡æ
ä¿ã®å転信çšæ ïŒãå転信çšæ ãïŒãæäŸããŠããŸãã2023幎12æ22æ¥ã«ç· çµãããäžä¿¡å¥çŽã®ä¿®æ£ç¬¬3å·ã¯ãäžè¬äŒæ¥ç®çã®ããã«åå
¥èœåã18åãã«ã«å¢å ããã17åãã«ã®å転ã³ãããã¡ã³ãã¯2028幎12æ22æ¥ã«æºæãè¿ããæ®ãã®1å1åäžãã«ã®å転ã³ãããã¡ã³ãã¯2027幎10æ31æ¥ã«æºæãè¿ããŸãã2024幎1æ24æ¥ã«ã¯ãäžä¿¡å¥çŽã®æè¡çãªä¿®æ£ãè¡ãããã«ä¿®æ£ç¬¬4å·ãç· çµããŸããã2024幎9æ30æ¥çŸåšãå転信çšæ ã®äžã§ã®åå
¥èœåã¯18åãã«ã§ãã
ãªãã«ãã³ã°ã¯ã¬ãžãããã¡ã·ãªãã£ã統治ããäžä¿¡å¥çŽã«ã¯ããã®ä»ã®ããšã®äžã§ã次ã®ãããªäžè¬çãªçŽæãå«ãŸããŠããŸãã(i) äžä¿¡å¥çŽã«å®çŸ©ãããèšç®ããã調æŽåŸEBITDAã«å¯Ÿããçµ±åè³éè² åµã®æ¯çã4.00察1.00以äžïŒãããã¯ãé©æ ŒãªéèŠãªååŸåŸã¯4.50察1.00以äžïŒã§ããããšã(ii) äžä¿¡å¥çŽã«å®çŸ©ãããèšç®ãããçµ±åå©æ¯è²»çšã«å¯Ÿãã調æŽåŸEBITDAã®æ¯çã2.50察1.00以äžã§ããããšã(iii) äžä¿¡å¥çŽã«å®çŸ©ãããèšç®ãããããŒããã©ãªãªãã£ãã·ã¥ãããŒã«å¯Ÿããçµ±åè³éè² åµã®æ¯çã5.00察1.00以äžïŒãããã¯ãé©æ ŒãªéèŠãªååŸåŸã¯5.50察1.00以äžïŒã§ããããšã
2024幎9æ30æ¥ã®æç¹ã§ã財åå¥çŽã«æºæ ããŠããŸããã
調æŽåŸEBITDAããã³ããŒããã©ãªãªãã£ãã·ã¥ãããŒã¯ãäžä¿¡å¥çŽã«å«ãŸããç¹å®ã®éèŠãªå¶çŽã®éèŠãªéšåã§ããéGAAPæµåæ§ææšã§ããäžä¿¡å¥çŽã®äžã§ã®è²¡åå¶çŽã«éåãããšã貞ãæãæã
ã«åããå
šé¡ãå³åº§ã«è¿æžããããèŠæ±ããå¯èœæ§ããããŸãããããã®è²¡åå¶çŽãæºããããšãã§ããªãå Žåãäžä¿¡å¥çŽã«åºã¥ããŠæã
ã¯è¿œå ã®åå
¥ãé
åœã®æ¯æããç¹å®ã®æ¯æãã®å®æœãè³ç£ã®ååŸããã³åŠåãªã©ã®ç¹å®ã®æŽ»åãè¡ãããšãçŠæ¢ãããŸãã
äžè¡šã¯ãäžä¿¡å¥çŽã«ãããããããã®å®çŸ©ã«åºã¥ããŠèšç®ããã調æŽåŸEBITDAããã³ããŒããã©ãªãªãã£ãã·ã¥ãããŒã瀺ããŠããŸãïŒåäœïŒåïŒ:
2023幎9æ30æ¥ãŸã§ã®3ã¶æé 2023幎9æ30æ¥ãŸã§ã®9ã¶æé 2024 2023 2024 2023 ããŒããã©ãªãªåå
¥ $ 734,624  $ 637,160  $ 2,059,602  $ 2,312,807  éå¶ããã³å°éçãªã³ã¹ãã®æ¯æã (55,232) (54,961) (163,804) (188,839) 調æŽåŸEBITDAïŒéGAAPïŒ $ 679,392  $ 582,199  $ 1,895,798  $ 2,123,968  æ¯æå©æ¯ãããã
(62,464) (53,967) (121,318) (102,706) ããŒããã©ãªãªãã£ãã·ã¥ãããŒïŒéGAAPïŒ $ 616,928  $ 528,232  $ 1,774,480  $ 2,021,262 Â
調æŽåŸEBITDAããã³ããŒããã©ãªãªãã£ãã·ã¥ãããŒã¯ãç¹å®ã®é
ç®ã®åœ±é¿ãé€å€ããéGAAPæµåæ§ææšã§ãããGAAPã«åŸã£ãŠèšç®ãããŠããŸããã èªè
ã«ã¯ã調æŽåŸEBITDAããã³ããŒããã©ãªãªãã£ãã·ã¥ãããŒã®å®çŸ©ã«åŸã£ãŠç€ºãããéé¡ããä»ã®äŒæ¥ãã¢ããªã¹ãã䜿çšããé¡äŒŒã®ææšãšã¯ç°ãªãå Žåãããããšã泚æåèµ·ããŸãã å¶æ¥æŽ»åã«ãã£ãŠæäŸãããçŽçŸé 調æŽåŸEBITDAããã³ããŒããã©ãªãªãã£ãã·ã¥ãããŒã®æãè¿ãGAAPææšãžã®èª¿æŽãã以äžã«ç€ºãããŠããŸãïŒååäœã§ïŒïŒ
2023幎9æ30æ¥ãŸã§ã®3ã¶æé 2023幎9æ30æ¥ãŸã§ã®9ã¶æé 2024 2023 2024 2023 å¶æ¥æŽ»åã«ããçŽçŸéåå
¥ïŒGAAPïŒ $ 703,614  $ 573,520  $ 2,026,461  $ 2,215,174  調æŽ: 売åŽçšæ䟡蚌åžããã®åç (1), (2)
2,880 â 7,200 â æåæ³é©çšäŒç€Ÿããã®åé
(2)
11,489 4,458 20,397 39,225 æ¯æå©æ¯ãããã (2)
62,464 53,967 121,318 102,706 éçºæ®µéã®è³éæ¯æã - ç¶ç¶äž 500 500 1,500 1,500 éçºæ®µéã®è³éæ¯æã - åæãããã³ãã€ã«ã¹ããŒã³ â 50,000 â 50,000 ã¬ã¬ã·ãŒéæ¯é
æåãžã®åé
- ããŒããã©ãªãªåå
¥ (2)
(101,555) (100,246) (281,078) (284,637) 調æŽåŸEBITDAïŒéGAAPïŒ $ 679,392  $ 582,199  $ 1,895,798  $ 2,123,968  æ¯æå©æ¯ãããã (2)
(62,464) (53,967) (121,318) (102,706) ããŒããã©ãªãªãã£ãã·ã¥ãã㌠(éGAAP)
$ 616,928 Â $ 528,232 Â $ 1,774,480 Â $ 2,021,262 Â
(1) 2023幎ã®ç¬¬4ååæã«ããµã€ãã«ã€ããã£ãã¯ã¹åæ¥å°å
¥è³éã®ãã©ã³ã·ã§1ã«ã€ããŠååæããšã®è¿æžãåãå§ããŸããïŒãã£ãã·ã¥ãããŒèšç®æžã«æ¬¡ã®ããã«ç€ºãããŠããŸãïŒã 売åŽçšæ䟡蚌åžããã®åç ïŒãã£ãã·ã¥ãããŒèšç®æžã«æ¬¡ã®ããã«ç€ºãããŠããŸãïŒã
(2) 以äžã®è¡šã¯ãå調æŽã®ã©ã€ã³ã¢ã€ãã ãšããã®ã©ã€ã³ã¢ã€ãã ããã£ãã·ã¥ãããŒèšç®æžã«èšèŒãããŠããçŽæ¥ã®äœçœ®ã瀺ããŠããŸãã
調æŽã®èª¿æŽ ãã£ãã·ã¥ãããŒã®åé¡ æ¯æå©æ¯ãããã
å¶æ¥æŽ»åïŒ æ¯æå©æ¯ æžå° ååå©æ¯ )
æåæ³é©çšäŒç€Ÿããã®é
åœ æè³æŽ»å 売åŽçšæ䟡蚌åžããã®åç æè³æŽ»å æ§éæ¯é
æ ªäž»æåãžã®åé
- ããŒããã©ãªãªåå
財å掻å
è³æ¬ã®çšé
ãã€ã€ã«ãã£ã®ååŸ
ç§ãã¡ã¯ãããŸããŸãªæ§é ãéããŠããŒãããŒã®ããŒãºã«åãããŠèª¿æŽã§ããæ¹æ³ã§è£œåã®ãã€ã€ãªãã£ãååŸããŸãïŒ
⢠ãµãŒãããŒãã£ã®ãã€ã€ãªã㣠â é«ãåæ¥çå¯èœæ§ãæã€æ¿èªæžã¿ãŸãã¯éçºåŸæã®æ²»çæ³ã«é¢ããæ¢åã®ãã€ã€ãªãã£ããã€ã€ãªãã£ãšã¯ãã©ã€ã»ã³ã¹å¥çŽè
ã«ãã補åããã¯ãããžãŒããŸãã¯ç¥ç財ç£ã®äœ¿çšããã®å£²äžé«ã®äžå®å²åãåããå¥çŽäžã®æš©å©ã§ããçŸåšã®ããŒããã©ãªãªã®å€§éšåã¯ãµãŒãããŒãã£ã®ãã€ã€ãªãã£ã§æ§æãããŠããŸãã
⢠åæãã€ã€ãªã㣠â æ¿èªããããŸãã¯åŸæéçºæ®µéã®çæ³ã«ãããæ°ãã«åµåºããããã€ã€ãªãã£ã§ã匷åãªããŒãã®èšŒæ ãšé«ãåæ¥çæœåšèœåãæã£ãŠããŸããåæãã€ã€ãªãã£ãšã¯ãçæ³ã®éçºè
ãŸãã¯è²©å£²è
ã«ãã売äžã®äžå®å²åã«å¯Ÿããå¥çŽäžã®æš©å©ã§ããã®å¯ŸäŸ¡ãšããŠè³éãæäŸããŸããåæãã€ã€ãªãã£ã«ã¯ãæ¡ä»¶ä»ãã®ãã€ã«ã¹ããŒã³æ¯æããå«ãŸããå ŽåããããŸããç§ãã¡ã¯ãŸããå°æ¥ã®ãã€ã€ãªãã£ãšãã€ã«ã¹ããŒã³ã®å¯ŸäŸ¡ãšããŠãè³éæäŸããŠãã補åãŸãã¯é©å¿çãæ¿èªãããå Žåã«ããã€ãªå»è¬åäŒæ¥ã®ç 究éçºãç¶ç¶çã«è³éæäŸããŸãã
⢠ããŒã³ãããã³éçºè³æ¬ â ã«ã¹ã¿ãã€ãºãããè¿œå è³éãœãªã¥ãŒã·ã§ã³ã¯ãäžè¬çã«ååŒæã®äžéšãšããŠå«ãŸããç§ãã¡ã®è³æ¬ã®èŠæš¡ãæ¡å€§ããŸããããŒã³ãããã³éçºè³æ¬ã¯éåžžãè¬ã®çºå£²ã«é¢ããäºã決ããããã¹ã±ãžã¥ãŒã«ã«åºã¥ããåºå®æ¯æãã®é·æçãªæµããšåŒãæãã«æäŸãããŸããããŒã³ãããã³éçºè³æ¬ã«ã¯ãäŒæ¥ã®å
¬éæ ªåŒãžã®çŽæ¥æè³ãå«ãŸããå ŽåããããŸãã
⢠å䜵ããã³è²·åïŒãM&AãïŒé¢é£ â å䜵ããã³è²·åååŒã«é¢é£ããŠãã€ã€ã«ãã£ãååŸããŸããããã¯ããã€ãªå»è¬åäŒç€Ÿã®è²·ååŸã«ã察象äŒç€Ÿã®éæŠç¥çè³ç£ãåŠåããéã«è²·ãæããååŸããããšãå€ãã§ãããŸããéèŠãªãã€ã€ã«ãã£ãææããä»ã®ãã€ãªå»è¬åäŒç€ŸãååŸããããã«äŒæ¥ãšææºããããšãç®æããŠããŸããããã«ãéèŠãªãã€ã€ã«ãã£ãæã€ãã€ãªå»è¬åäŒç€Ÿã®ååŸãæ€èšãããã次ã®ååŒã§ãã€ã€ã«ãã£ãåµåºã§ããäŒç€Ÿã®ååŸãç®æãããšããããŸãã
ããã«ãç§ãã¡ã®èœåã掻çšããè¿œå ã®æ©äŒããã©ãããã©ãŒã ããŸãã¯æè¡ãç¹å®ããããšãã§ãããããããŸããã
æ ªäž»ãžã®é
åœ
åœç€Ÿã¯ãã¯ã©ã¹Aæ®éæ ªåŒã®ä¿æè
ã«é
åœãæ¯æããŸããã 2å8280äžãã« ããã³ 2å6900äžãã« ããã¯ããããã2024幎ãš2023幎ã®æåã®9ã¶æã«ãããéé¡ã§ãã åœç€Ÿã«ã¯ãååæé
åœãŸãã¯ç¹å®ã®çã§ã®é
åœãæ¯æãæ³ç矩åã¯ãããŸããã
ã¯ã©ã¹Aæ®éæ ªã®èªå·±æ ªåŒè²·ãæ»ã
2023幎3æãåœç€Ÿã®åç· åœ¹äŒã¯ãã¯ã©ã¹Aæ®éæ ªåŒãæ倧10åãã«ãŸã§å賌å
¥ããããã°ã©ã ãæ¿èªããŸããããã®å賌å
¥ããã°ã©ã ã®æ¿èªã¯2027幎6æ23æ¥ã«æéãåããŸããæ ªåŒã®å賌å
¥ã¯ãå
¬éåžå ŽãŸãã¯ç§çã«äº€æžãããååŒã§è¡ãããå ŽåããããŸãã2024幎ã®æåã®9ã¶æã§ã660äžæ ªãçŽ1å7970äžãã«ã®ã³ã¹ãã§å賌å
¥ããŸããã 2023幎ã®æåã®9ã¶æã§ã890äžæ ªãçŽ2å7860äžãã«ã®ã³ã¹ãã§å賌å
¥ããŸããã2024幎9æ30æ¥çŸåšãå賌å
¥ããã°ã©ã ã®äžã§çŽ5å1560äžãã«ãæ®ã£ãŠããŸãã
ãã®ä»ã®è³é調éæ¹æ³
2024幎5æã«ãµã€ãã«ã€ããã£ãã¯ã¹ãšã®æ¡å€§è³éæäŸã³ã©ãã¬ãŒã·ã§ã³ã®äžç°ãšããŠãCk-586ã®èšåºè©Šéšã«è³éæäŸãè¡ãããšã«åæããŸããã2024幎5æã«5,000äžãã«ãåæãããŸããã2024幎9æ30æ¥çŸåšãããã«æ倧1å5,000äžãã«ã®è³éæäŸã®ãªãã·ã§ã³ããããŸããããŸã è¡äœ¿ããŠããŸããã
åœç€Ÿã¯ããµã€ãã«ã€ããã£ãã¯ã¹ãšã®éã§ãåèš5å2500äžãã«ã®7åã®åå²æããããªãé·æçãªè³é調éå¥çŽãçµãã§ããŸãïŒããµã€ãã«ã€ããã£ãã¯ã¹åæ¥éå§è³éãïŒã2024幎9æ30æ¥ã®æç¹ã§ããµã€ãã«ã€ããã£ãã¯ã¹åæ¥éå§è³éã®äžã§3å5000äžãã«ãåŒãåºãå¯èœã§ããããµã€ãã«ã€ããã£ãã¯ã¹ã¯5000äžãã«ãæäœéåŒãåºãå¿
èŠããããŸãã
2023幎11æã«ããªã©ã³ã¶ãã³LAIïŒTEV-749ïŒã®ç¶ç¶çãªéçºãè³éæäŸããããã«ããããšæ倧10000äžãã«ã®è³éæäŸå¥çŽãçµã³ãŸããã2024幎9æ30æ¥çŸåšããããšã®å¥çŽã«é¢é£ããæªè³éã®çŽæã¯1800äžãã«ã§ããã
åœç€Ÿã¯ãéçºããŒãããŒã«ããç 究éçºæŽ»åã«è³éæäŸããå¥çŽäžã®çŸ©åããããã®ä»ã®è³é調éã®åã決ããããå¯èœæ§ããããŸãããŸããAvillion Entitiesã«ãããæåæ³æè³ã«é¢é£ããè³é調éã®åã決ãããããŸããåœç€Ÿã®ã³ãããããè³æ¬èŠä»¶ã¯éçºã®ãã§ãŒãºã«åºã¥ããŠããããããããå®äºããããšã¯éåžžã«äžç¢ºå®ã§ããããããã®è³é調éã®åã決ãã®ããšã§çŸåšã®éçºæ®µéãè³éæäŸããããã«å¿
èŠãªè³æ¬ã®ã¿ãã³ããããããè³æ¬ãšèŠãªãããŸãã 2024幎9æ30æ¥çŸåšã§çŽ1830äžãã«ã§ããã
ç¹å®ã®éçºãèŠå¶æ¿èªããŸãã¯åæ¥çãã€ã«ã¹ããŒã³ã®æåããéæã«åºã¥ããŠãã«ãŠã³ã¿ãŒããŒãã£ãŒã«æ¯æãããç¹å®ã®ãã€ã«ã¹ããŒã³ããããŸãããããã®æ¡ä»¶ä»ããã€ã«ã¹ããŒã³ã®æ¯æãã¯å¥çŽäžã®çŸ©åãšã¯èŠãªãããŸããã2024幎ã®æåã®9ãæã«ããªã«ãã·ã©ã³ã«é¢é£ãã5,000äžãã«ã®èŠå¶ãã€ã«ã¹ããŒã³ãæ¯æãããŸããã2023幎ã®æåã®9ãæã«ã¯ããšã«ãªãŒãã«é¢é£ãã1240äžãã«ã®å£²äžããŒã¹ã®ãã€ã«ã¹ããŒã³ãšãã¢ãã£ã«ã ãã³ã«é¢ããŠãµã€ãã«ã€ããã£ãã¯ã¹ãžã®5,000äžãã«ã®èšåºãã€ã«ã¹ããŒã³æ¯æããè¡ããŸããã
åµåãµãŒãã¹
2024幎9æ30æ¥çŸåšãç§ãã¡ã®ããŒãã«åºã¥ãä»åŸ5幎éããã³ãã®åŸã®å
æ¬ãšå©æ¯ã®æ¯æãã¯ä»¥äžã®éãã§ãïŒååäœã§ïŒïŒ
幎 å
æ¬è¿æž å©æ¯æ¯æã 2024幎ã®æ®ã $ â $ â 2025 1,000,000 257,792 2026 â 226,600 2027 1,000,000 226,600 2028 â 209,100 ãã以é 5,800,000 2,753,800 åèš (1)
$ 7,800,000 Â $ 3,673,892 Â
(1) 2024幎9æ30æ¥çŸåšã1å9260äžãã«ã®æªååŽã®åµåå²åŒããã³çºè¡ã³ã¹ããé€å€ããŠããããããã¯åºç€ãšãªãåµå矩åã®æ®ãã®æéã«ãããå©æ¯è²»çšãšããŠååŽãããŸãã
éå¶åã³äººä»¶è²»
管çå¥çŽã«åºã¥ãããã€ã€ãªãã£æè³ãŸãã¯ããŒããã©ãªãªåå
¥ããã®çŸéåå
¥ã®6.5%ã«çžåœããååææ¯ã®éå¶ããã³äººä»¶è²»ã®æ¯æããšãåååææ«ã®GAAPã«åºã¥ãã»ãã¥ãªãã£æè³ã®0.25%ãæ¯æããŸããéå¶ããã³äººä»¶è²»ã®æ¯æãã¯ããŒããã©ãªãªåå
¥ã«åºã¥ããŠæ±ºå®ããããããéé¡ã¯å€æ°ã§ããéå¶ããã³äººä»¶è²»ã®æ¯æãã¯ã éå¶ããã³å°éçãªã³ã¹ãã®æ¯æã ãã£ãã·ã¥ãããŒèšç®æžã«è¡šç€ºãããæãéèŠãªèŠçŽ ãå ããŸããããã«ãéå¶ããã³äººä»¶è²»ã®æ¯æãã«é¢ããŠçºçããè²»çšã¯ãä»åŸãG&Aè²»çšã®æãéèŠãªæ§æèŠçŽ ãšãªãããšãæåŸ
ãããŠããŸãã
ä¿èšŒäººã®è²¡åæ
å ±
ããŒãã«åºã¥ãåœç€Ÿã®çŸ©åã¯ãRPããŒã«ãã£ã³ã°ã¹ã«ãã£ãŠå®å
šãã€ç¡æ¡ä»¶ã«ä¿èšŒãããŠããŸãããã®RPããŒã«ãã£ã³ã°ã¹ã¯ãå®å
šåäŒç€Ÿã§ã¯ãªãåäŒç€Ÿã§ãïŒä»¥äžãä¿èšŒåäŒç€ŸããšãããŸãïŒãåœç€Ÿã®æ®ãã®åäŒç€ŸïŒä»¥äžãéä¿èšŒåäŒç€ŸããšãããŸãïŒã¯ãããŒããä¿èšŒããŠããŸãããããŒããèŠå®ããä¿¡èšå¥çŽã®æ¡ä»¶ã«åŸãããã€ã€ã«ãã£ãã¡ãŒã plc ããã³ä¿èšŒåäŒç€Ÿã¯ãããããå®å
šãã€ç¡æ¡ä»¶ã«ãå
±åã§ãã€åç¬ã§ãããŒãã«å¯Ÿããå©æ¯ãå
æ¬ããã³ãã¬ãã¢ã ïŒè©²åœããå ŽåïŒã®æ¯æããä¿èšŒããŸãã2024幎9æ30æ¥çŸåšãçºè¡ãããŠããå
šããŒãã®ããŒã»ããªã¥ãŒããã³ãã£ãªã³ã°ã»ããªã¥ãŒã¯ããããã78åãã«ããã³76åãã«ã§ããã
以äžã®è²¡åæ
å ±ã¯ããã€ã€ã«ãã£ãã¡ãŒã plc ãš RP ããŒã«ãã£ã³ã°ã¹ã®2024幎9æ30æ¥åã³2023幎12æ31æ¥æç¹ã®åç®ãã©ã³ã¹ã·ãŒãæ
å ±ãåã³2024幎ã®æåã®9ã¶æéã®åç®æçèšç®æžæ
å ±ãèŠçŽããŠç€ºããŠããŸãããã€ã€ã«ãã£ãã¡ãŒã plc ãš RP ããŒã«ãã£ã³ã°ã¹éã®ãã¹ãŠã®ç€Ÿå
æ®é«åã³ååŒã¯ãåç®è²¡åè«žè¡šã®æ瀺ã«ãããŠæé€ãããŠããŸããRP ããŒã«ãã£ã³ã°ã¹ã®æãéèŠãªè³ç£ã¯éå¶åäŒç€Ÿãžã®æè³ã§ãããéä¿èšŒåäŒç€Ÿãžã®æè³ãé€å€ããããã«äžã®è¡šã§ã¯é€å€ãããŠããŸããç§ãã¡ã®éå¶åäŒç€Ÿã¯ãçŸéåã³çŸéåçç©ãåžå Žæ§ã®ãã蚌åžåã³è²¡åãã€ã€ã«ãã£è³ç£ã®å€§éšåãä¿æããŠããŸãããã®ãããããŒãã®å¿
èŠãªæ¯æããè¡ãèœåã¯ãéå¶åäŒç€Ÿã®æ¥çžŸåã³ç§ãã¡ãžã®è³éé
åèœåã«äŸåããŠããŸããéå¶åäŒç€Ÿããã®é
åã«å¯ŸããéèŠãªå¶éã¯ãããŸããã以äžã«ç€ºãéé¡ã¯ãç§ãã¡ã®ç·åçãªéé¡ã瀺ããŠããŸããïŒååäœïŒ:
èŠçŽãããé£çµè²žå察ç
§è¡š 2024幎9æ30æ¥çŸåš 2023幎12æ31æ¥æç¹
æµåè³ç£ $ 4,443 $ 42,474 éä¿èšŒåäŒç€Ÿããã®ç€Ÿå
åå
¥ã«å¯ŸããçŸåšã®å©æ¯åå 42,109 13,086 éä¿èšŒåäŒç€Ÿããã®ç€Ÿå
åå
¥ã®çŸåšã®åå 243,741 â éæµåè³ç£ 3,329 4,107 éä¿èšŒåäŒç€Ÿããã®éæµå瀟å
åå
¥ 2,027,596 1,921,576 æµåè² åµ 1,042,689 53,390 çŸåšã®éä¿èšŒåäŒç€Ÿãžã®èŠªäŒç€ŸéããŒãã®å©æ¯ 9,374 13,086 çŸåšã®éä¿èšŒåäŒç€Ÿãžã®èŠªäŒç€ŸéããŒãã®æ¯æã 243,741 â æµåè² åµ 6,607,306 6,134,383 éçŸéã®éä¿èšŒåäŒç€Ÿãžã®èŠªäŒç€ŸéããŒãã®æ¯æã 1,618,553 1,550,204Â
èŠçŽé£çµå¶æ¥å ±åæž 2024幎9æ30æ¥ãŸã§ã®9ã¶æéã®ãã ä¿èšŒäººã§ãªãåäŒç€Ÿããã®ç€Ÿå
èè³ã«å¯Ÿããå©æ¯åå
¥
$ 70,880 ãã®ä»ã®åå
¥ 762 å¶æ¥è²»çš 173,926 ä¿èšŒäººã§ãªãåäŒç€Ÿãžã®ç€Ÿå
èè³ã«å¯Ÿããå©æ¯æ¯åº
38,145 çŽæ倱 140,429Â
éèŠãªäŒèšæ¹éãšèŠç©ããã®äœ¿çš
ã¢ã¡ãªã«åè¡åœã®äžè¬ã«å
¬æ£åŠ¥åœãšèªããããäŒèšååã«åŸã£ãŠè²¡åè«žè¡šãäœæããããã«ã¯ãè³ç£ããã³è² åµã®å ±åé¡ãåçããã³è²»çšã®å ±åé¡ã«åœ±é¿ãäžããæšå®ãå€æãä»®å®ã䜿çšããå¿
èŠããããŸãããããã®ããªã·ãŒã®ããã€ãã¯ãç§ãã¡ã®è²¡åçš®é¡ãæ¥çžŸã«æãéèŠãªåœ±é¿ãäžãããããæ¹å€çãšèŠãªãããæãå°é£ã§äž»èŠ³çãŸãã¯è€éãªå€æãå¿
èŠãšããŸããããã¯ãåºæã«äžç¢ºå®ãªäºæã®åœ±é¿ã«ã€ããŠæšå®ãè¡ãå¿
èŠããããããå€ãã®å ŽåãããªããŸããç¶ç¶çã«ãç§ãã¡ã¯ãæŽå²ççµéšãšãç¶æ³ã«ãããŠåççã§ãããšèããããããŸããŸãªãã®ä»ã®ä»®å®ã«åºã¥ãæšå®ãè©äŸ¡ããŸãããããã®è©äŸ¡ã®çµæã¯ãè³ç£ããã³è² åµã®åž³ç°¿äŸ¡é¡ããä»ã®æ
å ±æºããã¯æããã§ã¯ãªãåå
¥ããã³è²»çšã®å ±åé¡ã«ã€ããŠã®å€æãè¡ãããã®åºç€ã圢æããŸããå°æ¥ã®åºæ¥äºãšãã®åœ±é¿ã確å®ã«æ±ºå®ããããšã¯ã§ããªããããå®éã®çµæã¯ç§ãã¡ã®ä»®å®ãæšå®ãšç°ãªãå¯èœæ§ãããããã®ãããªå·®ç°ã¯éèŠã§ããå¯èœæ§ããããŸãã
åœç€Ÿã®æãéèŠãªäŒèšæ¹éã¯ã財åãã€ã€ã«ãã£è³ç£ã«é¢é£ããŠããŸããåæ§ã«ãçµå¶é£ãé©çšããæãéèŠãªå€æããã³èŠç©ããã¯ã財åãã€ã€ã«ãã£è³ç£ã®ååŽå䟡ã«ãã枬å®ã«é¢é£ããŠããŸãã財åãã€ã€ã«ãã£è³ç£ããã®å©æ¯åå
¥ãèšç®ããããã«å°æ¥ã®ã¢ãããŒããé©çšããã«ã¯ãåºç€ãšãªããã€ã€ãªãã£ã®å°æ¥ã®ãã£ãã·ã¥ãããŒãäºæž¬ããéã®çµå¶é£ã®å€æãå¿
èŠãšããŸããå¹Žæ¬¡å ±åæžForm 10-kã«èšè¿°ãããŠãããšãããåœç€Ÿã®éèŠãªäŒèšæ¹éããã³èŠç©ããã«å¯Ÿããå®è³ªçãªå€æŽã¯ãããŸããã§ããã
é
ç® 3. åžå Žãªã¹ã¯ã«é¢ããå®éçããã³å®æ§çé瀺
2023幎12æ31æ¥çµäºã®å¹ŽåºŠã«é¢ãã10-Kãã©ãŒã ã®å¹Žæ¬¡å ±åæžã®ãé
ç®7A. åžå Žãªã¹ã¯ã«é¢ããå®éçããã³å®æ§çé瀺ãã«ç€ºãããé瀺ã«åœ±é¿ãäžããåžå Žãªã¹ã¯ã®ãšã¯ã¹ããŒãžã£ãŒã«éèŠãªå€æŽã¯ãããŸããã
é
ç® 4. ãããã³ã³ãããŒã«ãšæé
é瀺ã³ã³ãããŒã«ããã³æç¶ãã®è©äŸ¡
åœç€Ÿã®çµå¶é£ã¯ãCEOãšCHIEF FINANCIALã®åå ã®ããšã1934幎蚌åžååŒæ³ããã³æ¹æ£æ³ã®ã«ãŒã«13a-15(e)ã§å®çŸ©ãããé瀺ã³ã³ãããŒã«ããã³æç¶ããããã®ååæå ±åæžïŒForm 10-QïŒã®æåºåã«è©äŸ¡ããŸããããã®è©äŸ¡ã«åºã¥ããåœç€Ÿã®CEOããã³CHIEF FINANCIALã¯ããã®ååæå ±åæžïŒForm 10-QïŒã§ã«ããŒãããæéã®çµäºæç¹ã«ãããŠãåœç€Ÿã®é瀺ã³ã³ãããŒã«ããã³æç¶ãã¯ãèšèšããã³ååŒçš®é¡ã«ãããŠãåççãªä¿èšŒã¬ãã«ã§å¹æçã§ãããšçµè«ä»ããŸããã
財åå ±åã«é¢ããå
éšçµ±å¶ã®å€æŽ
2024幎床第3ååæã«ãããŠã管çã«ããè©äŸ¡ã«åºã¥ã蚌åžååŒæ³ã®èŠå13a-15(d)ãŸãã¯15d-15(d)ã«åŸã£ãŠã財åå ±åã«é¢ããå
éšçµ±å¶ã«ãããŠç¹ã«åœ±é¿ãåãŒãããŸãã¯åççã«åœ±é¿ãåãŒãå¯èœæ§ãããå€æŽã¯ç¹å®ãããªãã£ãã
ã³ã³ãããŒã«ã®æå¹æ§ã«é¢ããå
åšçå¶é
å¶åŸ¡è£
眮ã¯ãã©ããªã«è¯ãèãããéçšãããŠããŠããç®æšãéæãããŠãããšããåççãªä¿èšŒããæäŸã§ããŸããããã¹ãŠã®å¶åŸ¡è£
眮ã«ã¯åºæã®å¶éããããããå¶åŸ¡ã®è©äŸ¡ã«ãã£ãŠãäŒç€Ÿå
ã®ãã¹ãŠã®å¶åŸ¡åé¡ãæ€åºããããšãã絶察çãªä¿èšŒãåŸãããšã¯ã§ããŸããããããã£ãŠãåœç€Ÿã®é瀺å¶åŸ¡ãšæç¶ãã¯ãåœç€Ÿã®é瀺å¶åŸ¡ã·ã¹ãã ã®ç®æšãéæãããŠãããšããåççãªä¿èšŒãæäŸããããã«èšèšãããŠããŸãããããŠäžèšã®éããåœç€Ÿã®æé«çµå¶è²¬ä»»è
ããã³æé«è²¡å責任è
ã¯ãæ¬å ±åæžã®å¯Ÿè±¡æéæ«æç¹ã®è©äŸ¡ã«åºã¥ããŠãåœç€Ÿã®é瀺å¶åŸ¡ãšæç¶ããåœç€Ÿã®é瀺å¶åŸ¡ã·ã¹ãã ã®ç®æšãæºããããŠãããšããåççãªä¿èšŒãæäŸããããã«æå¹ã§ãã£ããšçµè«ä»ããŠããŸãã
第IIéš.     ãã®ä»ã®æ
å ±
ã¢ã€ãã 1.         æ³çæç¶ã
æ³çæç¶ãã«ã€ããŠã®èª¬æã¯ã泚13âã³ãããã¡ã³ãããã³å¶çºäºè±¡ãåç
§ããŠãã ãã ãããã¯ããã«åŒçšãšããŠçµã¿èŸŒãŸããŠããŸãã
é
ç® 1A.    ãªã¹ã¯èŠå
以äžã«ãç§ãã¡ã®ããžãã¹ã«è©²åœãããšèãããããªã¹ã¯ã説æããŸãããããã®ãªã¹ã¯ã«é¢ãã以äžã®æ
å ±ãæ
éã«æ€èšããããã«ãçµå¶è
ã«ãã財åç¶æ³åã³æ¥çžŸã®åæããšé¡ãããã»ã¯ã·ã§ã³ããç§ãã¡ã®èŠçŽãããé£çµè²¡åè«žè¡šãšé¢é£ãã泚èšãå«ãŸããååæå ±åæžForm 10-Qã«èšèŒãããŠãããã®ä»ã®æ
å ±ãèæ
®ããŠãã ããã . çŸåšç§ãã¡ãç¥ããªãããŸãã¯çŸåšéèŠã§ãªããšèããŠããè¿œå ã®ãªã¹ã¯ãäžç¢ºå®æ§ããç§ãã¡ã®ããžãã¹ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ãªã¹ã¯èŠå ã®æŠèŠ
ç§ãã¡ã®ããžãã¹ã¯ãããžãã¹ã財åçš®é¡ããŸãã¯æ¥çžŸã«æªåœ±é¿ãåãŒãå¯èœæ§ã®ããããã€ãã®ãªã¹ã¯ã®åœ±é¿ãåããå¯èœæ§ããããŸãããããã®ãªã¹ã¯ã«ã€ããŠã¯ã以äžã§ãã詳ãã説æãããŠããããªã¹ã¯ã«é¢é£ãããã®ãå«ããããããã«éå®ãããŸããïŒ
åœç€Ÿããžãã¹ã«é¢é£ãããªã¹ã¯
⢠åœç€Ÿããã€ã€ãªãã£ãåãåããã€ãªå»è¬å補åã®è²©å£²ã«é¢é£ãããªã¹ã¯ã
⢠ãã€ã€ã«ãã£åžå Žã®æé·;
⢠ç§ãã¡ãååŸããããã®é©åãªè³ç£ãèå¥ããããã®ãããŒãžã£ãŒã®èœåã
⢠éçºæ®µéã®ãã€ãªå»è¬ååè£ã®å©çã®ååŸã«é¢é£ããäžç¢ºå®æ§ãšã補åããŒããã©ãªãªã«éçºæ®µéã®è£œååè£ãè¿œå ããæŠç¥;
⢠ãã€ãªå»è¬åäŒç€Ÿã®æœåšçãªæŠç¥çè²·å;
⢠è³æ¬é
åã«é¢é£ããã¬ãã¬ããžã®äœ¿çšã«ã€ããŠ;
⢠競äºåã®åŒ·ã¿ã掻çšããèœåã
⢠ç§ãã¡ã®ãã€ã€ã«ãã£ãçã¿åºã補åã®ããŒã±ã¿ãŒã¯ç§ãã¡ã®ç®¡çå€ã«ãããéçºãç¶ç¶çãªèŠå¶æ¿èªã®è¿œæ±ãåæ¥åã補é æ¥ããã³ããŒã±ãã£ã³ã°ã«å¯ŸããŠè²¬ä»»ããããŸãã
⢠ãã€ãªè£œè¬æ¥çš®ã«é¢ããæ¿åºã®èŠå¶;
⢠éå©ãªã¹ã¯ãå€åœçºæ¿ã®å€åãããã³ã€ã³ãã¬;
⢠å¿
èŠãªãã¹ãŠã®ãµãŒãã¹ãæäŸããŠãããããã«ãããŒãžã£ãŒã«äŸåãããããŒãžã£ãŒã®äž»èŠã¡ã³ã㌠ã®ã·ãã¢ã¢ããã€ã¶ãªãŒããŒã ;
⢠ãããŒãžã£ãŒããã³ãã®é¢é£äŒç€Ÿãšã®å®éããã³æœåšçãªå©ççžå;
⢠ãããŒãžã£ãŒãŸãã¯ãã®é¢é£äŒç€Ÿãéåžžã«åªç§ãªå°é家ãåŒãä»ããç¶æããèœå
⢠ç§ãã¡ã®ããžãã¹ã¢ãã«ã®æ ¹åºã«ããä»®å®;
⢠éãããæ°ã®è£œåã«äŸåããŠããããš;
⢠ãã€ãªè£œè¬æ¥çš®ã®ç«¶äºçãªæ§è³ª;
åœç€Ÿã®çµç¹ãšæ§é ã«é¢é£ãããªã¹ã¯
⢠ç§ãã¡ã®ææ ªäŒç€ŸãšããŠã®å°äœãå«ãçµç¹æ§é ;
åœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒã«é¢ãããªã¹ã¯
⢠åœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒã®åžå ŽäŸ¡æ Œã®å€å;
⢠ã€ã®ãªã¹æ³ã®äžã§ã®ç§ãã¡ã®æ³äººå;
çšã«é¢ãããªã¹ã¯
⢠çšæ³ã®å€æŽãšç§ãã¡ã®çšåç¶æ³ãžã®åœ±é¿;
äžè¬çãªãªã¹ã¯èŠå
⢠ãµã€ããŒæ»æããã®ä»ã®éä¿¡ãŸãã¯æ
å ±ãã¯ãããžãŒã·ã¹ãã ã®é害;
⢠COVID-19ã®ãããªææçãäŒæç
ã®å°æ¥çãªçºçãç§ãã¡ã®æ¥åã«åœ±é¿ãäžããããšã
åœç€Ÿããžãã¹ã«é¢é£ãããªã¹ã¯
ãã€ãªå»è¬åã¯è²©å£²ãªã¹ã¯ã®åœ±é¿ãåããŸãã
ãã€ãªå»è¬åã®è£œå販売ã¯ãäŸ¡æ Œå§åãéèŠäžè¶³ã補å競äºãèšåºè©Šéšã®å€±æãåžå Žå容ã®æ¬ åŠãããŒã±ã¿ãŒã®æŠç¥çåªå
äºé
ã®å€æŽãé³è
åãæ¿åºã®å»çããã°ã©ã ãæ°éä¿éºãã©ã³ã«ããåãå
¥ãã®æ¬ åŠãç¹èš±ä¿è·ã®åªå€±ãæ¿åºèŠå¶ãã®ä»ã®èŠå ãªã©ãããŸããŸãªçç±ã«ããäºæ³ãããäœããªãå ŽåããããŸãã補åã«é¢ããŠäºæããªãå¯äœçšãå®å
šæ§ãæå¹æ§ã®æžå¿µãçãããšã補åã®ãªã³ãŒã«ãæ€åã売äžã®æžå°ã蚎èšã«ç¹ããå¯èœæ§ããããŸãããã®çµæããã€ã€ãªãã£ã®æ¯æããæžå°ããããåæ¢ãããããšããããŸãããŸãããããã®æ¯æããé
ããããšã«ãããçæçãªè²¡åå®çžŸãäºæ³ãããäœäžããå¯èœæ§ããããŸãã
ãã€ã€ãªãã£åžå Žã¯ãéå»ãšåãããŒã¹ã§æé·ããªãããå
šãæé·ããªãããããããããžãã¹ã®æé·ãç¶æããããã«ååãªãã€ã€ãªãã£ãç²åŸã§ããªãå¯èœæ§ããããŸãã
ç§ãã¡ã¯äž»ã«ãã€ã€ã«ãã£ãååŸããããšã§ãé·å¹Žã«ãããããžãã¹ãæé·ãããããšãã§ããŸãããããããå°æ¥çã«ç§ãã¡ã«å©çšå¯èœãªè³æ¬ã®å
šé¡ããŸãã¯ç®æšãšããéé¡ããã³é
åçã§æè³ããã®ã«ååãªæ°ã®ãã€ã€ã«ãã£ããŸãã¯ååãªèŠæš¡ã®ãã€ã€ã«ãã£ãç¹å®ãååŸã§ããªãå¯èœæ§ããããŸããããã«ãããæé·æŠç¥ãå®è¡ã§ããªããªã£ãããããžãã¹ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãããã€ã€ã«ãã£åžå Žã®æ§é ãåå è
ãæé·çã®å€åããã€ãªå»è¬åæ¥çš®ã«ãããè³é調éæ¹æ³ã®å€åãããã€ãªå»è¬åæ¥çš®ã®æé·ã®æžå°ãªã©ã¯ããã€ã€ã«ãã£ãååŸããæ©äŒãæžå°ãããããå©çšå¯èœãªãã€ã€ã«ãã£ãå°ãªããªã£ããããã€ã€ã«ãã£ã«å¯Ÿãã競äºãæ¿åããããšã«ã€ãªããå¯èœæ§ããããŸããããšããã€ã€ã«ãã£ãååŸãç¶ãããšããŠããååŒæ§é ãåºç€ãšãªã補åã«é¢ããç¶æ³ããŸãã¯ãã®ä»ã®èŠå ã«ãããäžè¬çã«ã¯æ°å¹Žéæå³ã®ãããªã¿ãŒã³ãçãŸãªãããå
šãçãŸãªãããšãå€ãã§ãããã®çµæãéå»ã®ããã«ãã€ã€ã«ãã£ãååŸãç¶ããããããžãã¹ãæé·ãããããšãã§ããªãå¯èœæ§ããããŸãã
éçºæ®µéã®ãã€ãªå»è¬ååè£ãžã®æè³ããã®ãã€ã€ã«ãã£ã®ååŸã¯ãè¿œå ã®ãªã¹ã¯ãäžç¢ºå®æ§ã«ãããããŸãã
æã
ã¯ããŸã èŠå¶åœå±ã«ãã£ãŠè²©å£²æ¿èªãåããŠããªãããŸãã¯åæ¥åãããŠããªãéçºæ®µéã®è£œååè£ã«å¯ŸããŠãããå€ãã®ãã€ã€ãªãã£ãååŸããå¯èœæ§ããããŸããFDAãå»è¬åããã³ãã«ã¹ã±ã¢è£œåèŠå¶åºïŒMHRAïŒã欧å·å»è¬ååºïŒEMAïŒãå»è¬åããã³å»çæ©åšç·åæ©æ§ïŒPMDAïŒãŸãã¯ãã®ä»ã®èŠå¶åœå±ããããã®è£œåãæ¿èªããããšãããããã®è£œåãé©æã«åžå Žã«æå
¥ãããããšããããã¯åžå Žããããã®è£œåã«åãå
¥ããããããšãä¿èšŒããããšã¯ã§ããŸããã以åã«ãèšåºéçºãäž»ãªç®çãéæã§ããªãã£ããªã©ã®çç±ã§äžæ¢ãããéçºæ®µéã®è£œååè£ã«å¯ŸããŠãã€ã€ãªãã£ãååŸããããšããããŸãããããã®å€±æã¯éçŸéã®æžæè²»çšããã®ä»ã®æè³ã®äŸ¡å€æžå°ã«ã€ãªãããå°æ¥ã®å€±æãåæ§ã®çµæãæãå¯èœæ§ããããŸãã
FDAãMHRAãEMAãPMDAãŸãã¯ãã®ä»ã®èŠå¶åœå±ãç§ãã¡ã®ãã€ã€ã«ãã£ãçã¿åºãéçºæ®µéã®è£œååè£ãæ¿èªããå Žåããã®è£œåã®è¡šç€ºãå
è£
ã補é æ¥ã adverse event reportingãä¿ç®¡ãåºåãããã¢ãŒã·ã§ã³ããã³èšé²ç®¡çã¯ãåºç¯ã§ç¶ç¶çãªèŠå¶èŠä»¶ã«åŸãããšã«ãªããŸãã補åã«é¢ãã以åç¥ãããŠããªãã£ãåé¡ãäºæããªãéç床ãŸãã¯é »åºŠã®å¯äœçšãçºèŠããããšã補åã®ããŒã±ãã£ã³ã°ã«å¶éã課ããã補åãåžå Žããæ€åãããå¯èœæ§ããããŸãã
ããã«ããããã®éçºæ®µéã®è£œååè£ã®éçºè
ã¯ãçºèŠãéçºãããã³åæ¥å掻åãç¶ç¶ããããã«è¿œå ã®è³æ¬ã調éã§ããªãå Žåããããããã«ãã圌ãã®èšåºè©ŠéšãR&Dããã°ã©ã ã®ãã¡ã®1ã€ãŸãã¯è€æ°ãé
延ãçž®å°ããŸãã¯æé€ãããå¯èœæ§ããããŸããä»ã®è£œåéçºè
ãããã€ã€ã«ãã£ãçã補åãããå¹æçãå®å
šããŸãã¯äœã³ã¹ããªè£œåã玹ä»ããŠåžå Žã«æå
¥ããå ŽåããŸãã¯ãããã®éçºè
ããã€ã€ã«ãã£ã®ç«¶å補åããå
ã«èªç€Ÿã®è£œåãæå
¥ããå Žåãç§ãã¡ãæè³ããŠãã補åã¯åæ¥çæåãåãããããçµæãšããŠç§ãã¡ã®åçãæžå°ãããããã€ã€ã«ãã£ãæžå°ãããããå¯èœæ§ãããããããç§ãã¡ã®ããžãã¹ã財åç¶æ³ããŸãã¯æ¥åçµæã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
ããã«ããããã®è£œåã®éçºè
ã¯è²©å£²ãããŒã±ãã£ã³ã°ããŸãã¯æµéã®èœåãæã£ãŠããªãå¯èœæ§ããããŸããåãå
¥ãå¯èœãªæ¡ä»¶ã§ããããã¯å
šã販売ãããŒã±ãã£ã³ã°ããŸãã¯æµéã®åã決ããã§ããªãå Žåã圱é¿ãåãã補åã¯æåè£ã«åæ¥åã§ããªãå¯èœæ§ãããããã®çµæãæ倱ãçºçããããšã«ãªããŸãããã®ãããªè³ç£ããã®æ倱ã¯ãç§ãã¡ã®ããžãã¹ã財åç¶æ
ããŸãã¯æ¥çžŸã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
ç§ãã¡ã¯ãé©æ°è
ã«è³æ¬ãæäŸãã補ååè£ã®èšåºéçºãå
±åè³éæäŸããããšãæå³ããŠããŸããããã«å¯ŸããŠãå°æ¥ã®ãã®è³ç£ã®åçã·ã§ã¢ãæ±ããŸããããã®éãç§ãã¡ã¯èšåºéçºã管çããããšã¯ãããŸããããã®ãããªç¶æ³ã§ã¯ãé©æ°è
ãã¹ã±ãžã¥ãŒã«éãã«æŽ»åãå®äºããªãã£ãããç§ãã¡ã®æåŸ
ã«æ²¿ããªãã£ãããé©çšãããæ³åŸãèŠå¶ãéµå®ããªãã£ããããããšããããŸããããã«ãããè³éãæäŸããéçºæ®µéã®è£œååè£ã®éçºãæ¿èªã補é ããŸãã¯åæ¥åãé
ãããããŸãã¯é»æ¢ãããå¯èœæ§ããããŸãã
éçºæ®µéã®è£œååè£ã«é¢ããäžç¢ºå®æ§ã¯ãå
éšã¢ãã«ã®æ£ç¢ºãªä»®å®ãéçºããããšãããå°é£ã«ããæšå®ã«æ¯ã¹ãŠãã€ã€ã«ãã£ãæžå°ããå¯èœæ§ããããŸããéçºæ®µéã®è£œååè£ã®æ¿èªãéèŠãªå£²äžãéæããå¯èœæ§ã«é¢ããä»®å®ãæ£ãããšèšŒæãããä¿èšŒã¯ãªããèŠå¶åœå±ããã®ãããªéçºæ®µéã®è£œååè£ãæ¿èªããããšããŸããã®ãããªéçºæ®µéã®è£œååè£ãé©æã«åžå Žã«æå
¥ãããããšããããã¯å
šãæå
¥ãããªãããšããŸããã®ãããªè£œåãåæ¥çæåãåããããšããåœç€Ÿã®æšå®ãšäžèŽãããã€ã€ã«ãã£ãããããããšã®ä¿èšŒããããŸããã
ãã€ãªå»è¬åäŒç€Ÿã®æŠç¥çè²·åãè¡ã£ããããã€ãªå»è¬åäŒç€Ÿã®èšŒåžãååŸãããããå¯èœæ§ããããŸãããããã®è²·åã«ãã£ãŠæåŸ
ãããå©çãå®çŸã§ããªãå Žåãããžãã¹ã財åã®çš®é¡ããŸãã¯æ¥åã®çµæã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
éèŠãªãã€ã€ã«ãã£è³ç£ãæã€äŒæ¥ããéèŠãªåæãã€ã€ã«ãã£ãåµé ã§ãããšèããããäŒæ¥ãååŸããå¯èœæ§ããããŸãããããã®ååŸãŸãã¯åµé ããããã€ã€ã«ãã£è³ç£ã¯ãåœç€Ÿã®äºæž¬éãã«æ©èœããªãå¯èœæ§ããããŸããããã«ãéå¶ãããã€ãªãã¡ãŒãäŒæ¥ã®ååŸã¯ãåœç€Ÿã®ä»ã®ãã€ã€ã«ãã£ååŸã«ã¯å
åšããªããååŸããããžãã¹ã®è² åµãåŒãåããããããããããããããšãæå³ãã補å責任è«æ±ãžã®çŽæ¥çãªé²åºãé«ãåºå®è²»ããŸãã¯åœç€Ÿã®æ¥åããã³è²»çšæ§é ã®æ¡å€§ã䌎ããæçµçã«ã¯å©çãæžå°ããå¯èœæ§ããããŸããå°æ¥ã®ååŸã«é¢é£ããçµå¶é£ã®æ³šæã®åæ£ãé
延ãŸãã¯å°é£ã¯ãé²è¡äžã®ããžãã¹éå¶ã®æ··ä¹±ãåŒãèµ·ããå¯èœæ§ããããŸããããžãã¹ã財åãæ³çãªãã¥ãŒããªãžã§ã³ã¹ã®åªåã«ãããããããååŸæ©äŒã®è©äŸ¡ã«é¢ããŠã¯éãããçµéšãããªãããã®ããæçµçã«ã¯ãã®ãããªååŸã«é¢é£ãããã¹ãŠã®ãªã¹ã¯ãç¹å®ãŸãã¯è©äŸ¡ã§ããªãå¯èœæ§ããããŸããããã«ãããžãã¹ã補åãååŸããããã«ãå
¬éãŸãã¯ç§çãªåµåãŸãã¯æ ªåŒãã¡ã€ãã³ã¹ãéããŠè¿œå ã®è³éã調éããå¿
èŠãããããããããããã«ããæ ªäž»ã®åžèåãåµåã®çºçãçããå¯èœæ§ããããŸãããã®çµæããã€ãªãã¡ãŒãäŒæ¥ã®ååŸã¯åœç€Ÿã®ããžãã¹ã財åç¶æ³ããŸãã¯æ¥çžŸã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
åœç€Ÿã¯ããã€ãªå»è¬åäŒç€Ÿãçºè¡ãã蚌åžãååŸããããšã«ãã£ãŠåžå Žæ©äŒãæ¡å€§ããããšãæ€èšããå ŽåããããŸããããžãã¹éçºæŽ»åã®å¯ŸäŸ¡ãšããŠå
šã»ã¯ã¿ãŒã®äžéšãŸãã¯å
šéšãšããŠæ ªåŒèšŒåžãååŸããå Žåããã®èšŒåžã®äŸ¡å€ã¯å€åããæžäŸ¡ããå¯èœæ§ããããŸããåœç€Ÿã蚌åžãååŸããäŒç€Ÿãã³ã³ãããŒã«ããããšã¯ããããã§ããããã®çµæãçµå¶ãéå¶ã®ææ決å®ãæ¹éãå€æããèœåã¯éãããå¯èœæ§ããããŸããããã«ããã®ãããªååŒã¯ããã¥ãŒã»ãã£ãªãžã§ã³ã¹ã®åãçµã¿ã§ã¯çºèŠã§ããªããªã¹ã¯ãè² åµãåœç€Ÿã«é瀺ãããªããã®ããŸãã¯åœç€Ÿãäžååã«è©äŸ¡ãããã®ã«çŽé¢ããå¯èœæ§ããããŸããå ããŠãåœç€Ÿã®æŽ»åã®çµæãšããŠããã®ä»ã®äŒç€Ÿã«é¢ããéèŠãªéå
¬éæ
å ±ãå
¥æããããšããããŸãããã®ãããªæ
å ±ãåœç€Ÿãä¿æããæ ªåŒèšŒåžã«é¢é£ããäŒç€Ÿã«é¢ãããã®ã§ããå Žåãåœç€Ÿã¯æ¬æ¥ã§ããã°å£²åŽãããæã«ãã®èšŒåžã®å£²åŽãé
ãããã劚ããããå¯èœæ§ãããããã®é
延ãŸãã¯çŠæ¢ããã®èšŒåžã®æ倱ãŸãã¯å©çã®æžå°ãåŒãèµ·ããå¯èœæ§ããããŸãã
è³æ¬ã®é
åã«é¢é£ããŠã¬ãã¬ããžãå©çšããŠãããååŸãããã€ã€ã«ãã£ãååãªåå
¥ãçã¿åºããªãå Žåãæ倱ã®å¯èœæ§ãæ¡å€§ããŸãã
åå
¥éã䜿çšããŠãæå
¥è³æ¬ã®ããªãã®å²åãè³é調éããŠããŸãããŠã»ã©ã®äœ¿çšã¯ããªã¿ãŒã³ã®å¢å ã®æ©äŒãçã¿åºããŸãããè³ç£ãååãªãã£ãã·ã¥ãããŒãçã¿åºããªãå Žåã«ã¯æ倱ã®ãªã¹ã¯ãå¢å€§ããŸããããããåå
¥ã«é¢ããŠçºçããå©æ¯è²»çšããã®ä»ã®ã³ã¹ãã¯ããã£ãã·ã¥ãããŒã«ãã£ãŠã«ããŒãããªãå¯èœæ§ããããŸããããã«ããŠã»ã©ã¯éå¶ã®æè»æ§ã劚ããé
åœã«å©çšã§ãããã£ãã·ã¥ãããŒãèªç€Ÿæ ªè²·ããè¡ãããã®ãã£ãã·ã¥ãããŒãæžå°ãããå¯èœæ§ããããŸãã
ç§ãã¡ã®è² åµã®ã¬ãã«ã¯ãå€åããããžãã¹ç°å¢ã«å¯Ÿå¿ããèœåãå¶éããå¯èœæ§ããããŸããç§ãã¡ã®åå
¥ã«é¢é£ããããŸããŸãªå¥çŽã¯ãéå¶ããã³è²¡åã®å¶çŽã課ãå¯èœæ§ãããããããè¿œæ±ã§ãããã€ã€ã«ãã£ã®æ°ãèŠæš¡ã«åœ±é¿ãäžããå¯èœæ§ããããŸãããããã£ãŠãè² åµã«é¢ããå¶çŽæ¡é
ã®çµæãšããŠãæå©ãªæ¡ä»¶ãæ©äŒã掻çšã§ãããã©ããã«ã€ããŠã¯ä¿èšŒã§ããŸããããŸããæ¢åã®åµåéèã眮ãæãããããŸãã¯å¢å ãããããã®è¿œå ã®åµåéèãå¿
èŠãªãšãã«å©çšå¯èœã§ãããã©ããããŸããå©çšå¯èœã§ããå Žåã§ãåæ¥çã«åŠ¥åœãªæ¡ä»¶ã§å
¥æã§ãããã©ããã«ã€ããŠãä¿èšŒã§ããŸããã
ã¬ãã¬ããžã«é¢é£ããè¿œå ã®ãªã¹ã¯ã«ã¯ä»¥äžãå«ãŸããŸãïŒ
⢠åå
¥éå©ãäžæããçšåºŠã«å¿ããŠãåå
¥ã³ã¹ããå¢å ããã¬ãã¬ããžæŠç¥ãããã³ã¹ãé«ã«ãªããããçŽå©çã®æžå°ã«ã€ãªããå¯èœæ§ããããŸãã
⢠æã
ã¯ãè² åµã管çããå¥çŽã«ãããŠãç¹å®ã®ã¬ãã¬ããžæ¯çãã«ãã¬ããžæ¯çãç¶æããèŠæ±ãå«ãããŸããŸãªè²¡åå¥çŽã«åŸããªããã°ãªããããããããžãã¹ç®æšãéæããèœåã«åœ±é¿ãåãŒãå¯èœæ§ãããã
⢠é
åœãæ¯æã£ããã·ã§ã¢ãè²·ãæ»ãããããèœåãå¶éãããå¯èœæ§ããããŸãã
⢠ç§ãã¡ã®ãã€ã€ã«ãã£ã¯ãç§ãã¡ã®åå
¥ã®æ
ä¿ãšããŠäœ¿çšãããå ŽåããããŸãã
⢠æ
ä¿åå
¥éã®ããã©ã«ããçºçããå ŽåãåŒç€Ÿã®åµæš©è
ãŸãã¯ãã®è²å人ã®äžäººä»¥äžããåŒç€Ÿã®ãã€ã€ãªãã£ã®ç®¡çæš©ãååŸããå¯èœæ§ããããããç·æ¥è²©å£²ãè¡ãããå Žåããããã®åµæš©è
ã¯ãåŒç€Ÿãå®çŸã§ãããããã¯ããã«äœã䟡å€ã§ãããã®ãã€ã€ãªãã£ãåŠåããããšãã§ããå¯èœæ§ããããŸãã
èªç€Ÿã®äººå¡ãéçšãããå¿
èŠãªãã¹ãŠã®ãµãŒãã¹ã«é¢ããŠãããŒãžã£ãŒã«å®å
šã«äŸåããŠããŸãã
åœç€Ÿã¯ãå€éšç®¡çãã§ãããããèªç€Ÿã®äººå¡ãéçšããã代ããã«ãã¹ãŠã®ãµãŒãã¹ãæäŸããããã«ãããŒãžã£ãŒããã®çµå¶å¹¹éšããã³åŸæ¥å¡ã«äŸåããŸãããããŒãžã£ãŒã¯ãåœç€Ÿã®æè³åºæºãæºãããã€ã€ãªãã£ããã€ã«ã¹ããŒã³ããã³ãã®ä»ã®å¥çŽåå
¥ããã³é¢é£è³ç£ã®ååŸãéžæãã管çããåœç€Ÿã®ãã®ä»ã®ç®¡çãµãŒãã¹ãæäŸããŸãããããã£ãŠãåœç€Ÿã®æåã¯ãããŒãžã£ãŒã®çµå¶å¹¹éšããã³åŸæ¥å¡ã®å°éç¥èãšãµãŒãã¹ã«äŸåããŠããŸãããããžã¡ã³ãå¥çŽã¯ååæéã10幎ã§ããããã®åŸã¯ååæéãŸãã¯æŽæ°æéã®æºäº180æ¥åã«æã
ãŸãã¯ãããŒãžã£ãŒã®ãããããéæŽæ°éç¥ãè¡ããªãéããããã«3幎ã®è¿œå æéã«æŽæ°ã§ããŸããååãŸãã¯æŽæ°æéäžã«ãåå ã®ãªãéããããŒãžã£ãŒã解任ããããšã¯ã§ããŸãããåœç€Ÿã®ãããžã¡ã³ãå¥çŽã¯ããã®å¹¹éšã«ãçäºäŒã®æ¿èªããªãéããç§ãã¡ãRPI 2019 ICAVãŸãã¯æ§RPIã«é¢é£ããã¬ã¬ã·ãŒããŒã¯ã«ã®ç®¡çã«ã»ãŒãã¹ãŠã®æéãæ§ããããšãèŠæ±ããŸããããããã®ãªãœãŒã¹ã¯åœç€Ÿã®ããŒãºãæºããã«ã¯äžååã§ããå¯èœæ§ããããŸãã
ç§ãã¡ã®ããžãã¹ã®æåã¯ããããŒãžã£ãŒã®ã¢ããã€ã¶ãªãŒããŒã ã®éèŠãªã¡ã³ããŒã«äŸåããŠããŸããã圌ãã¯ãããŒãžã£ãŒã®ããã«åãç¶ããªãå¯èœæ§ããããŸãã
ç§ãã¡ã¯ãç§ãã¡ã®è³ç£ãè©äŸ¡ã亀æžãæ§ç¯ãå®è¡ãç£èŠããã³ãµãŒãã¹ãããããŒãžã£ãŒã®ã¢ããã€ã¶ãªãŒããŒã ã®äž»èŠã¡ã³ããŒã®å°éç¥èãã¹ãã«ããã³ããžãã¹äžã®äººèã«äŸåããŠããŸããç§ãã¡ã®å°æ¥ã®æåã¯ããããŒãžã£ãŒã®ã¢ããã€ã¶ãªãŒããŒã ãç¹ã«ã¬ãŽã¬ã¿æ°ã®ç¶ç¶çãªãµãŒãã¹ãšèª¿æŽã«å€§ããäŸåããŠããŸãã管çå¥çŽã«åŸãããããŒãžã£ãŒã®å¹¹éšã¯ãåç· åœ¹äŒãæ¿èªããªãéããã»ãŒãã¹ãŠã®ããžãã¹æéãç§ãã¡ã®ç®¡çã«è²»ãããªããã°ãªããŸãããããã«ãããããããã¬ãŽã¬ã¿æ°ããã³ãããŒãžã£ãŒã®ã¢ããã€ã¶ãªãŒããŒã ã®ä»ã®äž»èŠã¡ã³ããŒã¯ãä»ã®èŠæ±ãããå¯èœæ§ãããã圌ããç§ãã¡ã®ããžãã¹ã«ç©æ¥µçã«é¢äžãç¶ãããã©ããã¯ä¿èšŒã§ããŸããããããã®å人ã¯ãã¹ãŠãããŒãžã£ãŒã®åŸæ¥å¡ã§ãããç§ãã¡ãšã®éçšå¥çŽã®å¯Ÿè±¡ã§ã¯ãªããããç§ãã¡ã¯ãããŒãžã£ãŒã®ã¢ããã€ã¶ãªãŒããŒã ã®æ§æããããã®å人ã®å ±é
¬ãè·æ¥éçºãæ瀺ããããšãã§ããŸããããããã®å人ã®éè·ã圌ãã®æéã«å¯Ÿãã競åã®èŠæ±ã¯ãç§ãã¡ã®ããžãã¹ã財åç¶æ³ãŸãã¯æ¥çžŸã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ãããŒãžã£ãŒã®äž»èŠãªã¢ããã€ã¶ãªãŒãããã§ãã·ã§ãã«ã¯ããã€ãªãã¡ãŒãæ¥çããã¡ã€ãã³ã·ã£ã«ã€ã³ã¹ãã£ãã¥ãŒã·ã§ã³ãºããã®ä»ã®ã¢ããã€ã¶ãªãŒãããã§ãã·ã§ãã«ãšã®é¢ä¿ãæããŠãããç§ãã¡ã¯æœåšçãªè³ç£ååŸæ©äŒãæ¢ãããã«ããã«äŸåããŠããŸãããããŒãžã£ãŒã®äž»èŠãªã¢ããã€ã¶ãªãŒãããã§ãã·ã§ãã«ããã®ãããªé¢ä¿ãç¶æã§ããªãå ŽåããŸãã¯ãã®ä»ã®ãœãŒã¹ãšã®æ°ããé¢ä¿ãç¯ããªãå ŽåãããŒããã©ãªãªãæé·ãããããšãã§ããªããããããŸãããããã«ããããã®é¢ä¿ãç¶æãããå Žåã§ããå°æ¥çã«ãã€ã€ãªãã£ååŸæ©äŒãçã¿åºãä¿èšŒã¯ã§ããŸããã
å©ççžåãç·©åããããã«ç¢ºç«ããããªã·ãŒãæç¶ãããå¹æçã«æ©èœããä¿èšŒã¯ãããŸããã
ãããŒãžã£ãŒã¯ãRPI 2019 ICAVãŸãã¯Old RPIã«é¢é£ããã¬ã¬ã·ãŒããŒã¯ã«ãé€ããŠããã€ã€ãªãã£ã«æè³ãŸãã¯ååŸããä»ã®æ³äººã管çããããšã¯ã§ããŸããããããŒãžã£ãŒã®ãã¹ãŠã®äžçŽç®¡çè·ã¯ãéçšãäœããã®çç±ã§çµäºããåŸã18ã¶æéæå¹ãªç«¶æ¥çŠæ¢å¥çŽã®å¯Ÿè±¡ãšãªããŸããç§ãã¡ã¯ãããã®å¥çŽã®åçè
ã§ããããã«ããããŒãžã£ãŒã®åœ¹å¡ã¯ãåç· åœ¹äŒã®æ¿èªããªãéããç§ãã¡ããã³RPI 2019 ICAVãŸãã¯Old RPIã«é¢é£ããã¬ã¬ã·ãŒããŒã¯ã«ã®ç®¡çã«ã»ãŒãã¹ãŠã®æéãæ§ããªããã°ãªããŸãããããã«ããããããããããŒãžã£ãŒããã³ãã®åœ¹å¡ãåŸæ¥å¡ãä»ã®ããžãã¹æŽ»åã«åŸäºããèœåã¯ãç§ãã¡ãšã®ãããžã¡ã³ãå¥çŽã®æ¡ä»¶ã«åŸãéãããããŒãžã£ãŒããã®åœ¹å¡ããã®ä»ã®åŸæ¥å¡ãç§ãã¡ã®ç®¡çã«è²»ããæéãæžå°ãããå¯èœæ§ããããŸãã
ç§ãã¡ãšã¢ããã€ã¶ãªãŒããŒãœãã«ãšã®éã«ã¯ãå©ççžåãçããå¯èœæ§ããããŸããäŸãã°ãç§ãã¡ã®æé«çµå¶è²¬ä»»è
ã§ããã¬ãŽã¬ã¿æ°ã¯ããã¡ãŒãã³ã³ã¢ããã€ã¶ãŒã®å
±ååµèšè
ã§ãããããã®åœ±é¿åã¯å€§ããããããŒãžã£ãŒãšç©ççãªå Žæãå
±æããŠããŸãããã¡ãŒãã³ã³ã¯BioPharma Credit PLCïŒLSE: BPCRïŒããã®ä»ã®æè³æ段ã管çããŠããããããã¯ãã€ãªå»è¬åæ¥çã«å¯Ÿããè² åµè³æ¬ã®äž»èŠãªæäŸè
ã§ããã¬ãŽã¬ã¿æ°ã¯BioPharma Creditã«å¯Ÿã㊠substantial ãªæè³ãããŠããŸããããã«ãã¬ãŽã¬ã¿æ°ã¯ProKidney Corp.ã®åç· åœ¹äŒã®è°é·ãåããŠãããå»çç 究è³éãåãããæäŸããããã財å£ãèšç«ããåå ããŠããŸãããã¡ãŒãã³ã³ãBioPharma Credit PLCãProKidney Corp.ããã³äžèšã®è²¡å£ãªã©ã®çµç¹ã«é¢äžããŠããã«ãããããããã¬ãŽã¬ã¿æ°ã¯ãããŒãžã£ãŒããã³ç§ãã¡ã«å²ãããšãã§ããæéã«å¯ŸããŠãå®è³ªçãªå¶çŽã¯ãããŸããããããŒãžã£ãŒãšãã¡ãŒãã³ã³ãé¡äŒŒã®æè³æ©äŒãè¿œæ±ããå¯èœæ§ãããäžæ¹ã§ãå®éã®å©ççžåã¯ç°ãªãæè³æŠç¥ã«åºã¥ããããããã«ãã€ã€ã«ãã£ä¿æè
ãæ±ããååŒã®çš®é¡ãå€æããäºå®ãããŸãã§ãããšä¿¡ããŠããŸãããã¡ãŒãã³ã³ãšã®åã決ãã«åºã¥ãããããŒãžã£ãŒã¯ãã¡ãŒãã³ã³ã«ãªãã£ã¹ã¹ããŒã¹ããµããªãŒã¹ããŠãããäž¡è
ã¯äºãã«ç 究ãããžãã¹éçºãæ³åãã³ã³ãã©ã€ã¢ã³ã¹ã財åããã³ç®¡çãµãŒãã¹ãæäŸããããšããããŸãããããŒãžã£ãŒãšãã¡ãŒãã³ã³ã¯ãäžæ¹ãä»æ¹ã«åãåã以äžã«å®è³ªçã«å€ãã®ãµãŒãã¹ãæäŸããå Žåãäºãã«è²»çšãè£å¡«ããŸããããã«ããããŒãžã£ãŒã®äžéšã®åŸæ¥å¡ã¯ãã¡ãŒãã³ã³ããå ±é
¬ãåãåãããšããããŸãã
ãããŒãžã£ãŒã®å ±é
¬ã®åã決ãã¯äºæããªãçµæãæãå¯èœæ§ããããŸããããŒããã©ãªãªã®åå
¥ãšåååæã®çµäºæç¹ã«ãããã»ãã¥ãªãã£æè³ã®æ䟡ã«åºã¥ããŠããããŒãžã£ãŒãŸãã¯ãã®é¢é£äŒç€Ÿã«ååæããšã«éå¶è²»ããã³äººä»¶è²»ïŒãéå¶ããã³äººä»¶è²»ã®æ¯æããïŒãæ¯æãããšã«åæããŸããããããã£ãŠããããŒãžã£ãŒã¯ãç§ãã¡ã®æè³ããã®æåŸ
ãããå©çã«ããããããæè³ãè¡ãããã«ã€ã³ã»ã³ãã£ããæã€å¯èœæ§ããããããã¯ç§ãã¡ãŸãã¯ç§ãã¡ã®æ ªäž»ã®å©çãšäžèŽããªãå ŽåããããŸãã
è² åµãå±¥è¡ãããã®ä»ã®ç¶ç¶çãªæµåæ§ããŒãºãæºããããã«ã¯ãçžåœãªçŸéãå¿
èŠã§ããçŸéãçã¿åºãèœåã¯ãç§ãã¡ã®å¶åŸ¡ãè¶
ããå€ãã®èŠå ã«äŸåããŠããŸããå¿
èŠãªçŸéãçã¿åºããªãå Žåãè² åµã«åºã¥ãå¿
èŠãªæ¯æããã§ããªãå¯èœæ§ããããŸãã
2024幎9æ30æ¥æç¹ã§ãåœç€Ÿã®çºè¡æžã¿ã®ã·ãã¢ç¡æ
ä¿ããŒãã®ç·é¡ã¯78åãã«ã§ãããããã«ããªãã«ãã³ã°ã¯ã¬ãžãããã¡ã·ãªãã£ïŒä»¥äžã§å®çŸ©ïŒã«åºã¥ãå©çšå¯èœãªå転ã³ãããã¡ã³ãã¯æ倧ã§18åãã«ã§ããRPããŒã«ãã£ã³ã°ã¹ãé€ããã·ãã¢ç¡æ
ä¿ããŒããä¿èšŒããªãåœç€Ÿã®åäŒç€Ÿã¯ãã·ãã¢ç¡æ
ä¿ããŒãã«åºã¥ããŠæ¯æãããã¹ãéé¡ãæ¯æã矩åãããã®éé¡ãé
åœãåé
ãããŒã³ãŸãã¯ãã®ä»ã®æ¯æãã«ããæ¯æãããã«è³éãæäŸãã矩åãè² ããŸãããåœç€Ÿã®ããžãã¹ããè² åµãè¿æžãããããã®ä»ã®æµåæ§ããŒãºãæºããããããã®ã«ååãªãã£ãã·ã¥ãããŒãçã¿åºããã©ããã¯ä¿èšŒã§ããŸããã
ååãªãã£ãã·ã¥ãããŒããªãå Žåããªãã¡ã€ãã³ã¹ã®èœåããªãå Žåãæ¯æã矩åã®äžè¶³ãè£ãããã«è³ç£ã売ãã«åºããããåŸãªãå¯èœæ§ããããŸããããããæ¢åã®æªæãåµåã管çããå¥çŽã®æ¡ä»¶ã¯ãåœç€Ÿããã³åœç€Ÿã®åäŒç€Ÿã®è³ç£å£²åŽèœåãå¶éãããã®å£²åŽã«ããåçã®äœ¿çšãå¶éããŠããŸãããããã£ãŠãåµåã«å¯Ÿãã矩åãæããããã«ãè³ç£ãååãªé¡ã§è¿
éã«å£²åŽã§ããªãå¯èœæ§ããããŸãã
ç§ãã¡ã®ããžãã¹ã¯ãéå©ãå€åœçºæ¿ãã€ã³ãã¬åã³éè¡æ¥çš®ã®ãªã¹ã¯ã«ãããããŠããŸãã
åœç€Ÿã¯ãå転信çšæ ã«åºã¥ãåå
¥éããã³å€§éšåãå€æ°éå©ãæã€ãããŒããŒã±ããå£åº§ãæµåæ§èšŒåžãžã®æè³ãéããŠãéå©å€åãªã¹ã¯ã«ãããããŠããŸãããŸããæ
ä¿ä»ãç¿æ¥éèéå©ïŒãSOFRãïŒã®ãããªåºæºéå©ã®äžæ¢ãå€æŽããŸãã¯ãã®ä»ã®æ¹é©ã¯ãäžç¢ºå®æ§ãçã¿åºããç¹å®ã®å¥çŽãä¿®æ£ããå¿
èŠãçããããéå©è²»çšãå¢å ãããããå¯èœæ§ããããŸããäžè¬çã«éå©ãäžæããå Žåãåå
¥ã³ã¹ããå¢å ããæã
ã®ã¬ãã¬ããžæŠç¥ãããã³ã¹ãé«ãšãªããçµæãšããŠçŽå©çãæžå°ããããšã«ãªããŸãã
ç¹å®ã®è£œåã¯ãç±³ãã«ä»¥å€ã®é貚ã§ãã€ã€ã«ãã£ãæ¯æããããããæ©èœé貚ããã³å ±åé貚ãç±³ãã«ã§ããããšãããEuroãCanadian DollarãBritish PoundãSwiss FrancãJapanese Yenã«é¢ããŠäž»ã«å€åœçºæ¿ãªã¹ã¯ãçããŸããããã«ãåœç€Ÿã®å¶æ¥çµæã¯ããã€ã€ã«ãã£åå
¥ãŸãã¯ãã€ã€ã«ãã£å£²äžé«ãèªèããæç¹ãšååŒã決æžãããæç¹ããŸãã¯ãã€ã€ã«ãã£ã®æ¯æããåãåãæç¹ãšã®éã®çºæ¿ã¬ãŒãã®å€åã«ããååŒã®æŽé²ãéããŠå€åœçºæ¿ãªã¹ã¯ã®åœ±é¿ãåããŸããããŸããŸãªè£œåã«å¯ŸããŠå
šäžçã®å£²äžã«å¯Ÿãããã€ã€ã«ãã£æš©ãæãããããããŒã±ã¿ãŒãå°å
é貚ããç±³ãã«ã«æ¯æé¡ãæç®ããéã«ååæã®å¹³åçºæ¿ã¬ãŒãã䜿çšãããããå€åœé貚ã«å¯Ÿããåºç€çãªæŽé²ããããŸãããããã£ãŠãåãåã£ãçŸéã¯ãé貚ã®å€åã«åºã¥ãæšå®æªåéé¡ãšç°ãªãå ŽåããããŸãã
ãã¯ãçµæžç圱é¿ã䌎ãéèŠãªåºæ¥äºã«ãã£ãŠåŒãèµ·ãããããªã¹ã¯ãäžç¢ºå®æ§ã®åœ±é¿ãåããŸããããã«ã¯ããã·ã¢ã»ãŠã¯ã©ã€ãçŽäºãäžæ±ã®çŽäºãã€ã³ãã¬ãšInterest Ratesã®äžæãéèæ¿çã®å€æŽãéèãµãŒãã¹ã»ã¯ã¿ãŒã®äžå®å®æ§ãæ¯æ°åŸéãã°ããŒãã«ãã³ãããã¯ãå€åœCurrencyã®å€åãå«ãŸããŸãããããã«éããŸãããCurrencyã®äŸ¡å€ãç±³ãã«ã«å¯ŸããŠå€åããããç±³ãã«ä»¥å€ã®Currencyã䜿çšããŠããåœã§é«ãã€ã³ãã¬ãçºçãããšãåçãã³ã¹ããçµè²»ããããŠè²¡åã¬ã€ãã³ã¹ã«åœ±é¿ãåãŒããŸãã
éè¡æ¥ã«åœ±é¿ãäžãããã®ä»ã®åºæ¥äºã¯ãç§ãã¡ã®çŸéãäžç«ããéè¡æ©é¢ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸããç§ãã¡ã®äž»èŠãªéå¶å£åº§ã¯ãé£éŠé éä¿éºå
¬ç€Ÿã®é床é¡ã倧å¹
ã«è¶
ããŠããŸããéè¡ãç Žç¶»ããå Žåãç§ãã¡ã¯éè¡ã®äžè¬åµæš©è
ãšèŠãªãããå¯èœæ§ããããéè¡ã«é ããçŸéã®äžéšãŸãã¯ãã¹ãŠã倱ãå¯èœæ§ããããŸããéè¡ãç Žç¶»ã®å±éºã«ãããããŠãããšèªèãããå Žåã§ããç§ãã¡ã¯ãã®åœ±é¿ãé¿ããããã«éè¡ããçŸéãæéå
ã«åŒãåºããã移転ãããã§ããªããããããŸããã
æã
ã賌å
¥ãããã€ã€ã«ãã£ã«é¢é£ãããã€ãªå»è¬å補åã«é¢ããæ
å ±ã¯éãããŠããå¯èœæ§ãããããã®ããå補åããã³ãã®å°æ¥ã®ãã£ãã·ã¥ãããŒãåæããèœåãåæ§ã«éãããŠããå¯èœæ§ããããŸãã
ååŸãè©äŸ¡ããŠãããã€ã€ãªãã£ãçã¿åºã補åã«é¢ããæ
å ±ã¯éãããŠããå¯èœæ§ããããŸãããã°ãã°ããã€ã€ãªãã£ã®ååŸåŸã®è£œåã«é¢ããæ
å ±ã¯ãå
¬éãããŠããæ
å ±ã«éãããŠããããšãå€ãã§ãããããã£ãŠãç¥ããããæã£ãŠããªãããŸãã¯å
¥æã§ããªãéèŠãªæ
å ±ãååšããå¯èœæ§ããããŸããäŸãã°ã補åã®ããŒã±ã¿ãŒããã®ä»ã®é¢ä¿è
ãè¡ã£ãç 究ã®çµæããå»åž«ããŠãŒã¶ãŒããã®äœããã®èŠæ
ã®æ§è³ªãéã«ã€ããŠãåžžã«ç¥ã£ãŠããããã§ã¯ãããŸããããŸããç¬èªã«ååŸããåžå ŽããŒã¿ãäžå®å
šãŸãã¯äžæ£ç¢ºã§ããå¯èœæ§ããããŸãããããã®èŠå ããã®ä»ã®èŠå ã«ããããã€ã€ãªãã£ããã®å®éã®ãã£ãã·ã¥ãããŒã¯ãç§ãã¡ã®èŠç©ããããã倧å¹
ã«äœããªãå¯èœæ§ããããŸãã
å°æ¥ã®åå
¥ã¯å€ãã®ãã€ã€ãªãã£ç¹æã®ä»®å®ã«äŸåããŠããããããã®ä»®å®ãæ£ç¢ºã§ãªãããšãå€æããå ŽåãæåŸ
ããããªã¿ãŒã³çãéæã§ããªãå¯èœæ§ããããŸãã
ç§ãã¡ã®ããžãã¹ã¢ãã«ã¯ã補åã®è²©å£²ã«é¢ããæ°å¹Žã«ãããå
éšããã³å€éšã®äºæž¬ãšãåãã€ã€ãªãã£ç²åŸã«é¢é£ããå€æ°ã®è£œååºæã®ä»®å®ã«åºã¥ããŠããŸãã補åã«é¢ããæ
å ±ãéãããŠããå ŽåããããŸããããããã®ä»®å®ãç§ãã¡ã®è²¡åã¢ãã«ãç¹ã«è£œåã®è²©å£²ã競äºãç¹èš±ã®æéãç¬å æ¡é
ãã©ã€ã»ã³ã¹æ¡ä»¶ããŸãã¯ããŒããã©ãªãªã«åºã¥ã補åã®ã©ã€ã»ã³ã¹çµäºã«é¢ããŠæ£ç¢ºã§ãããšããä¿èšŒã¯ãããŸããããããã®ä»®å®ã«ã¯ã䞻芳çãªå€æã倧ããé¢äžããŠãããéå»ã«ã¯ãååŸåŸã®åžå Žæ¡ä»¶ã®å€åãåºç€ãšãªã補åã«åœ±é¿ãäžãããã®ä»ã®èŠå ã«ãã£ãŠæªåœ±é¿ãåããããšããããŸããããããã®ä»®å®ã«é¢é£ãããªã¹ã¯ã¯ãéçºæ®µéã®è£œååè£ã«ã€ããŠã¯ããããã®éçºãã©ããªã³ã°ãèŠå¶æ¿èªãåæ¥åã®ã¿ã€ãã³ã°ã補é ããã³äŸçµŠã競å補åãŸãã¯é¢é£èŠå ã«é¢ããäžç¢ºå®æ§ã®ããã«æªåããå¯èœæ§ããããŸãããŸãããã€ã€ãªãã£ãæ¯æã矩åã®ããããŒãããŒã®è²¡åå®å®æ§ãéå¶ãŸãã¯ããŒã±ãã£ã³ã°èœåã«é¢ããç§ãã¡ã®ä»®å®ããéå»ã«ãããŠã誀ã£ãŠããããšã蚌æãããŠããŸããããããã®èŠå ããã®ä»ã®èŠå ã«ãããç§ãã¡ã®çŸåšã®ããŒããã©ãªãªå
ã®è³ç£ãå°æ¥ã®è³ç£ãäºæ³ããããªã¿ãŒã³ãéå»ã®è²¡åå®çžŸã«èŠåã£ããªã¿ãŒã³ãçæããªãå¯èœæ§ãããããã®ããç§ãã¡ã®ããžãã¹ã財åç¶æ³ããŸãã¯ååŒçµæã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
å¥çŽäžå®ããããŠããªãæéã«ã€ããŠã¯ãã€ã€ãªãã£ã®æéã«é¢ããŠä»®å®ãç«ãŠãŠããããã€ã€ãªãã£ã®æéãççž®ããããšãå®è³ªéå©ã®äœäžããã€ã€ãªãã£ããã®åå
¥ã®æžå°ãæåŸ
ã«å¯Ÿãããã€ã€ãªãã£æ¯æãã®å€§å¹
ãªæžå°ããŸãã¯æä¹
çãªæžæã«ã€ãªããå¯èœæ§ããããŸãã
ã¢ã¡ãªã«åè¡åœã®äžè¬ã«èªããããäŒèšååïŒãGAAPãïŒã«åŸããååŸããã»ãšãã©ã®ãã€ã€ãªãã£è³ç£ããASC 835-30ã§èª¬æãããŠããæåŸ
å¹æçå©æ¯æ³ã䜿çšããŠãååŽã³ã¹ãã§æž¬å®ãããéèè³ç£ãšããŠåé¡ããŸããæå¹å©çã¯ãåææè³é¡ã«å¯Ÿããè³ç£ã®å¯¿åœã«ããã£ãŠåãåããšäºæ³ããããã£ãã·ã¥ãããŒãäºæž¬ããããšã«ãã£ãŠèšç®ããã賌å
¥ãããåµæš©ã¯å·®ãåŒãããŸãããã®ãããªäºæž¬ã®éèŠãªèŠçŽ ã¯ããã€ã€ãªãã£ã®æéã«é¢ããåœç€Ÿã®ä»®å®ã§ãã
ãã€ã€ã«ãã£ã®æéã¯ããã€ã€ã«ãã£ã®åç¶æéã«ãããå©æ¯åå
¥ãæ£ç¢ºã«æž¬å®ããããã«éèŠã§ããå¥çŽäžã§åºå®ãããŠããªãæ¡ä»¶ã®ãã€ã€ã«ãã£ã®æéã«é¢ããä»®å®ãç«ãŠãéã«ã¯ãæ¢åã®ç¹èš±ä¿è·ã®åŒ·ãããžã§ããªãã¯å»è¬åã®æåŸ
ãããåå
¥ãå°ççç¬å æéãåã³åºç€è£œåã«é¢é£ããç¹èš±æéã®å»¶é·ã®å¯èœæ§ãèæ
®ããŸãã
ãã€ã€ãªãã£ã®æéã¯éåžžãåœããšã«ç°ãªããç¹èš±ã®æéã補åãåç¬ã§è²©å£²ããããçµã¿åããã§è²©å£²ãããããèŠå¶ã®ç¬å æ§ãç¹èš±ä¿è·ããã補åã®æåã®åæ¥è²©å£²ããã®å¹Žæ°ã競åãããžã§ããªãã¯è£œåãŸãã¯ãã€ãªã·ãã©ãŒè£œåã®åå
¥ããŸãã¯ãã€ã€ãªãã£ã管çããå¥çŽã«å®ãããããã®ä»ã®æ¡ä»¶ãªã©ãè€æ°ã®èŠå ã«åºã¥ãå ŽåããããŸãããã€ã€ãªãã£ã®æéã¯ãç¹èš±ã®ä»äžãç¹èš±æéã®å»¶é·ãç¹èš±ã®ç¡å¹åãç¹èš±ã®äžæ£äœ¿çšã®äž»åŒµãç¹èš±ãå¶åŸ¡ããåœäºè
ãšç¹èš±ã®ç¬¬äžè
ææŠè
ãšã®éã®èšŽèšã第äžè
ãæå¹ãªç¹èš±ãåé¿ãŸãã¯è¿åããèœåãèŠå¶ã®ç¬å æéã延é·ã®ä»äžããžã§ããªãã¯ãŸãã¯ãã€ãªã·ãã©ãŒã®ç«¶å補åã®å°çã¿ã€ãã³ã°ãç¥ç財ç£æš©ãå»è¬åã®èŠå¶ã«åœ±é¿ãäžããæ³çãŸãã¯èŠå¶ã®æ çµã¿ã®å€æŽã補åã©ã€ããµã€ã¯ã«ãæ¥çš®ã®çµ±åãªã©ãæéã®çµéãšãšãã«äºæž¬å€ã®ãã©ã¹ãŸãã¯ãã€ãã¹ã®å±éã«ãããæ©æãŸãã¯é
延ããŠæºäºããããšãäžè¬çã§ãã
äºæããªããã€ã€ã«ãã£æéã®ççž®ãçºçããå Žåãè³ç£ã®å®è³ªéå©ã®äœäžããã€ã€ã«ãã£ããã®åå
¥ã®æžå°ãæåŸ
ã«æ¯ã¹ãŠãã€ã€ã«ãã£ã®æ¯æãã®å€§å¹
ãªæžå°ããŸãã¯æä¹
çãªæžæãçããå¯èœæ§ããããŸãã
ç§ãã¡ã®ãã€ã€ãªãã£ã®å€§éšåã¯ãååŽå䟡ã§æž¬å®ãããéèè³ç£ãšããŠåé¡ãããŠãããæå¹éå©æ³ã«åºã¥ããŠãããããGAAPã®å¶æ¥çµæã¯å€åããããäºæž¬äžå¯èœã§ãã
GAAPã«åŸããååŸããã»ãšãã©ã®ãã€ã€ãªãã£è³ç£ã¯ãã£ãã·ã¥ãããŒã®ã¹ããªãŒã ãžã®æè³ãšèŠãªããããããã£ãŠéèè³ç£ãšããŠåé¡ãããŸãããã®åé¡ã®äžã§ã¯ãéèãã€ã€ãªãã£è³ç£ã¯ååŽå䟡ã§æž¬å®ããã貞ä»éã«äŒŒãå©åãã³ã³ããŒãã³ããæã€ãã®ãšèŠãªãããŸãããã®äŒèšææ³ã®äžã§ãéèãã€ã€ãªãã£è³ç£ããšã®å¹ççãªå©åçããéèãã€ã€ãªãã£è³ç£ã®åæååŸäŸ¡æ Œã«å¯ŸããæåŸ
ããããã£ãã·ã¥ãããŒã®äºæž¬ã䜿çšããŠèšç®ããŸããå©åãã¯ãåå ±åæéã®çµäºæã«èšç®ãããå°æ¥ã«ããã£ãŠé©çšãããéèãã€ã€ãªãã£è³ç£ã®æåŸ
ããã寿åœã«å¯Ÿããå¹æçãªå©åãã§ç§ãã¡ã®åçã«å¯ŸããŠèç©ããã圢ã§èªèãããŸãã
æå¹éå©æ³äŒèšææ³ã«é¢é£ããéçŸéè²»çšã®åœ±é¿ã«ãããæã
ã®åçèšç®æžã«ãããå€ãã®ãã€ã€ã«ãã£ã«é¢ãã掻åã¯å€åæ§ãé«ãäºæž¬äžå¯èœãªãã®ãšãªããŸãã 売ããµã€ãã®æ ªåŒèª¿æ»ã¢ããªã¹ãã®ã³ã³ã»ã³ãµã¹å£²äžäºæž¬ã®å°ããªæžå°ãé·æçãªèŠéã«ããã£ãŠçºçããã ãã§ãå®éã®çŸéæµå
¥ã¯äœå¹Žãå
ã«ãªãã«ãããããããå³åº§ã«éçŸéã®åçèšç®æžè²»çšèªèã«ã€ãªããããšããããŸãã äŸãã°ã2014幎æ«ã«æã
ã¯å¢èæ§ç·ç¶çã®ãã©ã³ãã£ã€ãºãååŸããããã¯éèãã€ã€ã«ãã£è³ç£ãšããŠåé¡ãããŸãã 2015幎第2ååæããã売ããµã€ãã®æ ªåŒèª¿æ»ã¢ããªã¹ãã®è¿ãå°æ¥ã®å£²äžäºæž¬ã®æžå°ã«ãããæã
ã¯åçèšç®æžã«éçŸéã®åŒåœè²»çšãèªèããããã«å¯Ÿå¿ãã环ç©åŒåœéãç©ã¿å¢ããéèãã€ã€ã«ãã£è³ç£ã®ç·æ®é«ãæžå°ãããŸããã 10ååæã®éã«ãæã
ã¯ãããã®äºæž¬ã®å€åã«èµ·å ããŠéçŸéã®åŒåœè²»çšãèªèãããã®äžã«ã¯2016幎ã«74320äžãã«ã®éçŸéè²»çšãå«ãŸããŠãããæçµçã«ã¯ãã®éèãã€ã€ã«ãã£è³ç£ã«é¢é£ããŠ2017幎9æ30æ¥ãŸã§ã«ç·çŽ¯ç©åŒåœéã13åãã«ã«éããŸããã 2019幎10æã«ããŒããã¯ã¹ã®äžéçµã¿åããçæ³ã§ããTrikaftaã®æ¿èªã«ããã売ããµã€ãã®æ ªåŒèª¿æ»ã¢ããªã¹ãã®ã³ã³ã»ã³ãµã¹å£²äžäºæž¬ã¯ããã倧ããªå¯Ÿè±¡åžå ŽãšTrikaftaã®ãã€ã€ã«ãã£ã®äºæ³æéã®å»¶é·ãåæ ããããã«å¢å ããŸããã å¢èæ§ç·ç¶çã®ãã©ã³ãã£ã€ãºã«å¯Ÿãã环ç©åŒåœéã®ããããªæžå°ã¯2017幎ãš2018幎ã«åŒåœåå
¥ãšããŠèªèãããŸããããTrikaftaã®æ¿èªã«é¢é£ãã売ããµã€ãã®æ ªåŒèª¿æ»ã¢ããªã¹ãã®ã³ã³ã»ã³ãµã¹å£²äžäºæž¬ã®å¢å ã«ããã2019幎ã«å
šé¡ãæžå°ããéçŸéåŒåœåå
¥ãšããŠ11åãã«ã®çŽ¯ç©åŒåœéãæ®ããŸãããæå¹éå©äŒèšææ³ã®é©çšã«ãã£ãŠåŒãèµ·ãããã財åè«žè¡šãžã®åœ±é¿ã¯ãç¹å®ã®æéã«ãããæã
ã®çµæã«å¯ŸããåŠå®çãªèªèãæãå¯èœæ§ããããŸãã
éãããæ°ã®è£œåã«äŸåããããšã¯ãããžãã¹ã財åç¶æ³ãåã³ååŒçš®é¡ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
çŸåšã®è³ç£ããŒããã©ãªãªã«ã¯ã35以äžã®è²©å£²äžè£œåã«é¢é£ãããã€ã€ãªãã£ãå«ãŸããŠããŸããã2024幎ã®æåã®9ãæéã«ãããŠãäžäœ5ã€ã®è£œåãã©ã³ãã£ã€ãºã¯åœç€Ÿã®ãã€ã€ãªãã£åå
¥ã®64ïŒ
ãå ããŸãããããã«ãåœç€Ÿã®è³ç£ããŒããã©ãªãªã¯ãå°åããã®ä»ã®åºæºã«ãã£ãŠååã«å€æ§åãããŠããªãå¯èœæ§ããããŸããè³ç£ããŒããã©ãªãªã®ããã補åããã®ãã£ãã·ã¥ãããŒãèããæªåãããšãããžãã¹ã財åç¶æ
ããŸãã¯æ¥çžŸã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ãã€ã€ãªãã£ã®ååŸãé©åãªãã€ã€ãªãã£ãèŠã€ããããšã«ãããŠç«¶äºã«çŽé¢ããŠããŸãã
é«å質ãªãã€ã€ãªãã£ãååŸããããã®é
åçã§é©ããæ©äŒã¯éãããŠããŸãããããã£ãŠããã®ãããªãã€ã€ãªãã£ãååŸããããã®ç«¶äºã¯æ¿ãããå¢å ããå¯èœæ§ããããŸããç§ãã¡ã¯ããã€ã€ãªãã£ãæ¯æããã補åãããŒã±ããããäŒæ¥ãæè³ããŒã¯ã«ããã®ä»ã®è³æ¬ããŒã«ããã¡ã€ãã³ã·ã£ã«ã€ã³ã¹ãã£ãã¥ãŒã·ã§ã³ãºãæ©é¢æè³å®¶ïŒæ¿åºç³»ãã¡ã³ãã幎éåºéãå«ãïŒãªã©ãä»ã®æœåšçãªååŸè
ãšãããã®æ©äŒã競ã£ãŠããŸãããããã®ç«¶äºçžæã¯ãããäœã³ã¹ãã®è³æ¬ã«ã¢ã¯ã»ã¹ã§ããå Žåããããç§ãã¡ããã倧èŠæš¡ã§ããå¯èœæ§ããããç§ãã¡ã«å
ç«ã£ãŠæ©äŒã«ã¢ã¯ã»ã¹ããé¢ä¿ãæã£ãŠããå Žåããç§ãã¡ãããäœãäºæž¬ãªã¿ãŒã³ã§ãã€ã€ãªãã£ãååŸããæ欲ãããå ŽåããããŸãã
ãã€ãªå»è¬åã¯å€§ããªç«¶äºã«ãããããŠããŸãã
ãã€ãªå»è¬åæ¥çš®ã¯ãéåžžã«ç«¶äºãæ¿ãããæ¥éã«é²åããŠããæ¥çš®ã§ãã補åã®åæ¥ç寿åœã¯ç¢ºå®ã«äºæž¬ããããšãã§ããŸããããã€ã€ã«ãã£ãåããæš©å©ã®ãã1ã€ãŸãã¯è€æ°ã®è£œåã¯ãæ°ãããŸãã¯ä»£æ¿ã®è£œåããããã¯ããã€ã€ã«ãã£ãåããæš©å©ã®ãªãæ¢åã®è£œåã®æ¹åã«ãã£ãŠãçŸåšã®è²©å£²è
ã«ãã£ãŠãããã¯ä»ã®è²©å£²è
ã«ãã£ãŠãæ代é
ããŸãã¯ç«¶äºåããªããªãå¯èœæ§ããããŸãã補åã®çŸåšã®è²©å£²è
ã¯ã補åãæ¹åããããç§ãã¡ã®ãã€ã€ã«ãã£ãæ¯æããªãããã«ããããã«ããããã®éçºåªåãè¡ãããšããããŸããé颚ã®ç«¶äºãé³è
åãæ¿åºãèŠå¶ã®æªçœ®ããããã¯å»çæ¿çã®å€æŽã¯ãç§ãã¡ã®ãã€ã€ã«ãã£ãçã¿åºã補åã®åçãç¹ã«ãã€ã€ã«ãã£é¢é£ã®åçã«å€§ããªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
å補åã®åžå Žå°äœãšæåã«åœ±é¿ãäžãã競äºèŠå ã¯æ¬¡ã®éãã§ã:
⢠å®å
šæ§ãå¯äœçšã®ãããã£ãŒã«ãå¹æãããŒã±ããã§ã®å容æ§;
⢠第äžè
ä¿éºã®æãæ»ãããªã·ãŒãå«ãäŸ¡æ Œ;
⢠ååã®ã¿ã€ãã³ã°ã玹ä»ããããŠã¬ãžã¹ã¿ã³ã¹ã
⢠ããŒã±ãã£ã³ã°ããã³åæ¥åã®æŠç¥ã®æå¹æ§ãšå®è¡;
⢠åžå Žå容æ§;
⢠補é æ¥ãäŸçµŠããã³æµé;
â¢ äŸ¡æ Œäžéãå«ãæ¿åºã®èŠå¶;
⢠äœäŸ¡æ Œã®ãžã§ããªãã¯å»è¬åããã€ãªã·ãã©ãŒã®å©çšå¯èœæ§;
⢠ç¥ç財ç£ä¿è·ãšç¬å æ§;
⢠補åã®å¿
èŠæ§ãæé€ãŸãã¯æå°éã«æããæ²»çé©æ°ïŒãããŠ
⢠補å責任è«æ±
ãã€ã€ãªãã£ãåãåãæš©å©ããã®ä»ã®å©æš©ããã補åã¯ããžã§ããªãã¯ããã€ãªã·ãã©ãŒãæ°ãã補åãæ¢å補åã®æ¹åãããŒã±ãã£ã³ã°ãŸãã¯åæ¥æŠç¥ãæ¿åºãŸãã¯èŠå¶åœå±ã®è¡åã«ãã£ãŠæ代é
ãã«ãªããã競äºåã倱ãå¯èœæ§ããããŸããããã«ããã€ãªå»è¬åäŒæ¥ã次äžä»£ã®è£œåãæ²»çæ³ã®é©æ°ã«å€ãã®è³æºãæå
¥ããã«ã€ããŠããã€ã€ãªãã£ãæãã補åã¯åæ¥åãé
åçã§ãªããªã£ãããæ代é
ãã«ãªãå¯èœæ§ããããŸãã補åã®åžå Žå容ãäœäžããããåžå Žããæ€éããããšããã€ãªå»è¬å補åã«é¢ããç¶ç¶çãªæ¯æããæééãã«è¡ãããªãããŸãã¯è¡ãããªãå¯èœæ§ããããããã«ãããã€ã€ãªãã£ãåãåãæš©å©ããã®è£œåã«å¯Ÿãããã®ä»ã®å©æš©ã®å©ç¹ãå®çŸããèœåã«åœ±é¿ãåãŒãå¯èœæ§ããããè³ç£ã®æžæè²»çšãçºçãããçµæãšãªããããããŸãããããã«ãæ¿èªããã補åãšç«¶åãããã€ã€ãªãã£ãåãåãæš©å©ããã®ä»ã®å©æš©ããã補åã¯ãäŸ¡æ Œç«¶äºãå
æãåæ¥çæåãåããããã«ãå¹æãå©äŸ¿æ§ãè容æ§ãå®å
šæ§ã«ãããŠåŒ·åãªå©ç¹ã瀺ããªããã°ãªããŸãããå€ãã®æ¿èªãããè¬å€ã¯ç¢ºç«ãããæ²»çæ³ã§ãããå»åž«ãæ£è
ã第äžè
æ¯æè
ã«ãã£ãŠåºãåãå
¥ããããŠããŸããä¿éºäŒç€Ÿããã®ä»ã®ç¬¬äžè
æ¯æè
ããžã§ããªãã¯è£œåã®äœ¿çšãä¿ãå¯èœæ§ããããŸãããããã®ããããã®é²å±ãããã€ã€ãªãã£ãæãã補åã«æªåœ±é¿ãåãŒãã°ãçµæçã«ããžãã¹ã財åç¶æ³ãéå¶çµæã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ç§ãã¡ã®ãã€ã€ã«ãã£ãçã¿åºã補åã®ããŒã±ã¿ãŒã¯ãç§ãã¡ã®ç®¡çå€ã«ãããŸãã
åœç€Ÿã®ãã€ã€ã«ãã£åµæš©ã®ã±ãŒã¹ã§ã¯ããã£ãã·ã¥ãããŒã¯äž»ã«è²©å£²è
ã«ãã£ãŠæ¯æããããã€ã€ã«ãã£ã«åºã¥ãæ¯æãã§æ§æãããŠããŸãããããã®è²©å£²è
ã¯ãåœç€Ÿã®å©å®³ãšã¯ç°ãªãå©çãæã£ãŠããå ŽåããããŸããäŸãã°ããããã®è²©å£²è
ã¯ãä»ã®è£œåã«ãªãœãŒã¹ãå²ãåœãŠãããšã«ãã£ãŠå
šäœçãªåå
¥ãæ倧åããå°æ¥çã«ã¯åœç€Ÿã®ãã€ã€ã«ãã£ãçã¿åºããŠãã補åã«å¯ŸããŠããŸã泚åããªããªããããŸãã¯åœç€Ÿã«ãã€ã€ã«ãã£ãçã¿åºããªã補åã®éçºã«ãªãœãŒã¹ãå²ãåœãŠãããšã決å®ãããããããŸããããããªã販売è
ãã販売è
ãšã®éã«äœæ¥é¢ä¿ãæã€äººããåœç€Ÿã®ãã€ã€ã«ãã£ãçã¿åºããŠãã補åãåŒãç¶ãçç£ã販売ãããã³ããŒã±ãã£ã³ã°ããããã®ååãªãªãœãŒã¹ãåæ©ãæã£ãŠãããšããä¿èšŒã¯ãããŸãããã©ã€ã»ã³ãµãŒãšã®å¥çŽæ¡ä»¶ã«åºã¥ããŠãç¹å®ã®ç¶æ³äžã§ããŒã±ã¿ãŒã®æŽ»åã«é¢é£ããéãããç£æ»æš©ãé€ããŠãåœç€Ÿã¯ããŒã±ã¿ãŒã®éå¶ã«å¯Ÿããç£èŠæš©ãæããã圌ãã®éå¶ãæŠç¥ãæ瀺ããæš©å©ãæããããŸãåœç€Ÿã®å¥çŽã¯åœŒãã®éå¶ã«å¯Ÿããããã©ãŒãã³ã¹åºæºãå«ãã§ããŸããããã€ã€ã«ãã£ã®æ¯æãã®èšç®ã¯ãåœç€Ÿã®ã«ãŠã³ã¿ãŒããŒãã®è²©å£²ããã³äŒèšæ©èœã®é©åãããã³æ£ç¢ºæ§ã«äŸåããŠããŸãã
補åã®è²©å£²ã«é¢ããç¹å®ã®æ
å ±ã¯ãç£æ»æš©ã®è¡äœ¿ãã©ã€ã»ã³ãµãŒããåãåããã€ã€ãªãã£å ±åæžã®ã¬ãã¥ãŒãéããŠåãåãããšãã§ãããããããŸãããããã®ãããªæ
å ±ã¯ãã€ã€ãªãã£ã®å£²äžé«ãèªèããåŸãäœã¶æãçµã£ãŠããåãåãããšããããåŸã®æéã«ãã€ã€ãªãã£ã®å£²äžé«ã調æŽããå¿
èŠããããç§ãã¡ã®åŽã§è²»çšããããå ŽåããããŸãã
ããŒã±ã¿ãŒã®æ¥åã«é¢ããæ
å ±ã¯éãããŠããŸããããŒã±ã¿ãŒãæã€å¯èœæ§ã®ãã補åã«é¢é£ããç¹å®ã®æ
å ±ãã¬ãã¥ãŒãããåãåã£ããããæš©å©ã¯ãããŸãããããã«ã¯ãããŒã±ã¿ãŒãä»ã®è
ãå®æœããç 究ã®çµæãã補åã®ãŠãŒã¶ãŒãå»åž«ããã®èŠæ
ãå«ãŸããŸãããã®ããããã€ã€ãªãã£ãçã¿åºã補åã®åžå Žããã©ãŒãã³ã¹ã¯ãç§ãã¡ã®ç®¡çå€ã®å€ãã®èŠå ã«åœ±é¿ãããå¯èœæ§ããããŸãã
ãã€ãªå»è¬åã®è£œåã®ããŒã±ãã£ã³ã°æ
åœè
ã¯ãäžè¬çã«ã補åã®ç¶ç¶çãªèŠå¶æ¿èªãåæ¥åã補é æ¥ãããŒã±ãã£ã³ã°ã«å®å
šã«è²¬ä»»ãè² ã£ãŠããŸãã
äžè¬ã«ã補åã«å¯Ÿãããã€ã€ã«ãã£ã®ä¿æè
ã¯ããããã®è£œåã®ããŒã±ã¿ãŒã«å¯ŸããŠãç¬å çãªèŠå¶æ¿èªãåæ¥åã補é æ¥ããã³ããŒã±ãã£ã³ã°ã®æš©å©ãä»äžããŠããŸããããŒã±ã¿ãŒã¯ããããã®åªåã«å¯ŸããŠå®å
šãªç®¡çæš©ãæã¡ã補åã®ããã°ã©ã ã«ã³ããããããªãœãŒã¹ã®ç¯å²ãšåªå
é äœãå€æããåç¬ã®è£éãæã¡ãŸãããããã£ãŠã補åã®æåããåæ¥åã¯ããŒã±ã¿ãŒã®åªåã«äŸåããæã
ã®å¶åŸ¡ãè¶
ããŠããŸããããããŒã±ã¿ãŒã補åã®ç¶ç¶çãªéçºãèŠå¶æ¿èªãåæ¥åããã³è£œé æ¥ã«ååãªãªãœãŒã¹ãæå
¥ããªãã£ãããéæ³ãŸãã¯èš±å¯ãããŠããªãè¡çºã«é¢äžããå Žåã補åã®å£²äžã¯ååãªãã€ã€ã«ãã£ãçãããšãã§ããªããã補åã®å£²äžãäžæãããå¯èœæ§ãããããã®çµæãšããŠæã
ã®ããžãã¹ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸããããã«ããã€ãªå»è¬åã®è£œåããŒã±ã¿ãŒã補åããã°ã©ã ãäžæ¢ããããšã決å®ããããè³ç£ã®åæ¥çèŠéããæžå°ãããšå€æããå Žåããããã®ããã°ã©ã ãŸãã¯è³ç£ã«é¢é£ããéèãã€ã€ã«ãã£è³ç£ã«å¯ŸããŠéèŠãªéçŸéã®æžææ倱ãèªèããå¯èœæ§ããããŸãã
補åã«é¢ããã©ã€ã»ã³ã¹å¥çŽã¯ãå Žåã«ãã£ãŠã¯äžæ¹çã«è§£é€ãããããšããããçŽäºãçºçãããšãã€ã€ãªãã£ã«åœ±é¿ãäžããå¯èœæ§ããããŸãã
åœç€Ÿã®ãã€ã€ãªãã£ãçã¿åºã補åã«é¢ããã©ã€ã»ã³ã¹å¥çŽã¯çµäºããå¯èœæ§ããããããã«ãããã®è£œåã®è²©å£²ã«æªåœ±é¿ãåãŒãããããã£ãŠåœç€Ÿãåãåãæ¯æãã«ã圱é¿ãåºãå¯èœæ§ããããŸããããšãã°ãç¹å®ã®ã©ã€ã»ã³ã¹å¥çŽã®äžã§ãããŒã±ã¿ãŒã¯ã©ã€ã»ã³ãµãŒãšã®å¥çŽãäžæ¹çã«çµäºããæš©å©ãä¿æããŠããŸãã補åãã«ããŒããæåŸã®ç¹èš±ã倱å¹ãããããããã¯ä»ã®çç±ã§ç¡å¹ã«ãªããšãããŒã±ã¿ãŒã¯æ¯æãããã³ãã®ä»ã®çŸ©åãçµäºããããã«ããã¹ãŠãŸãã¯ç¹å®ã®åœã«é¢ããŠã©ã€ã»ã³ã¹å¥çŽãçµäºããçµæžçãªåæ©ãæã€ããšããããŸãããã®ãããªçµäºãçºçããå Žåãã©ã€ã»ã³ãµãŒã¯ã©ã€ã»ã³ã¹å¥çŽè
ããæåŸ
ããŠãããã¹ãŠã®æ¯æããåããããªããªãå¯èœæ§ãããããŸãçµäºããã©ã€ã»ã³ã¹å¥çŽãšåããŸãã¯é¡äŒŒã®æ¡ä»¶ã§è£œåã®éçºããã³åæ¥åãç¶ç¶ããããã®ä»ã®äŒç€ŸãèŠã€ããããšãã§ããªããªãå¯èœæ§ããããŸãã
ããã«ãã©ã€ã»ã³ã¹å¥çŽã¯ãã©ã€ã»ã³ã¹ååŸè
ã®å±¥è¡å€±æãçŽäºãçºçããå Žåã«ãã©ã€ã»ã³ãµãŒã«ååãªä¿è·ãæäŸããªãå¯èœæ§ããããŸããç§ãã¡ã®ãã€ã€ãªãã£ã®åºç€ãšãªã補åã«é¢é£ããã©ã€ã»ã³ã¹å¥çŽã¯è€éã§ããããã®ãããªå¥çŽã®ç¹å®ã®æ¡é
ã¯è€æ°ã®è§£éã®åœ±é¿ãåããå¯èœæ§ããããŸããçºçãããããããªãå¥çŽè§£éã«é¢ãã察ç«ã®è§£æ±ºã¯ãã©ã€ã»ã³ãµãŒãé¢é£ããç¥ç財ç£æš©ããã¯ãããžãŒã«å¯Ÿããæš©å©ã®ç¯å²ã ãšèãããã®ãçããããã©ã€ã»ã³ã¹ååŸè
ã®åœè©²å¥çŽã«åºã¥ã財åçãŸãã¯ãã®ä»ã®çŸ©åãæžå°ããããããå¯èœæ§ãããããã®ããããç§ãã¡ã®ãã€ã€ãªãã£ã®äŸ¡å€ã«åœ±é¿ãäžããçµæãšããŠç§ãã¡ã®ããžãã¹ã財åç¶æ
ããŸãã¯æ¥çžŸã«æªåœ±é¿ãåãŒãããšããããŸããããããŒã±ã¿ãŒãã©ã€ã»ã³ã¹å¥çŽã«åºã¥ã矩åãå±¥è¡ããªãã£ãå Žåãã©ã€ã»ã³ãµãŒã®ææžæ段ã¯ãç¹å®ã®åœã«é¢é£ããç¹å®ã®ã©ã€ã»ã³ã¹ãçµäºããããšãããã®åœã«é¢ããã©ã€ã»ã³ã¹å¥çŽãäžè¬çã«çµäºãããããšã«éããããããããŸããããã®ãããªå Žåãç§ãã¡ã¯ã©ã€ã»ã³ãµãŒã®æš©å©ãè¡äœ¿ããããã®æš©å©ãæããŠããªãããããããã©ã€ã»ã³ãµãŒãã©ã€ã»ã³ã¹ååŸè
ã«å¯ŸããŠãã®æš©å©ãè¡äœ¿ããããã®ãªãœãŒã¹ãšæ欲ã«äŸåããããšãæ±ãããããããããŸããã
ãããã®ãããã®ç¶æ³ã«ãããŠããã©ã€ã»ã³ã¹å¥çŽã«åºã¥ãæåŸ
ãããæ¯æããå®çŸããªãå Žåãåœç€Ÿã«ãšã£ãŠé倧ãªæ倱ããããããããžãã¹ã財åç¶æ³ãŸãã¯æ¥çžŸã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ããŒã±ã¿ãŒã®ç Žç£ã¯ãç§ãã¡ãäžç«ããŠããé¢é£ãã€ã€ã«ãã£ããã®ãã£ãã·ã¥ãããŒã®åãåãã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
ããããŒã±ã¿ãŒãç Žç£ããç±³åœæ³å
žç¬¬11ã¿ã€ãã«ç¬¬11ç« ïŒæ¹æ£ããããã®ïŒã«åºã¥ããŠåç·šãæ±ããå Žåããç Žç£æ³ç¬¬7ç« ïŒãŸãã¯å€åœã®åçæ³ïŒã«åºã¥ããŠæž
ç®ãè¡ãå Žåããã®ãããªåºæ¥äºã¯ãç Žç£æç¶ãã®è§£æ±ºãåŸ
ã€éã«ã©ã€ã»ã³ã¹å¥çŽã«åºã¥ãæ¯æéé¡ã®æ¯æããé
延ãããã劚ãããããå¯èœæ§ããããŸããç Žç£æç¶ãã®éå§åã«çºçããæªæãã®ãã€ã€ã«ãã£æ¯æãã¯ããŒã±ã¿ãŒã«å¯Ÿããç¡æ
ä¿è«æ±ãšãªããå
šé¡ãŸãã¯å
šãæ¯æãããªãå¯èœæ§ããããŸããç Žç£æç¶ãã®éå§åŸã®æéã«å¯ŸããŠçºçãããã€ã€ã«ãã£æ¯æãã¯ãããé«ãåªå
床ãæã€ç®¡çè²»çšãšããŠè³æ ŒãåŸããããããŸãããããã®ãããªç³è«åŸã®ãã€ã€ã«ãã£æ¯æãã®å®éã®æ¯æãã¯é·æéé
延ããå¯èœæ§ããããã©ã€ã»ã³ã¹å¥çŽã«åºã¥ããŠæ¯æãããã¹ãå
šé¡ã«ã¯éããªãå¯èœæ§ããããŸããã©ã€ã»ã³ãµãŒã¯ãç Žç£æç¶ãã«ãããŠèªåçã«åæ¢ããããããç Žç£è£å€æã®èš±å¯ãªãã«æš©å©ãè¡äœ¿ããããã®è¡åãåãããšã¯ã§ããŸãããããã«ãããŒã±ã¿ãŒã¯ã©ã€ã»ã³ã¹å¥çŽãæåŠããããšãéžæããå¯èœæ§ãããããã®å Žåãã©ã€ã»ã³ãµãŒã¯ä»ã®æµéæ¥è
ãšå
±ã«é©çšè£œåã®ããŒã±ãã£ã³ã°ãæ¹ããŠè¡ããªããã°ãªããªããªããŸãããã®ãããªæç¶ãã¯ãæ¯æãè
ããã€ã€ã«ãã£ã«é¢ããŠæ¯æããè¡ãèœåã«æªåœ±é¿ãåãŒããçµæãšããŠç§ãã¡ã®ããžãã¹ã財åç¶æ³ããŸãã¯æ¥çžŸã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
æ°ããªãã€ã€ãªãã£ãååŸããããã®å€±æã¯ã significantãªã³ã¹ããåŒãèµ·ããããã®åŸã®ãã®ä»ã®è³ç£ãèŠã€ããŠååŸããè©Šã¿ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
åç¹å®ã¿ãŒã²ããã®ãã€ã€ã«ãã£ã«é¢ãã調æ»ããé¢é£ããå¥çŽã®äº€æžãèæ¡äœæãå®è¡ã«ã¯å€å€§ãªç®¡çæéãšæ³šæãå¿
èŠã§ãäŒèšå£«ãåŒè·å£«ããã³ãã®ä»ã®äººã
ã« substantial ãªã³ã¹ããçºçããŸããç¹å®ã®è²·åãå®äºããªããšãã決å®ãäžãããå Žåãææ¡ãããååŒã«ãããã³ã¹ãã¯ç¬¬äžè
ããååã§ããŸãããããã«ãç¹å®ã®ã¿ãŒã²ããè³ç£ã«é¢é£ããåæã«éãããšããŠããå
Œ
±ã®äŒç€Ÿãšã®ããžãã¹ã³ã³ãããŒã·ã§ã³ãéããŠãã€ã€ã«ãã£ãååŸããå Žåãã¿ãŒã²ããäŒç€Ÿã®å
¬è¡æ ªäž»ããã®æ¿èªãå«ããæ§ã
ãªçç±ã«ããè²·åãå®äºã§ããªãå¯èœæ§ããããŸããæ°ãããã€ã€ã«ãã£ãååŸããããšããè€æ°ã®æªéã®è©Šã¿ã¯ãç§ãã¡ã®è©å€ãæãªãå¯èœæ§ãããã significant ãªã³ã¹ãããããŒãžã£ãŒã®æéã®éå¹çãªäœ¿çšãããããããšããããŸãã管çããã³è²¡æ¿è³æºã転çšããããšã®æ©äŒè²»çšã¯ããã®ä»ã®è³ç£ãæ¢ããååŸããèœåã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
åœç€Ÿã®ãã€ã€ãªãã£ãçã¿åºã補åã¯ãå»çé¢é£ã®åéæ¿çã管çå»çã®èæ
®äºé
ãäŸ¡æ Œå§åãåã³å»çæ¥çš®ã®èŠå¶ã«é¢é£ããäžç¢ºå®æ§ã®åœ±é¿ãåããŸãã
ç±³åœåžå Žããã³éç±³åœåžå Žã®äž¡æ¹ã«ãããŠããã€ãªå»è¬å補åã®è²©å£²ãšãã®æåã¯ãæ¿åºã®èŠå¶ããªãã³ã«å
¬çä¿éºããã°ã©ã ãæ°éä¿éºãã©ã³ãå«ã第äžè
ã®æ¯æãè
ããã®ã«ãã¬ããžåã³åéã®å¯çšæ§ãšç¯å²ã«ãã£ãŠäžéšåœ±é¿ãããŸãã
ã¢ã¡ãªã«åè¡åœã§ã¯ãå»è¬åã®äŸ¡æ Œèšå®ã¯æ¿åºã®èŠå¶ãå
Œ
±ã®ç£èŠãæ¹é©ãæ±ãã声ãé«ãŸã£ãŠããŸããäŸãã°ãã€ã³ãã¬åæžæ³ïŒ"IRA"ïŒã®å»è¬åäŸ¡æ Œã«é¢ããèŠå®ã¯ã2022幎8æã«æ³åŸãšããŠçœ²åããã2023幎ã«å®æœãéå§ãããä»åŸæ°å¹Žéã«ããã£ãŠå®æœãç¶ããããŸãã2023幎8æã«ããã€ãã³æ¿æš©ã¯ãã¡ãã£ã±ã¢è¬äŸ¡äº€æžããã°ã©ã ãã®å¯Ÿè±¡ãšãªãæåã®å»è¬åãçºè¡šããç¹å®ã®å»è¬åã®è£œé ã¡ãŒã«ãŒãã¢ã¡ãªã«é£éŠæ¿åºãšæ°ããªã¡ãã£ã±ã¢äŸ¡æ Œãèšå®ããããã»ã¹ã«åå ããããšãæ±ããããããã¯2026幎ã«çºå¹ããããšã«ãªããŸãããŸããã¢ã¡ãªã«ã®æ£è
ä¿è·ããã³å»çä¿éæ³ïŒACAïŒã¯ããã«ã¹ã±ã¢ããã³æè²ã®èª¿æŽæ³ã«ãã£ãŠä¿®æ£ããã2010幎3æã«è°äŒã«ãã£ãŠæç«ãããæ°ã«ã®ãŒãæ°ããªãªããŒããå²åŒãçšéã«ãã£ãŠéšåçã«è³éæäŸããã倧èŠæš¡ãªãã«ã¹ã±ã¢ã«ãã¬ããžã®æ¡å€§ã確ç«ããŸãããåæ³ã¯ãåœç€Ÿããã€ã€ãªãã£ãçæãã補åã補é ããäŒæ¥ã«å¯ŸããŠãè²»çšãå©çã«å€§ããªåœ±é¿ãäžããŠããŸãããããã®äŒæ¥ããã®è£œåã¯ãIRAãACAã®äžéšãŸãã¯å
šãŠã®æ¡é
ãå»æ¢ãããã倧å¹
ã«ä¿®æ£ããããç¡å¹ã«ããããã®é£éŠã®ç«æ³ããã³è¡æ¿ã®åªåã«ããäžç¢ºå®æ§ã«çŽé¢ããŠããŸãã
ãã®ä»ã®ç±³åœé£éŠãŸãã¯å·ã®ç«æ³ãèŠå¶æªçœ®ãæ¿çåªåã¯ãå»çæ¥çš®ã«æªåœ±é¿ãäžããå¯èœæ§ããããå
·äœçã«ã¯ã補åäŸ¡æ Œã«é¢ããè¿œå ã®éææ§ãå¶éãäŸ¡æ Œãšè£œé æ¥è
ã®æ£è
ããã°ã©ã ãšã®é¢ä¿ã®èŠçŽããäžè¬çãªäºç®ç®¡çæªçœ®ãç¹èš±æ³ã®å€æŽã競äºæ³ã®è§£éã®å€æŽãæ¿åºã®è³éã«ããé©æ°ã«é¢ããæš©å©ã®è¡äœ¿ãç±³åœå€ããã®åŠæ¹è¬ã®èŒžå
¥ã«é¢ããŠååœæ¿åºã«ããèŠå¶ãããäŸ¡æ Œã§ã®ååŒãæ¿åºããã°ã©ã ã®äžã§ã®ãã€ãªå»è¬åã®åéã«é¢ããæ¹èšãç±³åœã«ãããæ¶è²»è
ãžã®çŽæ¥åºåã®å¶éãå»çå°é家ãšã®çžäºäœçšã®å¶éãªã©ãå«ãŸããŸãããããã®æ³åŸãèŠå¶ãããžãã¹ã財åç¶æ
ããŸãã¯æ¥åçµæã«æªåœ±é¿ãäžããªããšããä¿èšŒã¯æäŸã§ããŸããã
è¬ã®äŸ¡æ Œã«å¯Ÿããå³ããå
¬ç scrutiny ã®ç¶ç¶ã«å ããæ¿åºãæ¯æè
ã®ååãã補é è
ãããŒã±ãã£ã³ã°æ
åœè
ã補åã®äŸ¡å€ã«åºã¥ããŠäŸ¡æ Œãèšå®ãŸãã¯èª¿æŽããèœåãå¶éããå¯èœæ§ããããŸããæ°ãã補åãææ¡ããã補åãã³ã¹ãå¹æããããšèŠãªãããããšãããã®ãããªè£œåã®è£œé è
ãããŒã±ãã£ã³ã°æ
åœè
ãé©åãªãªã¿ãŒã³ãå®çŸããã®ã«ååãªäŸ¡æ Œæ°Žæºãç¶æã§ããããã«ãé©åãªç¬¬äžè
ã®è£åãåŸãããä¿èšŒã¯ãããŸããããããã®äŸ¡æ Œå§åã¯ãçŸåšã®ãã€ã€ãªãã£ã«æªåœ±é¿ãäžããå°æ¥ã®ãã€ã€ãªãã£ã®ååŸã®é
åã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ã¢ã¡ãªã«ä»¥å€ã§ã¯ãEUãæ¥æ¬ãäžåœãªã©ã®å€ãã®äž»èŠåžå Žã§ã¯ãå»çã«å¯Ÿããæ¿åºã®èŠå¶ãåºç¯å²ã«ããã£ãŠãããå»çè³éãžã®æ¿åºã®é¢äžãååšãããã®ç¹ã«ãããŠå»è¬åã®äŸ¡æ Œããã³æãæ»ããåºå®ããŠããŸãããããã£ãŠããããã®åžå Žã§ã¯ãåœç€Ÿã®ãã€ã€ã«ãã£ãçã¿åºã補åã¯æ¿åºã®ææ決å®ããã³äºç®æªçœ®ã®åœ±é¿ãåããŸãã
ããã«ãç§ãã¡ã®ããŒããã©ãªãªã«ããå€ãã®è£œåã¯èŠå¶ã®ç¬å çå°äœããæ©æµãåããŠããŸããäŸ¡æ ŒãèŠå¶ããããã®åªåã®çµæãèŠå¶ã®ç¬å çå°äœãç¶æãããªãå Žåãããžãã¹ã財åã®çš®é¡ãŸãã¯å¶æ¥æ瞟ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ãã€ãªå»è¬åæ¥çš®ã¯ãé£éŠæ¿åºã®èµ€ååæžæ¿çã«ãã£ãŠæªåœ±é¿ãåããå¯èœæ§ãããããããäžç«ãããã€ã€ãªãã£ã®äŸ¡å€ãæžå°ãããæãããããŸãã
ã¢ã¡ãªã«ã®é£éŠèµ€åãæå¶ããããã®åªåãšããŠããã€ãªè£œè¬æ¥çš®ã¯ç«æ³ææ¡ãéããŠç¯çŽã®æœåšçãªæºãšèŠãªãããå¯èœæ§ããããŸããã¡ãã£ã±ã¢ãã¡ãã£ã±ã€ãããã®ä»ã®å
Œ
±è³éãŸãã¯è£å©éãåºãå¥åº·ããã°ã©ã ãå«ãã¢ã¡ãªã«ã®é£éŠæ¯åºãåæžããããã®æ¿åºã®è¡åããå»è¬åæ¯åºãæžå°ãããããšã¯ãåœç€Ÿã®ãã€ã€ãªãã£ãçã補åã®æ¯æãã«åœ±é¿ãäžããå¯èœæ§ããããŸãããããããã³ãã®ä»ã®ã³ã¹ã管çããããã¯èµ€ååæžã®äžç°ãšããŠãã€ãªè£œè¬æ¥çš®ã«èª²ãããå¯èœæ§ã®ããé倧ãªè¿œå çšéãææ°æã¯ãåœç€Ÿã®ãã€ã€ãªãã£ããã®ãã£ãã·ã¥ãããŒãæžå°ããããã®çµæãåœç€Ÿã®ããžãã¹ã財åç¶æ
ããŸãã¯å¶æ¥æ瞟ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ãã€ã€ãªãã£ãçã¿åºã補åã®è²©å£²ã¯ãã¢ã¡ãªã«ããã³æµ·å€ã®èŠå¶åœå±ã®æ¿èªãè¡åã«åœ±é¿ãããããžãã¹ã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
åæ¥åã®ããã®ãã€ãªå»è¬å補åã®æ¿èªæç¶ãã¯åœã«ãã£ãŠç°ãªããè¿œå ã®è©Šéšãšæéãå¿
èŠã«ãªãå ŽåããããŸãããããã®æç¶ãã«ã¯ãèšåºè©ŠéšçŸå Žã補é æœèšã«ãããèŠå¶åœå±ã«ããçŸå°æ€æ»ãå«ãŸããå Žåãããããã³ãããã¯ããã®ä»ã®ææçã«å¯Ÿå¿ããŠèª²ããããæ
è¡å¶éã«ãã£ãŠããããã®æ€æ»ãé
ããããšããããŸããFDAã«ããæ¿èªã¯ãä»ã®åœã®èŠå¶åœå±ã«ããæ¿èªãä¿èšŒãããã®ã§ã¯ãªãã1ã€ã®å€åœã®èŠå¶åœå±ã«ããæ¿èªã¯ãä»ã®å€åœã®èŠå¶åœå±ãFDAã«ããæ¿èªãä¿èšŒãããã®ã§ã¯ãããŸãããå€åœã®èŠå¶æ¿èªããã»ã¹ã«ã¯ãFDAæ¿èªãååŸããéã«é¢é£ãããã¹ãŠã®ãªã¹ã¯ãå«ãŸããå¯èœæ§ããããå€ãã®å ŽåãäŸ¡æ Œæ¿èªã®ãããªè¿œå ã®ãªã¹ã¯ãå«ãããšããããŸãã
ãããã®èŠå¶æ¿èªãä»äžãããããåãæ¶ãããããšãå¶éãããããšããªããšããä¿èšŒã¯ãªãããã®çµæãåœè©²è£œåã®è²©å£²ããåœç€Ÿãžã®ãã€ã€ãªãã£ã®æ¯æãã«é¢ããŠæ¯æãè
ãæ¯æããè¡ãèœåã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ãã€ãªå»è¬åã®è£œé ãšæµéã¯ãèŠå¶æ©é¢ãäŸçµŠè
ã®äžåã«ãã£ãŠäžæãããå¯èœæ§ããããŸãã
ãã€ã€ãªãã£ãçã¿åºã補åã®è£œé ã¯éåžžè€éã§ãå³ããèŠå¶ãããŠããŸããç¹ã«ããã€ãªå»è¬åã¯ãã¢ã¡ãªã«åè¡åœã®FDAã®æ¿èªãšç¶ç¶çãªèŠå¶ãå¿
èŠãªå°éæœèšã§è£œé ãããŠããŸãããŸããã¢ã¡ãªã«ä»¥å€ã§è£œé ãããå Žåã¯ãFDAãšMHRAãEMAãªã©ã®éç±³åœèŠå¶æ©é¢ã®äž¡æ¹ã®æ¿èªãå¿
èŠã§ãã補åã«é¢ããŠã¯ããããã®æ©é¢ãèšå®ããéçšåºæºãéµå®ãããŠããªãå Žåã補é æœèšã¯ééããããããŸãã¯çç£ãäžæãããããšããããŸãããã®ãããªæ©é¢ã«ãã£ãŠææãããäžåãæ¯æ£ããããŸã§ã補é æœèšã¯ééãããããçç£ãäžæãããå¯èœæ§ããããŸãããã®ãããªééãŸãã¯äžæã¯ãäžç¢ºå®ãªæéã«ãããã補åã®è£œé ãšæµéã劚ããå¯èœæ§ããããããé¢é£ãããã€ãªå»è¬åè³ç£ããã®ãã£ãã·ã¥ãããŒã¯æåŸ
ããã倧å¹
ã«å°ãªããªãå ŽåããããŸãã
ããã«ã補åã®è£œé æ¥è
ã¯ãããã±ãŒãžã³ã°ã補åã®è£œé ã«äœ¿çšããããã«ã¯åææã®äŸçµŠãªã©ã補åéçºã®ç¹å®ã®åŽé¢ã«å¯ŸããŠç¬¬äžè
ã«äŸåããããšããããŸããã¢ã¡ãªã«åè¡åœã§ã¯ãFDAã¯å»è¬åã販売ããå
šãŠã®äŸçµŠè
ãšãã¢ã¡ãªã«åè¡åœã§ãŸãã¯ã¢ã¡ãªã«åè¡åœãã販売ãããå
šãŠã®å»è¬åã®è£œé æ¥è
ããFDAã®çŸåšã®ãè¯å¥œãªè£œé åºæºãã«é¢ããèŠå¶ããã³ã¬ã€ãã©ã€ã³ã«åŸãããšãèŠæ±ããŠãããã¢ã¡ãªã«åè¡åœå€ã®åžæ³ç®¡èœåºåã§ãåæ§ã®èŠä»¶ããããŸãããã€ãªå»è¬å補åã®ããŒã±ã¿ãŒã¯ãäžè¬çã«å°æ°ã®éèŠãªé«åºŠã«å°éåããäŸçµŠè
ã補é æ¥è
ãããã±ãŒãžã£ãŒã«äŸåããŠããŸãããããããããã®è£œé æ¥ããã³ããã±ãŒãžã³ã°æœèšã®éå¶ã«ããããããªãäžæããããšãæå°éã§ãã£ãŠããçç£ã補åã®è²©å£²ã«æªåœ±é¿ãåãŒãå¯èœæ§ãããããã®çµæãããžãã¹ã財æ¿çç¶æ
ããŸãã¯ååŒçš®é¡ã®çµæã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
補å責任ã®è«æ±ã¯ããã€ãªå»è¬åã®å©çãæžå°ãããå¯èœæ§ããããŸãã
補åã®éçºè
ã補é è
ããŸãã¯ããŒã±ãã£ã³ã°æ
åœè
ã¯ã補å責任ã®è«æ±ã«ãããããå¯èœæ§ããããŸãã補å責任ã®è«æ±ã¯ããã®äžèº«ã«é¢ãããã補åã®è²©å£²ã«æªåœ±é¿ãåãŒããé¢é£ãããã€ã€ãªãã£ã®æ¯æãé¡ã«ã圱é¿ãäžããå¯èœæ§ããããããã«ã¯æ¯æè
ããã€ã€ãªãã£ã«é¢ããŠæ¯æããè¡ãèœåã«ãæªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ååã®ãã€ã€ãªãã£ãçæããéçºè
ã補é è
ã販売è
ããã®ä»ã®å£²ãæã«å¯Ÿãã補åã®è²¬ä»»è«æ±ããã£ãå Žåãèªç€Ÿã¯è²¬ä»»ãè² ããªããšèããŠããŸãããããããã®ãããªè£œå責任è«æ±ããã£ãå Žåãããžãã¹ã財åç¶æ
ããŸãã¯æ¥çžŸã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
éåžžããã€ã€ã«ãã£ãçã¿åºã補åã®ç¹èš±æš©ã®ç¶æãå·è¡ãåã³é²åŸ¡ã«ã¯é¢äžããŠããŸããã
åœç€Ÿããã€ã€ã«ãã£ãåãåãæš©å©ã¯ãäžè¬ã«ãã¢ã¡ãªã«åè¡åœããã³äžçã®ä»ã®å Žæã«ãããŠãç»é²ãŸãã¯çºè¡ãããç¹èš±ã®æå¹ãã€åŒ·å¶å¯èœãªæš©å©ã®ååšã«äŸåããŠããŸãã åœç€Ÿãæ¯æããåãã補åã¯ç¹èš±ä¿è·ã«äŸåããŠããããããã®è£œåã®è£œé ã販売ã販売ã第äžè
ã®ç¥ç財ç£æš©ã䟵害ãççšããŸãã¯ãã®ä»ã®åœ¢ã§éåããªãããšãåæã§ãã äžè¬çã«ãåœç€Ÿã¯ç¹èš±æš©ã®èšŽè¿œãç¶æã匷å¶ããŸãã¯ãã£ãã§ã³ã¹ãå¶åŸ¡ããèœåãæã£ãŠããŸããããåœç€Ÿã®ããŒãããŒããã®ããŒã±ã¿ãŒããããè¡ãæ欲ãšèœåã«äŸåããªããã°ãªããŸããã ãããã®ç¬¬äžè
ããããã®æš©å©ãç©æ¥µçã«èšŽè¿œãç¶æã匷å¶ããŸãã¯ãã£ãã§ã³ã¹ããããšãä¿èšŒããããšã¯ã§ããŸããã ããšããããã®ç¬¬äžè
ããããã®æš©å©ã蚎远ãç¶æã匷å¶ããŸãã¯ãã£ãã§ã³ã¹ããããšããŠããæåãããšã¯éããŸããã
ãã€ãªãã¯ãããžãŒããã³å»è¬åäŒæ¥ã®ç¹èš±ã®äœçœ®ã¯äžè¬çã«éåžžã«äžç¢ºå®ã§ãããè€éãªæ³çããã³äºå®äžã®åé¡ãå«ã¿ãå€ãã®èšŽèšã®å¯Ÿè±¡ãšãªã£ãŠããŸããããã«ãã¢ã¡ãªã«åè¡åœãä»ã®ç®¡èœåºåã«ãããç¹èš±æ³ã®å€æŽãç¹èš±æ³ã®è§£éã¯ãç¹èš±åºé¡ã«é¢ããæåããè¿œåããããŒãããŒã«ããçºè¡ãããç¹èš±ã®æåããå·è¡ãŸãã¯ãã£ãã§ã³ã¹ã«é¢ããäžç¢ºå®æ§ãå¢å€§ãããå¯èœæ§ãããããããã¯å
šãŠãã€ãªå»è¬åè³ç£ã«é¢é£ããç¹èš±ä¿è·ã®äŸ¡å€ãæžå°ãããå¯èœæ§ããããŸãããã®çµæãããŒãããŒããã®ããŒã±ã¿ãŒã®ç¹èš±æš©ã®çºè¡ãç¯å²ã劥åœæ§ãå·è¡å¯èœæ§ããã³åæ¥ç䟡å€ã¯éåžžã«äžç¢ºå®ã§ããå ããŠã第äžè
ã®ä¿çäžåã³å°æ¥ã®ç¹èš±åºé¡ã¯ã圌ãã®è£œåãéçºæ®µéã®è£œååè£ãæè¡ãä¿è·ããç¹èš±ã«çµã³ã€ããªãå¯èœæ§ããããä»è
ã競äºè£œåãéçºæ®µéã®è£œååè£ãæè¡ãåæ¥åããã®ãå®è³ªçã«é²ãããšãã§ããªããããããŸãããããã«ãç¹èš±åºé¡ã§äž»åŒµãããã«ãã¬ããžã¯ãç¹èš±ãçºè¡ãããåã«å€§å¹
ã«æžå°ããå¯èœæ§ããããçºè¡åŸã«ãã®ç¯å²ãå解éãããããšããããŸãã
ããšãããŒãããŒããã®ããŒã±ã¿ãŒãã©ã€ã»ã³ã¹ãŸãã¯ææããç¹èš±åºé¡ãç¹èš±ãšããŠèªå¯ãããŠããããã圌ãã«ãšã£ãŠæå³ã®ããä¿è·ãæäŸãããã競åä»ç€Ÿããã®ä»ã®ç¬¬äžè
ã競äºããã®ãé²ãã ãããããã¯ãã®ä»ã®ç«¶äºäžã®åªäœæ§ãæäŸããããã圢ã§èªå¯ããããšã¯éããŸããã競åä»ç€Ÿããã®ä»ã®ç¬¬äžè
ã¯ã䟵害ããããšãªãåæ§ãŸãã¯ä»£æ¿ã®è£œåãéçºããããšã«ãã£ãŠãããŒãããŒããã®ããŒã±ã¿ãŒã®ç¹èš±ãåé¿ã§ããå¯èœæ§ããããŸããç¹èš±ã®çºè¡ã¯ãã®çºæè
ãç¯å²ãæå¹æ§ããŸãã¯å·è¡å¯èœæ§ã«é¢ããŠæ±ºå®çãªãã®ã§ã¯ãªããã¢ã¡ãªã«åœå
å€ã®è£å€æãç¹èš±ãªãã£ã¹ã§ç°è°ãå±ããããå¯èœæ§ããããŸãããã®ãããªç°è°ç³ãç«ãŠã¯ç¬å æš©ã®åªå€±ãæããããç¹èš±è«æ±ãå¶éãããããç¡å¹åãããããå·è¡äžå¯èœãšããããããå Žåããããããã«ããããŒãããŒããã®ããŒã±ã¿ãŒãä»è
ã«é¡äŒŒãŸãã¯åäžã®ãã¯ãããžãŒã補åã䜿çšãŸãã¯åæ¥åããã®ãé²ãèœåãå¶éããããã圌ãã®è£œåãéçºæ®µéã®è£œååè£ãããã³ãã¯ãããžãŒã®ç¹èš±ä¿è·ã®æéãå¶éãããå¯èœæ§ããããŸãã
åœç€Ÿã®ãã€ã€ãªãã£ãçã¿åºã補åã«å¯Ÿããç¹èš±ä¿è·ã®ç¯å²ãæéã®æ倱ãŸãã¯æžå°ããŸãã¯ãã®ãããªè£œåãä¿è·ããç¹èš±ãæåè£ã«èšŽè¿œãç¶æã匷åãŸãã¯é²åŸ¡ã§ããªãããšã¯ããã®è£œåã®è²©å£²éã®æžå°ãšåœç€Ÿã«æ¯æãããé¢é£ãã€ã€ãªãã£ã®æžå°ãããããå¯èœæ§ããããŸãããã®ãããªåºæ¥äºã¯ãæ¯æãè
ãåœç€Ÿã«ãã€ã€ãªãã£ãæ¯æãèœåã«æªåœ±é¿ãåãŒããããŸãã¯åœç€Ÿã®ãã€ã€ãªãã£ã®äŸ¡å€ãæžå°ãããå¯èœæ§ãããããã®çµæãåœç€Ÿã®ããžãã¹ã財åç¶æ
ããŸãã¯éå¶çµæã«æªåœ±é¿ãäžããå¯èœæ§ããããŸããåœç€Ÿã®ããŒãããŒãšã®å¥çŽäžã®åã決ããèš±å¯ããå Žåã第äžè
ã«ãã£ãŠæèµ·ãããç¹èš±èšŽèšã«åå ããããšãã§ããããããã¯ããªãã®èšŽèšè²»çšã䌎ããçµå¶é£ã®æ³šæãåœç€Ÿã®ã³ã¢ããžãã¹ããéžããåå ãšãªãå¯èœæ§ãããããã®ãããªèšŽèšãæåããä¿èšŒã¯ãããŸããã
補åã«é¢é£ãã第äžè
ã®ç¹èš±ã®ååšã¯ãããŒã±ã¿ãŒã«è¿œå ã®ã³ã¹ãããããããç§ãã¡ã«æ¯æããããã€ã€ãªãã£ã®é¡ãæžå°ãããå¯èœæ§ããããŸãã
補åã®åæ¥çæåã¯ãéšåçã«ä»è
ã®ç¥ç財ç£æš©ãå°ææè¡ã®äŸµå®³ãäžæ£äœ¿çšããŸãã¯ãã®ä»ã®éåãé¿ããããšã«äŸåããŠããŸãã補åã補é ããåžè²©ããããã«å¿
èŠãŸãã¯æçšãªäž»é¡ãè«æ±ãã第äžè
ã®ç¹èš±ãç¹èš±ç³è«ãä»åŸååšãããçºè¡ãããå¯èœæ§ããããŸãããã®ãããªç¬¬äžè
ã®ç¹èš±ãç¹èš±ç³è«ã«ã¯ã補åã®çµæã補é ãäœçšæ©åºããŸãã¯ãã®ä»ã®ç¬èªã®ç¹åŸŽã«é¢é£ããè«æ±ãå«ãŸããŠããå ŽåããããŸãããã®ãããªäŸµå®³ãååšããå ŽåãããŒã±ã¿ãŒã«å¯ŸããŠãã®äž»é¡ã«é¢ããã©ã€ã»ã³ã¹ãå©çšå¯èœã§ãããšããä¿èšŒã¯ãããŸããããããæäŸãããå Žåã§ããåççãŸãã¯åæ¥çã«å®è¡å¯èœãªæ¡ä»¶ã§æäŸãããä¿èšŒããããŸããããã®ãããªã©ã€ã»ã³ã¹ããªãå Žåã第äžè
ããã®ç¹èš±ããã®ä»ã®ç¥ç財ç£æš©ã«åºã¥ããŠãã®è£œåã®ããŒã±ã¿ãŒã«å¯ŸããŠäŸµå®³ããã®ä»ã®ç¥ç財ç£æš©ã®äž»åŒµãè¡ãå¯èœæ§ããããŸãã
ããšãããŒã±ã¿ãŒãã©ã€ã»ã³ã¹ãååŸã§ãããšããŠããããã¯éç¬å çãªãã®ã§ããã競åä»ç€Ÿããã®ä»ã®ç¬¬äžè
ã«ãåãæè¡ãžã®ã¢ã¯ã»ã¹ãäžããå¯èœæ§ããããŸããå ããŠããã€ã€ãªãã£ãçã¿åºã補åã®ããŒã±ã¿ãŒã第äžè
ããã©ã€ã»ã³ã¹ãååŸããå¿
èŠãããå ŽåãããŒã±ã¿ãŒã¯ãå Žåã«ãã£ãŠã¯ããã®ç¬¬äžè
ãžã®ã©ã€ã»ã³ã¹ããã³ãã€ã€ãªãã£ã®æ¯æãããããŒãããŒã«å¯ŸããŠæ¯æãããã¹ããã€ã€ãªãã£ããçžæ®ºããæš©å©ãæã€ããšããããŸããããã«ãããæçµçã«ã¯ãã€ã€ãªãã£ã®å©çã®äŸ¡å€ãæžå°ããå¯èœæ§ããããŸãã䟵害ããã®ä»ã®ç¥ç財ç£é¢é£ã®æç¶ãã§ã®äžå©ãªçµæã¯ãããŒã±ã¿ãŒã第äžè
ã«å¯Ÿããé倧ãªè²¬ä»»ã«ãããå¯èœæ§ããããäºãããŠããæš©å©ã第äžè
ããã©ã€ã»ã³ã¹ãååŸããªããã°ãªããªãã£ãããããŒã±ã¿ãŒã圱é¿ãåãã補åã®è£œé ãããŒã±ãã£ã³ã°ãããã³æµéãäžæ¢ãŸãã¯å€æŽããªããã°ãªããªãå Žåãããããããã¯ãããã圱é¿ãåãã補åã«ãã£ãŠçã¿åºããããã£ãã·ã¥ãããŒããç§ãã¡ã«æ¯æãããã¹ããã€ã€ãªãã£ãæžå°ãããå¯èœæ§ãããããããã£ãŠç§ãã¡ã®ããžãã¹ã財åç¶æ
ããŸãã¯å¶æ¥æ瞟ã«æªåœ±é¿ãåãŒãããšã«ãªããŸãã
補åã®ããŒã±ã¿ãŒã®å¶æ¥ç§å¯ã®é瀺ã¯ãåœç€Ÿã®ãã€ãªå»è¬åè³ç£ã®åºç€ãšãªã補åã®ç«¶äºåã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
åœç€Ÿã®ãã€ã€ãªãã£ãçã¿åºã補åã®ããŒã±ãã£ã³ã°é¢ä¿è
ã¯ãç¹èš±ã«ãã£ãŠä¿è·ãããŠããªãååŒç§å¯ãããŠããŠããã¯ãããžãŒã«éšåçã«äŸåããŠãããããã«ãã補åã®ç«¶äºåãç¶æããŠããŸãããããã®æ
å ±ã¯ãéåžžãååããŒãããŒãã©ã€ã»ã³ãµãŒãåŸæ¥å¡ãã³ã³ãµã«ã¿ã³ããªã©ã®æ
å ±ã«ã¢ã¯ã»ã¹ã§ããé¢ä¿è
ãšã®æ©å¯ä¿æå¥çŽãéããŠä¿è·ãããŠããŸãããããã®é¢ä¿è
ã®ãããããå¥çŽã«éåããŠæ©å¯æ
å ±ãé瀺ãããã競åä»ç€Ÿãç¬èªã«æ
å ±ãéçºãããåŠãã ãããå Žåã補åã®ç«¶äºåã«æªåœ±é¿ãåãŒãããã®çµæãåœç€Ÿã®ãã€ã€ãªãã£ããçãããã£ãã·ã¥ãããŒãæžå°ããå¯èœæ§ããããŸãã
å®æçãªé
åœãæ ªäž»ã«æ¯æã£ãããã·ã§ã¢ãè²·ãæ»ãããããèœåã¯ãã€ã®ãªã¹æ³ã®é©çšèŠå®ãå¥çŽäžã®å¶éããã³çŸ©åã«ãã£ãŠå¶éãããå¯èœæ§ããããŸãã
ã€ã®ãªã¹æ³ã®äžã§ã¯ãé
åœã宣èšããããåé
ãè¡ã£ãããæ ªåŒãè²·ãæ»ãããšã¯ïŒãã®ç®çã®ããã«æ°ãã«çºè¡ããæ ªåŒã®åç以å€ã§ã¯ïŒåé
å¯èœãªå©çããã®ã¿å¯èœã§ããåé
å¯èœãªå©çãšã¯ã以åã«åé
ãŸãã¯è³æ¬åã§å©çšãããŠããªãç¯å²ã§ã®èç©ãããå®çŸå©çãããæ£åŒã«è¡ãããè³æ¬ã®æžå°ãŸãã¯åç·šæã§ä»¥åã«æ¹æ¶ãããŠããªãç¯å²ã§ã®èç©ãããå®çŸæ倱ãå·®ãåŒãããã®ã§ããç§ãã¡ã®åé
å¯èœãªæºåéã®é¡ã¯çŽ¯ç©çãªèšç®ã§ããåäžã®è²¡æ¿å¹ŽåºŠã§å©çãäžããŠããèç©ãããå®çŸå©çãéå»ã®å
šãŠã®å¹ŽåºŠã®èç©ãããå®çŸæ倱ãçžæ®ºããªãéããé
åœãæ¯æã£ããæ ªåŒãè²·ãæ»ãããããããšã¯ã§ããŸããããŸããç§ãã¡ã¯çŽè³ç£ãç·åŒã³åºãæ ªåŒè³æ¬ãšåé
ã§ããªãæºåéã®åèšé¡ä»¥äžã§ãªãéãåé
ãè¡ãããšã¯ã§ãããåé
ããããã®è³ç£ã®é¡ããã®åèšé¡ä»¥äžã«æžå°ãããªãå Žåã«éããåé
ãè¡ãããšãã§ããŸãã
åœç€Ÿã®åµåãŸãã¯ãã®ä»ã®å¥çŽäžã®çŸ©åã®æ¡ä»¶ã«åŸããäžéé
åœã®æ¿èªããã³æ¯æãã¯åç· åœ¹äŒã®åç¬è£éã«å§ããããŠãããåç· åœ¹äŒã¯ãã€ã§ãé
åœæ¿çãå€æŽããããšãã§ããŸãããŸããæçµé
åœã®æ¯æãã¯ãåœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒããã³ã¯ã©ã¹Bæ®éæ ªåŒã®ä¿æè
ã«ããéåæ°ã®æ¿èªã«åŸãå¿
èŠããããåå Žåã«ãããŠè±æ³ã«åºã¥ããŠãã®ç®çã®ããã«å©çšå¯èœãªå©çããæ¯æãããŸããåœç€Ÿã®äŒåã¯ãå©çããã®ç®çã®ããã«å©çšå¯èœã§ãããšèªããããéããæ ªäž»ã®æ¿èªãªãã«åç· åœ¹äŒãäžéé
åœãæ¿èªããããšãèªããŠããŸããåç· åœ¹äŒã¯ãŸããæ ªäž»ç·äŒã§ã®æçµé
åœã®æ¿èªãšå®£èšãæšå¥šããããšãã§ããŸãããã®ãããªé
åœã¯ãåç· åœ¹äŒãæšå¥šããéé¡ãè¶
ããããšã¯ã§ããŸããã
ååæãŸãã¯ãã®ä»ã®é
åœãæ¯æããããããŸãã¯ã·ã§ã¢ã®è²·ãæ»ããè¡ããããã«ã€ããŠãä¿èšŒã¯ãããŸãããæ ªäž»ã«é
åœãæ¯æãããã·ã§ã¢ã®è²·ãæ»ããè¡ããã¯ãäžè¬çãªçµæžããã³ããžãã¹ã®ç¶æ³ãæŠç¥èšç»ãèŠéããããžãã¹ãè²·åã®æ©äŒã財åç¶æ³ãŸãã¯éå¶çµæãé転è³æ¬ã®èŠä»¶ãšäºæ³ãããçŸéå¿
èŠéãå¥çŽäžã®å¶çŽããã³çŸ©åãçŸåšããã³å°æ¥ã®è³æ¬ã®ã³ãããã¡ã³ãã®å±¥è¡ãæ³çãçšåããã³èŠå¶äžã®å¶çŽãæ ªäž»ãžã®é
åœæ¯æãã«é¢ãããã®ä»ã®å¶çŽã圱é¿ããŸãã¯ã·ã§ã¢ã®è²·ãæ»ããè¡ãããšã«ã€ããŠãåç· åœ¹äŒãé¢é£ããããšèŠãªããã®ä»ã®èŠå ãå«ããããã€ãã®èŠå ã«ãã£ãŠç°ãªããŸãã
äžæ£ãªé
åãè¡ãããããšãç¥ã£ãŠãããããŸãã¯åççãªçç±ãããæ ªäž»ã¯ããã®é
åïŒãŸãã¯ãã®äžéšïŒãç§ãã¡ã«è¿éãã矩åããããŸãã
ããç§ãã¡ã1940幎ã®ã¢ã¡ãªã«æè³äŒç€Ÿæ³ã®äžã§æè³äŒç€ŸãšèŠãªãããããšã決å®ãããå Žåãé©çšãããå¶éã«ãããç§ãã¡ãèããŠããããžãã¹ãç¶ããããšãéçŸå®çã«ãªãå¯èœæ§ããããç§ãã¡ã®ããžãã¹ã財åç¶æ
ããŸãã¯æ¥çžŸã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
ããžãã¹ãè¡ãã«ããããç±³åœã®æè³äŒç€Ÿæ³ã®äžã§æè³äŒç€ŸãšããŠèŠå¶ãããªãããã«ããã€ããã§ããäžè¬çã«ãé©çšå¯èœãªå
é€ããªãå Žåãæ³äººã¯ãç±³åœã®æè³äŒç€Ÿæ³ã®ç®çã§ã(i) äž»ã«èšŒåžã®æè³ãåæè³ãååŒãè¡ã£ãŠããããŸãã¯ãã®ãããªæŽ»åãè¡ãããšãææ¡ããŠãããšèªãã瀺ãå ŽåããŸã㯠(ii) èªç€Ÿã®ç·è³ç£ã®40%以äžã®äŸ¡å€ãæã€æè³èšŒåžãææããŸãã¯ååŸããããšãææ¡ããŠããå Žåãæè³äŒç€Ÿã§ãããšå€æãããŸãïŒç±³åœæ¿åºèšŒåžããã³çŸéé
ç®ã¯é€å€ïŒããããICA 40%ãã¹ããšåŒã³ãŸãã
åœç€Ÿã¯ãäž»ã«èšŒåžã®æè³ãåæè³ããŸãã¯ååŒã«åŸäºããŠãããšèªèãããäž»ã«ãã®ãããªããžãã¹ã«åŸäºããããšãææ¡ããŠããããã§ã¯ãããŸãããåœç€Ÿã¯ãç±³åœæè³äŒç€Ÿæ³ã«åºã¥ãã1ã€ä»¥äžã®åäŒç€ŸãéããŠãç¹å®ã®åµåã®è³Œå
¥ãŸãã¯ååŸã«äž»ã«åŸäºããŠãããšèããŠããŸãããããã®åäŒç€Ÿã¯ãç±³åœæè³äŒç€Ÿæ³ã®ã»ã¯ã·ã§ã³3(c)(5)(A)ã«åºã¥ãããã®è³ç£ã®å°ãªããšã55%ããååãä¿éºããµãŒãã¹ã®è²©å£²äŸ¡æ Œã®äžéšãŸãã¯å
šäœãè¡šãæ圢ããã©ãããåå
¥ã売æéããã³ãã®ä»ã®åµåãã«æè³ããããšãæ±ããããŠããŸãããããã®è³ç£ã¯ICAäŸå€é©æ Œè³ç£ãšåŒã°ããŠããŸãã
2010幎8æ13æ¥ä»ã®ç¡è¡åæžç°¡ã«ãããŠãåœç€Ÿã®åä»»è
ã«å¯ŸããŠãSECè·å¡ã¯ãç¹å®ã®ã©ã€ã»ã³ã¹å¥çŽã«åºã¥ãç¥ç財ç£ã䜿çšããç¹å®ã®ãã€ãªå»è¬åè³ç£ã®è²©å£²äŸ¡æ Œã«çŽæ¥åºã¥ããã€ã€ã«ãã£ååæš©ãåéããæš©å©ãçºè¡è
ã«äžãããã€ã€ã«ãã£å©çããã»ã¯ã·ã§ã³3(c)(5)(A)ã«ãããICAäŸå€é©æ Œè³ç£ã§ãããšãã解éãçºè¡šããŸããããã®ç¡è¡åæžç°¡ã«åºã¥ããä¿æããŠãããã€ãªå»è¬åè³ç£ã«é¢é£ãããã€ã€ã«ãã£ååæš©ã¯ãã»ã¯ã·ã§ã³3(c)(5)(A)ããã³ã»ã¯ã·ã§ã³3(c)(6)ã«ãããICAäŸå€é©æ Œè³ç£ã§ãããšããç«å ŽãåããŸãã
æè³äŒç€ŸãšããŠç»é²ãã矩åããªãããšã確èªããããã«ãICA 40%ãã¹ãã§æäŸãããŠããéŸå€ãè¶
ããŠã¯ãªããŸãããICA 40%ãã¹ãã®ç®çã«ãããŠãæè³èšŒåžãšããçšèªã«ã¯ãç±³åœæ¿åºèšŒåžããæè³äŒç€Ÿã§ã¯ãªããç±³åœæè³äŒç€Ÿæ³ã®ã»ã¯ã·ã§ã³3(c)(1)ãã»ã¯ã·ã§ã³3(c)(7)ã«äŸåããŠããªã倧å€æ°ã®åäŒç€Ÿãçºè¡ãã蚌åžã¯å«ãŸããŸãããäŸãã°ãã»ã¯ã·ã§ã³3(c)(5)(A)ã«äŸåããŠãã倧å€æ°ã®åäŒç€Ÿãªã©ã§ãããŸããç§ãã¡ã¯ãSECã¹ã¿ããã®è§£èª¬ã³ã¡ã³ãã«åºã¥ããã»ã¯ã·ã§ã³3(c)(6)ã«ãäŸåã§ããããã«ããã°ãç§ãã¡ã¯çŽæ¥ãŸãã¯å€§å€æ°ã®åäŒç€ŸãéããŠãè³ç£ã®å°ãªããšã55%ããããã§é¢é£ããããã«ãã»ã¯ã·ã§ã³3(c)(5)(A)ã«äŸåããããžãã¹ã«æè³ããå¿
èŠããããŸãããããã£ãŠãç§ãã¡ãšç§ãã¡ã®åäŒç€Ÿãä¿æãååŸããè³ç£ã¯ãç±³åœæè³äŒç€Ÿæ³ããã³ããã«åºã¥ããŠçå®ãããèŠåãšèŠå¶ã®èŠå®ã«ãã£ãŠå¶éãããŠããŸãã
ããå°æ¥SECãŸãã¯ãã®ã¹ã¿ããããåä»»è
ã«å¯ŸããŠæäŸãããç¡æªçœ®æžã®è§£éãšã¯å察ã®è§£éãæ¡çšãããããŸãã¯ç¡æªçœ®æžã®çµè«ãå¶éãããã€ã€ãªãã£ã€ã³ã¿ã¬ã¹ããã»ã¯ã·ã§ã³3(c)(5)(A)ããã³ã»ã¯ã·ã§ã³3(c)(6)ã®ç®çã§ICAäŸå€é©æ Œè³ç£ãšããŠæ±ãããªããªã£ãå ŽåããŸãã¯SECãŸãã¯ãã®ã¹ã¿ãããå°æ¥ãç¡æªçœ®æžããã€ãªå»è¬åè³ç£ã«é¢é£ãããã€ã€ãªãã£ååã«å¯ŸããŠäžéšãŸãã¯ãã¹ãŠã®ã¿ã€ãã«é©çšãããªããšå€æããå Žåãåœç€Ÿã®ããžãã¹ã¯é倧ãã€æªåœ±é¿ãåããããšã«ãªããŸããç¹ã«ãåœç€Ÿã¯ç±³åœãŸãã¯ãã®å·ã®æ³åŸã«åºã¥ããŠèšç«ãããæ³äººã«è»¢æãããïŒããã«ããç±³åœã®é£éŠæ³äººæåŸçšã®å¯Ÿè±¡ãšãªãå¯èœæ§ããããŸãïŒããŸãã¯æè³äŒç€ŸãšããŠã®ç»é²ãSECããèš±å¯ããããŸã§ãç±³åœã§ã®ãã¹ãŠã®ããžãã¹æŽ»åãåæ¢ããªããã°ãªããªããªããŸãããã®ãããªç³è«ãæ¿èªãããå¯èœæ§ã¯äœããä»®ã«æ¿èªããããšããŠããæè³äŒç€Ÿæ³ã«èª²ããããèŠä»¶ïŒè³æ¬æ§é ã«å¯Ÿããå¶éãé¢é£äŒç€Ÿãšã®ååŒèœåãäž»èŠãªåŸæ¥å¡ãžã®å ±é
¬ã®æ¯æãèœåãªã©ïŒã¯ãåœç€ŸãçŸç¶ã®ãŸãŸããžãã¹ãç¶ç¶ããããšãéçŸå®çã«ããå¯èœæ§ããããŸããæè³äŒç€ŸãšããŠã®ç»é²å
é€ã®è³æ Œã倱ãããšã¯ãåœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªã®äŸ¡å€ããã¯ã©ã¹Aæ®éæ ªã«å¯Ÿããé
åœã®æ¯æãèœåã«é倧ãã€æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ãããŒãžã£ãŒã®é¢é£äŒç€Ÿã«æ¯æãããæ ªåŒããã©ãŒãã³ã¹è³ã¯ãç§ãã¡ã®æ ªäž»ã®å©çãšå®å
šã«ã¯äžèŽããªãã€ã³ã»ã³ãã£ããçãå¯èœæ§ããããŸãã
ç¹å®ã®æ¡ä»¶ã«åŸããåäŒèšååæã®çµäºæã«ããããŒãžã£ãŒã®é¢é£äŒç€Ÿã¯ãåœè©²ããŒããã©ãªãªã«å¯ŸããŠRPããŒã«ãã£ã³ã°ã¹ããã®æ ªåŒã®åœ¢ã§é
åãåããæš©å©ãæããåœè©²ããŒããã©ãªãªã®ãããçµæžå©çïŒåœè©²ããŒããã©ãªãªã«ããããã¹ãŠã®æ°èŠããŒããã©ãªãªæè³ã®åèšçŸéåå
¥ãããåœè©²ããŒããã©ãªãªã«é¢ããç·è²»çšïŒå©æ¯è²»çšãéå¶è²»çšããã³ååŸè²»çšã®ååãå«ãïŒãå·®ãåŒãããã®ïŒã«åºã¥ããŠ20%ã«çžåœãããã®ãšããŸãïŒããšã¯ã€ãã£ããã©ãŒãã³ã¹ã¢ã¯ãŒããïŒããšã¯ã€ãã£ããã©ãŒãã³ã¹ã¢ã¯ãŒãã®æš©å©ãããããŒãžã£ãŒã«ãªã¹ã¯ã®é«ããããã¯ããææ©çãªè³ç£ååŸãè¡ãã€ã³ã»ã³ãã£ããäžããå¯èœæ§ããããŸããããã«ããããŒãžã£ãŒã¯ãæã
ãããå€ãã®è² åµãè² æ
ããããè¿œå ã®è³ç£ååŸãèè³ãããããŸãã¯è³ç£ååŸã«é¢é£ããŠããå€ãã®ã¬ãã¬ããžãå©çšããåå ãåŒãèµ·ããå¯èœæ§ããããŸããäžè¬çã«ãã¬ãã¬ããžã®äœ¿çšã¯æè³ã®åççãäžããå¯èœæ§ããããããæã
ã®å©çãå¢å ãããããšãã§ããŸããç¹å®ã®ç¶æ³äžã§ã¯ãåå
¥éã®äœ¿çšã¯æã
ã®ããžãã¹ã«ãšã£ãŠããé«ããªã¹ã¯ããããããããããã©ã«ãã®å¯èœæ§ãé«ãããããããšãããããããæ ªäž»ã«ãšã£ãŠäžå©çãããããããšã«ãªããŸããããã«ãæã
ã®å©çãšåç· åœ¹äŒã®é
åœæ¯æã矩åãšã®éã«ã¯çžé¢é¢ä¿ããããŸããããããã£ãŠãæ ªäž»ã¯éãããé
åœããåãåããªããããŸãã¯å
šãåãåããªãå¯èœæ§ããããäžæ¹ã§ãããŒãžã£ãŒã®é¢é£äŒç€Ÿã¯æã
ã®ãããçµæžå©çã«åºã¥ããŠãšã¯ã€ãã£ããã©ãŒãã³ã¹ã¢ã¯ãŒããåãåãæš©å©ãæããŸãããŸããããŒããã©ãªãªããšã«æ¯æããããšã¯ã€ãã£ããã©ãŒãã³ã¹ã¢ã¯ãŒãã¯ãé¢é£äŒç€Ÿãåå¥ã®æè³ã«å¯ŸããŠãšã¯ã€ãã£ããã©ãŒãã³ã¹ã¢ã¯ãŒããåãåãããšãå±éºã«ãªãã®ãé²ãããïŒããŒããã©ãªãªã¯é£ç¶ãã2幎éã®æè³ã§æ§æãããïŒãæã
ã®å
šäœçãªæè³ããŒããã©ãªãªã®ããã©ãŒãã³ã¹ãè¯å¥œã§ãªããŠãããšã¯ã€ãã£ããã©ãŒãã³ã¹ã¢ã¯ãŒãããããŒãžã£ãŒã®é¢é£äŒç€Ÿã«æ¯æãããå¯èœæ§ããããŸãã
åœç€Ÿã®åç· åœ¹äŒã¯ãæ ªäž»ã«å¯ŸããŠé
åœãæ¯æãããªãããŸãã¯åœç€Ÿã®æ®éæ ªåŒã®å賌å
¥ãè¡ãããªãçµæã«ãªãå¯èœæ§ã®ãããåœç€Ÿã®æ¥åããçããçŸéã«é¢ãã決å®ãè¡ãå ŽåããããŸãã
åœç€Ÿã®åç· åœ¹äŒã¯é
åœãæ¯æã矩åãåé
ãè¡ã矩åããŸãã¯æ®éæ ªåŒã®å賌å
¥ãè¡ã矩åã¯ãªããé
åœãåé
ããŸãã¯æ®éæ ªåŒã®å賌å
¥ã®ä»£ããã«è³ç£ã®ååŸãéå¶ã®è³éãšããŠçŸéã䜿çšããããšã決å®ããå ŽåããããŸããåç· åœ¹äŒãé
åœãæ¯æããªãå Žåãæ®éæ ªåŒãå賌å
¥ããªãå Žåã§ããåœç€Ÿã®çŽçµæžå©çã«åºã¥ããŠãããŒãžã£ãŒã®é¢é£äŒç€Ÿã«ãšã¯ã€ãã£ããã©ãŒãã³ã¹ã¢ã¯ãŒããæ¯æããŸããåç· åœ¹äŒã®çŸéã«é¢ãã決å®ã«ãããæ ªäž»ã«å¯Ÿããé
åœããªãå Žåãæ®éæ ªåŒãå賌å
¥ãããªãå ŽåããããŸããããã«ãé
åœãæ®éæ ªåŒã®å賌å
¥ã«é¢ããåç· åœ¹äŒã®æ±ºå®ã¯ãåœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒã®åžå ŽäŸ¡æ Œã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸããããžãã£ããªåå
¥ãçã¿åºããŠããé
åœãéãããŠãããæ¯æãããªãå Žåãã¯ã©ã¹Aæ®éæ ªåŒã®ä¿æè
ã¯ãã¯ã©ã¹Aæ®éæ ªåŒã«é¢ããŠç±³åœé£éŠæåŸçšç®çã§ç¹å®ã®éžæãè¡ã£ãŠããå Žåãåãåã£ãå®éã®çŸéé
åœãè¶
ããåœç€Ÿã®åå
¥ã«å¯ŸããŠçšè² æ
ãè² ãå¯èœæ§ããããŸããåç· åœ¹äŒãé
åœãæ®éæ ªåŒã®å賌å
¥ãå¶éããããšã決å®ããå Žåãã¯ã©ã¹Aæ®éæ ªåŒã®ä¿æè
ã«ãšã£ãŠã®äž»ãªææžæ段ã¯ãçŸè¡ã®åžå ŽäŸ¡æ Œã§æ ªåŒã売åŽããããšã«ãªããæ倱ãåºãããšããããããã¯é
åœãæ®éæ ªåŒã®å賌å
¥ã®äžå©ãŸãã¯äžè²«æ§ã®ãªãããã«äœããªãå¯èœæ§ããããŸãã
ç²åŸãããã€ã€ãªãã£ã¯ãã€ãªè£œè¬æ¥çš®ã®ç¯å²å€ã«å
¥ãå¯èœæ§ãããããã®ãããªè³ç£ãããã«äŒŽããã£ãã·ã¥ãããŒã¯ãçŸåšã®ããŒããã©ãªãªã®è³ç£ãšã¯äŒŒãŠããªãå¯èœæ§ããããŸãã
ååŸããè³ç£ã®çš®é¡ã«ã€ããŠã¯ãè£éããããŸãããããŒãžã£ãŒãäž»ã«ãã€ãªå»è¬åæ¥çš®ã«è©²åœããè³ç£ãååŸãããšäºæ³ããŠããŸãããå¿
ãããããããå¿
èŠã¯ãªãããã€ãªå»è¬åæ¥çš®ã«é¢é£ãããããŸãã¯ãã以å€ã®ãã®ä»ã®çš®é¡ã®è³ç£ãååŸããããšããããŸãããã®çµæãå°æ¥ã®è³ç£ååŸããã®è³ç£ããã®ãã£ãã·ã¥ãããŒã¯ãçŸåšã®ããŒããã©ãªãªå
ã®è³ç£ãšã¯ç°ãªãå ŽåããããŸããç§ãã¡ããããŒãžã£ãŒã¯ããã€ãªå»è¬åæ¥çš®ã«é¢é£ãããããã以å€ã®è³ç£ãååŸããçµéšãéãããŠãããããããŸãããå°æ¥ååŸãããè³ç£ããçŸåšã®ããŒããã©ãªãªå
ã®è³ç£ããæåŸ
ããããªã¿ãŒã³ãšé¡äŒŒãããªã¿ãŒã³ãæã€ããšããå
šãå©çãäžããä¿èšŒã¯ãããŸããã
ãããŒãžã£ãŒã¯ãç§ãã¡ã®ããžãã¹ã財åçš®é¡ããŸãã¯æ¥åçµæã«æªåœ±é¿ãåãŒãå¯èœæ§ã®ããéå¶ã®æ··ä¹±ãåŒãèµ·ãããããªæ¯é
æš©ã®å€æŽã®å¯Ÿè±¡ãšãªãå¯èœæ§ããããŸãã
ãããŒãžã£ãŒã®ç®¡çæš©ãå€æŽãããå¯èœæ§ãããããã®å Žåãæ°ãã管çå
ã¯ç°ãªãå²åŠãæã£ãŠããå¯èœæ§ããããçµéšã®æµ
ãã¢ããã€ã¶ãªãŒå°é家ãéçšãããããã€ã€ãªãã£ååŸã®æ©äŒãç¹å®ããã®ã«å€±æãããããããŒãžã£ãŒã®æåããå®çžŸã»ã©ã®æåããªãããšããããŸããåè¿°ã®äºæ
ãçºçããå Žåãç§ãã¡ã¯æ°ããè³ç£ã®ååŸã«é£ãããæããå¯èœæ§ããããæ¢åã®è³ç£ãããžãã¹ãçµæžç¶æ
ããŸãã¯å¶æ¥æ瞟ã®äŸ¡å€ã倧ããæãªãããå¯èœæ§ããããŸãã
ãããŒãžã£ãŒã®è²¬ä»»ã¯ãããžã¡ã³ãå¥çŽã«åºã¥ããŠå¶éãããŠãããç§ãã¡ã¯ç¹å®ã®è²¬ä»»ã«ã€ããŠãããŒãžã£ãŒãè£åããããšã«åæããŠããŸãããã®çµæãç§ãã¡ã¯äžå©ãªéå¶çµæãçµéšãããããããŒãžã£ãŒã責任ãè² ããªãæ倱ã被ãå¯èœæ§ããããŸãã
ãããŒãžã£ãŒã¯ã管çå¥çŽã«åºã¥ããŠèŠæ±ããããµãŒãã¹ãæäŸããããšä»¥å€ã®è²¬ä»»ãè² ããŸããããããŒãžã£ãŒããã³ãã®é¢é£äŒç€ŸïŒRPI EPA Holdings, LPïŒãEPA HoldingsãïŒãå«ãïŒããã³ããããã®åœ¹å¡ãåç· åœ¹ãæ ªäž»ãã¡ã³ããŒãåŸæ¥å¡ã代ç人ãããŒãããŒãåã³è£åãåããæš©å©ã®ãããã®ä»ã®äººïŒãããããè£å察象è
ãïŒã¯ã管çå¥çŽã«åŸã£ãŠè¡ãããè¡çºãŸãã¯äžäœçºã«ã€ããŠãç§ãã¡ãç§ãã¡ã®åäŒç€Ÿããã®åç· åœ¹ãæ ªäž»ããŸãã¯åäŒç€Ÿã®æ ªäž»ãããŒãããŒã«å¯ŸããŠè²¬ä»»ãè² ãããè©æ¬ºãäžæ£è¡çºãæ
æã®äžæ£è¡çºãé倧ãªé倱ïŒãã¥ãŒãšãŒã¯å·æ³ã«åºã¥ã解éã®äžã§ïŒããæ¯æ£ãããªãã£ã管çå¥çŽã®é倧ãªéåããŸãã¯é©çšããã蚌åžæ³ã®éåã«ãã£ãŠçãããã®ãé€ããŸãã
ããã«ãæ³åŸãèš±ãç¯å²å
ã§ãç§ãã¡ã¯ãããããè«æ±ãè² åµãæ害ãæ倱ã眰éã蚎èšãå€æ±ºãã³ã¹ãåã³è²»çšïŒå€æ±ºã®å±¥è¡ãå解åã³ settlement ã«æ¯æã£ãéé¡ã眰éåã³ä»ã®è²»çšãããããè«æ±ãŸãã¯äž»åŒµãããè«æ±ã«å¯Ÿãã調æ»åã¯åŒè·ã®ããã®åççãªè²»çšãå«ãïŒã«å¯ŸããŠããã¹ãŠã® Indemnitee ãè£åããããšã«åæããŸãããããã«ã¯ãæ¢ç¥ãŸãã¯æªç¥ã®æ§è³ªã確å®çãŸãã¯æªç¢ºå®ããããŠããã¹ãŠã® Indemnitee ã被ãå¯èœæ§ã®ãããã®ãå«ãŸããŸããããã¯ãç§ãã¡ãŸãã¯åœç€Ÿã®åäŒç€Ÿã®ããã«è¡ããã掻åã«èµ·å ãããã®ã§ãå Indemnitee ã®è¡çºãè©æ¬ºãæªæãæ
æã®äžæ£è¡çºã倧ããªé倱ïŒãã¥ãŒãšãŒã¯å·æ³ã«åºã¥ã解éã«ãããŠïŒã解æ¶ãããŠããªã Management Agreement ã®é倧ãªéåããŸãã¯é©çšããã蚌åžæ³ã®éåãæ§æããªãå Žåã«éããŸãããã®çµæãç§ãã¡ã¯ãäžå©ãªå¶æ¥çµæãçµéšãããããããŒãžã£ãŒã責任ãè² ããªãæ倱ã被ãå¯èœæ§ããããŸãã
æ¥åäžã®ãªã¹ã¯ã¯ãããžãã¹ã劚ããããæ倱ããããããããæé·ãå¶éããå¯èœæ§ããããŸãã
ç§ãã¡ã¯ããããŒãžã£ãŒã®è²¡åãäŒèšãæ
å ±åã³ãã®ä»ã®ããŒã¿åŠçã·ã¹ãã ãšã¯ã©ãŠãã³ã³ãã¥ãŒãã£ã³ã°ãµãŒãã¹ãããã«ã¯çŸåšããã³å°æ¥ã®ååè
ãå¥çŽè
ãŸãã¯ã³ã³ãµã«ã¿ã³ãã®ãããã«å€§ããäŸåããŠããŸãããããã®ã·ã¹ãã ã¯ãã³ã³ãã¥ãŒã¿ãŠã€ã«ã¹ãããŒã¿ã®ç Žæããµã€ããŒé¢é£ã®æ»æãäžæ£ã¢ã¯ã»ã¹ãèªç¶çœå®³ããã³ãããã¯ããããæŠäºãé»æ°éä¿¡ããã³é»åã®æ
éãã被害ãåãããäžæãããããè匱æ§ããããŸãããããã®äºè±¡ã®ãããããçºçããã·ã¹ãã ãæ£åžžã«æ©èœããªããç¡å¹åãããããŸãã¯ããŒã¿ã®äžæ£é瀺ããã£ãå ŽåïŒæ¹ããããããã¯ãŒã¯ã»ãã¥ãªãã£ã·ã¹ãã ã®äŸµå®³ããµã€ããŒã»ãã¥ãªãã£ã®è匱æ§ãŸãã¯æ»æãªã©ã®çµæãšããŠïŒãç§ãã¡ã¯ substantialãªçµæžçæ倱ãã³ã¹ãã®å¢å ãããžãã¹ã®äžæãå¶æ¥ç§å¯ããã®ä»ã®å°ææ
å ±ã®åªå€±ãç§ãã¡ã«å¯Ÿãã責任ãèŠå¶åœå±ã®ä»å
¥ããŸãã¯è©å€ã®æ害ã被ãå¯èœæ§ããããŸãã
ããã«ãããŒã¿ã®ãã©ã€ãã·ãŒããã³ä¿è·ã«é¢ããé£éŠãå·ãåœéçãªæ³åŸãèŠå¶ãäŸãã°2018幎5æã«æœè¡ããã欧å·é£åã®äžè¬ããŒã¿ä¿è·èŠåã2020幎1æã«æœè¡ãããã«ãªãã©ã«ãã¢æ¶è²»è
ãã©ã€ãã·ãŒæ³ã¯ãç§ãã¡ãèŠå¶åœå±ã«ããå·è¡æªçœ®ã調æ»ã«ãããå¯èœæ§ããããæ
å ±ãã¯ãããžãŒã®ã»ãã¥ãªãã£å¯ŸçãããŒã¿ã®ãã©ã€ãã·ãŒããã³ä¿è·ã³ã³ãã©ã€ã¢ã³ã¹ã®åªåã倱æããå ŽåãèŠå¶äžã®çœ°åãé倧ãªæ³ç責任ã«ã€ãªããå¯èœæ§ããããŸããå ããŠãç§ãã¡ã¯æ
å ±ã·ã¹ãã ãšãã¯ãããžãŒã«å€§ããäŸåããããžãã¹ãéå¶ããŠããŸãããããŒãžã£ãŒã®æ
å ±ã·ã¹ãã ãšãã¯ãããžãŒã¯ãç§ãã¡ã®æé·ãæ¯ãç¶ããããšãã§ããªããããããããã®ãããªã·ã¹ãã ãç¶æããã³ã¹ããå¢å ããå¯èœæ§ããããŸãããã®æé·ãæ¯ããããªããªãããšããŸãã¯ãã®ãããªæ
å ±ã·ã¹ãã ã«é¢é£ããã³ã¹ãã®å¢å ã¯ãç§ãã¡ã®ããžãã¹ã財åç¶æ
ããŸãã¯æ¥çžŸã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ç§ãã¡ã®ããžãã¹ãæ¯ããå
Œ
±ã€ã³ãã©ã«ãããçœå®³ãŸãã¯æ··ä¹±ãç¹ã«ç§ãã¡ãååŒå
ã䜿çšããé»åéä¿¡ããã®ä»ã®ãµãŒãã¹ã«é¢ããæ··ä¹±ã¯ãç§ãã¡ã®ããžãã¹ãäžæããããšãªãç¶ç¶ããèœåã«æªåœ±é¿ãäžããå¯èœæ§ããããŸããç§ãã¡ããããŒãžã£ãŒã®çœå®³åŸ©æ§ããã°ã©ã ã¯ããã®ãããªçœå®³ãæ··ä¹±ããçããæ害ã軜æžããã«ã¯ååã§ãªããããããŸãããããã«ãä¿éºããã®ä»ã®ä¿è·æ段ã¯ãç§ãã¡ã®æ倱ãå®å
šã«è£åããã®ã§ã¯ãªããéšåçã«ããè£åããªãå¯èœæ§ããããŸãã
ããã«ãæé·ãç¶æããããã«ã¯ãç§ãã¡ããããŒãžã£ãŒãæ°ããå°é家ãããŒã ã«å ããããã«ãè¿œå ã®ç®¡çãéå¶ã財æ¿è³æºãæå
¥ããé©åãªéå¶ããã³è²¡æ¿ã·ã¹ãã ãç¶æããŠæ¡åŒµãååã«ãµããŒãããå¿
èŠããããããããŸãããåªããå°é家ãéçšããããã®åžå Žã¯ç«¶äºãæ¿ãããããåžæããããŒã¹ã§æé·ã§ããªãå¯èœæ§ããããŸãã
ç§ãã¡ã¯ãè±åœã®èŽåè³é²æ¢æ³ãç±³åœã®æµ·å€è
æè¡çºé²æ¢æ³ãããã³ãã®ä»ã®è
æé²æ¢æ³ãããã«èŒžåºç®¡çæ³ã茞å
¥ããã³é¢çšæ³ãååŒããã³çµæžå¶è£æ³ããªãã³ã«ç§ãã¡ã®æ¥åãèŠå¶ãããã®ä»ã®æ³åŸã®é©çšãåããŸãã
åœç€Ÿã®éå¶ã¯ã2010幎ã®è±åœèŽè³æ³ïŒãèŽè³æ³ãïŒã1977幎ã®ç±³åœå€åœè
æè¡çºé²æ¢æ³ïŒæ¹èšçïŒãFCPAãã18 U.S.C. §201 ã«å«ãŸããç±³åœåœå
èŽè³æ³ãç±³åœæ
è¡æ³ããã®ä»ã®ããžãã¹ãè¡ãåœã§é©çšãããåè
ææ³ãå«ãåè
ææ³ã®å¯Ÿè±¡ã§ããèŽè³æ³ãFCPAããã³ãããã®ä»ã®æ³åŸã¯ãäžè¬çã«ãåœç€Ÿããã³åŸæ¥å¡ã仲ä»è
ããæ£åœã§ã¯ãªããŸãã¯çŠæ¢ãããŠããæ¯æãããŸãã¯ãã®ä»ã®äŸ¡å€ã®ãããã®ããæ¿åºåœå±è
ãä»ã®äººã«å¯ŸããŠãããžãã¹ãååŸãŸãã¯ä¿æããããããããã¯ãã®ä»ã®ããžãã¹äžã®å©çãåŸãããã«ãçŽæ¥çãŸãã¯éæ¥çã«èªå¯ãçŽæãæäŸããŸãã¯æäŸããããšãçŠæ¢ããŠããŸããèŽè³æ³ã®äžã§ã¯ãåœç€Ÿã¯ãåœç€Ÿã«é¢é£ããè
ãèŽè³çœªãç¯ãã®ãé²ãããšãã§ããªãã£ãå Žåã«è²¬ä»»ãè² ãå¯èœæ§ããããŸããç§ãã¡ããã³ãã€ã€ã«ãã£ãçã¿åºã補åã®ããŒã±ãã£ã³ã°æ
åœè
ã¯ãèŽè³æ³ãFCPAã®éåã®é«ããªã¹ã¯ãæã€ããã€ãã®ç®¡èœå°åã§æŽ»åããŠãããåœç€Ÿã¯ãèŽè³æ³ãFCPAããŸãã¯çŸå°ã®åè
ææ³ã®ããšã§è²¬ä»»ãè² ãå¯èœæ§ããããæ±è·ãŸãã¯éæ³è¡çºãè¡ã第äžè
ãšã®åæ¥ãé¢ä¿ã«åå ããŠããŸããããšãåœç€Ÿããã®ãããªæŽ»åãæ瀺çã«èªå¯ããŠããªãå Žåããå®éã®ç¥èããªããŠãã§ããããã«ãåœç€Ÿã®åœéçãªäºæ¥ãåŸãå¯èœæ§ã®ããå°æ¥ã®èŠå¶èŠä»¶ã®æ§è³ªãç¯å²ããŸãã¯åœ±é¿ããæ¢åã®æ³åŸãã©ã®ããã«å·è¡ãŸãã¯è§£éãããããäºæž¬ããããšã¯ã§ããŸããã
ç§ãã¡ã¯ãã€ã®ãªã¹ãšã¢ã¡ãªã«åè¡åœã®æ¿åºãåã³æ¬§å·é£åã®åœå±ã«ãã£ãŠç®¡çãããèŠå¶ãå«ããåœéçãªæ¥åãèŠå¶ãããã®ä»ã®æ³åŸãèŠå¶ã«ãåŸããªããã°ãªããŸãããããã«ã¯ãé©çšããã茞åºç®¡çèŠå¶ãç¹å®ã®åœã人ç©ã«å¯Ÿããçµæžå¶è£ããã³çŠèŒžæªçœ®ããããŒãã³ããªã³ã°é²æ¢æ³ã茞å
¥ããã³é¢çšèŠä»¶ãçºæ¿ååŒèŠå¶ãå«ãŸãããããå
šäœããååŒç®¡çæ³ããšåŒã³ãŸãã
é©çšããããã¹ãŠã®åè
ææ³ãç¹ã«èŽåè³é²æ¢æ³ãFCPAããŸãã¯ãã®ä»ã®æ³çèŠä»¶ã貿æ管çæ³ã«æºæ ããããšãå®å
šã«å¹æçã§ããä¿èšŒã¯ãããŸãããèŽåè³é²æ¢æ³ãFCPAããã®ä»ã®åè
ææ³ãŸãã¯è²¿æ管çæ³ã«æºæ ããŠããªãå Žåãåäºããã³æ°äºã®çœ°éãå©çå奪ããã®ä»ã®å¶è£ããã³æ¯æ£æªçœ®ãæ³çè²»çšã®å¯Ÿè±¡ãšãªãå¯èœæ§ãããããããããžãã¹ã財åç¶æ
ãæ¥çžŸããã³æµåæ§ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸããåæ§ã«ãã€ã®ãªã¹ãã¢ã¡ãªã«åè¡åœãŸãã¯ãã®ä»ã®åœå±ã«ããèŽåè³é²æ¢æ³ãFCPAããã®ä»ã®åè
ææ³ãŸãã¯è²¿æ管çæ³ã®æœåšçãªéåã«é¢ãã調æ»ã¯ãç§ãã¡ã®è©å€ãããžãã¹ã財åç¶æ
ãæ¥çžŸã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
第äžè
ãšã®ããžãã¹å¥çŽãé©çšãããå»çé¢é£æ³èŠãéµå®ããããšã確ä¿ããããã®åªåã¯ãããªãã®ã³ã¹ãã䌎ããŸãããããã®æ³åŸã®åºç¯å²ãšãå©çšå¯èœãªæ³å®äŸå€ããã³å®å
šæž¯ã®çããèæ
®ãããšãåœç€Ÿã®ããžãã¹æŽ»åã第äžè
ãšã®ããžãã¹å¥çŽã®äžéšãããããã®æ³åŸã®äžã€ãŸãã¯è€æ°ã«åºã¥ããŠç°è°ãå±ããããå¯èœæ§ããããŸããæ¿åºåœå±ããåœç€Ÿã®ããžãã¹æ
£è¡ãåœç€Ÿã®ãã€ã€ãªãã£ãçã¿åºã補åã®ããŒã±ãã£ã³ã°æ¥è
ã®ããžãã¹æ
£è¡ããçŸåšãŸãã¯å°æ¥ã®æ³ä»€ãèŠå¶ããŸãã¯é©çšãããè©æ¬ºããã³èåŸ
ã«é¢ããæ³èŠãšå€äŸæ³ãéµå®ããŠããªããšçµè«ã¥ããå¯èœæ§ããããŸããåœç€Ÿã®æ¥åãŸãã¯åœç€Ÿã®ãã€ã€ãªãã£ãçã¿åºã補åã®ããŒã±ãã£ã³ã°æ¥è
ã®æ¥åãããããã®æ³åŸããã®ä»ã®æ¿åºèŠå¶ã«éåããŠãããšèŠãªãããå Žåãåœç€ŸãŸãã¯åœç€Ÿã®ãã€ã€ãªãã£ãçã¿åºã補åã®ããŒã±ãã£ã³ã°æ¥è
ã¯ãééçå¶è£ãæå®³è³ åã眰éãåãæ¶ããå人ã®æ²åœ¹ããããŠã¡ãã£ã±ã¢ãã¡ãã£ã±ã€ããªã©ã®æ¿åºè³éã«ããå»çããã°ã©ã ãžã®åå ããã®æé€ãè¿œå ã®å ±åèŠä»¶ãç£èŠãåããå¯èœæ§ããããŸãããŸããåœç€ŸãŸãã¯åœç€Ÿã®ãã€ã€ãªãã£ãçã¿åºã補åã®ããŒã±ãã£ã³ã°æ¥è
ãããããã®æ³åŸã®éµå®ã®äžå±¥è¡ã®çãã解決ããããã®äŒæ¥èª å®æ§å¥çŽãŸãã¯é¡äŒŒã®å¥çŽã®å¯Ÿè±¡ãšãªã£ãå Žåã reputational harmãåœç€ŸãŸãã¯åœç€Ÿã®ãã€ã€ãªãã£ãçã¿åºã補åã®ããŒã±ãã£ã³ã°æ¥è
ã¯ãæ¥åãçž®å°ãŸãã¯åæ§ç¯ããå¿
èŠãããå Žåãããããããã¯åœç€Ÿã®ããžãã¹éå¶èœåãæ¥çžŸã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ãããã®æ³åŸã«éåããŠãããšèŠãªããããªã¹ã¯ã¯ãå€ãã®æ³åŸãèŠå¶åœå±ãè£å€æã«ãã£ãŠå®å
šã«è§£éãããŠããªãäºå®ãããã®æ¡é
ãæ§ã
ãªè§£éã«éãããŠããããšã«ãã£ãŠé«ãŸããŸãããããã®æ³åŸã«éåãããšããŠç§ãã¡ã«å¯Ÿããæªçœ®ãåãããå Žåãããšãç§ãã¡ãããã«å¯ŸããŠæåè£ã«é²åŸ¡ã§ãããšããŠããéèŠãªæ³çè²»çšãçºçããçµå¶é£ã®æ³šæãããžãã¹ã®éå¶ããéžããå¯èœæ§ããããŸããå€åãç¶ããã³ã³ãã©ã€ã¢ã³ã¹ç°å¢ãšãç°ãªãã³ã³ãã©ã€ã¢ã³ã¹ãå ±åèŠä»¶ãæã€è€æ°ã®æ³åã«é©å¿ããããã«å
ç¢ã§æ¡åŒµå¯èœãªã·ã¹ãã ãæ§ç¯ãç¶æããå¿
èŠæ§ã¯ããã«ã¹ã±ã¢äŒæ¥ãäžã€ãŸãã¯è€æ°ã®èŠä»¶ã«éåããå¯èœæ§ãé«ããŸãã
代æ¿æè³ãã¡ã³ããããŒãžã£ãŒã«é¢ããEUæ什ïŒãAIFmæ什ãïŒã¯ãåœç€Ÿã®ã³ã³ãã©ã€ã¢ã³ã¹ã³ã¹ãã倧å¹
ã«å¢å ãããå¯èœæ§ããããŸãã
AIFmæ什ã¯ã欧å·çµæžå°åããã³ã€ã®ãªã¹ã®å€§å€æ°ã®å çåœã®åœå
æ³ã«å®æœãããŠããŸãïŒååœããAIFmåœããšåŒã³ãŸãïŒãAIFmæ什ã¯ãAIFmåœã«ããã代æ¿æè³ãã¡ã³ãïŒåœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒãªã©ïŒã«å¯Ÿããæš©çã®ããŒã±ãã£ã³ã°ã«é¢é£ããæäœæ¡ä»¶ãå®ããŠãããAIFmåœã«ãããæè³å®¶ãåŒãä»ããèœåã«åœ±é¿ãäžããå¯èœæ§ããããåœç€Ÿããã³ãããŒãžã£ãŒã®ã³ã³ãã©ã€ã¢ã³ã¹ã³ã¹ãã倧å¹
ã«å¢å ãããå¯èœæ§ããããŸãããã®ãããªæ¡ä»¶ã«ã¯ãã¯ã©ã¹Aæ®éæ ªåŒãæè³å®¶ã«ããŒã±ãã£ã³ã°ããããã«ãé¢é£ããAIFmåœã®é©åãªåœå±ã«ç»é²ããèŠä»¶ãé¢é£ããAIFmåœã®é©åãªåœå±ã«å®æå ±åãæåºããèŠä»¶ãããã³é¢é£ããAIFmåœã®æè³å®¶ã«é¢ããé瀺ããã³å ±å矩åãéµå®ããèŠä»¶ãå«ãŸããŠããŸãããã®ãããªå ±åããã³é瀺ã¯äžè¬ã«å
¬éãããå¯èœæ§ããããŸããæã
ã®ã¯ã©ã¹Aæ®éæ ªåŒãããŒã±ãã£ã³ã°ãããAIFmåœã«é¢é£ããŠãããã®æ¡ä»¶ãæºããããŠããå Žåã§ããä»åŸãããã§ããä¿èšŒã¯ãããŸãããããããAIFmæ什ã¯ãåœè©²AIFmåœã§ã¯ã©ã¹Aæ®éæ ªåŒãããŒã±ãã£ã³ã°ãããŠããªãç¶æ³ã«ãããŠãæè³å®¶ãèªçºçã«åœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒãåŒãåããããšãçŠæ¢ããŠããŸããããã®ãããæè³å®¶ãèªçºçã«è¡ã£ãããšãæã
ãšãããŒãžã£ãŒã«ç€ºãéããåœç€Ÿã¯ãã®ãããªæè³å®¶ã«ã¯ã©ã¹Aæ®éæ ªåŒãçºè¡ããããšãã§ããŸãã
åAIFmå·ã«ãããŠãåœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒã¯ãAIFmæ什ãå®æœããå°åçæªçœ®ã«åŸã£ãŠã®ã¿æè³å®¶ã«æäŸãããå ŽåããããŸããæè³å®¶ãšãåœç€Ÿã«æè³ãã決å®ãè¡ãããŸãã¯ãã®æ¯æŽãè¡ãä»»æã®äººç©ã¯ãAIFmå·ã«ãããŠãåœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒãéå
¬åçºè¡ã«ãŒã«ã«åŸã£ãŠæäŸãããŠããªãå°åã«æåšããå±
äœããããç»é²äºåæãæã€å Žåã§ããåœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒã«æè³ãŸãã¯æè³ãè¡ãããšãã§ããŸããããã ããèªå·±ã®ã€ãã·ã¢ãã£ãã§è¡ãå Žåã«éããŸãããã®ãããªAIFmå·ã«ãããŠãèªå·±ã®ã€ãã·ã¢ãã£ãã§åœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒãååŸããæè³å®¶ã¯ãåœç€Ÿããã®AIFmå·ã«ãããŠããŒã±ãã£ã³ã°ã®ããã«ç»é²ãããŠããªããããé¢é£ããAIFmå·ã®äž»ç®¡åœå±ã«å¯ŸããŠåœç€Ÿã«ãããŸãã¯åœç€Ÿã«é¢ããŠæåºãããå ±åã¯è¡ããããæè³å®¶ã¯AIFmæ什ã«åŸã£ãŠããŒã±ãã£ã³ã°ããããªã«ã¿ããã£ãæè³ãã¡ã³ãã«é¢ããŠçŸ©åä»ããããé瀺ãå ±åãåããæš©å©ããªãããšã«çæããå¿
èŠããããŸãã
ã€ã®ãªã¹ã¯ã2013幎ã®ä»£æ¿æè³ãããŒãžã£ãŒèŠåããã³éèè¡åç£èŠæ©æ§ã®ãã³ãããã¯ãéããŠAIFmæ什ãå®æœããŸãããã€ã®ãªã¹ã®EUããã®è±éãšç§»è¡æéã®çµäºã«äŒŽããã€ã®ãªã¹ããã³ãã®ä»ã®AIFmè«žåœã«ããã代æ¿æè³ãã¡ã³ãã®æåã®ããŒã±ãã£ã³ã°ã«é©çšãããã«ãŒã«ã¯å€§éšåãäžèŽããŠããŸãããããããçŸåšã§ã¯ãã€ã®ãªã¹ããã®ä»ã®AIFmè«žåœã®æè³å®¶ã«æã
ã®ã¯ã©ã¹Aæ®éæ ªåŒãããŒã±ãã£ã³ã°ããéã«ãããå€ãã®æéãšè€éããçããå¯èœæ§ãããåéãååšããããã«ãããã³ã³ãã©ã€ã¢ã³ã¹ã³ã¹ãã倧å¹
ã«å¢å ããå¯èœæ§ããããŸãã
åœç€Ÿã®çµç¹ãšæ§é ã«é¢é£ãããªã¹ã¯
ç§ãã¡ã¯ãäºæ¥ãè¡ã£ãŠããªãããŒã«ãã£ã³ã°ã«ã³ãããŒã§ããã財åäžã®çŸ©åãæãããé
åœãæ¯æãããã«å¿
èŠãªè³éãåäŒç€ŸããåŸãŠããŸãã
åœç€Ÿã¯ãå®è³ªçãªçŽæ¥äºæ¥ãæããªãææ ªäŒç€Ÿã§ããåœç€Ÿã®äž»èŠãªè³ç£ã¯ãRPããŒã«ãã£ã³ã°ã¹ã«å¯Ÿããæ¯é
æåã§ãããã®ããã財æ¿äžã®çŸ©åãæãããé
åœãæ¯æã£ããæ ªäž»ã«åé
ãè¡ãããã«å¿
èŠãªè³éãåŸãã«ã¯ãåäŒç€Ÿããã®è²žä»ãé
åœåã³ãã®ä»ã®æ¯æãã«äŸåããŠããŸããåœç€Ÿã®åäŒç€Ÿã¯æ³çã«åœç€Ÿãšã¯ç°ãªãååšã§ãããç¹å®ã®æ¡ä»¶äžã§è²žä»ãæäŸããããé
åœãæ¯æã£ããããã®ä»ã®åœ¢ã§åœç€Ÿã«è³éãäŸçµŠããããšãçŠæ¢ãŸãã¯å¶éãããå ŽåããããŸããåäŒç€ŸããåãåãçŸéã財æ¿äžã®çŸ©åãå±¥è¡ããã®ã«äžååãªå Žåãåœç€Ÿã¯åµåãè² æ
ããããæ ªåŒãçºè¡ããããè³ç£ã売åŽããŠè³éã調éããå¿
èŠããããããããŸããããããããããã®æ段ã§çŸéã調éã§ããä¿èšŒã¯ãããŸãããåäŒç€Ÿãåœç€Ÿã«å¯ŸããŠé
åœãåé
ãæ¯æããè¡ãèœåãèŠå¶ãæ³çèŠä»¶ãç Žç£ãåµåäžå±¥è¡ããŸãã¯è²¡æ¿çå¥å
šæ§ã®è©äŸ¡ãç¶æããå¿
èŠæ§ã«ãã£ãŠå®è³ªçã«å¶çŽãããŠããå Žåããããã¯å¶æ¥çµæããã®ä»ã®èŠå ã«ãã£ãŠå¶éãããŠããå Žåãåœç€Ÿã®è²¡æ¿äžã®çŸ©åãå±¥è¡ããé
åœãæ¯æã£ããæ ªäž»ã«åé
ãè¡ãèœåã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
æã
ã®æ§é ã¯ãRPããŒã«ãã£ã³ã°ã¹ã®ã¯ã©ã¹Cç¹å¥å©çã®çµæãšããŠãçšéã®åé
ããããããŸãã
RPããŒã«ãã£ã³ã°ã¹ã¯ãç±³åœé£éŠæåŸçšã®ç®çã§ããŒãããŒã·ãããšããŠæ±ãããç±³åœé£éŠæåŸçšã®å¯Ÿè±¡ãšãªãææè
ãããŸããRPããŒã«ãã£ã³ã°ã¹ã¯ãRPããŒã«ãã£ã³ã°ã¹ã¯ã©ã¹Cç¹å¥å©çã®çŽæ¥ææè
ãŸãã¯å®è³ªçææè
ã«å¯ŸããŠãäžè¬çã«çšçããã¹ãŠã®åå人ã«åçã§ãããšä»®å®ããçšçã䜿çšããŠèšç®ãããçŸéé
åãŸãã¯çšé
åãè¡ãããšã矩åä»ããããŠããŸããRPããŒã«ãã£ã³ã°ã¹ãçšé
å矩åãæºããããã«äœ¿çšããè³éã¯ãç§ãã¡ã®ããžãã¹ãžã®åæè³ãé
åœããŸãã¯ã·ã§ã¢ã®èªç€Ÿæ ªè²·ãã«ã¯å©çšã§ããŸããã
æ®éæ ªåŒã«é¢ãããªã¹ã¯
åœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒã®åžå ŽäŸ¡æ Œã¯ãããŸã§å€åããããä»åŸãå€åããå¯èœæ§ããããããã«ããæ ªäž»ã®æè³äŸ¡å€ãæžå°ããå¯èœæ§ããããŸãã
åœç€Ÿã®Aã¯ã©ã¹æ®éæ ªåŒã®åžå ŽäŸ¡æ Œã¯å€åã倧ãããä»åŸã倧ããªå€åã«åœ±é¿ãããå¯èœæ§ããããŸããäžçäžã®èšŒåžåžå Žã¯äŸ¡æ Œãšåºæ¥é«ã®å€§ããªå€åãçµéšããŠããŸãã2023幎12æ31æ¥ããã£ãŠçµäºãã幎ã®éãåœç€Ÿã®Aã¯ã©ã¹æ®éæ ªåŒã®1æ ªãããã®ååŒäŸ¡æ Œã¯ã$26.21ã®å®å€ãã$39.40ã®é«å€ãŸã§å€åããŸãããåžå Žã®å€åæ§ããªãã³ã«äžè¬çãªçµæžã»åžå Žã»æ¿æ²»ç¶æ³ã¯ãåœç€Ÿã®æ¥çžŸã«ãããããããAã¯ã©ã¹æ®éæ ªåŒã®åžå ŽäŸ¡æ ŒãæŒãäžããå¯èœæ§ããããŸãããŸãã10-Kãã©ãŒã ã®å¹Žæ¬¡å ±åæžã§è°è«ãããèŠå ã«å ããŠãåœç€Ÿã®æ¥çžŸã¯ãå
Œ
±åžå Žã®ã¢ããªã¹ããæè³å®¶ã®æåŸ
ãäžåãå¯èœæ§ãããã以äžã®ãããªããŸããŸãªæœåšçèŠå ã圱é¿ããããšããããŸãã
⢠äžè¬çãªæ ªåŒåžå Žã®åžå Žç¶æ³ããŸãã¯ç¹ã«æ¥çš®ã«ãããåžå Žç¶æ³;
⢠ååæã®å¶æ¥çµæãæ ªäž»ãžã®é
åœãã·ã§ã¢ã®è²·æ»ãã®å€åïŒ
⢠ãããŒãžã£ãŒã«ãããéèŠãªç®¡çè·ã®äººå¡ã®è¿œå ãŸãã¯é¢è·;
⢠è³æ¬é
åã®ã¿ã€ãã³ã°ãšæ¯çãèŠç©ããã«å¯Ÿããçžå¯Ÿçãªãã®ãå«ãã
⢠ããŒããã©ãªãªã®æ§æãååŸæŠç¥ã®å€æŽ;
⢠ã¢ããªã¹ãã®å©çäºæ³ãäžåã
⢠æ¥çš®ã«é¢ãããªãµãŒãã¬ããŒãã®çºè¡;
⢠第äžè
å»çè²»åéã®æ¹éãšå®è·µ;
⢠蚎èšããã³æ¿åºã®èª¿æ»ïŒ
⢠æ³åŸãèŠå¶ã®å€æŽãŸãã¯ææ¡ãããå€æŽããŸãã¯ããã«é¢é£ãã解説ã³ã¡ã³ããæœè¡ãç§ãã¡ã®ããžãã¹ã«åœ±é¿ãäžããå Žå;
⢠ãã€ã€ãªãã£ãçã¿åºã補åã®ããŒã±ã¿ãŒããã®çµæãŸãã¯äºæž¬çµæã¯ãããŸãã;
⢠éçºæ®µéã®è£œååè£ã«åºã¥ããã€ãªå»è¬åã®è³ç£ãããããªè£œåã«é¢ãããã®ä»ã®åé¡ãäŸãã°èŠå¶åœå±ã®æ¿èªãåæ¥åãå«ãèšåºè©Šéšããã°ã©ã ã®çµæãé
延ã
⢠å°æ¥æã
ãè² æ
ããå¯èœæ§ã®ããåµåãçºè¡ããå¯èœæ§ã®ãã蚌åžã«å¯Ÿããåžå Žã®æªåœ±é¿;
⢠åæ§ã®äŒæ¥ã®åžå Žè©äŸ¡ã®å€åããå ±éãæè³ã³ãã¥ããã£ã§ã®æ¶æž¬;
⢠競åä»ç€Ÿã«ããéèŠãªå¥çŽãè²·åãè²æž¡ãæŠç¥çããŒãããŒã·ãããååŒäºæ¥ãŸãã¯è³æ¬ã³ãããã¡ã³ãã«é¢ããçºè¡š;
⢠ãã³ãããã¯ãã€ã³ãã¬ãéå©ã®å€åãã°ããŒãã«ãªçŽäºãªã©ã®çµæžçããã³æ¿æ²»çæ¡ä»¶ãŸãã¯åºæ¥äº;
⢠ç§ãã¡ãç§ãã¡ãåå ããŠããæ¥çããŸãã¯åã
ã®ã¹ãã£ã³ãã«ã«é¢ããæªåœ±é¿ã®ãã宣äŒã
ãããåã³ãã®ä»ã®èŠå ã«ãããæã
ã®ã¯ã©ã¹Aæ®éæ ªåŒã®åžå ŽäŸ¡æ ŒãéèŠã倧ããå€åããå¯èœæ§ãããããããæ ªäž»ã賌å
¥äŸ¡æ ŒãŸãã¯ãã以äžã®äŸ¡æ Œã§ã¯ã©ã¹Aæ®éæ ªåŒãå販ããããšãå¶éãŸãã¯åŠšããå¯èœæ§ããããŸãã
æ ªåŒåžå Žã¯äžè¬çã«ãææã極端ãªäŸ¡æ Œãåºæ¥é«ã®å€åãçµéšããŠããŸããããæè¿ã®æ°ã¶æã§ããããèŠãããŸãããå ããŠãéå»ã«ã¯ãå
šäœåžå ŽãäŒæ¥ã®èšŒåžã®åžå ŽäŸ¡æ Œã®å€åããã£ãåŸã«ãå
¬éäŒæ¥ã«å¯ŸããŠèšŒåžã¯ã©ã¹ã¢ã¯ã·ã§ã³èšŽèšããã°ãã°æèµ·ãããŠããŸããããã®ãããªèšŽèšãç§ãã¡ã«å¯ŸããŠæèµ·ãããå Žåãããªãã®ã³ã¹ããçºçããçµå¶é£ã®æ³šæããªãœãŒã¹ãéžè±ããå¯èœæ§ããããŸãã
åœç€Ÿã®å®æ¬Ÿã«ã¯ãã€ã³ã°ã©ã³ãããã³ãŠã§ãŒã«ãºã®è£å€æãã蚌åžæ³ããã³ååŒææ³ã«åºã¥ã蚎ããé€ãå
šãŠã®æ ªäž»ã®èŠæ
ã解決ããããã®ç¬å çãªãã©ãŒã©ã ã§ããããšããªãã³ã«ãç±³åœé£éŠå°æ¹è£å€æãã蚌åžæ³ããã³ååŒææ³ã«åºã¥ã蚎ãã䞻匵ããæ ªäž»ã®èŠæ
ã解決ããããã®ç¬å çãªãã©ãŒã©ã ã§ããããšãå®ããããŠããŸãã
åœç€Ÿã®å®æ¬Ÿã«ã¯ãã€ã³ã°ã©ã³ãããã³ãŠã§ãŒã«ãºã®è£å€æãã蚌åžæ³ããã³ååŒææ³ã«åºã¥ã蚎å ã䞻匵ããæ ªäž»ã¯ã¬ãŒã ãé€ããã¹ãŠã®æ ªäž»ã¯ã¬ãŒã ã解決ããããã®ç¬å çãªãã©ãŒã©ã ã§ããããšãå®ããããŠãããç±³åœé£éŠå°è£ã蚌åžæ³ããã³ååŒææ³ã«åºã¥ã蚎å ã䞻匵ãããããªãæ ªäž»ã¯ã¬ãŒã ã解決ããããã®ç¬å çãªãã©ãŒã©ã ã§ããããšãå®ããããŠããŸãããã®ãã©ãŒã©ã ã®éžææ¡é
ã¯ãæ ªäž»ãåœç€ŸãŸãã¯åœç€Ÿã®åç· åœ¹ã圹å¡ããã®ä»ã®åŸæ¥å¡ãšã®éã®çŽäºã«å¯ŸããŠå¥œãŸãããšèããåžæ³ãã©ãŒã©ã ã§è«æ±ãæèµ·ããèœåãå¶éããå¯èœæ§ãããã蚎èšãæå¶ããããšããããŸããããè£å€æãåœç€Ÿã®å®æ¬Ÿã«å«ãŸãããããã®ãã©ãŒã©ã ã®éžææ¡é
ãé©çšäžå¯èœãŸãã¯å·è¡äžèœãšå€æããå Žåãä»ã®ç®¡èœåºåã§ã®ãã®ãããªèšŽèšã解決ããããã«è¿œå ã®ã³ã¹ããçºçããå¯èœæ§ãããããããåœç€Ÿã®æ¥åçµæããã³è²¡æ¿ç¶æ
ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ã¢ã¡ãªã«ã®æè³å®¶ã¯ãåœç€Ÿãåœç€Ÿã®åç· åœ¹ããŸãã¯äžçŽç®¡çè·ãããã«èšèŒãããå°é家ã«å¯ŸããŠãæ°äºè²¬ä»»ã匷å¶ããããšã«å°é£ãæããå ŽåããããŸãã
ç§ãã¡ã¯ãã€ã®ãªã¹ã«ç»é²ããããªãã£ã¹ãæã€å
¬éæ ªåŒäŒç€Ÿã§ãããåäŒç€Ÿã¯ã¢ã¡ãªã«åè¡åœä»¥å€ã®ããŸããŸãªæ³åã«èšç«ãããŠããŸããç§ãã¡ã®åç· åœ¹ã®äžäººã¯ã¢ã¡ãªã«åè¡åœã®å±
äœè
ã§ã¯ãªããç§ãã¡ã®è³ç£ããã³ãã®åç· åœ¹ã®è³ç£ã®å€§éšåã¯ã¢ã¡ãªã«åè¡åœã®å€ã«ãããŸãããã®ãããæè³å®¶ãã¢ã¡ãªã«åè¡åœã«ãããŠãã®åç· åœ¹ã«å¯Ÿãæç¶ãã®ééãè¡ã£ãããã¢ã¡ãªã«ã®è£å€æã§åŸãå€æ±ºãç§ãã¡ãŸãã¯ãã®åç· åœ¹ã«å¯ŸããŠãã¢ã¡ãªã«ã®èšŒåžæ³ã®æ°äºè²¬ä»»èŠå®ãŸãã¯ãã®ä»ã«åºã¥ããŠåŒ·å¶ããããšãé£ããå ŽåããããŸãããã®ãããªèšŽèšãæèµ·ããããšã«æåããæ ªäž»ã§ãã£ãŠããã€ã®ãªã¹ã®æ³åŸã«ããæ ªäž»ã¯ç§ãã¡ã®è³ç£ãŸãã¯åç· åœ¹ããã³å·è¡åœ¹å¡ã®è³ç£ã«å¯ŸããŠå€æ±ºã匷å¶ã§ããªããªãå¯èœæ§ããããŸããããã«ãã€ã®ãªã¹ã®è£å€æããããã®æ°äºè²¬ä»»èŠå®ã«åºã¥ãã¢ã¡ãªã«ã®èšŒåžæ³ã®äžã§ã®å蚎ãŸãã¯ã¢ã¡ãªã«ã®è£å€æã®å€æ±ºã匷å¶ãããã©ããã¯çãããã§ããå ããŠãã¢ã¡ãªã«ãä»ã®å Žæã§æèµ·ããã蚎èšã«ãããæ²çœ°çæå®³è³ åã®è³ã¯ãã€ã®ãªã¹ã§ã¯åŒ·å¶ãããªãå¯èœæ§ããããŸããã¢ã¡ãªã«ã®èšŒåžæ³ã«åºã¥ãééçæ害ã®è³ã¯ãè«æ±è
ã被ã£ãæ倱ãæ害ãè£åããªãå Žåã被åã眰ããããšãç®çãšããå Žåãæ²çœ°çã§ãããšèŠãªãããå¯èœæ§ããããŸããã€ã®ãªã¹ã§ã®å€æ±ºã®åŒ·å¶åã¯ãäºä»¶ã®ç¹å®ã®äºå®åã³ãã®æç¹ã§æœè¡ãããŠããæ³åŸãæ¡çŽã«äŸåããŸããã¢ã¡ãªã«åè¡åœãšã€ã®ãªã¹ã¯ãæ°äºããã³åæ¥çãªäºé
ã«ãããå€æ±ºïŒä»²è£è£å®ãé€ãïŒã®æ¿èªããã³å·è¡ã«é¢ããæ¡çŽãçŸåšæã£ãŠããŸããããã®ãããæ ªäž»ã¯ã¢ã¡ãªã«ã®å
¬éäŒç€Ÿã®æ ªäž»ã§ããå Žåããããç§ãã¡ã®çµå¶é£ãåç· åœ¹ããŸãã¯ä»ã®æ ªäž»ã«å¯Ÿãã蚎èšãéããŠèªå·±ã®å©çãä¿è·ããããšãé£ãããããããŸããã
åœç€Ÿã®æ ªäž»ã®æš©å©ã¯ãç±³åœã®äŒæ¥ã®æ ªäž»ã«éåžžæäŸãããæš©å©ãšã¯ç°ãªãå ŽåããããŸãã
ç§ãã¡ã¯ã€ã®ãªã¹æ³ã®äžã§æ³äººåãããŠããŸããç§ãã¡ã®æ ªäž»ã®æš©å©ã¯ã€ã®ãªã¹æ³ãç¹ã«2006幎äŒç€Ÿæ³ïŒãã€ã®ãªã¹äŒç€Ÿæ³ãïŒããã³ç§ãã¡ã®å®æ¬Ÿã«ãã£ãŠèŠå®ãããŠããŸãããããã®æš©å©ã¯ãå
žåçãªç±³åœã®æ³äººã®æ ªäž»ã®æš©å©ãšã¯ããã€ãã®ç¹ã§ç°ãªããŸãã
ã€ã®ãªã¹ã«ãããè²·åããã³å䜵ã«é¢ããåžã³ãŒãïŒãè²·åã³ãŒãããšåŒã°ããïŒã¯ãç»é²äºåæãã€ã®ãªã¹ïŒãŸãã¯ãã£ãã«è«žå³¶ããã³å³¶ïŒã«ããã蚌åžãã€ã®ãªã¹ïŒãŸãã¯ãã£ãã«è«žå³¶ããã³å³¶ïŒã®èŠå¶åžå Žã§ååŒãããŠããªãäžå ŽäŒæ¥ã«å¯Ÿãããªãã¡ãŒãå«ããã®ä»ã®äºæã«é©çšãããŸãããã®äŒç€Ÿãè²·åããã³å䜵ã«é¢ããããã«ïŒãè²·åããã«ããšåŒã°ããïŒã«ãã£ãŠã€ã®ãªã¹ïŒãŸãã¯ãã£ãã«è«žå³¶ããã³å³¶ïŒã«ãããŠäžå€®ç®¡çããã³å¶åŸ¡ã®å ŽæããããšèŠãªãããå Žåããã®ããšã¯ãå±
äœãã¹ãããšããŠç¥ãããŠããŸããè²·åã³ãŒãã«åºã¥ããè²·åããã«ã¯ãåç· åœ¹äŒã®æ§æãåç· åœ¹ã®æ©èœãããã³åœŒãã®å±
äœå°ãå«ãããŸããŸãªèŠå ãèæ
®ããªãããç§ãã¡ã®äžå€®ç®¡çããã³å¶åŸ¡ã®å Žæãã€ã®ãªã¹ã«ãããã©ãããå€æããŸãã
ç§ãã¡ã®äžå€®ç®¡çããã³çµ±å¶ãã€ã®ãªã¹ïŒãŸãã¯ãã£ã³ãã«è«žå³¶ããã³å³¶ïŒå€ã«ããããšãèæ
®ãããšããã€ã¯ãªãŒããŒã³ãŒãã®å¯Ÿè±¡ã«ãªããšã¯èããŠããŸããããããããããã€ã¯ãªãŒããŒãªãã¡ãŒã®éã«ãã€ã¯ãªãŒããŒããã«ãç§ãã¡ã®äžå€®ç®¡çããã³çµ±å¶ã®å Žæãã€ã®ãªã¹ïŒãŸãã¯ãã£ã³ãã«è«žå³¶ããã³å³¶ïŒã«ãããšå€æããå Žåãç§ãã¡ã¯ä»¥äžã®ãããªå€ãã®ã«ãŒã«ãå¶éã®å¯Ÿè±¡ãšãªããŸãïŒïŒiïŒå
¥æè
ãšã®ååŒä¿è·å¥çŽãçµã¶èœåã¯éåžžã«å¶éãããã§ãããïŒïŒiiïŒæ ªäž»ã®æ¿èªãªãã«ãæ ªåŒã®çºè¡ãååŸãåŠåãªã©ããªãã¡ãŒã劚害ããå¯èœæ§ã®ããç¹å®ã®è¡åãè¡ãããšã¯ã§ããªããããããŸããïŒãããŠïŒiiiïŒãã¹ãŠã®èª å®ãªç«¶äºå
¥æè
ã«å¯ŸããŠå¹³çã«æ
å ±ãæäŸãã矩åããããŸãã
ã€ã®ãªã¹æ³ã®äžã§ã¯ãåœç€Ÿãè²·åã³ãŒãã®å¯Ÿè±¡ã§ãããåŠãã«ããããããåœç€Ÿã«å¯Ÿããææ¡è
ã次ã®èŠä»¶ãæºããå Žåãããªãã¡ã(i) 察象ãšãªãæ ªåŒã®äŸ¡å€ã® 90% åã³ (ii) ææ¡ã«é¢é£ããæ ªåŒã®æ祚暩㮠90% ãååŸããå Žåã«ãæ³å®ã®å§ææš©ãè¡äœ¿ããŠåæããªãå°æ°æ ªäž»ã®æ ªåŒã匷å¶çã«ååŸããããšãã§ããŸãããã ããåœç€Ÿã«å¯Ÿããææ¡ãã¹ããŒã ãªãã¢ã¬ã³ãžã¡ã³ãã®åœ¢ã§å®æœãããå Žåãææ¡è
ãäŒç€Ÿã®æ ªåŒã® 100% ãååŸããããã®éŸå€ã¯äºã€ã®éšåããæãç«ã£ãŠããŸãã(i) æ ªäž»ç·äŒã«åºåžãæ祚ããåã¯ã©ã¹ã®äŒç€Ÿã®æ ªäž»ã®éåæ°ã«ããæ¿èªïŒåã³ (ii) ãã®äŒè°ã«åºåžãæ祚ããåã¯ã©ã¹ã®äŒç€Ÿã®æ ªäž»ã®äžã§ã䟡å€ã® 75% 以äžã代衚ããäŒç€Ÿã®æ ªäž»ã«ããæ¿èªã
ã€ã®ãªã¹ã®å
¬éæéäŒç€ŸãšããŠãç¹å®ã®è³æ¬æ§é ã«é¢ãã決å®ã«ã¯æ ªäž»ã®æ¿èªãå¿
èŠãšãªããè³æ¬æ§é ã管çããæè»æ§ãå¶éãããå¯èœæ§ããããŸãã
ç§ãã¡ã¯ãã€ã³ã°ã©ã³ãããã³ãŠã§ãŒã«ãºã®æ³åŸã«åºã¥ããŠèšç«ãããå
¬éæéäŒç€Ÿã§ããã€ã®ãªã¹ã®æ³åŸã§ã¯ãåç· åœ¹äŒã¯æ ªäž»ã®äºåæ¿èªããªããã°æ ªåŒïŒãŸãã¯æ ªåŒã«åŒãæããããæ ªåŒãååŸããæš©å©ïŒãã¢ãããããããšãã§ããªããšå®ããŠããŸãããã®æ¿èªã«ã¯ãã«ããŒãããæ ªåŒã®åç®åèšé¡ãæèšãããå®æ¬ŸãŸãã¯é¢é£ããæ ªäž»æ±ºè°ã§æå®ãããŠããæ倧5幎éæå¹ã§ããç§ãã¡ã¯ãäŒç€Ÿã®æ¬¡åã®å®ææ ªäž»ç·äŒã®çµäºãŸã§ããŸãã¯æ©ããã°2024幎6æ6æ¥ãã15ãæåŸã®æ¥ã®å¶æ¥çµäºãŸã§ã®æéã«è¿œå æ ªåŒãã¢ãããããããã®æ ªäž»ã®æš©éãååŸããŸãããäŒç€Ÿã¯ãæ¯å¹Žã®æ ªäž»ç·äŒã§ãã®æ¿èªã®æŽæ°ãæ±ããäºå®ã§ãã
ã€ã®ãªã¹ã®æ³åŸã§ã¯ãæ ªäž»ã®æ®é決è°ïŒããªãã¡ãæ ªäž»ã«ãã£ãŠæ祚ãããéåæ°ïŒã«ããäºåã®æ¿èªãªãã«ãéåžå Žè³Œå
¥ãã«ãã£ãŠèªç€Ÿã®æ ªåŒãåååŸããããšãçŠæ¢ãããŠããŸãããŸããä»ã®åœ¢åŒçãªæç¶ããå¿
èŠã§ãããã®ãããªæ¿èªã¯æé·ã§5幎éã®æéãšããããšãã§ããŸããããã£ãšé »ç¹ã«æ±ããããšãã§ããŸããã€ã®ãªã¹ã®æ³åŸã§ã¯ãæ ªåŒããã¹ããã¯ã«äžå ŽãããŠããããããåžå Žå
賌å
¥ããè¡ãããšãçŠæ¢ãããŠãããèªèãããæè³ååŒæã§ã¯ååŒãããŸããã
æ ªäž»ã¯ã2022幎6æ23æ¥ãã5幎以å
ã«å€±å¹ããç¹å®ã®ãåžå Žå€è³Œå
¥ãã®æ¿èªãè¡ããŸããããã®å€±å¹æ¥ããåã«æ ªäž»ã«ãã£ãŠæŽæ°ãããªãéããæ ªäž»ã«å¯ŸããŠããããã®è¡åã«å¯Ÿããæ ªäž»ã®æ¿èªèŠä»¶ãæ ªäž»ã®éèŠãªè³æ¬ç®¡çã¡ãªããã奪ãäºæ
ãçããªãããšãä¿èšŒããããšã¯ã§ããŸããã
ã€ã®ãªã¹ã®æ¬§å·é£åããã®é¢è±ãšç°ãªãèŠå¶å¶åºŠã¯ãã°ããŒãã«ãªçµæžç¶æ³ãéèåžå ŽããããŠããžãã¹ã«æªåœ±é¿ãåãŒãå¯èœæ§ãããããããç§ãã¡ã®ã¯ã©ã¹Aæ®éæ ªã®åžå ŽäŸ¡æ Œãäžããå¯èœæ§ããããŸãã
ã€ã®ãªã¹ã®æ¬§å·é£åããã®é¢è±ïŒäžè¬ã«ããã¬ã°ãžããããšåŒã°ããïŒã¯ã2020幎1æ31æ¥ã«çºå¹ããŸããããã¬ã°ãžããã¯ãä»åŸã®ã€ã®ãªã¹ã®çµæžçããã³æ¿æ²»çé¢ä¿ã«é¢ããŠäžç¢ºå®æ§ãåŒãèµ·ãããŠãããããã¯ããžãã¹ã®çšéãã³ã¹ãã®å¢å ããããããçºæ¿ååŒããã³Interest Ratesã«ãããå€åãé«ããå¯èœæ§ããããŸãããŸãããã¬ã°ãžããã¯ã€ã®ãªã¹ã欧å·é£åããããŠäžçäžã®æ¿æ²»çãèŠå¶çãçµæžçãªæ¡ä»¶ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããæ¿æ²»æ©é¢ãèŠå¶æ©é¢ãéèåžå Žã®äžå®å®ãã«å¯äžããããšã«ãªããŸããããã¯ãåœç€Ÿã®äºæ¥ãã¯ã©ã¹Aæ®éæ ªã®åžå ŽäŸ¡æ Œã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
åœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒãDTCã®æœèšå
ã§åŒãç¶ãå
¥éããã³æž
ç®ã®å¯Ÿè±¡ãšãªã£ãŠããªãå Žåãåœç€Ÿã®èšŒåžã«ãããååŒã¯äžæãããå¯èœæ§ããããŸãã
ãããžããªãŒãã©ã¹ãã«ã³ãããŒïŒ"DTC"ïŒã®æœèšã¯ãDTCã·ã¹ãã ã®åå è
éã§ã®è¿
éãªé»åçæ ªåŒç§»è»¢ãå¯èœã«ããåºã䜿çšãããŠããã¡ã«ããºã ã§ããåå è
ã«ã¯å€ãã®éè¡ã仲ä»äŒç€Ÿãå«ãŸããŸããåœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒã¯ãDTCã·ã¹ãã å
ã§ã®å
¥éããã³æ±ºæžã®å¯Ÿè±¡ã§ãããDTCã¯åœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒã«å¯ŸããŠãããžããªããã³æ±ºæžæ©é¢ãšããŠã®æ©èœãåæ¢ããè£éãæã¡ããã®çç±ãšããŠè±åœæ³ã®å€æŽãã¯ã©ã¹Aæ®éæ ªåŒã«é¢é£ããå°çŽçšãå°çŽçšæºåçšã®ç¶æ³ãå€ããå ŽåããããŸããDTCãã¯ã©ã¹Aæ®éæ ªåŒãåŒãç¶ããã®æœèšå
ã§å
¥éããã³æ±ºæžã®å¯Ÿè±¡ã§ãªããšå€æããå Žåãåœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒã¯ãã¹ããã¯ã§ã®äžå Žãç¶ç¶ããè³æ Œããªããªããã¯ã©ã¹Aæ®éæ ªåŒã®ååŒãäžæãããå¯èœæ§ããããŸããäžå Žãç¶æããååŒãç¶ç¶ããããã®ä»£æ¿çãè¿œæ±ããŸããããããªãäžæãåœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒã®åžå ŽäŸ¡æ Œãè³æ¬åžå Žãžã®ã¢ã¯ã»ã¹ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
äžå ŽäŒæ¥ã§ããããã®èŠä»¶ã¯ãåœç€Ÿã®ãªãœãŒã¹ã«è² æ
ããããçµå¶é£ã®æ³šæãéžãããé©æ Œãªåç· åœ¹äŒã¡ã³ããŒãåŒãä»ããç¶æããèœåã«åœ±é¿ãäžããå¯èœæ§ããããŸãã
å
¬éäŒç€ŸãšããŠãåœç€Ÿã¯ååŒææ³ã®å ±åèŠä»¶ãç±³åœãµãŒãã€ã³ãºã»ãªã¯ã¹ãªãŒæ³ïŒ2002幎ïŒããµãŒãã€ã³ãºã»ãªã¯ã¹ãªãŒæ³ãã®èŠä»¶ãè±åœäŒç€Ÿæ³ã®èŠä»¶ã«åŸãå¿
èŠãããã該åœããå Žåã¯ãè²·åã³ãŒãã«ãåŸãå¿
èŠããããŸãããããã®èŠåãšèŠå¶ã®èŠä»¶ã¯ãåœç€Ÿã®æ³çããã³è²¡åçã³ã³ãã©ã€ã¢ã³ã¹ã³ã¹ããå¢å ãããäžéšã®æŽ»åãããå°é£ã«ããæéãããããã³ã¹ãããããåå ãšãªããåœç€Ÿã®ã·ã¹ãã ããªãœãŒã¹ãžã®éèŠãå¢å ãããŸãã
ç§ãã¡ã¯ãSECã«å¹Žæ¬¡ããã³ååæã®æ
å ±ããã³ååŒææ³ã§æå®ããããã®ä»ã®å ±åæžãæåºãã矩åãããããã®ããããã¹ãŠã®SECå ±åèŠä»¶ã«é©åãã財åè«žè¡šãã¿ã€ã ãªãŒã«æºåããèœåãæã€å¿
èŠããããŸããããã«ããã¹ããã¯ã®ç¹å®ã®èŠä»¶ãããµãŒãã³ã¹ã»ãªã¯ã¹ãªãŒæ³ããã³ãã®äžã§å¶å®ãããèŠå¶ã®ç¹å®ã®èŠå®ãªã©ããã®ä»ã®å ±åããã³ã³ãŒãã¬ãŒãã¬ããã³ã¹èŠä»¶ã«åŸãå¿
èŠããããããã«ãã£ãŠç§ãã¡ã«ã¯éèŠãªã³ã³ãã©ã€ã¢ã³ã¹çŸ©åã課ããããŸãã
ç§ãã¡ã¯ã財åå ±åããã³é瀺管çã«é¢ããå
éšçµ±å¶ã®æå¹æ§ã«ã€ããŠã®çµå¶è
ã«ããè©äŸ¡ãèŠæ±ãããSarbanes-Oxleyæ³ã®ã»ã¯ã·ã§ã³404ãéµå®ããå¿
èŠããããŸããããã財åå ±åãé瀺管çã«é¢ããå¹æçãªå
éšçµ±å¶ãç¶æã§ããªãå Žåã財åæ
å ±ãæ£ç¢ºã«èšé²ãåŠçãå ±åããèœåããå¿
èŠãªæéå
ã«è²¡åè«žè¡šãäœæããèœåã«æªåœ±é¿ãåãŒãå¯èœæ§ããããããã«ãããSECã«ããå¶è£ãå«ãèŠå¶äžã®çµæã«çŽé¢ããç§ãã¡ã®è²¡åè«žè¡šã«å¯Ÿããæè³å®¶ã®ä¿¡ææºèœãæªåããè³æ¬åžå Žãžã®ã¢ã¯ã»ã¹ãå¶éãããç§ãã¡ã®ã¯ã©ã¹Aæ®éæ ªåŒã®åžå ŽäŸ¡æ Œã«æªåœ±é¿ãåãŒãããšããããŸãã
åœç€Ÿã®ååŒææ³ããµãŒãã³ã¹ã»ãªã¯ã¹ãªãŒæ³ãè±åœäŒç€Ÿæ³ãããã³è©²åœããå Žåã¯è²·åã³ãŒãããã³ãã®äžçã«ãŒã«ãšèŠå¶ã«å¯Ÿããéµå®ã¯ãæ³çããã³è²¡åçãªéµå®ã³ã¹ããå¢å ãããããã€ãã®æŽ»åãããæéãããããè²»çšãããããã®ã«ããŠããŸãããããã®ã«ãŒã«ãšèŠå¶ã«ãããåç· åœ¹ããã³åœ¹å¡ã®è²¬ä»»ä¿éºãååŸããããšãããå°é£ã«ãªããä»åŸãå¶éãããä¿éºéé¡ãè£åãåãå
¥ããããåçãŸãã¯é¡äŒŒã®è£åãååŸããããã«å€§å¹
ã«é«ãã³ã¹ããè² æ
ããªããã°ãªããªãå¯èœæ§ããããŸãããã®çµæãåç· åœ¹äŒã圹å¡ãšããŠå€åããããã®æè³æ Œè
ãæ¹ãã€ããç¶æããããšãããå°é£ã«ãªããããããŸãããå°æ¥ãè¿œå ã®ã³ã¹ãã®éé¡ããã®çºçææãæ£ç¢ºã«äºæž¬ãŸãã¯æšå®ããããšãã§ããªããããããŸããã
çšã«é¢ãããªã¹ã¯
ç§ãã¡ã®æ§é ã¯æ確ãªåäŸãæš©éãååšããªãçšæ³ã®è€éãªæ¡é
ãå«ãŸããŠããŸãããŸããç§ãã¡ã®æ§é ã¯æœåšçãªæ³ä»€ãåžæ³ããŸãã¯è¡æ¿ã®å€æŽåã³ç°ãªã解éã«åŸãå¯èœæ§ããããå Žåã«ãã£ãŠã¯é¡åçã«åœ±é¿ãåããå¯èœæ§ããããŸãã
åœç€Ÿã®çšååŠçãã¢ã€ã«ã©ã³ããè±åœãåã³ç±³åœé£éŠæåŸçšã®åŠçã¯ãå Žåã«ãã£ãŠã¯ãæ確ãªåäŸãæš©éãååšããªãé©çšçšæ³ã®è€éãªèŠå®ã®äºå®ã®å€æã解éã«äŸåããŸããåœç€Ÿã®çšåããžã·ã§ã³ã¯ç念ããèªç±ã§ã¯ãªãããšãé©çšãããçšã«ãŒã«ã¯äžè¬çã«ç«æ³æ©é¢ãè¡æ¿æ©é¢ãé¢é£ããçšååœå±ããŸããçµæžååéçºæ©æ§ïŒãOECDãïŒã«ããç¶ç¶çãªã¬ãã¥ãŒã®å¯Ÿè±¡ã§ããããšãç解ããŠããã¹ãã§ããOECDã¯ãæ¢åã®çšã«ãŒã«ã®å€æŽã«é¢ããæšå¥šãåžžã«æ€èšããŠããŸããããã«ãG20/OECDã®å
æ¬çæ çµã¿ã«å±ãã140ãè¶
ããå ç管èœåºåããOECDã®åºç€äŸµé£ãšå©çé
åãããžã§ã¯ãïŒãBEPSãïŒã®äžç°ãšããŠãããžã¿ã«çµæžã®çšå課é¡ã«å¯ŸåŠããããã®äºæ¬æ±ã®è§£æ±ºçã«åå ããŠãããããã«ã¯åžå Žã®ç®¡èœåºåéã§ã®èª²çšæš©ã®åé
åãã15%ã®ã°ããŒãã«æå°çšçïŒããã©ãŒ2ãïŒãå«ãŸããŸããæ§ã
ãªç®¡èœåºåã«ãããã©ãŒ2èŠåã®ç¶ç¶çãªçºè¡šã®äžç°ãšããŠã2023幎7æ11æ¥ã«ã財æ¿ïŒç¬¬2ïŒæ³2023ïŒãè±åœæ³ãïŒãæç«ããOECDã®BEPSãã©ãŒ2ã®æåŸå
æ¬èŠåãå®æœããŠããŸããããã«ã¯ãå€åœç±äŒæ¥ã®è¿œå çšãšã2023幎12æ31æ¥ä»¥éã«éå§ããäŒèšæéã«å¯Ÿãã15%ã®æå°å¹æçšçãžã®åœå
è¿œå çšãå«ãŸããŸããè±åœæ³ã«ã¯ã2026幎12æ31æ¥ä»¥åã«éå§ããäŒèšæéã«å¯Ÿãã移è¡å®å
šæž¯ã®éžæè¢ãå«ãŸããŠããŸããã¢ã€ã«ã©ã³ãã§ã¯2023幎12æ18æ¥ã«åæ§ã®ç«æ³ãæç«ããŸããïŒãã¢ã€ã«ã©ã³ãæ³ãïŒãåœç€Ÿã¯ãã©ãŒ2èŠåãåœç€Ÿã«é©çšããããšã¯èããŠããŸãããããã©ãŒ2ãå®æœããé¢é£ãã管èœåºåã®çšååœå±ããè±åœæ³ãã¢ã€ã«ã©ã³ãæ³ãåã³OECDã®BEPSãã©ãŒ2ã¢ãã«èŠåãšé¢é£ãã解説ã³ã¡ã³ãã«é¢ããåœç€Ÿã®ç解ãšççŸãã圢ã§ãç«æ³ã声æããŸãã¯ã¬ã€ãã³ã¹ãæ¡çšãŸãã¯è§£éãããªã¹ã¯ãæ®ã£ãŠããŸããçšæ³å€æŽã®ææ¡ãBEPSãã¬ãŒã ã¯ãŒã¯ã®å®æœã¯ãããªã亀æžã®å¯Ÿè±¡ã§ãããããçšæ³ãæ³ä»€ãèŠåãèŠå¶ããŸãã¯æ¡äŸã®å€æŽã®ç¯å²åã³ãã®çµæãããžãã¹ã«åãŒãæçµçãªåœ±é¿ãçŸåšäºæž¬ããããšã¯ã§ããŸããããããã®ã¬ãã¥ãŒéçšã¯ã確ç«ãããæŠå¿µã®å解éãæ³ä»€ã®å€æŽãèŠå¶ã®æ¹èšãåã³ãã®ä»ã®ä¿®æ£ã解éãããããå¯èœæ§ããããŸããããã«è¿°ã¹ãçšååé¡ã«é¢ããŠãé¢é£ããçšååœå±ããã®è£å®ãæ±ããããšã¯ãªããé¢é£ããçšååœå±ãåœç€Ÿã®çšåããžã·ã§ã³ã«ææŠãããã®ææŠãæåããªãä¿èšŒããããŸããããããã®ãããªããžã·ã§ã³ãæåè£ã«ææŠããããšãåœç€Ÿã®çšåå ±åãçšåè² æ
ã倧å¹
ã«å¢å ãããããåœç€Ÿã®å©çããã£ãã·ã¥ãããŒã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
åœéçšæ³ã«ãããŠã¯ããã¹ãŠã®å€åœç±äŒæ¥ã®çšåã³ã³ãã©ã€ã¢ã³ã¹ã®è€éããè² æ
ãã³ã¹ããå¢å ãããéèŠãªå€æŽããªããããŸãææ¡ãããŠããŸãããããããã³ãã®ä»ã®åœéçšæ³ã®ååãåŒãç¶ãç£èŠããŠããäºå®ã§ãã
ç¹å®ã®æåŸçšæ¡çŽã®å©çã«å¯Ÿããé©æ Œæ§ã®å€åããæåŸçšæ¡çŽã®é©çšã«é¢ããçšåäžã®ç«å Žãžã®ææŠã«ãããé倧ãªçšéã«å¯ŸããŠè²¬ä»»ãè² ãå¯èœæ§ããããŸãã
åœç€Ÿã®åäŒç€Ÿã¯ãç±³åœããã³éç±³åœã®äž¡æ¹ã®è³æºããåçãåããããšãæåŸ
ããŠããŸããäžè¬çã«ãåœç€Ÿã®åäŒç€Ÿã¯ã¢ã€ã«ã©ã³ããšåå
¥ãçºçãã管èœåºåãšã®éã®é©çšå¯èœãªæåŸçšæ¡çŽã®äžã§ã®æ©æµãåããè³æ ŒããããšæåŸ
ããŠããŸãããããããã®ç¹ã«ã€ããŠã®ä¿èšŒã¯ã§ãããçšååœå±ãåœç€Ÿã®åäŒç€Ÿã®ãããããæ¡çŽã®æ©æµãåããããã®é©çšèŠä»¶ãæºãããŠããªãçµæãšããŠãæ¡çŽã®æ©æµãåããè³æ Œããªããšäž»åŒµããå¯èœæ§ããããŸããããçšååœå±ãé©çšå¯èœãªæåŸçšæ¡çŽã®é©çšã«é¢ããåœç€Ÿã®ç«å Žã«ç°è°ãå±ããå Žåãåœç€Ÿã¯å¢å ããæºæ³åŸŽåçšã®å¯Ÿè±¡ã«ãªãå¯èœæ§ãããããã®çšéã¯çžåœãªé¡ã«ãªãå¯èœæ§ããããŸãã
ç¹å®ã®ç±³åœæºã®åå
¥ã«é¢ããŠãåœç€Ÿã®åäŒç€Ÿãç±³åœïŒã¢ã€ã«ã©ã³ãã®æåŸçšæ¡çŽïŒä»¥äžãæ¡çŽãïŒã®äžã§å©çã享åã§ããåœè©²æ¡çŽã®äžã«ãããŠããã®ãããªç±³åœæºã®æ¯æãã«å¯ŸããŠç±³åœã®æºæ³åŸŽåçšã課ãããªããšäºæ³ããŠããŸããåœç€Ÿã®ç±³åœæºã®æ¯æãã«é¢ããçŸåšã®æ¡çŽã®ç«å Žã¯ãåœè©²æ¡çŽã®ç®çäžå®çŸ©ãããç±³åœåžæ°ãŸãã¯çšåå±
äœè
ããçŽæ¥ãŸãã¯éæ¥çã«ãç±³åœæºã®åå
¥ãåŸãååäŒç€Ÿã®å®è³ªçãªå©çã®å°ãªããšã50%ãææãããŸãã¯ååäŒç€Ÿã®æ祚暩ããã³äŸ¡å€ã®åèšã®å°ãªããšã50%ãææããããšã«éšåçã«äŸåããŠããŸããåœç€Ÿã®æ¡çŽã®ç«å Žã¯ãRP Holdingsããã³Old RPIã®æ¢åéæ¥æè³å®¶ã®å€§å€æ°ã®çŸåšã®ç±³åœã®å°äœã«åºã¥ããŠããŸããäžéšã®äŸå€ãé€ããRP Holdingsã®æ¢åã®éæ¥ç±³åœæè³å®¶ã¯ã圌ãã®æåãåœç€Ÿã®å
¬éååŒãããAã¯ã©ã¹ã®æ®éæ ªåŒãšäº€æããæš©å©ãæã£ãŠããŸãããã®ãããªå
¬éååŒãããAã¯ã©ã¹ã®æ®éæ ªåŒã¯ãä»ã®äººã«å¯ŸããŠå
¬éåžå Žã§æŽã«è²æž¡ãããå¯èœæ§ããããŸãããããã£ãŠãæéãçµã€ã«ã€ããŠç±³åœã®äººã
ãéæ¥çã«åèšã§åœç€Ÿã®åäŒç€Ÿã®æåã®50%æªæºãææããããšã«ãªãå¯èœæ§ããããŸããçŸåšãåœç€Ÿã®Aã¯ã©ã¹ã®æ®éæ ªåŒããã³RP Holdingsããã³Old RPIã«ãããä»ã®æ¢åã®éæ¥æåã¯ãç±³åœåžæ°ãŸãã¯çšåå±
äœè
ã«ãã£ãŠååãªéã§åŒãç¶ãææããããšäºæ³ããŠãããæ¡çŽã®äžã§ã®50%ã®ææèŠä»¶ãæºããããã«ããã®æææš©ã確ç«ã§ãããšèããŠããŸããããããRP Holdingsããã³Old RPIãç±³åœåžæ°ãŸãã¯å±
äœè
ã«ãã£ãŠååã«çŽæ¥ãŸãã¯éæ¥çã«ææããç¶ãããã50%ã®ç±³åœææèŠä»¶ãæºããããã«ãIRSã®æºè¶³ã§ãã®ãããªæææš©ã確ç«ã§ãããã©ããã¯ä¿èšŒã§ããŸãããåœç€Ÿã®åäŒç€Ÿã«ãããéæ¥çãªç±³åœæææš©ã50%æªæºã«ãªãå ŽåïŒãŸãã¯ãã®ãããªæææš©ã確ç«ã§ããªãå ŽåïŒãå°æ¥çã«æ¡çŽã®äžã§ã®ç±³åœæºæ³åŸŽåããå¥ã®é©çšå¯èœãªå
é€ãåŸãããšãã§ãããããããŸãããããã®ç¹ã«ã€ããŠã¯ä¿èšŒã§ããŸããã åœç€Ÿã®å£²äžé«ã®ããªãã®éšåã¯ããã€ã€ã«ãã£ãå©åããŸãã¯æ¡çŽã®ç®çäžã®ããã®ä»ã®æåŸããªã©ã®ç±³åœæºã®åå
¥ã«ç±æ¥ããŠãããåŒãç¶ããã®ãããªåå
¥ããåŸããããšäºæ³ãããŠããŸãããããã£ãŠãåœç€Ÿã®åäŒç€Ÿãæ¡çŽã®äžã§ã®ç±³åœæºæ³åŸŽåçšã®å
é€è³æ Œãæºãããªãå ŽåïŒ50%ã®ç±³åœææèŠä»¶ãŸãã¯ä»£æ¿æ¡çŽå
é€ã®ãããããæºãããªãå ŽåïŒã«ã¯ããã®ãããªæåŸã30%ã®ç±³åœæºæ³åŸŽåçšã®å¯Ÿè±¡ãšãªã£ãå Žåãåœç€Ÿã®è²¡åç¶æ³ãåçæ§ããã³ãã£ãã·ã¥ãããŒã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ããã«ã2016幎8æ25æ¥ã«ã¢ã€ã«ã©ã³ã財åçã¯ã2016幎2æã«ã¢ã¡ãªã«åè¡åœè²¡åçã«ãã£ãŠæ¹èšãããã¢ã¡ãªã«ã¢ãã«æåŸçšæ¡çŽã®å
¬è¡šã«é¢é£ããŠãã¢ã¡ãªã«åè¡åœè²¡åçãšã®éã§æ¡çŽã®ç¹å®ã®èŠçŽ ãæŽæ°ããããã®è°è«ãå§ãŸã£ãããšãçºè¡šããŸãããçŸæç¹ã§ã¯ãæ¡çŽã®ã©ã®èŠçŽ ãæŽæ°ãããå¯èœæ§ãããã®ãããŸããã®ãããªæŽæ°ããã€æœè¡ãããã®ãã¯æ確ã§ã¯ãããŸãããããããæ¹èšãããã¢ã¡ãªã«ã¢ãã«æåŸçšæ¡çŽã®ç¹å®ã®èŠçŽ ãæ¡çŽã®æŽæ°ã«å«ãŸããå Žåãåœç€Ÿã®åäŒç€Ÿãæ¡çŽã®æ©æµãåããããªããªã£ãããåœç€Ÿã«å¯ŸããŠæ¬æ¥åŸãããã¯ãã®æ¡çŽã®æ©æµãæ¶å€±ãŸãã¯æžå°ããå¯èœæ§ããããŸããåœç€Ÿã®åäŒç€Ÿãæ¡çŽã®æ©æµãåããããªããªã£ãå ŽåããŸãã¯åœç€Ÿã«å¯ŸããŠæ¬æ¥åŸãããã¯ãã®æ¡çŽã®æ©æµãæ¶å€±ãŸãã¯æžå°ããå Žåãåœç€Ÿã®å
šåå
¥ãŸãã¯äžéšãæºæ³åŸŽåçšã®å¯Ÿè±¡ãšãªãå¯èœæ§ãããããã®ãããªçšéã¯éåžžã«é倧ã§ãåœç€Ÿã®è²¡æ¿ç¶æ
ãåçæ§ããã³ãã£ãã·ã¥ãããŒã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
åœç€Ÿã®åäŒç€Ÿãç±³åœã®ååŒãŸãã¯ããžãã¹ã«åŸäºããŠãããšèŠãªãããå Žåãåœç€Ÿã¯é倧ãªç±³åœã®èª²çšã«å¯ŸããŠè²¬ä»»ãè² ãå¯èœæ§ããããŸãã
äžè¬çã«ããã€ã€ã«ãã£ãã¡ãŒã plc ã®ãããªå€åœæ³äººãã¢ã¡ãªã«ã®ååŒãŸãã¯ããžãã¹ã«åŸäºããŠãããšèŠãªãããå Žåããã®æ³äººã®ã¢ã¡ãªã«ã®ååŒãŸãã¯ããžãã¹ã«å®è³ªçã«é¢é£ããåå
¥ã®ã·ã§ã¢ã¯ãéåžžãã¢ã¡ãªã«ã®é£éŠæåŸçšïŒçŸåšãæé«çšç㯠21%ïŒããããããŒã¹ã§èª²ããããããã«ããã®ã¢ã¡ãªã«ã®ååŒãŸãã¯ããžãã¹ã«å®è³ªçã«é¢é£ããåå
¥ã«èµ·å ããé
åœã«ã¯ãè¿œå 㧠30% ã®ã¢ã¡ãªã«ã®ãæ¯åºå©çãçšã課ããããå¯èœæ§ããããŸããå ããŠããã®ãããªæ³äººãã¢ã¡ãªã«åœå
ã®å·ãŸãã¯å°æ¹ã®æ³åã«ãã£ãŠãããããŒã¹ã§èª²çšãããå¯èœæ§ããããŸããç§ãã¡ã¯ãåäŒç€ŸãéããŠæŽ»åãè¡ããç§ãã¡ãåŸãåå
¥ãã¢ã¡ãªã«ã®ååŒãŸãã¯ããžãã¹ã«å®è³ªçã«é¢é£ããªãããã«ããéåžžã®ã¢ã¡ãªã«ã®é£éŠæåŸçšããããããŒã¹ã§èª²ããããªãããã«ããæåã§ãããã®æ¹æ³ã§æŽ»åãè¡ãããšãã§ããã°ãç§ãã¡ãåŸãåå
¥ãŸãã¯å©çã¯ã¢ã¡ãªã«ã®ãããé£éŠæåŸçšã®å¯Ÿè±¡ãšã¯ãªããªãã§ãããããããããã®ç¹ã«ã€ããŠã¯ä¿èšŒã§ããŸãããç§ãã¡ã®åå
¥ãšå©çã®ã¢ã¡ãªã«çšåäžã®é©åãªåé¡ã¯äžç¢ºãã§ãããç§ãã¡ã®åå
¥ãšå©çã®å
šãŠãŸãã¯äžéšãã¢ã¡ãªã«ã®ååŒãŸãã¯ããžãã¹ã«ãå®è³ªçã«é¢é£ãããåå
¥ãšããŠåé¡ãããå¯èœæ§ããããŸããããç§ãã¡ã®åå
¥ãšå©çãã¢ã¡ãªã«ã®ååŒãŸãã¯ããžãã¹ã«å®è³ªçã«é¢é£ããŠãããšåé¡ãããå Žåãç§ãã¡ã¯å€§ããªã¢ã¡ãªã«ã®çšéãå©æ¯ãããã«ã¯å¯èœæ§ã®ãã眰éã課ããããç§ãã¡ã®è²¡æ¿ç¶æ³ããã£ãã·ã¥ãããŒãããã³åçæ§ã«é倧ãã€æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
æã
ã¯ãRPããŒã«ãã£ã³ã°ã¹ãçšåäžåç¬ã§è±åœã®å±
äœè
ãšããŠæ±ãããããã«éå¶ãç¶ããããšãæåŸ
ããŠããŸãããæã
ã®ç®¡çããã³çµç¹æ§é ã®å€æŽããæã
ã掻åããŠããä»ã®åœã®çšåå±
äœæ³ã®å€æŽããé¢é£ããçšååœå±ã«ãã£ãŠæã
ãRPããŒã«ãã£ã³ã°ã¹ãçšåäžä»ã®åžæ³ç®¡èœåºåã®å±
äœè
ãšããŠæ±ãããåå ãšãªãå¯èœæ§ããããŸãã
çŸåšã®è±åœã®çšæ³ã®äžã§ã¯ãè±åœã«èšç«ãããäŒç€Ÿã¯ã(i) ä»ã®çšç®¡èœå°åã§çšåäžã®å±
äœè
ãšããŠåæã«æ±ãããå ŽåïŒãã®ä»ã®ç®¡èœåºåã§ã®çšåå±
äœè
ã®æ±ºå®ã«é¢ããèŠåãé©çšïŒã§ãã〠(ii) ãã®çšæ¡çŽã«ãããŠçšåäžã®å±
äœå°ãä»ã®ç®¡èœåºåã«é
åããå±
äœè
tie-breaker æ¡é
ãååšããå Žåãé€ããçšåç®çã§è±åœã®å±
äœè
ãšèŠãªãããŸãã
ç§ãã¡ã®äºæ³ããã管çããã³çµç¹æ§é ã«åºã¥ããŠãç§ãã¡ãšRPããŒã«ãã£ã³ã°ã¹ã¯ãçšåäžã®å±
äœè
ãšããŠè±åœã®ã¿ãšèŠãªãããã¹ãã ãšèããŠããŸãããã ãããã®åæã¯éåžžã«äºå®ã«åºã¥ããŠãããç§ãã¡ã®ç®¡çããã³çµç¹æ§é ã®å°æ¥ã®å€æŽããç§ãã¡ãéå¶ããŠããä»ã®ç®¡èœåºåã®çšåå±
äœæ³ã®å°æ¥ã®å€æŽã«äŸåããå¯èœæ§ããããããå°æ¥ã®çšåå±
äœã®æ±ºå®ã«é¢ããŠã¯ä¿èšŒã§ããŸããã
è±åœã®çšåå±
äœè
ã§ããäŒæ¥ãšããŠãç§ãã¡ãšRPããŒã«ãã£ã³ã°ã¹ã¯ãå
šäžçã®èª²çšå¯Ÿè±¡å©çããã³å©çã«å¯ŸããŠè±åœæ³äººçšã®å¯Ÿè±¡ãšãªããŸããç§ãã¡ïŒãŸãã¯RPããŒã«ãã£ã³ã°ã¹ïŒãè±åœä»¥å€ã®å°åã«å±
äœè
ãšããŠæ±ãããå Žåãç§ãã¡ïŒãŸãã¯RPããŒã«ãã£ã³ã°ã¹ã該åœããå ŽåïŒã¯ãã®å°åã§èª²çšãããå¯èœæ§ããããé¢é£ããçšæ³ã«åºã¥ãæºæ³åŸŽåçšãŸãã¯å ±å矩åãå«ãæ°å€ãã®éèŠãã€åœ¢åŒçãªçšå矩åã«åŸãå¿
èŠããããããããŸãããããã«ããè¿œå ã®ã³ã¹ããçµè²»ãçºçããå¯èœæ§ããããŸãã
ç§ãã¡ã¯ãè±åœã®ãæ¯é
å€åœäŒç€Ÿãã«ãŒã«ã«åºã¥ããŠãè±åœéå±
äœçšã®åäŒç€Ÿã®ç¹å®ã®å©çã«é¢ããŠãè±åœã®æ³äººçšã®å¯Ÿè±¡ã«ãªããªããšä¿¡ããŠããŸãããããã¯ä»åŸãç¶ãä¿èšŒã¯ã§ããŸããã
è±åœã®çšæ³äžã®å±
äœè
äŒæ¥ãšããŠãç§ãã¡ãšRPããŒã«ãã£ã³ã°ã¹ã¯ãè±åœã®ãæ¯é
å€åœäŒç€ŸãèŠåïŒãè±åœCFCèŠåãïŒã®å¯Ÿè±¡ãšãªããŸããè±åœCFCèŠåã¯ãåºçŸ©ã«ã¯ãè±åœã®å±
äœè
äŒæ¥ããåç¬ãŸãã¯ç¹å®ã®ä»ã®è
ãšå
±åã§ãè±åœã«å±
äœããªãäŒç€ŸïŒãæ¯é
å€åœäŒç€ŸãïŒã«å¯ŸããŠæåãæãããã®æ¯é
ãè±åœã®å人ãŸãã¯å人ã«ãã£ãŠè¡ãããå Žåã«ãè±åœã®çšéã課ããããå¯èœæ§ãããããšã瀺ããŠããŸããè±åœCFCèŠåã«åºã¥ã課çšã¯ãæ¯é
å€åœäŒç€Ÿãçããç¹å®ã®çš®é¡ã®èª²çšå©çã«åºã¥ããŠé©çšããããã®å©çãåé
ããããã©ããã«ããããããç¹å®ã®å
é€ãåããããšããããŸããæ¯é
å€åœäŒç€Ÿãè±åœCFCèŠåã«åºã¥ãæ³äººçšã®èª²çšå¯Ÿè±¡ãšãªãå¯èœæ§ã®ããå©çã®çš®é¡ã«ã¯ãè±åœã§ã®æŽ»åã«ãã£ãŠç®¡çãããè³ç£ããªã¹ã¯ã«èµ·å ããæ¯é
å€åœäŒç€Ÿã®ããžãã¹å©çããŸãã¯é¢é£ããè±åœå±
äœè
äŒæ¥ããçŽæ¥ãŸãã¯éæ¥çã«æ¯é
å€åœäŒç€Ÿã«è²¢ç®ãããè³æ¬ããã®ä»ã®è³ç£ããçããæ¯é
å€åœäŒç€Ÿã®ç¹å®ã®éèå©çãå«ãŸããŸãã
ç§ãã¡ã25ïŒ
以äžã®æåãä¿æããç¹å®ã®éè±åœæ³äººã¯ãRPI 2019 ICAVïŒã¢ã€ã«ã©ã³ãã«çšåå±
äœããæ³äººïŒããOld RPIïŒã¢ã€ã«ã©ã³ãã«çšåå±
äœããRP Holdingsãžã®åå ãéããŠéæ¥çã«ä¿æããæ³äººïŒãå«ããŠãè±åœçšç®çã®ããã®ç®¡çå€åœæ³äººãšãªããŸããç§ãã¡ãšRP Holdingsã¯ããããã®æ³äººã«å¯ŸããçŽæ¥çããã³éæ¥çãªæåã«é¢ããŠãCFCã«ãŒã«ãç¶ç¶çã«é©çšããå¿
èŠããããŸããç§ãã¡ã¯ãèããè±åœæ³äººçšã®èª²çšãç§ãã¡ã®ãã€ã€ãªãã£è³ç£ãè³é調éã®åã決ãã«ãããŠãè±åœCFCã«ãŒã«ã«åºã¥ããŠçãããšã¯äºæž¬ããŠããŸããããä»åŸããããªããšä¿èšŒããããšã¯ã§ããŸãããè±åœCFCã«ãŒã«ã¯éåžžã«è€éã§äºå®ã«äŸåãããã®ã§ããããããã®ã«ãŒã«ã«å¯Ÿããå€æŽãäžå©ãªè§£éããŸãã¯RPI 2019 ICAVãä»ã®éè±åœäŒæ¥ã®å°æ¥ã®æŽ»åã®å€åã¯ããã®ç«å Žãå€æŽããå¯èœæ§ããããç§ãã¡ã®ã°ã«ãŒãã®å®å¹çšçã«åœ±é¿ãäžããå¯èœæ§ããããŸãã
ç§ãã¡ãšRPããŒã«ãã£ã³ã°ã¹ãåãåãé
åœã¯ãã€ã®ãªã¹ã®æ³äººçšããå
é€ãããã¹ãã ãšèããŠããŸãããä»åŸãããã§ããããšã¯ä¿èšŒã§ããŸããã
ã€ã®ãªã¹ã®çšæ³ã«åºã¥ãå±
äœæ³äººã¯ãä¿ææ ªåŒã«é¢ããŠåãåãé
åœããã®ä»ã®åå
¥åé
ã«å¯ŸããŠã€ã®ãªã¹æ³äººçšã®å¯Ÿè±¡ãšãªããŸããããããã®é
åœããã®ä»ã®åé
ãå
é€ã¯ã©ã¹ã«è©²åœããå Žåã¯ãã®éãã§ã¯ãããŸãããç§ãã¡ã¯ãRP Holdingsããåãåãé
åœãšãRP HoldingsãRPI 2019 ICAVããåãåãé
åœã¯ããã®ãããªå
é€ã¯ã©ã¹ã«è©²åœãããšæããããããã€ã®ãªã¹æ³äººçšã®å¯Ÿè±¡ãšã¯ãªããªãã¯ãã§ãããããããã®ãããªé
åœããã®çšå
é€ã«è©²åœããããã«ã¯ãããã€ãã®æ¡ä»¶ãæºããããå¿
èŠããããŸããç¹ã«ãã¢ã€ã«ã©ã³ãã«å±
äœããRPI 2019 ICAVãæ¯æãé
åœã«é¢ããŠã¯ãã¢ã€ã«ã©ã³ãã®çšæ³ã®é©çšã«é¢ããæ¡ä»¶ãå«ãŸããŸãããã®ããã«ãåé
ã«é¢ããã€ã®ãªã¹ã®çšå
é€ã®æ¡ä»¶ãåžžã«æºãããããšä¿èšŒããããšã¯ã§ããŸãããç§ãã¡ãŸãã¯RP Holdingsãåãåãåé
ãå
é€ã¯ã©ã¹ã«è©²åœããªãå Žåããã®åé
ã¯åœæã®æ³äººçšçã§ã€ã®ãªã¹æ³äººçšã®å¯Ÿè±¡ãšãªãå¯èœæ§ããããŸãã
ããšãåé
ãå
é€ã¯ã©ã¹ã«è©²åœããå Žåã§ããç¹å®ã®é²æ¢ããã³ååé¡ã«ãŒã«ãé©çšãããããšããããŸããäŸãã°ãRPI 2019 ICAVããäŒèšæéå
ã«æè³ã®60%以äžãåµåžã»åµå蚌åžãå©åã®ãããéïŒæè³åŸ
ã¡ã®çŸéãé€ãïŒãç¹å®ã®å·®é決æžååŒå¥çŽããŸãã¯ãåæ§ã«æè³ã®60%以äžããããã®è³ç£ã«æè³ããŠããä»ã®ãªãã·ã§ã¢ãã¡ã³ãã®ä¿æã«å
åœããŠããå ŽåãU.K.ã®çšç®çã«ãããŠããªãã·ã§ã¢ãã¡ã³ãããšèŠãªãããããšããããŸãããã®å ŽåãRP Holdingsã®RPI 2019 ICAVã«å¯Ÿããã·ã§ã¢ããŒã«ãã£ã³ã°ã¯ãæ³å®ããããããŒã³é¢ä¿ããšããŠU.K.æ³äººçšã®å¯Ÿè±¡ãšãªãå¯èœæ§ãããããã®çµæãRP HoldingsãRPI 2019 ICAVããåãåãé
åœã¯ãæ³å®ãããå©æ¯ãšããŠU.K.çšã®å¯Ÿè±¡ãšãªãå¯èœæ§ããããŸãããŸããRP Holdingsã¯RPIã«ãããã·ã§ã¢ããŒã«ãã£ã³ã°ã®å
¬æ£åžå ŽäŸ¡å€ã®å¢å ã«å¯ŸããŠU.K.æ³äººçšã®å¯Ÿè±¡ãšãªããããããŸãããããªãã·ã§ã¢ãã¡ã³ãããšããçšèªã¯ãU.K.çšç®çã«ãããŠç¹æ§ã«åºã¥ãã¢ãããŒãã«ãã£ãŠå®çŸ©ãããŠããã倧ãŸãã«ã¯ãåççãªæè³å®¶ãçŽè³ç£äŸ¡å€ã«åºã¥ããŠèªãã®æè³ãå®å
šãŸãã¯ã»ãŒå®å
šã«ååã§ãããšæåŸ
ããéU.K.å±
äœæ³äººã«ãã£ãŠæ§æãããåã決ããå«ãããšãã§ããŸããæã
ã¯ãRP Holdingsã®RPI 2019 ICAVã«å¯Ÿããã·ã§ã¢ããŒã«ãã£ã³ã°ã¯ãããã®ã«ãŒã«ã«è©²åœããªããšä¿¡ããã¢ããã€ã¹ãåããŠããŸãããä»åŸããããå€ãããªããšããä¿èšŒã¯æäŸã§ããŸããããªãã·ã§ã¢ãã¡ã³ãã«ãŒã«ã®å€æŽãæªåœ±é¿ãåãŒã解éããŸãã¯æã
ã®æè³ã®æ§è³ªã®å€åãããã®å°äœãå€ããå¯èœæ§ããããæã
ã®ã°ã«ãŒãã®å®å¹çšçã«åœ±é¿ãäžããå¯èœæ§ããããŸãã
åœç€Ÿã¯ãç±³åœé£éŠæåŸçšã®ç®çã§PFICãšããŠåé¡ãããããšãäºæ³ãããŠãããããã«ããåœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒãä¿æããç±³åœã®ä¿æè
ã¯ç±³åœé£éŠæåŸçšã«äžå©ãªåœ±é¿ãåããå¯èœæ§ããããŸãã åœç€Ÿãå人ããã³ãã®ä»ã®æ³äººä»¥å€ã®ç±³åœä¿æè
ã«æ¯æãé
åœã¯ãæžçšçã§èª²çšãããè³æ Œããªããããåœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒã®äŸ¡å€ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
äžè¬çã«ãããã·ãã€ã³ã«ã ããäž»ã«æ§æãããåœç€Ÿã®åå
¥ãšãããã·ãã€ã³ã«ã ãçã¿åºãè³ç£ããäž»ã«æ§æãããåœç€Ÿã®è³ç£ããçŸåšããã³å°æ¥ã®èª²çšå¹ŽåºŠã«ãããŠåœç€ŸãPFICãšããŠæ±ãããçµæã«ãªããšäºæ³ããŠããŸããç±³åœã®ä¿æè
ã«ã¯ãåœç€Ÿã®ãŠã§ããµã€ãã§ãç±³åœé£éŠæåŸçšç®çã§ã®ãé©æ ŒéžæåºéïŒQEFïŒãéžæãè¡ãããã«å¿
èŠãªæ
å ±ãå«ããPFIC幎éæ
å ±æžããæ¯å¹ŽæäŸããæå³ããããŸããåœç€Ÿã«å¯ŸããŠQEFéžæãè¡ããªãç±³åœã®ä¿æè
ããåœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒã«é¢ããŠåžå ŽäŸ¡æ Œè©äŸ¡éžæãè¡ããªãç±³åœã®ä¿æè
ã¯ãïŒiïŒåœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒã®è²æž¡ã«äŒŽããããªãå©çãéåžžã®æåŸãšããŠæ±ãããããšããïŒiiïŒãã®å©çã«å¯Ÿããé
延å©æ¯ã®é©çšãåœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒã«å¯Ÿããç¹å®ã®åé
ã®åãåããå«ããæœåšçã«é倧ãªäžå©ãªçšã®åœ±é¿ãåããããšã«ãªããŸããããã«ãåœç€Ÿã«å¯ŸããŠQEFãŸãã¯åžå ŽäŸ¡æ Œè©äŸ¡éžæãè¡ããããã©ããã«ããããããç±³åœã®ä¿æè
ã¯ãIRSãèŠæ±ããPFICã«å¯Ÿãããã®é¢å¿ã«é¢ããæ
å ±ãå«ãIRSãã©ãŒã 8621ã®å¹Žæ¬¡å ±åæžãæåºããå¿
èŠããããŸããåé©çšèª²çšå¹ŽåºŠã«å¯ŸããIRSãã©ãŒã 8621ã®æåºãæ ããšãé倧ãªçœ°åã課ããããIRSã«ããç£æ»ã®å¯Ÿè±¡ã«ãªãå¯èœæ§ããããŸããããã«ãããåœç€Ÿãç±³åœã®ä¿æè
ãåœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒãææããŠããéã«PFICã§ããå Žåãäžè¬çã«ãPFICã®å°äœã®ããã®åºæºèŠä»¶ãæºãããªããªã£ãå Žåã§ãããã®ç±³åœã®ä¿æè
ã«é¢ããŠãã¹ãŠã®åŸç¶å¹ŽåºŠã«ããã£ãŠPFICãšããŠæ±ããç¶ããããšã«ãªããŸãããã ããç±³åœã®ä¿æè
ãIRSãã©ãŒã 8621ã§ç¹å¥ãªãæµåãéžæãè¡ã£ãå Žåãé€ããŸãããããã®äžå©ãªçšã®åœ±é¿ã¯ãç±³åœã®æ ªäž»ã«æªåœ±é¿ãäžããç±³åœã®æè³å®¶ã«ãšã£ãŠåœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒãžã®æè³ãé
åçã§ãªãããå¯èœæ§ããããŸãã
æ³äººã§ãªãç±³åœä¿æè
ã«å¯Ÿããåé
ã¯ãç¹å®ã®ç±³åœæ³äººåã³ãé©æ Œå€åœæ³äººããæ¯æãé
åœéã«äžè¬çã«é©çšãããæžçšçšçã®é©çšå¯Ÿè±¡ãšã¯ãªããªããããã¯ãåœç€ŸãPFICã§ããããã§ãããé©æ Œãªæ³äººé
åœéã«é©çšãããããæå©ãªçšçã«ãããå人ã¯åœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒãžã®æè³ãä»ã®æ³äººã®æ ªåŒãžã®æè³ãããé
åããªããšèªèããå¯èœæ§ãããããã®èªèã¯åœç€Ÿã®ã¯ã©ã¹Aæ®éæ ªåŒã®äŸ¡å€ã«æªåœ±é¿ãåãŒãå¯èœæ§ãããã
äžè¬çãªãªã¹ã¯èŠå
ãµã€ããŒã»ãã¥ãªãã£ã®è匱æ§ãæ
å ±ã·ã¹ãã ã®ãã®ä»ã®é害ã¯ãæ
å ±ã®çé£ãããŒã¿ã®ç ŽæããããŠããžãã¹ã®éå¶ã«é倧ãªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ãµã€ããŒã»ãã¥ãªãã£ã®è匱æ§ãè
åšãã³ã³ãã¥ãŒã¿ãŠã€ã«ã¹ãåã³æè¿å¢å ããŠãããã©ã³ãµã ãŠã§ã¢ãããã£ãã·ã³ã°æ»æã®ãããªããæŽç·Žãããæšçãçµã£ããµã€ããŒé¢é£ã®æ»æãããã«äººçãšã©ãŒãç«çœã措氎ãããªã±ãŒã³ãç«å·»ã®ãããªå£æ»
çãªäºä»¶ãæè¡çãšã©ãŒã«èµ·å ãããµã€ããŒã»ãã¥ãªãã£ã®å€±æã¯ãæã
ã®ã·ã¹ãã ãšããŒã¿ã«ãªã¹ã¯ããããããŸããæ»æã«ãããã»ãã¥ãªãã£äŸµå®³ãçé£ãããŒã¿ã®åªå€±ãŸãã¯ç Žæãæ©å¯æ
å ±ãå人ããŒã¿ã®äžæ£äœ¿çšãå¶æ¥ç§å¯åã³åæ¥çã«äŸ¡å€ã®ããæ
å ±ã®åªå€±ãéå¶ã®ããŠã³ã¿ã€ã åã³æ¥åã®äžæãçºçããå¯èœæ§ããããŸãããããã®ãªã¹ã¯ã軜æžããããã«ãåŸæ¥å¡ã®èšç·Žãç£èŠãšãã¹ããä¿è·ã·ã¹ãã ãšç·æ¥èšç»ã®ç¶æãªã©ã®æ段ãè¬ããŠããŸãããéå»ã«ãµã€ããŒã»ãã¥ãªãã£ã®è匱æ§ã«ãããããããšããããä»åŸãããã«çŽé¢ããããšãäºæ³ãããŸãããµã€ããŒã»ãã¥ãªãã£ã®è匱æ§ãé²ãããšããã®åœ±é¿ã軜æžããããšãæåãããšããä¿èšŒã¯ãããŸããããµã€ããŒé¢é£ã®æ»æã倱æãããŒã¿ã®åªå€±ã¯ãããžãã¹ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸããããã«ããµã€ããŒé¢é£ã®æ»æããã®ä»ã®ããŒã¿ã»ãã¥ãªãã£äŸµå®³ã®çµæãšããŠã reputational harm ã被ã£ãã蚎èšã«çŽé¢ãããããå¯èœæ§ãããããããªãããŒã¿ä¿è·æªçœ®ãå®æœããããã«ããªãã®è¿œå è²»çšããããå¯èœæ§ããããŸãã
åœç€Ÿã¯ãããžãã¹æŽ»åã«é¢é£ããŠé»åæ
å ±ãåŠçãéä¿¡ãä¿åããããã«ãã¯ã©ãŠãã第äžè
ãµãŒãã¹ãããã€ããŒãå«ãæ
å ±ãã¯ãããžãŒã·ã¹ãã ããã³ãããã¯ãŒã¯ã«äŸåããŠããŸãããããã®æ
å ±ãã¯ãããžãŒã·ã¹ãã ããã³ãããã¯ãŒã¯ã¯ããœãããŠã§ã¢ãããŒã¿ããŒã¹ããŸãã¯éšåã®ã¢ããã°ã¬ãŒããŸãã¯äº€æããã»ã¹äžã®é害ãåé»ãããŒããŠã§ã¢ã®æ
éããŸãã¯ã³ã³ãã¥ãŒã¿ãŠã€ã«ã¹ã«ããæ害ãæ··ä¹±ããŸãã¯ã·ã£ããããŠã³ã«ææã§ããå¯èœæ§ããããŸãããããã®æ
å ±ãã¯ãããžãŒã·ã¹ãã ãé倧ãªæ害ãæ··ä¹±ãåããåé¡ãé©æã«è§£æ±ºãããªãå Žåãåœç€Ÿã®ããžãã¹ã財åç¶æ
ããŸãã¯éå¶ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
å ããŠã人工ç¥èœã«åºã¥ããœãããŠã§ã¢ïŒæ©æ¢°åŠç¿ãå«ãïŒã®äœ¿çšãç§ãã¡ã®æ¥çš®ã§å¢å ããŠããŸããå€ãã®çºå±éäžã®ãã¯ãããžãŒãšåæ§ã«ã人工ç¥èœã«åºã¥ããœãããŠã§ã¢ã¯ããã®ãããªãçºå±ãæ¡çšã䜿çšã«åœ±é¿ãåãŒããªã¹ã¯ãæ瀺ããŠãããããã«ããç§ãã¡ã®ããžãã¹ã«ã圱é¿ãåãŒãå¯èœæ§ããããŸããäŸãã°ãã¢ã«ãŽãªãºã ã«ã¯æ¬ é¥ããããããããŸãããããŒã¿ã»ããã¯äžååã§ãã£ããã質ãäœãã£ãããåã£ãæ
å ±ãå«ãå¯èœæ§ããããŸãããŸããããŒã¿ãµã€ãšã³ãã£ã¹ãããšã³ãžãã¢ããšã³ããŠãŒã¶ãŒã«ããäžé©åãŸãã¯ç©è°ãéžãããŒã¿ã®åãæ±ããçµæã«æªåœ±é¿ãåãŒããããããŸããã人工ç¥èœïŒãAIãïŒã¢ããªã±ãŒã·ã§ã³ãäžå®å
šãŸãã¯äžæ£ç¢ºãªåæãäœæããå Žåã競äºäžã®æ害ãæœåšçãªæ³ç責任ããŸãã¯è©å€ã®æ害ã被ãå¯èœæ§ããããŸããAIã¢ã«ãŽãªãºã ã¯ãç¥ç財ç£æš©ãæš©çãäžæ確ãªç¬¬äžè
æ
å ±ã䜿çšããããšããããŸããç§ãã¡ã䜿çšããAIãœãªã¥ãŒã·ã§ã³ãäŸåããããŒã¿ããã®ä»ã®çŽ æãã³ã³ãã³ãã䜿çšããååãªæš©å©ãæã£ãŠããªãå Žåãé¢é£ããæ³åŸãèŠå¶ã第äžè
ã®ç¥ç財ç£ããã©ã€ãã·ãŒãŸãã¯ãã®ä»ã®æš©å©ãå¥çŽã®éåãéããŠè²¬ä»»ãè² ãå¯èœæ§ããããŸããAIãã¯ãããžãŒèªäœãéåžžã«è€éã§æ¥éã«çºå±ããŠãããããAIã®äœ¿çšã«é¢é£ããŠçºçããå¯èœæ§ã®ãããã¹ãŠã®æ³çãéçšããŸãã¯æè¡çãªã¹ã¯ãäºæž¬ããããšã¯äžå¯èœã§ãã
çŸåšãŸãã¯å°æ¥ã®ååè
ããã®ä»ã®å¥çŽè
ãŸãã¯ã³ã³ãµã«ã¿ã³ãã¯ããããã®ãµã€ããŒã»ãã¥ãªãã£ã®è匱æ§ãæ
å ±ã·ã¹ãã ã®ãã®ä»ã®é害ãããã³äººå·¥ç¥èœããŒã¹ã®ãœãããŠã§ã¢ãªã¹ã¯ããã®æ害ãŸãã¯äžæã®åœ±é¿ãåããããã§ãããã®ãããªäºè±¡ãå°æ¥çºçãã圌ãã®æäœã«äžæãåŒãèµ·ããå ŽåãååŒç§å¯ããã®ä»ã®ç¬èªæ
å ±ã®åªå€±ãŸãã¯ãã®ä»ã®é¡äŒŒã®äžæã«ãããã®ã§ãã£ãŠãã圌ãã®éçºããã³åæ¥åããã°ã©ã ãããžãã¹ãªãã¬ãŒã·ã§ã³ã«æ¯éããããå¯èœæ§ããããŸãããããäžæãŸãã¯ã»ãã¥ãªãã£äŸµå®³ããååŒå
ã®ããŒã¿ãã¢ããªã±ãŒã·ã§ã³ã®åªå€±ãŸãã¯æå·ããããã¯æ©å¯æ
å ±ãç¬èªæ
å ±ã®äžé©åãªé瀺ã«ã€ãªãããšããå Žåãç§ãã¡ã®ããŒãããŒã®ãªãã¬ãŒã·ã§ã³ã«æªåœ±é¿ãåãŒãå¯èœæ§ãããã圌ãã®è£œåãéçºæ®µéã®è£œååè£ããã³æè¡ã®éçºããã³åæ¥åãé
ããå¯èœæ§ããããŸãããã®ãããªäºè±¡ã¯é¢é£ãããã€ãªå»è¬å補åããçæããããã£ãã·ã¥ãããŒã®éãæžå°ãããããã«ãã£ãŠç§ãã¡ã®ããžãã¹ã財åç¶æ³ããã³ãªãã¬ãŒã·ã§ã³ã®çµæã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
ç±³åœè²¡åäŒèšåºæºå¯©è°äŒããã®ä»ã®åºæºèšå®æ©é¢ã«ãã£ãŠçºè¡šãããäŒèšåºæºã®é©çšã®å€æŽã¯ãåœç€Ÿã®è²¡åè«žè¡šã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ç§ãã¡ã®è²¡åè«žè¡šã¯GAAPã«åŸã£ãŠäœæãããŠãããå®æçã«æ¹èšã解éããŸãã¯æ¡åŒµãããŸããææãèªèãããæš©åšããæ©é¢ã«ãã£ãŠçºè¡ãããæ°ãããŸãã¯æ¹èšãããäŒèšåºæºãæ¡çšããå¿
èŠããããŸããå°æ¥æ¡çšããªããã°ãªããªãäŒèšåºæºã¯ãçŸåšç§ãã¡ãçµ±å財åè«žè¡šã«é©çšããŠããäŒèšåŠçã«å€æŽãèŠæ±ããå¯èœæ§ããããç§ãã¡ã®ã·ã¹ãã ã«é倧ãªå€æŽãå ããå¿
èŠããããããããŸããããã®ãããªå€æŽã¯ãç§ãã¡ã®è²¡åç¶æ
ãå¶æ¥çµæã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
COVID-19ããã®ä»ã®ææçãäŒæç
ã®å°æ¥çãªçºçã¯ãæ¥åã®çµæã財åã®çš®é¡ããã³ãã£ãã·ã¥ãããŒã«æªåœ±é¿ãäžããå¯èœæ§ããããŸãã
COVID-19ã®çºçãšãã®å€ç°æ ªã¯ãã°ããŒãã«ãªçµæžæŽ»åã«æ·±å»ãªåœ±é¿ãåãŒããéèåžå Žã«ãããŠèããå€åãšãã¬ãã£ããªå§åãåŒãèµ·ãããŸãããCOVID-19ããã®ä»ã®å°æ¥ã®å¥åº·ã®çºçåã³ãã³ãããã¯ã¯ãéé¢æªçœ®ãåŒãèµ·ãããããããžãã¹ãåŠæ ¡ã®ééã矩åä»ããããæ
è¡ãå¶éãããããŸãã¯ã°ããŒãã«ãªçµæžã®æžéããªã»ãã·ã§ã³ãåŒãèµ·ããå¯èœæ§ããããŸããCOVID-19ãä»ã®ãã³ãããã¯ã¯ããã®ä»ã®èŠå ã«ãããç§ãã¡ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãïŒ
⢠ããžãã¹æŽ»åã®äžè¬çãªæžå°;
⢠åžå Žã®äžå®å®åã¯ããã€ãªè£œè¬æ¥çš®ã®ããŒãããŒããç§ãã¡ã®ãã€ã€ã«ãã£ãçã¿åºã補åã®è²©å£²ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
⢠è³æ¬ããã³ä¿¡çšåžå Žã«å¯ŸããŠå¥œæ¡ä»¶ã§ã¢ã¯ã»ã¹ã§ããªãããŸãã¯å
šãã¢ã¯ã»ã¹ã§ããªãé£ããããã°ããŒãã«ãªéèåžå Žã«ãããæ·±å»ãªæ··ä¹±ãäžå®å®æ§ããããã¯ä¿¡çšããã³è³é調éæ¡ä»¶ã®æªåããããžãã¹éå¶ã«å¿
èŠãªè³æ¬ãžã®ã¢ã¯ã»ã¹ããæºæè² åµã«ã¿ã€ã ãªãŒã«å¯ŸåŠããèœåã«åœ±é¿ãåãŒãå¯èœæ§ãããã
⢠æã
ã®ãããŒãžã£ãŒã®é«ãè³æ Œãæã€äººå¡ã®å¥åº·ã«å¯Ÿããæœåšçãªæªåœ±é¿ãç¹ã«ãã®äžã®ããªãã®æ°ã«åœ±é¿ãåã¶å Žåã
⢠混乱æã«ããžãã¹ã®ç¶ç¶æ§ã確ä¿ããèœåã®äœäž
⢠äžæãæ¬ åãçŽåé
延ãããã³ããŒãããŒãžã®äŸçµŠã®äžæã®å¯èœæ§ã«ãããåœç€Ÿã®è³ç£ã«åºã¥ãéçºæ®µéã®è£œååè£ã®èšåºè©Šéšãé
ããå¯èœæ§ããããåœç€Ÿã®ãã€ã€ãªãã£ãçã¿åºã補åããæ¿èªãããå Žåã«ã¯åœç€Ÿã®è³ç£ã«åºã¥ãéçºæ®µéã®è£œååè£ã®åžå Žã·ã§ã¢ã®åªå€±ãåŒãèµ·ããå¯èœæ§ããããŸãããŸããåœç€Ÿã®ããŒãããŒããã€ã€ãªãã£ãçã¿åºã補åãã¿ã€ã ãªãŒã«é
åžãã顧客ã®éèŠãæºããèœåã劚ããå¯èœæ§ããããŸãã
⢠æ
è¡å¶éãé¿é£ææ¿çãŸãã¯å¶éããã®ä»ã®æ··ä¹±ãçºçããå¯èœæ§ããããããã«ããåœç€Ÿã®ããŒãããŒã®è£œé æ¥æ ç¹ã§é
延ããã®ä»ã®çŽæ¥çãªåœ±é¿ãåŒãèµ·ããããå¯èœæ§ãããããããåœç€Ÿã®ãã€ãªå»è¬åè³ç£ããã³åœç€Ÿã®ãã€ã€ã«ãã£ãçã¿åºã補åã®éçºæ®µéã®è£œååè£ã補é ããèœåã«åœ±é¿ãäžããå¯èœæ§ããããŸãïŒ
⢠éçºæ®µéã®è£œååè£ã«åºã¥ããã€ãªå»è¬åè³ç£ã«å¯ŸããããŒãããŒã®èšåºè©Šéšããã°ã©ã ãžã®æœåšçãªäžæã«ã¯ã以äžã®ãããªãã®ãå«ãŸããŸãïŒïŒiïŒèšåºè©Šéšã®å®æœãããã³ãããã¯ã®æžå¿µã«çŠç¹ãåœãŠãããã«å»çè³æºãéžè±ããå¯èœæ§ïŒïŒiiïŒç
é¢ãç 究æ©é¢ã®æ¹éããŸãã¯æ¿åºã®èŠå¶ã®å€æŽã«ãããããŒãããŒãèšåºè©Šéšãå®æœããèœåãé
延ãŸãã¯æªåœ±é¿ãåããå¯èœæ§ïŒããã³ïŒiiiïŒè©Šéšæç¶ãã®äžæãé
延ïŒç¹ã«éå¿
é ãšèŠãªãããæç¶ãïŒãæ£è
ãžã®æè¬ãããŒãããŒã®éçºæ®µéã®è£œååè£ã®åºè·ãèšåºè©Šéšææã®é
åžãç 究ã¢ãã¿ãªã³ã°ããµã€ãæ€æ»ããã³ããŒã¿åæããã³ãããã¯ã«é¢é£ããçç±ã§çºçããããšãããã«ããéçºæ®µéã®è£œååè£ã®éçºãŸãã¯æ¿èªã«æ··ä¹±ãé
延ãåŒãèµ·ããå¯èœæ§ããããŸãã
æ³çè«æ±ãæ³çæç¶ãã¯ãæã
ã®ããžãã¹ã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
ããŸããŸãªæ³çè«æ±ãæç¶ãã«çŽé¢ããå¯èœæ§ããããŸãããããã®è«æ±ã®åŠ¥åœæ§ã«é¢ãããã調æ»ãé²åŸ¡ã«ã¯ significant ãªæéãšè²»çšãå¿
èŠã«ãªãããšããããŸãã蚎èšã¯æ¬è³ªçã«äžç¢ºå®ã§ãããããç§ãã¡ããã®ãããªè«æ±ãæç¶ãã«å¯ŸããŠèªåèªèº«ãå®ãããšã«æåããä¿èšŒã¯ãããŸãããããããã®åé¡ã®éèŠæ§ã®è©äŸ¡ãé¢é£ããŠèšå®ãããåŒåœéãæçµçãªçµæãšäžèŽãããã©ãããä¿èšŒã§ããŸããããããã®åé¡ã«é¢é£ããåŒåœéã®èª¿æŽãŸãã¯å¢å ã¯ãç§ãã¡ã®ããžãã¹ã財åç¶æ
ããŸãã¯æ¥çžŸã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸãã
äŒæ¥ã®è²¬ä»»ã¯éèŠã§ãããé¢é£ããå ±å矩åã¯ç§ãã¡ã®ããžãã¹ã«åœ±é¿ãäžããå¯èœæ§ããããŸãã
ç±³åœããã³åœéã®èŠå¶åœå±ãæè³å®¶ããã®ä»ã®å©å®³é¢ä¿è
ã¯ãäŒæ¥ã®è²¬ä»»ã«é¢ããåé¡ã«ãŸããŸã泚ç®ããŠããŸããäŸãã°ã人æããã€ããŒã·ãã£ãæç¶å¯èœæ§ãæ°åå€åããµã€ããŒã»ãã¥ãªãã£ã«é¢ããäŒæ¥ã®è²¬ä»»ã«é¢ããæ°ããç±³åœããã³åœéæ³ä»€ãæ€èšäžãŸãã¯æ¡çšãããŠãããå
·äœçã§ã¿ãŒã²ãããæã£ãé瀺èŠä»¶ã矩åãå«ãå¯èœæ§ããããŸããç§ãã¡ã®å¯Ÿå¿ã«ã¯ãè¿œå çãªæè³ãæ°ããå®è·µã»å ±åããã»ã¹ã®å®æœãå¿
èŠã§ããããã¹ãŠãè¿œå ã®ã³ã³ãã©ã€ã¢ã³ã¹ãªã¹ã¯ã䌎ããŸããå ããŠãç§ãã¡ã¯ããã€ãã®äŒæ¥ã®è²¬ä»»ã«é¢ããã€ãã·ã¢ãã£ããç®æšãçºè¡šããŠãããããã«ã¯ç¶ç¶çãªæè³ãå¿
èŠãšããããããã®ç®æšãéæããä¿èšŒãç§ãã¡ã®ã€ãã·ã¢ãã£ããæå³ããææãéæããä¿èšŒã¯ãããŸããããããã®ç®æšãéæããããšããç§ãã¡ã®åªåã«å¯ŸããèŠæ¹ã¯ãã°ãã°å€§ããç°ãªããç§ãã¡ã®è©å€ã«ãªã¹ã¯ããããããŸããäŒæ¥ã®è²¬ä»»ã«é¢ããåé¡ãç®æšãžã®åãçµã¿ããçããè©å€ã®æå·ããŸãã¯ãããã®ç®æšãéæããªãããŸãã¯éæããªããšèŠãªãããããšã¯ãåŸæ¥å¡ã®å®çãç§ãã¡ãšããžãã¹ãè¡ãããŒãããŒã®æ欲ããŸãã¯æè³å®¶ãç§ãã¡ã®æ®éæ ªã賌å
¥ãŸãã¯ä¿æããæ欲ã«åœ±é¿ãäžããå¯èœæ§ããããããããç§ãã¡ã®ããžãã¹ã財æ¿ç¶æ
ãæ¥åçµæã«æªåœ±é¿ãåãŒãå¯èœæ§ããããŸããå ããŠãç§ãã¡ãããã€ãã®ã€ãã·ã¢ãã£ããå®æœããããããã€ãã®ç®æšãéæãããããèœåã¯ãå€éšèŠå ã«äŸåããŠããŸããäŸãã°ãç¹å®ã®æç¶å¯èœæ§ç®æšãã€ãã·ã¢ãã£ããéæããèœåã¯ãéšåçã«ç¬¬äžè
ã®ååãç·©åé©æ°ããŸãã¯çµæžçã«å®çŸå¯èœãªãœãªã¥ãŒã·ã§ã³ã®å¯çšæ§ã«äŸåãããããããŸããã
é
ç®2.ãããæªç»é²ã®æ ªåŒèšŒåžã®è²©å£²ãšåçã®äœ¿çš
æè¿ã®æªç»é²èšŒåžã®è²©å£²
ãªãã
çºè¡äœã«ããæ ªåŒèšŒåžã®è³Œå
¥
2024幎第3ååæã«ãããåœç€Ÿã®Aã¯ã©ã¹æ®éæ ªåŒã®èªç€Ÿæ ªè²·ã掻åã¯ä»¥äžã®éãã§ãïŒåäœã¯åã1æ ªãããã®éé¡ãé€ãïŒïŒ
æé 賌å
¥ããã·ã§ã¢ã®åèšæ° ã·ã§ã¢ãããã®å¹³å賌å
¥äŸ¡æ Œ å
¬è¡šãããããã°ã©ã ã®äžéšãšããŠè³Œå
¥ãããã·ã§ã¢ã®ç·æ° ããã°ã©ã ã®äžã§ãŸã 賌å
¥å¯èœãªã·ã§ã¢ã®æ倧éé¡ (1)
2024幎7æ1æ¥ - 2024幎7æ31æ¥ 910 $ 26.46 910 $ 586,744 2024幎8æ1æ¥ - 2024幎8æ31æ¥ 1,291 27.36 1,291 551,410 2024幎9æ1æ¥ - 2024幎9æ30æ¥ 1,276 28.10 1,276 515,585 åèš 3,477  27.40 3,477 Â
(1) 2023幎3æ27æ¥ã«ãåç· åœ¹äŒãç·é¡10åãã«ãŸã§ã®ã¯ã©ã¹Aæ®éæ ªåŒã®èªå·±æ ªåŒååŸããã°ã©ã ãæ¿èªããããšãçºè¡šããŸããããã®èªå·±æ ªåŒååŸããã°ã©ã ã¯2027幎6æ23æ¥ãŸã§æå¹ã§ãããã®ããã°ã©ã ã«ãããæäœéã®ã¯ã©ã¹Aæ®éæ ªåŒãååŸãã矩åã¯ãããŸãããèªå·±æ ªåŒååŸããã°ã©ã ã«åºã¥ããã¯ã©ã¹Aæ®éæ ªåŒã¯ç§ç亀æžãŸãã¯å
¬éåžå ŽååŒã§ååŸãããå¯èœæ§ããããããã¯ååŒæ³ã®ã«ãŒã«10b5-1ã«æºæ ããèšç»ã®äžã§ãè¡ãããŸãã
é
ç® 3.         äžçŽèšŒåžã«é¢ããããã©ã«ã
該åœããŸããã
é
ç® 4.        é±å±±å®å
šé瀺
該åœããŸããã
é
ç® 5.         ãã®ä»ã®æ
å ±
ã«ãŒã«10b5-1ååŒèŠå®
2024幎ã®ç¬¬3ååæäžãåç· åœ¹ãŸãã¯ã»ã¯ã·ã§ã³16ã®åœ¹å¡ã¯ æ¡çšããã ãä¿®æ£ãããã çµäºãã ãããªãã«ãŒã«10b5-1èšç»ãéã«ãŒã«10b5-1ååŒã®åã決ããã
é
ç® 6.         å±ç€ºç©
以äžã®å±ç€ºç©ã¯ããã®ååæå ±åæžãã©ãŒã 10-Qã®äžéšãšããŠæåºãããŸãã
å±ç€ºçªå·
å±ç€ºç©ã®èª¬æ
31.1*
31.2*
32*
101.INS
XBRLã€ã³ã¹ã¿ã³ã¹ããã¥ã¡ã³ãïŒã€ã³ã¹ã¿ã³ã¹ããã¥ã¡ã³ãã¯ããã®XBRLã¿ã°ãã€ã³ã©ã€ã³XBRLããã¥ã¡ã³ãã«åã蟌ãŸããŠãããããã€ã³ã¿ã©ã¯ãã£ãããŒã¿ãã¡ã€ã«ã«ã¯è¡šç€ºãããŸããïŒ
101.SCH
XBRL ã¿ã¯ãœãããŒæ¡åŒµ ã¹ããŒãããã¥ã¡ã³ã
101.CAL
XBRL ã¿ã¯ãœãããŒæ¡åŒµ èšç®ãªã³ã¯ããŒã¹ããã¥ã¡ã³ã
101.DEF
XBRL ã¿ã¯ãœãããŒæ¡åŒµ å®çŸ©ãªã³ã¯ããŒã¹ããã¥ã¡ã³ã
101.LAB
XBRL ã¿ã¯ãœãããŒæ¡åŒµ ã©ãã«ãªã³ã¯ããŒã¹ææž
101.PRE
XBRL ã¿ã¯ãœãããŒæ¡åŒµ ãã¬ãŒã³ããŒã·ã§ã³ãªã³ã¯ããŒã¹
104 ã«ããŒããŒãž ã€ã³ã¿ã©ã¯ãã£ã ããŒã¿ ãã¡ã€ã« (Inline XBRL圢åŒã§ãExhibit 101ã«å«ãŸããŠããŸã)
* ããã«æåºãŸãã¯æäŸãããŠããŸã
眲å
蚌åžååŒæ³ã«åºã¥ããåœè©²å ±åæžãæ¿èªããç»é²è
ã¯ãæ£åœã«ä»£è¡šè
ã«ãã£ãŠçœ²åãããŸããã
ãã€ã€ã«ãã£ãã¡ãŒã PLC
(ç»é²è
)
/s/ ãããã»ã¬ãŽã¬ãã¿ ãããã»ã¬ãŽã¬ãã¿ æé«çµå¶è²¬ä»»è
æ¥ä»ïŒ 2024幎11æ6æ¥
/s/ ãã©ã³ã¹ã»ã³ã€ã³ ãã©ã³ã¹ã»ã³ã€ã³ æé«è²¡å責任è
æ¥ä»: 2024幎11æ6æ¥